{
      "Synthesis and preliminary pharmacological investigations of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives as potential atypical antipsychotic agents in mice .|In research towards the development of new atypical antipsychotic agents , one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system .|The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine ( 7 ) is described .|Compound 7e , 5 - { 2 - [ 4 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazinyl ] ethyl } - 2 , 3 - dihy dro - 1H - indol - 2 - one , from this series showed significant affinities at the 5 - HT1A and 5 - HT2A receptors and moderate affinity at the D2 receptor .|7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature .": {
            "[\"Synthesis\", \"is a process of\", \"1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine derivatives\"]": " \n[\"Synthesis\", \"is a process of\", \"1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine\"]\n[\"1 - ( 1 , 2 - dihydro - 2 - acenaphthylenyl ) piperazine\", \"derivatives\", \"are produced\"]\nGranularity: 2",
            "[\"Research\", \"is towards the development of\", \"new atypical antipsychotic agents\"]": " \n[\"Research\", \"is towards\", \"development\"]\n[\"Research\", \"is towards\", \"new atypical antipsychotic agents\"]\nGranularity: 2",
            "[\"Strategy\", \"is to modulate\", \"dopaminergic system\"]": " \n[\"Strategy\", \"modulates\", \"dopaminergic system\"]\nGranularity: 1",
            "[\"Manipulation\", \"is of\", \"serotonergic system\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Series\", \"is of\", \"potential atypical antipsychotic agents\"]": " \n[\"Series\", \"is of\", \"potential antipsychotic agents\"]\n[\"Series\", \"is of\", \"atypical antipsychotic agents\"]\nGranularity: 2",
            "[\"Compound 7e\", \"is a part of\", \"series of potential atypical antipsychotic agents\"]": " \n[\"Compound 7e\", \"is a part of\", \"series\"]\n[\"Compound 7e\", \"is a part of\", \"potential atypical antipsychotic agents\"]\nGranularity: 2",
            "[\"Compound 7e\", \"has significant affinities at\", \"5 - HT1A and 5 - HT2A receptors\"]": " \n[\"Compound 7e\", \"has significant affinities at\", \"5 - HT1A receptors\"]\n[\"Compound 7e\", \"has significant affinities at\", \"5 - HT2A receptors\"]\nGranularity: 2",
            "[\"Compound 7e\", \"has moderate affinity at\", \"D2 receptor\"]": " \n[\"Compound 7e\", \"has affinity at\", \"D2 receptor\"]\n[\"Compound 7e\", \"has moderate affinity\", \"D2 receptor\"]\nGranularity: 2",
            "[\"7e\", \"exhibits a high reversal of\", \"catalepsy induced by haloperidol\"]": "\n[\"7e\", \"exhibits\", \"high reversal of catalepsy\"]\n[\"7e\", \"exhibits\", \"catalepsy induced by haloperidol\"]\nGranularity: 2",
            "[\"High reversal of catalepsy\", \"indicates\", \"atypical antipsychotic nature\"]": " \n[\"High reversal of catalepsy\", \"indicates\", \"atypical antipsychotic nature\"]\nGranularity: 1"
      },
      "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts .|Adenosine triphosphate ( ATP ) and sodium nitroprusside ( SNP ) are administered to patients to induce and control hypotension during anesthesia .|SNP is authorized for clinical use in USA and UK , and ATP is clinically used in other countries such as Japan .|We investigated how these two drugs act on the cardiovascular systems of 20 dogs whose hearts had been denervated by a procedure we had devised .|ATP ( 10 dogs ) or SNP ( 10 dogs ) was administered to reduce mean arterial pressure by 30 % to 70 % of control .|Before , during and after induced hypotension , we measured major cardiovascular parameters .|Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure ( p less than 0 . 001 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 001 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , total body oxygen consumption ( p less than 0 . 05 ) , and heart rate ( p less than 0 . 001 ) ; all these variables returned normal within 30 min after ATP was stopped .|Cardiac output did not change .|During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure ( p less than 0 . 01 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 01 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , and oxygen content difference between arterial and mixed venous blood ( p less than 0 . 05 ) , while heart rate ( p less than 0 . 001 ) and cardiac output ( p less than 0 . 05 ) were increased .|Recoveries of heart rate and left ventricular end - diastolic pressure were not shown within 60 min after SNP had been stopped .|Both ATP and SNP should act on the pacemaker tissue of the heart .": {
            "[\"sodium nitroprusside\", \"is administered to\", \"induce and control hypotension\"]": " \n[\"sodium nitroprusside\", \"is administered to\", \"induce hypotension\"]\n[\"sodium nitroprusside\", \"is administered to\", \"control hypotension\"]\nGranularity: 2",
            "[\"sodium nitroprusside\", \"is authorized for clinical use in\", \"USA and UK\"]": " \n[\"sodium nitroprusside\", \"is authorized for clinical use in\", \"USA\"]\n[\"sodium nitroprusside\", \"is authorized for clinical use in\", \"UK\"]\nGranularity: 2",
            "[\"adenosine triphosphate\", \"is clinically used in\", \"other countries such as Japan\"]": "\n[\"adenosine triphosphate\", \"is clinically used in\", \"Japan\"]\nGranularity: 1",
            "[\"investigation\", \"was conducted on\", \"cardiovascular systems of 20 dogs\"]": " \n[\"investigation\", \"was conducted on\", \"cardiovascular systems\"]\n[\"cardiovascular systems\", \"of\", \"20 dogs\"]\nGranularity: 2",
            "[\"adenosine triphosphate\", \"was administered to\", \"10 dogs\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"sodium nitroprusside\", \"was administered to\", \"10 dogs\"]": " \n[\"sodium nitroprusside\", \"was administered to\", \"10 dogs\"]\nGranularity: 1",
            "[\"mean arterial pressure\", \"was reduced by\", \"30% to 70% of control\"]": "\n[\"mean arterial pressure\", \"was reduced by\", \"30% of control\"]\n[\"mean arterial pressure\", \"was reduced by\", \"70% of control\"]\nGranularity: 2",
            "[\"major cardiovascular parameters\", \"were measured during\", \"induced hypotension\"]": " \n[\"major cardiovascular parameters\", \"were measured\", \"during induced hypotension\"]\n[\"major cardiovascular parameters\", \"were measured\", \"during hypotension\"]\n[\"major cardiovascular parameters\", \"were measured\", \"induced hypotension\"]\n[\"major cardiovascular parameters\", \"were measured\", \"hypotension\"]\nGranularity: 4",
            "[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"mean pulmonary arterial pressure\"]": " \n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in mean pulmonary arterial pressure\"]\nGranularity: 1",
            "[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"central venous pressure\"]": " \n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in central venous pressure\"]\nGranularity: 1",
            "[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"left ventricular end-diastolic pressure\"]": " \n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in left ventricular end-diastolic pressure\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"left ventricular end-diastolic pressure\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"left ventricular\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"end-diastolic pressure\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"left ventricular\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"end-diastolic pressure\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused decreases in left ventricular\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused decreases in end-diastolic pressure",
            "[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"total peripheral resistance\"]": " \n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in total peripheral resistance\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in total peripheral resistance\"]\nGranularity: 2",
            "[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"rate pressure product\"]": " \n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in rate\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in pressure\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in product\"]\nGranularity: 3",
            "[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"total body oxygen consumption\"]": " \n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in total body oxygen consumption\"]\n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in total body oxygen consumption\"]\nGranularity: 2",
            "[\"hypotension induced by adenosine triphosphate\", \"caused decreases in\", \"heart rate\"]": " \n[\"hypotension induced by adenosine triphosphate\", \"caused\", \"decreases in heart rate\"]\nGranularity: 1",
            "[\"cardiac output\", \"did not change during\", \"adenosine triphosphate-induced hypotension\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"hypotension induced by sodium nitroprusside\", \"caused decreases in\", \"mean pulmonary arterial pressure\"]": " \n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"decreases in mean pulmonary arterial pressure\"]\nGranularity: 1",
            "[\"hypotension induced by sodium nitroprusside\", \"caused decreases in\", \"central venous pressure\"]": " \n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"decreases in central venous pressure\"]\n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"decreases in central venous pressure\"]\nGranularity: 2",
            "[\"hypotension induced by sodium nitroprusside\", \"caused decreases in\", \"left ventricular end-diastolic pressure\"]": " \n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"decreases in left ventricular end-diastolic pressure\"]\nGranularity: 1",
            "[\"hypotension induced by sodium nitroprusside\", \"caused decreases in\", \"total peripheral resistance\"]": " \n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"decreases in total peripheral resistance\"]\nGranularity: 1",
            "[\"hypotension induced by sodium nitroprusside\", \"caused decreases in\", \"rate pressure product\"]": "\n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"decreases in rate pressure product\"]\nGranularity: 1",
            "[\"hypotension induced by sodium nitroprusside\", \"caused decreases in\", \"oxygen content difference between arterial and mixed venous blood\"]": " \n[\"hypotension induced by sodium nitroprusside\", \"caused decreases in\", \"oxygen content difference between arterial and mixed venous blood\"]\nGranularity: 1",
            "[\"hypotension induced by sodium nitroprusside\", \"caused increases in\", \"heart rate\"]": " \n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"heart rate\"]\n[\"hypotension induced by sodium nitroprusside\", \"increases\", \"heart rate\"]\nGranularity: 2",
            "[\"hypotension induced by sodium nitroprusside\", \"caused increases in\", \"cardiac output\"]": " \n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"increases in cardiac output\"]\n[\"hypotension induced by sodium nitroprusside\", \"caused\", \"cardiac output\"]\nGranularity: 2",
            "[\"recoveries of heart rate and left ventricular end-diastolic pressure\", \"were not shown within\", \"60 min after SNP had been stopped\"]": " \n[\"recoveries of heart rate\", \"were not shown within\", \"60 min after SNP had been stopped\"]\n[\"left ventricular end-diastolic pressure\", \"were not shown within\", \"60 min after SNP had been stopped\"]\nGranularity: 2",
            "[\"both adenosine triphosphate and sodium nitroprusside\", \"should act on\", \"pacemaker tissue of the heart\"]": " \n[\"adenosine triphosphate\", \"should act on\", \"pacemaker tissue of the heart\"]\n[\"sodium nitroprusside\", \"should act on\", \"pacemaker tissue of the heart\"]\nGranularity: 2",
            "[\"adenosine triphosphate\", \"is administered to\", \"induce and control hypotension\"]": " \n[\"adenosine triphosphate\", \"is administered to\", \"induce hypotension\"]\n[\"adenosine triphosphate\", \"is administered to\", \"control hypotension\"]\nGranularity: 2"
      },
      "Histamine antagonists and d - tubocurarine - induced hypotension in cardiac surgical patients .|Hemodynamic effects and histamine release by bolus injection of 0 . 35 mg / kg of d - tubocurarine were studied in 24 patients .|H1 - and H2 - histamine antagonists or placebo were given before dosing with d - tubocurarine in a randomized double - blind fashion to four groups : group 1 - - placebo ; group 2 - - cimetidine , 4 mg / kg , plus placebo ; group 3 - - chlorpheniramine , 0 . 1 mg / kg , plus placebo ; and group 4 - - cimetidine plus chlorpheniramine .|Histamine release occurred in most patients , the highest level 2 minutes after d - tubocurarine dosing .|Group 1 had a moderate negative correlation between plasma histamine change and systemic vascular resistance ( r = 0 . 58 ; P less than 0 . 05 ) not present in group 4 .|Prior dosing with antagonists partially prevented the fall in systemic vascular resistance .|These data demonstrate that the hemodynamic changes associated with d - tubocurarine dosing are only partially explained by histamine release .|Thus prior dosing with H1 - and H2 - antagonists provides only partial protection .": {
            "[\"Histamine antagonists\", \"induced\", \"hypotension in cardiac surgical patients\"]": " \n[\"Histamine antagonists\", \"induced\", \"hypotension\"]\n[\"Histamine antagonists\", \"in cardiac surgical patients\", \"hypotension\"]\nGranularity: 2",
            "[\"Histamine release\", \"studied\", \"bolus injection of 0.35 mg/kg of d-tubocurarine\"]": " \n[\"Histamine release\", \"studied\", \"bolus injection\"]\n[\"Histamine release\", \"studied\", \"0.35 mg/kg of d-tubocurarine\"]\nGranularity: 2",
            "[\"H1- and H2-histamine antagonists or placebo\", \"given\", \"before dosing with d-tubocurarine\"]": " \n[\"H1- and H2-histamine antagonists\", \"given\", \"before dosing\"]\n[\"H1- and H2-histamine antagonists\", \"given\", \"with d-tubocurarine\"]\nGranularity: 2",
            "[\"Histamine release\", \"occurred\", \"in most patients\"]": " N/A (The triple is specific, conveying a singular relation between histamine release and patients.)\nGranularity: 0",
            "[\"Group 1\", \"had\", \"moderate negative correlation between plasma histamine change and systemic vascular resistance\"]": " \n[\"Group 1\", \"had\", \"moderate negative correlation\"]\n[\"plasma histamine change\", \"correlates negatively with\", \"systemic vascular resistance\"]\nGranularity: 2",
            "[\"Prior dosing with antagonists\", \"prevented\", \"the fall in systemic vascular resistance\"]": " \n[\"Prior dosing with antagonists\", \"prevented\", \"the fall in systemic vascular resistance\"]\nGranularity: 1",
            "[\"Hemodynamic changes associated with d-tubocurarine dosing\", \"partially explained\", \"by histamine release\"]": " \n[\"Hemodynamic changes\", \"associated with\", \"d-tubocurarine dosing\"]\n[\"d-tubocurarine dosing\", \"partially explained\", \"by histamine release\"]\nGranularity: 2",
            "[\"Prior dosing with H1- and H2-antagonists\", \"provides\", \"only partial protection\"]": " \n[\"Prior dosing\", \"with\", \"H1-antagonists\"]\n[\"Prior dosing\", \"with\", \"H2-antagonists\"]\n[\"provides\", \"partial protection\"]\nGranularity: 3"
      },
      "Acute neurologic dysfunction after high - dose etoposide therapy for malignant glioma .|Etoposide ( VP - 16 - 213 ) has been used in the treatment of many solid tumors and hematologic malignancies .|When used in high doses and in conjunction with autologous bone marrow transplantation , this agent has activity against several treatment - resistant cancers including malignant glioma .|In six of eight patients ( 75 % ) who we treated for recurrent or resistant glioma , sudden severe neurologic deterioration occurred .|This developed a median of 9 days after initiation of high - dose etoposide therapy .|Significant clinical manifestations have included confusion , papilledema , somnolence , exacerbation of motor deficits , and sharp increase in seizure activity .|These abnormalities resolved rapidly after initiation of high - dose intravenous dexamethasone therapy .|In all patients , computerized tomographic ( CT ) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans .|This complication appears to represent a significant new toxicity of high - dose etoposide therapy for malignant glioma .": {
            "[\"Acute neurologic dysfunction\", \"occurs after\", \"high-dose etoposide therapy\"]": " \n[\"Acute neurologic dysfunction\", \"occurs after\", \"high-dose etoposide therapy\"]\nGranularity: 1",
            "[\"Etoposide\", \"is used in the treatment of\", \"many solid tumors and hematologic malignancies\"]": " \n[\"Etoposide\", \"is used for\", \"solid tumors\"]\n[\"Etoposide\", \"is used for\", \"hematologic malignancies\"]\nGranularity: 2",
            "[\"Etoposide\", \"has activity against\", \"several treatment-resistant cancers\"]": "\n[\"Etoposide\", \"has activity against\", \"treatment-resistant cancers\"]\n[\"Etoposide\", \"has activity against\", \"several cancers\"]\nGranularity: 2",
            "[\"High-dose etoposide therapy\", \"causes\", \"sudden severe neurologic deterioration\"]": " \n[\"High-dose etoposide therapy\", \"causes\", \"sudden neurologic deterioration\"]\n[\"High-dose etoposide therapy\", \"causes\", \"severe neurologic deterioration\"]\nGranularity: 2",
            "[\"Neurologic deterioration\", \"occurs in\", \"six of eight patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Neurologic deterioration\", \"develops a median of\", \"9 days after initiation of high-dose etoposide therapy\"]": " \n[\"Neurologic deterioration\", \"develops after\", \"9 days\"]\n[\"Neurologic deterioration\", \"is associated with\", \"high-dose etoposide therapy\"]\nGranularity: 2",
            "[\"Clinical manifestations\", \"include\", \"confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity\"]": " \n[\"Clinical manifestations\", \"include\", \"confusion\"]\n[\"Clinical manifestations\", \"include\", \"papilledema\"]\n[\"Clinical manifestations\", \"include\", \"somnolence\"]\n[\"Clinical manifestations\", \"include\", \"exacerbation of motor deficits\"]\n[\"Clinical manifestations\", \"include\", \"sharp increase in seizure activity\"]\nGranularity: 5",
            "[\"Abnormalities\", \"resolve rapidly after\", \"high-dose intravenous dexamethasone therapy\"]": " \n[\"Abnormalities\", \"resolve\", \"rapidly\"]\n[\"Abnormalities\", \"resolve\", \"after\"]\n[\"Abnormalities\", \"resolve\", \"high-dose\"]\n[\"Abnormalities\", \"resolve\", \"intravenous\"]\n[\"Abnormalities\", \"resolve\", \"dexamethasone\"]\n[\"Abnormalities\", \"resolve\", \"therapy\"]\n[\"Abnormalities\", \"resolve rapidly\", \"after high-dose intravenous dexamethasone therapy\"]\nGranularity: 7",
            "[\"CT brain scans\", \"demonstrate\", \"stability in tumor size and peritumor edema\"]": " \n[\"CT brain scans\", \"demonstrate\", \"stability in tumor size\"]\n[\"CT brain scans\", \"demonstrate\", \"stability in peritumor edema\"]\nGranularity: 2",
            "[\"This complication\", \"represents\", \"a significant new toxicity of high-dose etoposide therapy\"]": "\n[\"This complication\", \"represents\", \"a significant new toxicity\"]\n[\"high-dose etoposide therapy\", \"has\", \"a significant new toxicity\"]\nGranularity: 2"
      },
      "Increased anxiogenic effects of caffeine in panic disorders .|The effects of oral administration of caffeine ( 10 mg / kg ) on behavioral ratings , somatic symptoms , blood pressure and plasma levels of 3 - methoxy - 4 - hydroxyphenethyleneglycol ( MHPG ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM - III criteria for agoraphobia with panic attacks or panic disorder .|Caffeine produced significantly greater increases in subject - rated anxiety , nervousness , fear , nausea , palpitations , restlessness , and tremors in the patients compared with healthy subjects .|In the patients , but not the healthy subjects , these symptoms were significantly correlated with plasma caffeine levels .|Seventy - one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks .|Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients .|Caffeine increased plasma cortisol levels equally in the patient and healthy groups .|Because caffeine is an adenosine receptor antagonist , these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine .|Patients with anxiety disorders may benefit by avoiding caffeine - containing foods and beverages .": {
            "[\"caffeine\", \"has\", \"anxiogenic effects\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and anxiogenic effects.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"subject-rated anxiety\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"nervousness\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and nervousness.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"fear\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and fear.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"nausea\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and nausea.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"palpitations\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and palpitations.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"restlessness\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and restlessness.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"tremors\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and tremors.)\nGranularity: 0",
            "[\"plasma caffeine levels\", \"correlate with\", \"symptoms in patients\"]": " \n[\"plasma caffeine levels\", \"correlate with\", \"symptoms\"]\n[\"plasma caffeine levels\", \"correlate with\", \"patients\"]\nGranularity: 2",
            "[\"71% of patients\", \"report\", \"similarity of caffeine effects to panic attacks\"]": " \n[\"71% of patients\", \"report\", \"caffeine effects\"]\n[\"71% of patients\", \"report\", \"similarity to panic attacks\"]\nGranularity: 2",
            "[\"caffeine\", \"does not alter\", \"plasma MHPG levels\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"caffeine\", \"increases\", \"plasma cortisol levels\"]": " N/A (The triple is specific, conveying a singular relation between caffeine and plasma cortisol levels.)\nGranularity: 0",
            "[\"adenosine receptor antagonist\", \"suggests\", \"abnormalities in neuronal systems\"]": "\n[\"adenosine receptor antagonist\", \"suggests\", \"abnormalities in neuronal systems\"]\nGranularity: 1",
            "[\"patients with anxiety disorders\", \"may benefit from\", \"avoiding caffeine-containing foods and beverages\"]": " \n[\"patients with anxiety disorders\", \"may benefit from\", \"avoiding caffeine-containing foods\"]\n[\"patients with anxiety disorders\", \"may benefit from\", \"avoiding caffeine-containing beverages\"]\nGranularity: 2"
      },
      "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .|The aims of this study were to examine vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS ) and to investigate the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .|Rats were divided into three groups : sham , VCM and VCM plus erdosteine .|VCM was administrated intraperitoneally ( i . p . ) with 200mgkg ( - 1 ) twice daily for 7 days .|Erdosteine was administered orally .|VCM administration to control rats significantly increased renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion but decreased superoxide dismutase ( SOD ) and catalase ( CAT ) activities .|Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion , and increased SOD activity , but not CAT activity in renal tissue when compared with VCM alone .|Erdosteine showed histopathological protection against VCM - induced nephrotoxicity .|There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .|Erdosteine caused a marked reduction in the extent of tubular damage .|It is concluded that oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .": {
            "[\"In vivo evidences\", \"suggesting\", \"the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .\"]": "\n[\"In vivo evidences\", \"suggesting\", \"the role of oxidative stress\"]\n[\"the role of oxidative stress\", \"in pathogenesis of\", \"vancomycin-induced nephrotoxicity\"]\n[\"vancomycin-induced nephrotoxicity\", \"protection by\", \"erdosteine\"]\nGranularity: 3",
            "[\"The aims of this study\", \"were to examine\", \"vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS )\"]": " \n[\"The aims of this study\", \"were to examine\", \"vancomycin ( VCM ) - induced oxidative stress\"]\n[\"vancomycin ( VCM ) - induced oxidative stress\", \"promotes\", \"production of reactive oxygen species ( ROS )\"]\nGranularity: 2",
            "[\"The aims of this study\", \"to investigate\", \"the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .\"]": " \n[\"The aims of this study\", \"to investigate\", \"the role of erdosteine\"]\n[\"the role of erdosteine\", \"has\", \"expectorant properties\"]\n[\"the role of erdosteine\", \"has\", \"antioxidant properties\"]\n[\"the role of erdosteine\", \"on\", \"kidney tissue\"]\n[\"kidney tissue\", \"against\", \"VCM-induced renal impairment\"]\n[\"VCM-induced renal impairment\", \"in\", \"rats\"]\nGranularity: 6",
            "[\"Rats\", \"were divided into\", \"three groups : sham , VCM and VCM plus erdosteine .\"]": " \n[\"Rats\", \"were divided\", \"into three groups\"]\n[\"three groups\", \"were divided\", \"into sham, VCM, and VCM plus erdosteine\"]\nGranularity: 2",
            "[\"VCM\", \"was administrated intraperitoneally ( i . p . )\", \"200mgkg ( - 1 ) twice daily for 7 days .\"]": " \n[\"VCM\", \"was administrated\", \"intraperitoneally\"]\n[\"VCM\", \"was administrated\", \"200mgkg\"]\n[\"VCM\", \"was administrated\", \"twice daily\"]\n[\"VCM\", \"was administrated\", \"for 7 days\"]\nGranularity: 4",
            "[\"Erdosteine\", \"was administered\", \"orally .\"]": " \n[\"Erdosteine\", \"was administered\", \"orally\"]\nGranularity: 1",
            "[\"VCM administration to control rats\", \"significantly increased\", \"renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion\"]": "\n[\"VCM administration\", \"controls rats\"]\n[\"VCM administration\", \"increases\", \"renal malondialdehyde\"]\n[\"VCM administration\", \"increases\", \"urinary N-acetyl-beta-d-glucosaminidase\"]\n[\"renal malondialdehyde\", \"is a marker of renal tubular injury\"]\n[\"urinary N-acetyl-beta-d-glucosaminidase\", \"is a marker of renal tubular injury\"]\nGranularity: 5",
            "[\"VCM administration to control rats\", \"decreased\", \"superoxide dismutase ( SOD ) and catalase ( CAT ) activities .\"]": " \n[\"VCM administration\", \"decreased\", \"superoxide dismutase activities\"]\n[\"VCM administration\", \"decreased\", \"catalase activities\"]\nGranularity: 2",
            "[\"Erdosteine administration with VCM injections\", \"caused significantly decreased\", \"renal MDA and urinary NAG excretion , and increased SOD activity , but not CAT activity in renal tissue when compared with VCM alone .\"]": " \n[\"Erdosteine administration\", \"caused\", \"decreased renal MDA\"]\n[\"Erdosteine administration\", \"caused\", \"increased SOD activity\"]\n[\"VCM injections\", \"caused\", \"decreased renal MDA\"]\n[\"VCM injections\", \"caused\", \"increased SOD activity\"]\n[\"Erdosteine administration\", \"caused\", \"decreased urinary NAG excretion\"]\n[\"VCM injections\", \"caused\", \"decreased urinary NAG excretion\"]\n[\"Erdosteine administration\", \"did not affect\", \"CAT activity in renal tissue\"]\n[\"VCM injections\", \"did not affect\", \"CAT activity in renal tissue\"]\nGranularity: 8",
            "[\"Erdosteine\", \"showed\", \"histopathological protection against VCM - induced nephrotoxicity .\"]": " \n[\"Erdosteine\", \"showed\", \"histopathological protection\"]\n[\"Erdosteine\", \"showed\", \"against VCM - induced nephrotoxicity\"]\nGranularity: 2",
            "[\"There\", \"were\", \"a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .\"]": " \n[\"VCM-treated rats\", \"showed\", \"a significant dilatation of tubular lumens\"]\n[\"VCM-treated rats\", \"showed\", \"extensive epithelial cell vacuolization\"]\n[\"VCM-treated rats\", \"showed\", \"atrophy\"]\n[\"VCM-treated rats\", \"showed\", \"desquamation\"]\n[\"VCM-treated rats\", \"showed\", \"necrosis\"]\n[\"VCM-treated rats\", \"showed\", \"more than those of the control group\"]\n[\"VCM-treated rats\", \"showed\", \"more than those of the erdosteine group\"]\nGranularity: 7",
            "[\"Erdosteine\", \"caused a marked reduction in the extent of\", \"tubular damage .\"]": "\n[\"Erdosteine\", \"caused\", \"a marked reduction\"]\n[\"Erdosteine\", \"reduced\", \"the extent of tubular damage\"]\nGranularity: 2",
            "[\"It is concluded\", \"that\", \"oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .\"]": " \n[\"oxidative tubular damage\", \"plays a role in\", \"VCM-induced nephrotoxicity\"]\n[\"oxidative stress\", \"is modulated by\", \"erdosteine\"]\n[\"VCM-induced kidney damage\", \"is reduced at\", \"biochemical level\"]\n[\"VCM-induced kidney damage\", \"is reduced at\", \"histological level\"]\nGranularity: 4"
      },
      "Comparison of laryngeal mask with endotracheal tube for anesthesia in endoscopic sinus surgery .|BACKGROUND : The purpose of this study was to compare surgical conditions , including the amount of intraoperative bleeding as well as intraoperative blood pressure , during functional endoscopic sinus surgery ( FESS ) using flexible reinforced laryngeal mask airway ( FRLMA ) versus endotracheal tube ( ETT ) in maintaining controlled hypotension anesthesia induced by propofol - remifentanil total i . v .|anesthesia ( TIVA ) .|METHODS : Sixty normotensive American Society of Anesthesiologists I - II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol - remifentanil - TIVA were randomly assigned into two groups : group I , FRLMA ; group II , ETT .|Hemorrhage was measured and the visibility of the operative field was evaluated according to a six - point scale .|RESULTS : Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil .|CONCLUSION : In summary , our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS .": {
            "[\"Comparison\", \"of\", \"laryngeal mask with endotracheal tube\"]": " \n[\"Comparison\", \"of\", \"laryngeal mask\"]\n[\"Comparison\", \"of\", \"endotracheal tube\"]\nGranularity: 2",
            "[\"Study\", \"purpose\", \"to compare surgical conditions\"]": " \n[\"Study\", \"has the purpose of\", \"comparing surgical conditions\"]\n[\"Study\", \"aims to\", \"compare surgical conditions\"]\n[\"Study\", \"intends to\", \"compare surgical conditions\"]\n[\"Study\", \"seeks to\", \"compare surgical conditions\"]\nGranularity: 4",
            "[\"Surgical conditions\", \"including\", \"amount of intraoperative bleeding\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Surgical conditions\", \"including\", \"intraoperative blood pressure\"]": " \n[\"Surgical conditions\", \"include\", \"intraoperative blood pressure\"]\nGranularity: 1",
            "[\"Functional endoscopic sinus surgery\", \"using\", \"flexible reinforced laryngeal mask airway\"]": " \n[\"Functional endoscopic sinus surgery\", \"using\", \"flexible reinforced laryngeal mask\"]\n[\"Functional endoscopic sinus surgery\", \"using\", \"airway\"]\nGranularity: 2",
            "[\"Functional endoscopic sinus surgery\", \"using\", \"endotracheal tube\"]": " \n[\"Functional endoscopic sinus surgery\", \"uses\", \"endotracheal tube\"]\nGranularity: 1",
            "[\"Anesthesia\", \"induced by\", \"propofol-remifentanil total i.v. anesthesia\"]": " \n[\"Anesthesia\", \"induced by\", \"propofol-remifentanil total i.v. anesthesia\"]\nGranularity: 1",
            "[\"Sixty normotensive American Society of Anesthesiologists I-II adult patients\", \"undergoing\", \"FESS\"]": " \n[\"Sixty normotensive American Society of Anesthesiologists I-II adult patients\", \"undergoing\", \"FESS\"]\nGranularity: 1",
            "[\"Patients\", \"assigned into\", \"two groups\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Group I\", \"assigned\", \"FRLMA\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Group II\", \"assigned\", \"ETT\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hemorrhage\", \"measured\", \"visibility of the operative field\"]": " \n[\"Hemorrhage\", \"affects\", \"visibility of the operative field\"]\n[\"Hemorrhage\", \"impairs\", \"visibility of the operative field\"]\nGranularity: 2",
            "[\"Visibility of the operative field\", \"evaluated\", \"six-point scale\"]": "\n[\"Visibility of the operative field\", \"evaluated by\", \"six-point scale\"]\n[\"Visibility of the operative field\", \"has a\", \"six-point scale\"]\nGranularity: 2",
            "[\"Controlled hypotension\", \"achieved\", \"shorter period\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Laryngeal mask\", \"using\", \"lower rates of remifentanil infusion\"]": " \n[\"Laryngeal mask\", \"using\", \"lower rates\"]\n[\"Laryngeal mask\", \"using\", \"remifentanil infusion\"]\nGranularity: 2",
            "[\"Laryngeal mask\", \"using\", \"lower total dose of remifentanil\"]": " \n[\"Laryngeal mask\", \"uses\", \"lower total dose\"]\n[\"Laryngeal mask\", \"uses\", \"remifentanil\"]\nGranularity: 2",
            "[\"Results\", \"indicate\", \"airway management using FRLMA\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Airway management using FRLMA\", \"provided\", \"better surgical conditions\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Better surgical conditions\", \"in terms of\", \"quality of operative field and blood loss\"]": " \n[\"Better surgical conditions\", \"in terms of\", \"quality of operative field\"]\n[\"Better surgical conditions\", \"in terms of\", \"blood loss\"]\nGranularity: 2",
            "[\"Airway management using FRLMA\", \"allowed for\", \"convenient induced hypotension\"]": " \n[\"Airway management\", \"using FRLMA\", \"allowed for\"]\n[\"Airway management using FRLMA\", \"allowed for\", \"convenient induced hypotension\"]\nGranularity: 2",
            "[\"Convenient induced hypotension\", \"with\", \"low doses of remifentanil\"]": " \n[\"Convenient induced hypotension\", \"is induced with\", \"low doses of remifentanil\"]\nGranularity: 1",
            "[\"Low doses of remifentanil\", \"during\", \"TIVA in patients undergoing FESS\"]": " \n[\"Low doses of remifentanil\", \"during\", \"TIVA\"]\n[\"TIVA\", \"in patients undergoing\", \"FESS\"]\nGranularity: 2"
      },
      "Paclitaxel 3 - hour infusion given alone and combined with carboplatin : preliminary results of dose - escalation trials .|Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) by 3 - hour infusion was combined with carboplatin in a phase I / II study directed to patients with non - small cell lung cancer .|Carboplatin was given at a fixed target area under the concentration - time curve of 6 . 0 by the Calvert formula , whereas paclitaxel was escalated in patient cohorts from 150 mg / m2 ( dose level I ) to 175 , 200 , 225 , and 250 mg / m2 .|The 225 mg / m2 level was expanded for the phase II study since the highest level achieved ( 250 mg / m2 ) required modification because of nonhematologic toxicities ( arthralgia and sensory neuropathy ) .|Therapeutic effects were noted at all dose levels , with objective responses in 17 ( two complete and 15 partial regressions ) of 41 previously untreated patients .|Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels .|Carboplatin did not appear to add to the hematologic toxicities observed , and the paclitaxel / carboplatin combination could be dosed every 3 weeks .": {
            "[\"Paclitaxel\", \"is combined with\", \"carboplatin\"]": " N/A (The triple is specific, conveying a singular relation between Paclitaxel and carboplatin.)\nGranularity: 0",
            "[\"Paclitaxel\", \"is studied in\", \"phase I/II trial\"]": "\n[\"Paclitaxel\", \"is studied\", \"in phase I trial\"]\n[\"Paclitaxel\", \"is studied\", \"in phase II trial\"]\nGranularity: 2",
            "[\"Paclitaxel\", \"is escalated in\", \"patient cohorts\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Carboplatin\", \"is given at\", \"fixed target area\"]": " \n[\"Carboplatin\", \"is given\", \"at fixed target area\"]\nGranularity: 1",
            "[\"Carboplatin\", \"does not add to\", \"hematologic toxicities\"]": " N/A (The triple is specific, conveying a singular relation between Carboplatin and hematologic toxicities.)\nGranularity: 0",
            "[\"Therapeutic effects\", \"are noted at\", \"all dose levels\"]": " \n[\"Therapeutic effects\", \"are noted\", \"at all dose levels\"]\nGranularity: 1",
            "[\"Toxicities\", \"are compared with\", \"phase I trial of paclitaxel\"]": "\n[\"Toxicities\", \"are compared with\", \"phase I trial\"]\n[\"Toxicities\", \"are compared with\", \"paclitaxel\"]\nGranularity: 2",
            "[\"Paclitaxel/carboplatin combination\", \"can be dosed every\", \"3 weeks\"]": " \n[\"Paclitaxel/carboplatin combination\", \"can be dosed\", \"every 3 weeks\"]\nGranularity: 1",
            "[\"Paclitaxel\", \"is given by\", \"3-hour infusion\"]": " \n[\"Paclitaxel\", \"is given\", \"3-hour infusion\"]\nGranularity: 1"
      },
      "Quinine - induced arrhythmia in a patient with severe malaria .|It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( premature ventricular contraction ) while getting quinine infusion was reported .|A man , 25 years old , was admitted to hospital with high fever , chill , vomiting , jaundice .|The patient was fully conscious , blood pressure 120 / 80 mmHg , pulse rate 100 x / minute , regular .|On admission , laboratory examination showed Plasmodium falciparum ( + + + + ) , total bilirubin 8 . 25 mg / dL , conjugated bilirubin 4 . 36 mg / dL , unconjugated bilirubin 3 . 89 mg / dL , potassium 3 . 52 meq / L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5 % 500 mg / 8 hour .|On the second day the patient had vomitus , diarrhea , tinnitus , loss of hearing .|After 30 hours of quinine infusion the patient felt palpitation and electrocardiography ( ECG ) recording showed premature ventricular contraction ( PVC ) > 5 x / minute , trigemini , constant type - - sinoatrial block , positive U wave .|He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5 % / 24 hour and potassium aspartate tablet .|Quinine infusion was discontinued and changed with sulfate quinine tablets .|Three hours later the patient felt better , the frequency of PVC reduced to 4 - 5 x / minute and on the third day ECG was normal , potassium level was 3 . 34 meq / L .|He was discharged on 7th day in good condition .|Quinine , like quinidine , is a chincona alkaloid that has anti - arrhythmic property , although it also pro - arrhythmic that can cause various arrhythmias , including severe arrhythmia such as multiple PVC .|Administration of parenteral quinine must be done carefully and with good observation because of its pro - arrhythmic effect , especially in older patients who have heart diseases or patients with electrolyte disorder ( hypokalemia ) which frequently occurs due to vomiting and or diarrhea in malaria cases .": {
            "[\"Patient\", \"diagnosed with\", \"severe malaria with jaundice\"]": " \n[\"Patient\", \"diagnosed with\", \"severe malaria\"]\n[\"Patient\", \"diagnosed with\", \"jaundice\"]\nGranularity: 2",
            "[\"Patient\", \"received\", \"quinine infusion\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Quinine\", \"can cause\", \"various arrhythmias\"]": " \n[\"Quinine\", \"can cause\", \"atrial fibrillation\"]\n[\"Quinine\", \"can cause\", \"ventricular tachycardia\"]\n[\"Quinine\", \"can cause\", \"supraventricular tachycardia\"]\n[\"Quinine\", \"can cause\", \"bradycardia\"]\n[\"Quinine\", \"can cause\", \"ventricular fibrillation\"]\nGranularity: 5",
            "[\"Quinine\", \"has\", \"anti-arrhythmic property\"]": " N/A (The triple is specific, conveying a singular relation between Quinine and its anti-arrhythmic property.)\nGranularity: 0",
            "[\"Quinine\", \"also has\", \"pro-arrhythmic effect\"]": " N/A (The triple is specific, conveying a singular relation between Quinine and its pro-arrhythmic effect.)\nGranularity: 0",
            "[\"Patient\", \"experienced\", \"vomitus, diarrhea, tinnitus, loss of hearing\"]": " \n[\"Patient\", \"experienced\", \"vomitus\"]\n[\"Patient\", \"experienced\", \"diarrhea\"]\n[\"Patient\", \"experienced\", \"tinnitus\"]\n[\"Patient\", \"experienced\", \"loss of hearing\"]\nGranularity: 4",
            "[\"Patient\", \"felt\", \"palpitation\"]": " N/A (The triple is specific, conveying a singular relation between the patient and palpitation.)\nGranularity: 0",
            "[\"ECG\", \"showed\", \"premature ventricular contraction\"]": " \n[\"ECG\", \"showed\", \"premature ventricular contraction\"]\nGranularity: 1",
            "[\"Patient\", \"received\", \"lidocaine and potassium aspartate treatment\"]": " \n[\"Patient\", \"received\", \"lidocaine treatment\"]\n[\"Patient\", \"received\", \"potassium aspartate treatment\"]\nGranularity: 2",
            "[\"Quinine infusion\", \"was discontinued and changed with\", \"sulfate quinine tablets\"]": "\n[\"Quinine infusion\", \"was discontinued\"]\n[\"Quinine infusion\", \"was changed with\", \"sulfate quinine tablets\"]\nGranularity: 2",
            "[\"Patient\", \"felt better and\", \"PVC frequency reduced\"]": "\n[\"Patient\", \"felt better\"]\n[\"PVC frequency\", \"reduced\"]\nGranularity: 2",
            "[\"ECG\", \"showed\", \"normal readings\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"was discharged on\", \"7th day\"]": " \n[\"Patient\", \"was discharged\", \"on 7th day\"]\nGranularity: 1",
            "[\"Administration of quinine\", \"must be done\", \"carefully\"]": " N/A (The triple is specific, conveying a singular relation between administration of quinine and the need for carefulness.)\nGranularity: 0",
            "[\"Quinine\", \"induced\", \"arrhythmia\"]": " N/A (The triple is specific, conveying a singular relation between Quinine and arrhythmia.)\nGranularity: 0"
      },
      "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU - induced cortical dysplasia .|Cortical dysplasia is a malformation characterized by defects in proliferation , migration and maturation .|This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine - [ 1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure ] ( BCNU ) and to investigate the effects of exogenous melatonin upon cerebellar BCNU - induced cortical dysplasia , using histological and biochemical analyses .|Pregnant Wistar rats were assigned to five groups : intact - control , saline - control , melatonin - treated , BCNU - exposed and BCNU - exposed plus melatonin .|Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery .|Immuno / histochemistry and electron microscopy were carried out on the offspring cerebellum , and levels of malondialdehyde and superoxide dismutase were determined .|Histopathologically , typical findings were observed in the cerebella from the control groups , but the findings consistent with early embryonic development were noted in BCNU - exposed cortical dysplasia group .|There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU - exposed group , but a decreased immunoreactivity to glial fibrillary acidic protein , synaptophysin and transforming growth factor beta1 was observed , indicating a delayed maturation , and melatonin significantly reversed these changes .|Malondialdehyde level in BCNU - exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group ( P < 0 . 01 ) , while there were no significant differences in the superoxide dismutase levels between these groups .|These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU .": {
            "[\"Cortical dysplasia\", \"is characterized by\", \"defects in proliferation, migration and maturation\"]": "\n[\"Cortical dysplasia\", \"is characterized by\", \"defects in proliferation\"]\n[\"Cortical dysplasia\", \"is characterized by\", \"defects in migration\"]\n[\"Cortical dysplasia\", \"is characterized by\", \"defects in maturation\"]\nGranularity: 3",
            "[\"This study\", \"was designed to\", \"evaluate alterations in offspring rat cerebellum\"]": " \n[\"This study\", \"was designed to\", \"evaluate alterations\"]\n[\"offspring rat\", \"has\", \"cerebellum\"]\nGranularity: 2",
            "[\"Maternal exposure to BCNU\", \"induces\", \"cortical dysplasia\"]": " \n[\"Maternal exposure to BCNU\", \"induces\", \"cortical dysplasia\"]\nGranularity: 1",
            "[\"Histological and biochemical analyses\", \"were used to\", \"investigate effects of melatonin\"]": " \n[\"Histological analyses\", \"were used to\", \"investigate effects of melatonin\"]\n[\"Biochemical analyses\", \"were used to\", \"investigate effects of melatonin\"]\nGranularity: 2",
            "[\"Pregnant Wistar rats\", \"were assigned to\", \"five groups\"]": " \n[\"Pregnant Wistar rats\", \"were assigned\", \"to five groups\"]\nGranularity: 1",
            "[\"Rats\", \"were exposed to\", \"BCNU on embryonic day 15\"]": " \n[\"Rats\", \"were exposed\", \"BCNU\"]\n[\"Rats\", \"were exposed to\", \"embryonic day 15\"]\nGranularity: 2",
            "[\"Melatonin\", \"was given until\", \"delivery\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Immuno/histochemistry and electron microscopy\", \"were carried out on\", \"offspring cerebellum\"]": " \n[\"Immuno/histochemistry\", \"was carried out on\", \"offspring cerebellum\"]\n[\"electron microscopy\", \"was carried out on\", \"offspring cerebellum\"]\nGranularity: 2",
            "[\"Levels of malondialdehyde and superoxide dismutase\", \"were determined in\", \"offspring cerebellum\"]": " \n[\"Levels of malondialdehyde\", \"were determined in\", \"offspring cerebellum\"]\n[\"Levels of superoxide dismutase\", \"were determined in\", \"offspring cerebellum\"]\nGranularity: 2",
            "[\"Histopathologically\", \"typical findings were observed in\", \"control groups\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"BCNU-exposed cortical dysplasia group\", \"consistent with\", \"early embryonic development\"]": " \n[\"BCNU-exposed cortical dysplasia group\", \"is consistent with\", \"early embryonic development\"]\nGranularity: 1",
            "[\"TUNEL positive cells and nestin positive cells\", \"increased in\", \"BCNU-exposed group\"]": " \n[\"TUNEL positive cells\", \"increased in\", \"BCNU-exposed group\"]\n[\"nestin positive cells\", \"increased in\", \"BCNU-exposed group\"]\nGranularity: 2",
            "[\"Glial fibrillary acidic protein, synaptophysin, and transforming growth factor beta1\", \"decreased immunoreactivity to\", \"BCNU-exposed group\"]": " \n[\"Glial fibrillary acidic protein\", \"decreased immunoreactivity to\", \"BCNU-exposed group\"]\n[\"synaptophysin\", \"decreased immunoreactivity to\", \"BCNU-exposed group\"]\n[\"transforming growth factor beta1\", \"decreased immunoreactivity to\", \"BCNU-exposed group\"]\nGranularity: 3",
            "[\"Melatonin\", \"significantly reversed\", \"these changes\"]": " N/A (The triple is specific, conveying a singular relation between melatonin and the changes mentioned.)\nGranularity: 0",
            "[\"Malondialdehyde level\", \"increased in\", \"BCNU-exposed group\"]": " \n[\"Malondialdehyde level\", \"increased in\", \"BCNU-exposed group\"]\nGranularity: 1",
            "[\"Melatonin\", \"decreased\", \"malondialdehyde levels in BCNU group\"]": " \n[\"Melatonin\", \"decreased\", \"malondialdehyde levels\"]\n[\"Melatonin\", \"decreased\", \"in BCNU group\"]\nGranularity: 2",
            "[\"Superoxide dismutase levels\", \"no significant differences in\", \"between these groups\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"These data\", \"suggest\", \"that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum\"]": " \n[\"exposure of animals\", \"to BCNU during pregnancy\", \"leads to delayed maturation of offspring cerebellum\"]\n[\"exposure of animals\", \"to BCNU\", \"leads to delayed maturation of offspring cerebellum\"]\n[\"animals\", \"are exposed to\", \"BCNU during pregnancy\"]\n[\"offspring\", \"experience delayed maturation of\", \"cerebellum\"]\nGranularity: 4",
            "[\"Neuroprotective effects\", \"occurs upon\", \"offspring cerebellar cortex\"]": " \n[\"Neuroprotective effects\", \"occur upon\", \"offspring cerebellar cortex\"]\nGranularity: 1"
      },
      "Overexpression of copper / zinc - superoxide dismutase protects from kanamycin - induced hearing loss .|The participation of reactive oxygen species in aminoglycoside - induced ototoxicity has been deduced from observations that aminoglycoside - iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo .|We therefore hypothesized that overexpression of Cu / Zn - superoxide dismutase ( h - SOD1 ) should protect transgenic mice from ototoxicity .|Immunocytochemistry confirmed expression of h - SOD1 in inner ear tissues of transgenic C57BL / 6 - TgN [ SOD1 ] 3Cje mice .|Transgenic and nontransgenic littermates received kanamycin ( 400 mg / kg body weight / day ) for 10 days beginning on day 10 after birth .|Auditory thresholds were tested by evoked auditory brain stem responses at 1 month after birth .|In nontransgenic animals , the threshold in the kanamycin - treated group was 45 - 50 dB higher than in saline - injected controls .|In the transgenic group , kanamycin increased the threshold by only 15 dB over the respective controls .|The effects were similar at 12 and 24 kHz .|The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside - induced ototoxicity .|The results also suggest transgenic animals as suitable models to investigate the underlying mechanisms and possible strategies for prevention .": {
            "[\"Overexpression of copper / zinc - superoxide dismutase\", \"protects from\", \"kanamycin - induced hearing loss\"]": " \n[\"Overexpression of copper / zinc - superoxide dismutase\", \"protects from\", \"kanamycin - induced hearing loss\"]\nGranularity: 1",
            "[\"Reactive oxygen species\", \"participate in\", \"aminoglycoside - induced ototoxicity\"]": " \n[\"Reactive oxygen species\", \"participate in\", \"aminoglycoside-induced ototoxicity\"]\n[\"Reactive oxygen species\", \"participate in\", \"aminoglycoside\"]\n[\"Reactive oxygen species\", \"participate in\", \"ototoxicity\"]\nGranularity: 3",
            "[\"Aminoglycoside - iron complexes\", \"catalyze the formation of\", \"superoxide radicals\"]": " \n[\"Aminoglycoside - iron complexes\", \"catalyze\", \"superoxide radicals\"]\n[\"Aminoglycoside - iron complexes\", \"form\", \"superoxide radicals\"]\nGranularity: 2",
            "[\"Antioxidants\", \"attenuate\", \"ototoxicity\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Overexpression of Cu / Zn - superoxide dismutase\", \"should protect\", \"transgenic mice from ototoxicity\"]": "\n[\"Overexpression of Cu / Zn - superoxide dismutase\", \"should protect\", \"transgenic mice\"]\n[\"transgenic mice\", \"should be protected from\", \"ototoxicity\"]\nGranularity: 2",
            "[\"Immunocytochemistry\", \"confirmed expression of\", \"h - SOD1 in inner ear tissues\"]": " \n[\"Immunocytochemistry\", \"confirmed expression of\", \"h - SOD1\"]\n[\"h - SOD1\", \"in\", \"inner ear tissues\"]\nGranularity: 2",
            "[\"Transgenic and nontransgenic littermates\", \"received\", \"kanamycin\"]": " \n[\"Transgenic littermates\", \"received\", \"kanamycin\"]\n[\"Nontransgenic littermates\", \"received\", \"kanamycin\"]\nGranularity: 2",
            "[\"Auditory thresholds\", \"were tested by\", \"evoked auditory brain stem responses\"]": " \n[\"Auditory thresholds\", \"were tested by\", \"evoked auditory brain stem responses\"]\nGranularity: 1",
            "[\"In nontransgenic animals\", \"the threshold in the kanamycin - treated group\", \"was 45 - 50 dB higher than in saline - injected controls\"]": " \n[\"nontransgenic animals\", \"had a threshold\", \"45 - 50 dB higher than in saline - injected controls\"]\n[\"nontransgenic animals\", \"had a threshold\", \"in the kanamycin - treated group\"]\n[\"kanamycin - treated group\", \"had a threshold\", \"45 - 50 dB higher than in saline - injected controls\"]\nGranularity: 3",
            "[\"In the transgenic group\", \"kanamycin increased the threshold by\", \"only 15 dB over the respective controls\"]": " \n[\"In the transgenic group\", \"kanamycin increased the threshold by\", \"15 dB\"]\n[\"In the transgenic group\", \"kanamycin\", \"increased the threshold\"]\n[\"kanamycin\", \"increased\", \"the threshold\"]\n[\"kanamycin\", \"increased\", \"15 dB\"]\nGranularity: 4",
            "[\"The protection by overexpression of superoxide dismutase\", \"supports the hypothesis that\", \"oxidant stress plays a significant role in aminoglycoside - induced ototoxicity\"]": " \n[\"The protection by overexpression of superoxide dismutase\", \"supports\", \"the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced ototoxicity\"]\n[\"The protection by overexpression of superoxide dismutase\", \"overexpression\", \"superoxide dismutase\"]\n[\"superoxide dismutase\", \"supports\", \"the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced ototoxicity\"]\n[\"oxidant stress\", \"plays a significant role in\", \"aminoglycoside-induced ototoxicity\"]\nGranularity: 4",
            "[\"The results\", \"suggest\", \"transgenic animals as suitable models to investigate the underlying mechanisms and possible strategies for prevention\"]": " \n[\"The results\", \"suggest\", \"transgenic animals\"]\n[\"transgenic animals\", \"are suitable models to investigate\", \"underlying mechanisms\"]\n[\"transgenic animals\", \"are suitable models to investigate\", \"possible strategies for prevention\"]\nGranularity: 3"
      },
      "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers : a placebo - controlled trial .|Lamivudine is a novel 2 ' , 3 ' - dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo .|We performed a single - blind , placebo - controlled study to assess its effectiveness and safety in Chinese hepatitis B surface antigen ( HBsAg ) carriers .|Forty - two Chinese HBsAg carriers were randomized to receive placebo ( 6 patients ) or lamivudine orally in dosages of 25 mg , 100 mg , or 300 mg daily ( 12 patients for each dosage ) .|The drug was given for 4 weeks .|The patients were closely monitored clinically , biochemically , and serologically up to 4 weeks after drug treatment .|All 36 patients receiving lamivudine had a decrease in hepatitis B virus ( HBV ) DNA values of > 90 % ( P < . 001 compared with placebo ) .|Although 25 mg of lamivudine was slightly less effective than 100 mg ( P = . 011 ) and 300 mg ( P = . 005 ) , it still induced 94 % suppression of HBV DNA after the fourth week of therapy .|HBV DNA values returned to pretreatment levels within 4 weeks of cessation of therapy .|There was no change in the hepatitis B e antigen status or in aminotransferase levels .|No serious adverse events were observed .|In conclusion , a 4 - week course of lamivudine was safe and effective in suppression of HBV DNA in Chinese HBsAg carriers .|The suppression was > 90 % but reversible .|Studies with long - term lamivudine administration should be performed to determine if prolonged suppression of HBV DNA can be achieved .": {
            "[\"Lamivudine\", \"is a\", \"novel 2', 3'-dideoxy cytosine analogue\"]": " \n[\"Lamivudine\", \"is a\", \"novel analogue\"]\n[\"Lamivudine\", \"is a\", \"2', 3'-dideoxy cytosine analogue\"]\nGranularity: 2",
            "[\"Lamivudine\", \"has potent inhibitory effects on\", \"hepatitis B virus replication\"]": " \n[\"Lamivudine\", \"has inhibitory effects on\", \"hepatitis B virus replication\"]\n[\"Lamivudine\", \"has potent effects on\", \"hepatitis B virus replication\"]\n[\"Lamivudine\", \"inhibits\", \"hepatitis B virus replication\"]\n[\"Lamivudine\", \"has potent inhibitory effects on\", \"hepatitis B virus\"]\nGranularity: 4",
            "[\"Study\", \"assessed the effectiveness and safety of\", \"Lamivudine\"]": " \n[\"Study\", \"assessed\", \"effectiveness\"]\n[\"Study\", \"assessed\", \"safety\"]\n[\"Study\", \"assessed\", \"Lamivudine\"]\nGranularity: 3",
            "[\"42 Chinese HBsAg carriers\", \"were randomized to receive\", \"placebo or lamivudine\"]": " \n[\"42 Chinese HBsAg carriers\", \"were randomized\", \"to receive placebo\"]\n[\"42 Chinese HBsAg carriers\", \"were randomized\", \"to receive lamivudine\"]\nGranularity: 2",
            "[\"Lamivudine\", \"was given for\", \"4 weeks\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Patients\", \"were monitored\", \"up to 4 weeks after drug treatment\"]": " \n[\"Patients\", \"were monitored\", \"up to 4 weeks\"]\n[\"Patients\", \"were monitored\", \"after drug treatment\"]\nGranularity: 2",
            "[\"All 36 patients receiving lamivudine\", \"had a decrease in\", \"HBV DNA values\"]": " \n[\"36 patients\", \"received\", \"lamivudine\"]\n[\"lamivudine\", \"decreased\", \"HBV DNA values\"]\nGranularity: 2",
            "[\"25 mg of lamivudine\", \"was slightly less effective than\", \"100 mg and 300 mg\"]": " \n[\"25 mg of lamivudine\", \"was less effective than\", \"100 mg\"]\n[\"25 mg of lamivudine\", \"was less effective than\", \"300 mg\"]\nGranularity: 2",
            "[\"HBV DNA values\", \"returned to pretreatment levels within\", \"4 weeks of cessation of therapy\"]": " \n[\"HBV DNA values\", \"returned to\", \"pretreatment levels\"]\n[\"HBV DNA values\", \"within\", \"4 weeks\"]\n[\"cessation of therapy\", \"occurred within\", \"4 weeks\"]\nGranularity: 3",
            "[\"There was no change in\", \"hepatitis B e antigen status or\", \"aminotransferase levels\"]": " \n[\"There was no change\", \"in hepatitis B e antigen status\"]\n[\"There was no change\", \"in aminotransferase levels\"]\nGranularity: 2",
            "[\"A 4-week course of lamivudine\", \"was safe and effective in\", \"suppression of HBV DNA\"]": " \n[\"A 4-week course of lamivudine\", \"was safe and effective in\", \"suppression of HBV DNA\"]\nGranularity: 1",
            "[\"The suppression\", \"was\", \"> 90 % but reversible\"]": " \n[\"The suppression\", \"was\", \"> 90 %\"]\n[\"The suppression\", \"was\", \"reversible\"]\nGranularity: 2",
            "[\"Studies with long-term lamivudine administration\", \"should be performed to determine if\", \"prolonged suppression of HBV DNA can be achieved\"]": " \n[\"Studies\", \"should be performed to determine if\", \"prolonged suppression of HBV DNA can be achieved\"]\n[\"long-term lamivudine administration\", \"should be performed to determine if\", \"prolonged suppression of HBV DNA can be achieved\"]\n[\"prolonged suppression of HBV DNA\", \"can be achieved\"]\nGranularity: 3",
            "[\"Lamivudine\", \"is effective in\", \"suppressing hepatitis B virus DNA\"]": " \n[\"Lamivudine\", \"is effective in\", \"suppressing hepatitis B virus\"]\n[\"Lamivudine\", \"is effective in\", \"suppressing DNA\"]\nGranularity: 2"
      },
      "Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane .|A 69 - year - old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis .|Massive bleeding appeared during surgery which lasted for six hours .|Postoperative evolution under supportive therapy was favourable .|Complete recovery was confirmed by repeated controls performed over a period of one year after surgery .": {
            "[\"after\", \"anesthesia with\", \"methoxyflurane\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"under\", \"methoxyflurane anesthesia\", \"developed postoperatively\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"postoperatively\", \"developed\", \"69-year-old man\"]": " \n[\"postoperatively\", \"developed\", \"69-year-old man\"]\nGranularity: 1",
            "[\"lasted for\", \"six hours\", \"\"]": " \n[\"lasted\", \"for\", \"six hours\"]\nGranularity: 1",
            "[\"was\", \"favourable\", \"\"]": " N/A (The triple is not specific enough to be split into sub-triples. The object is missing, making it impossible to determine the relationships between the subject and object.)\nGranularity: 0",
            "[\"performed over a period of\", \"one year after\", \"surgery\"]": " \n[\"performed\", \"over a period of\", \"one year\"]\n[\"performed\", \"after\", \"surgery\"]\nGranularity: 2",
            "[\"Hepatitis\", \"and\", \"renal tubular acidosis\"]": " N/A (The triple does not convey a specific relationship and cannot be split into more specific sub-triples.)\nGranularity: 0",
            "[\"69-year-old man\", \"operated for\", \"acute cholecystitis\"]": " \n[\"69-year-old man\", \"underwent\", \"surgery\"]\n[\"acute cholecystitis\", \"was the reason for\", \"the operation\"]\nGranularity: 2",
            "[\"hepatic insufficiency syndrome\", \"and\", \"renal tubular acidosis\"]": " \n[\"hepatic insufficiency syndrome\", \"and\", \"renal tubular acidosis\"]\nGranularity: 1",
            "[\"Massive bleeding\", \"appeared during\", \"surgery\"]": " \n[\"Massive bleeding\", \"appeared during\", \"surgery\"]\nGranularity: 1",
            "[\"Postoperative evolution\", \"under\", \"supportive therapy\"]": " N/A (The terms 'Postoperative evolution' and 'supportive therapy' are already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Complete recovery\", \"confirmed by\", \"repeated controls\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine - induced hypotension and bradycardia .|The effects of microinjection of clonidine ( 1 - 10 micrograms in 1 microliter ) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in urethane - anesthetized rats .|Intramedullary administration of clonidine , but not saline vehicle , caused a dose - dependent decrease in both the mean arterial pressure and the heart rate .|The clonidine - induced hypotension was antagonized by prior spinal transection , but not bilateral vagotomy .|On the other hand , the clonidine - induced bradycardia was antagonized by prior bilateral vagotomy , but not spinal transection .|Furthermore , selective destruction of the spinal 5 - HT nerves , produced by bilateral spinal injection of 5 , 7 - dihydroxytryptamine , reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats .|The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine - induced hypotension and bradycardia .|The induced hypotension is brought about by a decrease in sympathetic efferent activity , whereas the induced bradycardia was due to an increase in vagal efferent activity .": {
            "[\"Participation of a bulbospinal serotonergic pathway\", \"in the rat brain\", \"in clonidine - induced hypotension and bradycardia\"]": " \n[\"Participation of a bulbospinal serotonergic pathway\", \"in\", \"clonidine-induced hypotension\"]\n[\"Participation of a bulbospinal serotonergic pathway\", \"in\", \"clonidine-induced bradycardia\"]\n[\"Participation of a bulbospinal serotonergic pathway\", \"in the rat brain\", \"in clonidine - induced hypotension\"]\n[\"Participation of a bulbospinal serotonergic pathway\", \"in the rat brain\", \"in clonidine - induced bradycardia\"]\nGranularity: 4",
            "[\"The effects of microinjection of clonidine\", \"assessed in urethane - anesthetized rats\", \"on cardiovascular function\"]": "\n[\"microinjection of clonidine\", \"assessed in\", \"urethane-anesthetized rats\"]\n[\"microinjection of clonidine\", \"assessed on\", \"cardiovascular function\"]\nGranularity: 2",
            "[\"Intramedullary administration of clonidine\", \"caused a dose - dependent decrease\", \"in both the mean arterial pressure and the heart rate\"]": " \n[\"Intramedullary administration of clonidine\", \"caused\", \"a dose-dependent decrease in mean arterial pressure\"]\n[\"Intramedullary administration of clonidine\", \"caused\", \"a dose-dependent decrease in heart rate\"]\nGranularity: 2",
            "[\"The clonidine - induced hypotension\", \"antagonized by\", \"prior spinal transection\"]": " \n[\"The clonidine - induced hypotension\", \"antagonized by\", \"spinal transection\"]\n[\"The clonidine - induced hypotension\", \"antagonized by\", \"prior transection\"]\nGranularity: 2",
            "[\"The clonidine - induced bradycardia\", \"antagonized by\", \"prior bilateral vagotomy\"]": " \n[\"The clonidine-induced bradycardia\", \"antagonized by\", \"prior bilateral vagotomy\"]\nGranularity: 1",
            "[\"Selective destruction of the spinal 5 - HT nerves\", \"produced by\", \"bilateral spinal injection of 5 , 7 - dihydroxytryptamine\"]": " \n[\"Selective destruction of the spinal 5 - HT nerves\", \"produced by\", \"bilateral spinal injection of 5 , 7 - dihydroxytryptamine\"]\nGranularity: 1",
            "[\"The data\", \"indicate\", \"that a bulbospinal serotonergic pathway is involved in development of clonidine - induced hypotension and bradycardia\"]": "\n[\"The data\", \"indicate\", \"a bulbospinal serotonergic pathway is involved\"]\n[\"a bulbospinal serotonergic pathway\", \"is involved in\", \"development of clonidine-induced hypotension\"]\n[\"a bulbospinal serotonergic pathway\", \"is involved in\", \"development of clonidine-induced bradycardia\"]\nGranularity: 3",
            "[\"The induced hypotension\", \"brought about by\", \"a decrease in sympathetic efferent activity\"]": " \n[\"The induced hypotension\", \"is brought about by\", \"a decrease in sympathetic efferent activity\"]\n[\"The induced hypotension\", \"is brought about by\", \"a decrease in sympathetic activity\"]\n[\"The induced hypotension\", \"is brought about by\", \"a decrease in efferent activity\"]\n[\"The induced hypotension\", \"is brought about by\", \"a decrease in sympathetic efferent activity\"]\n[\"The induced hypotension\", \"is brought about by\", \"a decrease in sympathetic activity\"]\n[\"The induced hypotension\", \"is brought about by\", \"a decrease in efferent activity\"]\nGranularity: 6",
            "[\"The induced bradycardia\", \"due to\", \"an increase in vagal efferent activity\"]": " \n[\"The induced bradycardia\", \"is caused by\", \"an increase in vagal efferent activity\"]\n[\"The induced bradycardia\", \"is a result of\", \"an increase in vagal efferent activity\"]\n[\"The induced bradycardia\", \"is due to\", \"an increase in vagal efferent activity\"]\n[\"The induced bradycardia\", \"is a consequence of\", \"an increase in vagal efferent activity\"]\n[\"The induced bradycardia\", \"is an effect of\", \"an increase in vagal efferent activity\"]\n[\"The induced bradycardia\", \"is a manifestation of\", \"an increase in vagal efferent activity\"]\n[\"The induced bradycardia\", \"is an outcome of\", \"an increase in vagal efferent activity\"]\n[\"The induced bradycardia\", \"is a product of\", \"an increase in"
      },
      "Treatment - related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter .|This report describes unique contrast enhancement of the white matter on T1 - weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy , which developed from acute lymphoblastic leukemia treated with high - dose methotrexate .|In both patients , the enhancement was more pronounced near the base of the brain than at the vertex .|Necropsy of the first case revealed loss of myelination and necrosis of the white matter .|Possible mechanisms causing such a leukoencephalopathy are discussed .": {
            "[\"Treatment\", \"related to\", \"disseminated necrotizing leukoencephalopathy\"]": " \n[\"Treatment\", \"related to\", \"disseminated necrotizing leukoencephalopathy\"]\nGranularity: 1",
            "[\"Disseminated necrotizing leukoencephalopathy\", \"characterized by\", \"contrast enhancement of the white matter\"]": " \n[\"Disseminated necrotizing leukoencephalopathy\", \"is characterized by\", \"contrast enhancement\"]\n[\"Disseminated necrotizing leukoencephalopathy\", \"is characterized by\", \"white matter\"]\nGranularity: 2",
            "[\"Disseminated necrotizing leukoencephalopathy\", \"developed from\", \"acute lymphoblastic leukemia treated with high-dose methotrexate\"]": " \n[\"Disseminated necrotizing leukoencephalopathy\", \"developed from\", \"acute lymphoblastic leukemia\"]\n[\"acute lymphoblastic leukemia\", \"treated with\", \"high-dose methotrexate\"]\nGranularity: 2",
            "[\"Patients\", \"exhibited\", \"unique contrast enhancement of the white matter on T1-weighted magnetic resonance images\"]": " \n[\"Patients\", \"exhibited\", \"contrast enhancement\"]\n[\"Patients\", \"exhibited\", \"white matter\"]\n[\"Patients\", \"exhibited\", \"T1-weighted magnetic resonance images\"]\nGranularity: 3",
            "[\"Enhancement\", \"more pronounced near\", \"the base of the brain\"]": " \n[\"Enhancement\", \"is more pronounced near\", \"the base of the brain\"]\nGranularity: 1",
            "[\"Necropsy\", \"revealed\", \"loss of myelination and necrosis of the white matter\"]": "\n[\"Necropsy\", \"revealed\", \"loss of myelination\"]\n[\"Necropsy\", \"revealed\", \"necrosis of the white matter\"]\nGranularity: 2",
            "[\"Possible mechanisms\", \"causing\", \"such a leukoencephalopathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Discussion\", \"involves\", \"mechanisms causing leukoencephalopathy\"]": " \n[\"Discussion\", \"involves\", \"mechanisms\"]\n[\"Discussion\", \"involves\", \"causing leukoencephalopathy\"]\nGranularity: 2",
            "[\"Acute lymphoblastic leukemia\", \"treated with\", \"high-dose methotrexate\"]": " \n[\"Acute lymphoblastic leukemia\", \"treated with\", \"high-dose methotrexate\"]\nGranularity: 1",
            "[\"High-dose methotrexate\", \"led to\", \"disseminated necrotizing leukoencephalopathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Disseminated necrotizing leukoencephalopathy\", \"found in\", \"two patients\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"T1-weighted magnetic resonance images\", \"showed\", \"unique contrast enhancement of the white matter\"]": " \n[\"T1-weighted magnetic resonance images\", \"showed\", \"contrast enhancement\"]\n[\"T1-weighted magnetic resonance images\", \"showed\", \"unique enhancement\"]\n[\"T1-weighted magnetic resonance images\", \"showed\", \"white matter enhancement\"]\nGranularity: 3",
            "[\"Contrast enhancement\", \"more pronounced\", \"near the base of the brain\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Possible mechanisms\", \"causing\", \"leukoencephalopathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Oxidative damage precedes nitrative damage in adriamycin - induced cardiac mitochondrial injury .|The purpose of the present study was to determine if elevated reactive oxygen ( ROS ) / nitrogen species ( RNS ) reported to be present in adriamycin ( ADR ) - induced cardiotoxicity actually resulted in cardiomyocyte oxidative / nitrative damage , and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach .|B6C3 mice were treated with a single dose of 20 mg / kg ADR .|Ultrastructural damage and levels of 4 - hydroxy - 2 - nonenal ( 4HNE ) - protein adducts and 3 - nitrotyrosine ( 3NT ) were analyzed .|Quantitative ultrastructural damage using computerized image techniques showed cardiomyocyte injury as early as 3 hours , with mitochondria being the most extensively and progressively injured subcellular organelle .|Analysis of 4HNE protein adducts by immunogold electron microscopy showed appearance of 4HNE protein adducts in mitochondria as early as 3 hours , with a peak at 6 hours and subsequent decline at 24 hours .|3NT levels were significantly increased in all subcellular compartments at 6 hours and subsequently declined at 24 hours .|Our data showed ADR induced 4HNE - protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared .|These results document for the first time in vivo that mitochondrial oxidative damage precedes nitrative damage .|The progressive nature of mitochondrial injury suggests that mitochondria , not other subcellular organelles , are the major site of intracellular injury .": {
            "[\"Oxidative damage\", \"precedes\", \"nitrative damage\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Adriamycin\", \"induces\", \"cardiac mitochondrial injury\"]": " \n[\"Adriamycin\", \"induces\", \"cardiac injury\"]\n[\"Adriamycin\", \"induces\", \"mitochondrial injury\"]\nGranularity: 2",
            "[\"Present study\", \"determines\", \"cardiomyocyte oxidative/nitrative damage\"]": " \n[\"Present study\", \"determines\", \"cardiomyocyte oxidative damage\"]\n[\"Present study\", \"determines\", \"cardiomyocyte nitrative damage\"]\nGranularity: 2",
            "[\"B6C3 mice\", \"receive\", \"single dose of 20 mg/kg ADR\"]": " \n[\"B6C3 mice\", \"receive\", \"single dose\"]\n[\"B6C3 mice\", \"receive\", \"20 mg/kg ADR\"]\nGranularity: 2",
            "[\"Ultrastructural damage\", \"analyzes\", \"levels of 4-hydroxy-2-nonenal (4HNE)-protein adducts and 3-nitrotyrosine (3NT)\"]": " \n[\"Ultrastructural damage\", \"analyzes\", \"levels of 4-hydroxy-2-nonenal (4HNE)-protein adducts\"]\n[\"Ultrastructural damage\", \"analyzes\", \"levels of 3-nitrotyrosine (3NT)\"]\nGranularity: 2",
            "[\"Quantitative ultrastructural damage\", \"shows\", \"cardiomyocyte injury as early as 3 hours\"]": " \n[\"Quantitative ultrastructural damage\", \"shows\", \"cardiomyocyte injury\"]\n[\"Quantitative ultrastructural damage\", \"shows\", \"early injury\"]\n[\"Quantitative ultrastructural damage\", \"shows\", \"injury at 3 hours\"]\nGranularity: 3",
            "[\"Mitochondria\", \"are\", \"most extensively and progressively injured subcellular organelle\"]": " \n[\"Mitochondria\", \"are\", \"extensively injured\"]\n[\"Mitochondria\", \"are\", \"progressively injured\"]\n[\"Mitochondria\", \"are\", \"subcellular organelle\"]\nGranularity: 3",
            "[\"4HNE protein adducts\", \"appear\", \"in mitochondria as early as 3 hours\"]": " \n[\"4HNE protein adducts\", \"appear\", \"in mitochondria\"]\n[\"4HNE protein adducts\", \"appear\", \"as early as 3 hours\"]\nGranularity: 2",
            "[\"3NT levels\", \"increase\", \"in all subcellular compartments at 6 hours\"]": " \n[\"3NT levels\", \"increase\", \"in subcellular compartments\"]\n[\"3NT levels\", \"increase\", \"at 6 hours\"]\nGranularity: 2",
            "[\"ADR\", \"induces\", \"4HNE-protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared\"]": " \n[\"ADR\", \"induces\", \"4HNE-protein adducts\"]\n[\"ADR\", \"induces\", \"mitochondrial injury\"]\n[\"mitochondrial injury\", \"appears at\", \"same time point\"]\nGranularity: 3",
            "[\"These results\", \"document\", \"in vivo that mitochondrial oxidative damage precedes nitrative damage\"]": " \n[\"These results\", \"document\", \"mitochondrial oxidative damage\"]\n[\"These results\", \"document\", \"nitrative damage\"]\nGranularity: 2",
            "[\"Progressive nature of mitochondrial injury\", \"suggests\", \"mitochondria are the major site of intracellular injury\"]": " \n[\"Progressive nature of mitochondrial injury\", \"suggests\", \"mitochondria are the major site of intracellular injury\"]\nGranularity: 1"
      },
      "Ifosfamide related encephalopathy : the need for a timely EEG evaluation .|BACKGROUND : Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas , lymphoma , gynecologic and testicular cancers .|Encephalopathy has been reported in 10 - 40 % of patients receiving high - dose IV ifosfamide .|OBJECTIVE : To highlight the role of electroencephalogram ( EEG ) in the early detection and management of ifosfamide related encephalopathy .|METHODS : Retrospective chart review including clinical data and EEG recordings was done on five patients , admitted to MD Anderson Cancer Center between years 2009 and 2012 , who developed ifosfamide related acute encephalopathy .|RESULTS : All five patients experienced symptoms of encephalopathy soon after ( within 12 h - 2 days ) receiving ifosfamide .|Two patients developed generalized convulsions while one patient developed continuous non - convulsive status epilepticus ( NCSE ) that required ICU admission and intubation .|Initial EEG showed epileptiform discharges in three patients ; run of triphasic waves in one patient and moderate degree diffuse generalized slowing .|Mixed pattern with the presence of both sharps and triphasic waves were also noted .|Repeat EEGs within 24_h of symptom onset showed marked improvement that was correlated with clinical improvement .|CONCLUSIONS : Severity of ifosfamide related encephalopathy correlates with EEG changes .|We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy .": {
            "[\"Encephalopathy\", \"has been reported in\", \"10 - 40% of patients receiving high - dose IV ifosfamide\"]": " \n[\"Encephalopathy\", \"has been reported in\", \"10 - 40% of patients\"]\n[\"Encephalopathy\", \"has been reported in\", \"high-dose IV ifosfamide\"]\nGranularity: 2",
            "[\"Objective\", \"is to highlight the role of\", \"electroencephalogram (EEG)\"]": " \n[\"Objective\", \"is to highlight\", \"the role of EEG\"]\nGranularity: 1",
            "[\"Retrospective chart review\", \"was done on\", \"five patients admitted to MD Anderson Cancer Center\"]": " \n[\"Retrospective chart review\", \"was done on\", \"five patients\"]\n[\"Retrospective chart review\", \"was done at\", \"MD Anderson Cancer Center\"]\nGranularity: 2",
            "[\"Five patients\", \"developed\", \"ifosfamide related acute encephalopathy\"]": " \n[\"Five patients\", \"developed\", \"ifosfamide related acute encephalopathy\"]\n[\"Five patients\", \"developed\", \"ifosfamide related encephalopathy\"]\n[\"Five patients\", \"developed\", \"acute encephalopathy\"]\n[\"Five patients\", \"developed\", \"ifosfamide related\"]\n[\"Five patients\", \"developed\", \"encephalopathy\"]\n[\"Five patients\", \"developed\", \"acute\"]\n[\"Five patients\", \"developed\", \"ifosfamide\"]\n[\"Five patients\", \"developed\", \"related\"]\nGranularity: 8",
            "[\"All five patients\", \"experienced symptoms of\", \"encephalopathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Two patients\", \"developed\", \"generalized convulsions\"]": " \n[\"Two patients\", \"developed\", \"generalized convulsions\"]\nGranularity: 1",
            "[\"One patient\", \"developed\", \"continuous non - convulsive status epilepticus (NCSE)\"]": " \n[\"One patient\", \"developed\", \"continuous NCSE\"]\n[\"One patient\", \"developed\", \"non-convulsive status epilepticus\"]\nGranularity: 2",
            "[\"Initial EEG\", \"showed\", \"epileptiform discharges in three patients\"]": " \n[\"Initial EEG\", \"showed\", \"epileptiform discharges\"]\n[\"epileptiform discharges\", \"were found in\", \"three patients\"]\nGranularity: 2",
            "[\"Initial EEG\", \"showed\", \"run of triphasic waves in one patient\"]": " \n[\"Initial EEG\", \"showed\", \"run of triphasic waves\"]\n[\"run of triphasic waves\", \"in one patient\", \"was observed\"]\nGranularity: 2",
            "[\"Initial EEG\", \"showed\", \"moderate degree diffuse generalized slowing\"]": " \n[\"Initial EEG\", \"showed\", \"moderate degree slowing\"]\n[\"Initial EEG\", \"showed\", \"diffuse slowing\"]\n[\"Initial EEG\", \"showed\", \"generalized slowing\"]\nGranularity: 3",
            "[\"Mixed pattern\", \"was noted with\", \"presence of both sharps and triphasic waves\"]": " \n[\"Mixed pattern\", \"was noted with\", \"presence of sharps\"]\n[\"Mixed pattern\", \"was noted with\", \"presence of triphasic waves\"]\nGranularity: 2",
            "[\"Repeat EEGs\", \"showed\", \"marked improvement correlated with clinical improvement\"]": " \n[\"Repeat EEGs\", \"showed\", \"marked improvement\"]\n[\"marked improvement\", \"correlated with\", \"clinical improvement\"]\nGranularity: 2",
            "[\"Severity of ifosfamide related encephalopathy\", \"correlates with\", \"EEG changes\"]": " \n[\"Severity of ifosfamide related encephalopathy\", \"correlates with\", \"EEG changes\"]\nGranularity: 1",
            "[\"We\", \"suggest\", \"a timely EEG evaluation\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Ifosfamide\", \"is an alkylating agent\", \"useful in the treatment of a wide range of cancers\"]": " \n[\"Ifosfamide\", \"is\", \"an alkylating agent\"]\n[\"Ifosfamide\", \"is useful in the treatment of\", \"a wide range of cancers\"]\nGranularity: 2"
      },
      "Dose - dependent neurotoxicity of high - dose busulfan in children : a clinical and pharmacological study .|Busulfan is known to be neurotoxic in animals and humans , but its acute neurotoxicity remains poorly characterized in children .|We report here a retrospective study of 123 children ( median age , 6 . 5 years ) receiving high - dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors , brain tumors excluded .|Busulfan was given p . o . , every 6 hours for 16 doses over 4 days .|Two total doses were consecutively used : 16 mg / kg , then 600 mg / m2 .|The dose calculation on the basis of body surface area results in higher doses in young children than in older patients ( 16 to 28 mg / kg ) .|Ninety - six patients were not given anticonvulsive prophylaxis ; 7 ( 7 . 5 % ) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing .|When the total busulfan dose was taken into account , there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg / kg ( 1 of 57 , 1 . 7 % ) and patients under 600 mg / m2 ( 6 of 39 , 15 . 4 % ) ( P less than 0 . 02 ) .|Twenty - seven patients were given a 600 - mg / m2 busulfan total dose with continuous i . v .|infusion of clonazepam ; none had any neurological symptoms .|Busulfan levels were measured by a gas chromatographic - mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg / m2 busulfan with clonazepam : busulfan cerebrospinal fluid : plasma ratio was 1 . 39 .|This was significantly different ( P less than 0 . 02 ) from the cerebrospinal fluid : plasma ratio previously defined in children receiving a 16 - mg / kg total dose of busulfan .|This study shows that busulfan neurotoxicity is dose - dependent in children and efficiently prevented by clonazepam .|A busulfan dose calculated on the basis of body surface area , resulting in higher doses in young children , was followed by increased neurotoxicity , close to neurotoxicity incidence observed in adults .|Since plasma pharmacokinetic studies showed a faster busulfan clearance in children than in adults , this new dose may approximate more closely the adult systemic exposure obtained after the usual 16 - mg / kg total dose , with potential inferences in terms of anticancer or myeloablative effects .|The busulfan dose in children and infants undergoing bone marrow transplantation should be reconsidered on the basis of pharmacokinetic studies .": {
            "[\"Dose-dependent neurotoxicity\", \"of\", \"high-dose busulfan in children\"]": " \n[\"Dose-dependent neurotoxicity\", \"of\", \"high-dose busulfan\"]\n[\"high-dose busulfan\", \"in children\", \"causes neurotoxicity\"]\nGranularity: 2",
            "[\"Busulfan\", \"is known to be\", \"neurotoxic in animals and humans\"]": " \n[\"Busulfan\", \"is known to be\", \"neurotoxic in animals\"]\n[\"Busulfan\", \"is known to be\", \"neurotoxic in humans\"]\nGranularity: 2",
            "[\"Busulfan\", \"remains poorly characterized\", \"acute neurotoxicity in children\"]": " \n[\"Busulfan\", \"has\", \"poor characterization\"]\n[\"Busulfan\", \"causes\", \"acute neurotoxicity\"]\n[\"acute neurotoxicity\", \"occurs in\", \"children\"]\nGranularity: 3",
            "[\"123 children\", \"receiving\", \"high-dose busulfan\"]": " \n[\"123 children\", \"receive\", \"high-dose busulfan\"]\nGranularity: 1",
            "[\"Busulfan\", \"was given\", \"p.o., every 6 hours for 16 doses over 4 days\"]": " \n[\"Busulfan\", \"was given\", \"p.o.\"]\n[\"Busulfan\", \"was given\", \"every 6 hours\"]\n[\"Busulfan\", \"was given\", \"16 doses\"]\n[\"Busulfan\", \"was given\", \"over 4 days\"]\nGranularity: 4",
            "[\"Two total doses\", \"were consecutively used\", \"16 mg/kg, then 600 mg/m2\"]": " \n[\"Two total doses\", \"were consecutively used\", \"16 mg/kg\"]\n[\"Two total doses\", \"were consecutively used\", \"600 mg/m2\"]\nGranularity: 2",
            "[\"Dose calculation\", \"on the basis of\", \"body surface area\"]": " \n[\"Dose calculation\", \"based on\", \"body surface area\"]\n[\"Dose calculation\", \"on the basis of\", \"body\"]\n[\"Dose calculation\", \"on the basis of\", \"surface area\"]\nGranularity: 3",
            "[\"Body surface area\", \"results in\", \"higher doses in young children\"]": "\n[\"Body surface area\", \"results in\", \"higher doses\"]\n[\"Body surface area\", \"results in\", \"young children\"]\nGranularity: 2",
            "[\"Ninety-six patients\", \"were not given\", \"anticonvulsive prophylaxis\"]": " \n[\"Ninety-six patients\", \"were not given\", \"anticonvulsive prophylaxis\"]\nGranularity: 1",
            "[\"7 patients\", \"developed\", \"seizures during the 4 days of the busulfan course\"]": "\n[\"7 patients\", \"developed\", \"seizures\"]\n[\"the busulfan course\", \"lasted for\", \"4 days\"]\nGranularity: 2",
            "[\"Total busulfan dose\", \"was taken into account\", \"significant difference in terms of neurotoxicity incidence\"]": " \n[\"Total busulfan dose\", \"was taken into account\", \"neurotoxicity incidence\"]\n[\"Total busulfan dose\", \"was taken into account\", \"significant difference\"]\nGranularity: 2",
            "[\"27 patients\", \"were given\", \"600-mg/m2 busulfan total dose with continuous i.v. infusion of clonazepam\"]": "\n[\"27 patients\", \"were given\", \"600-mg/m2 busulfan total dose\"]\n[\"27 patients\", \"were given\", \"continuous i.v. infusion of clonazepam\"]\nGranularity: 2",
            "[\"Busulfan levels\", \"were measured\", \"gas chromatographic-mass spectrometry assay\"]": " \n[\"Busulfan levels\", \"were measured by\", \"gas chromatographic-mass spectrometry\"]\n[\"Busulfan levels\", \"were measured with\", \"an assay\"]\nGranularity: 2",
            "[\"Busulfan cerebrospinal fluid:plasma ratio\", \"was significantly different\", \"1.39\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"This study\", \"shows\", \"busulfan neurotoxicity is dose-dependent in children\"]": "\n[\"This study\", \"shows\", \"busulfan neurotoxicity\"]\n[\"busulfan neurotoxicity\", \"is dose-dependent\", \"in children\"]\nGranularity: 2",
            "[\"Busulfan dose\", \"calculated on the basis of\", \"body surface area\"]": " \n[\"Busulfan dose\", \"calculated on the basis of\", \"body surface area\"]\nGranularity: 1",
            "[\"Busulfan dose\", \"followed by\", \"increased neurotoxicity\"]": " \n[\"Busulfan dose\", \"followed by\", \"neurotoxicity\"]\n[\"Busulfan dose\", \"followed by\", \"increased neurotoxicity\"]\nGranularity: 2",
            "[\"Plasma pharmacokinetic studies\", \"showed\", \"faster busulfan clearance in children than in adults\"]": "\n[\"Plasma pharmacokinetic studies\", \"showed\", \"faster busulfan clearance\"]\n[\"Plasma pharmacokinetic studies\", \"showed\", \"busulfan clearance in children\"]\n[\"Plasma pharmacokinetic studies\", \"showed\", \"busulfan clearance in adults\"]\nGranularity: 3",
            "[\"New dose\", \"may approximate more closely\", \"adult systemic exposure\"]": " \n[\"New dose\", \"may approximate\", \"adult systemic exposure\"]\n[\"New dose\", \"may more closely approximate\", \"adult systemic exposure\"]\nGranularity: 2"
      },
      "Impaired fear recognition in regular recreational cocaine users .|INTRODUCTION : The ability to read facial expressions is essential for normal human social interaction .|The aim of the present study was to conduct the first investigation of facial expression recognition performance in recreational cocaine users .|MATERIALS AND METHODS : Three groups , comprised of 21 cocaine naive participants ( CN ) , 30 occasional cocaine ( OC ) , and 48 regular recreational cocaine ( RC ) users , were compared .|An emotional facial expression ( EFE ) task consisting of a male and female face expressing six basic emotions ( happiness , surprise , sadness , anger , fear , and disgust ) was administered .|Mean percent accuracy and latencies for correct responses across eight presentations of each basic emotion were derived .|Participants were also assessed with the \" Eyes task \" to investigate their ability to recognize more complex emotional states and the Symptom CheckList - 90 - Revised to measure psychopathology .|RESULTS : There were no group differences in psychopathology or \" eyes task \" performance , but the RC group , who otherwise had similar illicit substance use histories to the OC group , exhibited impaired fear recognition accuracy compared to the OC and CN groups .|The RC group also correctly identified anger , fear , happiness , and surprise , more slowly than CN , but not OC participants .|The OC group was slower than CN when correctly identifying disgust .|The selective deficit in fear recognition accuracy manifested by the RC group can not be explained by the subacute effects of cocaine , or ecstasy , because recent and less recent users of these drugs within this group were similarly impaired .|Possible parallels between RC users and psychopaths with respect to impaired fear recognition , amygdala dysfunction , and etiology are discussed .": {
            "[\"Impaired fear recognition\", \"in\", \"regular recreational cocaine users\"]": "\n[\"Impaired fear recognition\", \"in\", \"regular recreational cocaine users\"]\nGranularity: 0",
            "[\"Ability to read facial expressions\", \"is essential for\", \"normal human social interaction\"]": " \n[\"Ability to read facial expressions\", \"is essential for\", \"normal human social interaction\"]\nGranularity: 1",
            "[\"Present study\", \"aimed to\", \"investigate facial expression recognition performance in recreational cocaine users\"]": " \n[\"Present study\", \"aimed to\", \"investigate performance\"]\n[\"Present study\", \"aimed to\", \"facial expression recognition\"]\n[\"Present study\", \"aimed to\", \"recreational cocaine users\"]\nGranularity: 3",
            "[\"Three groups\", \"comprised of\", \"21 cocaine naive participants, 30 occasional cocaine, and 48 regular recreational cocaine users\"]": "\n[\"Three groups\", \"comprised of\", \"21 cocaine naive participants\"]\n[\"Three groups\", \"comprised of\", \"30 occasional cocaine users\"]\n[\"Three groups\", \"comprised of\", \"48 regular recreational cocaine users\"]\nGranularity: 3",
            "[\"Emotional facial expression (EFE) task\", \"consisting of\", \"a male and female face expressing six basic emotions\"]": " \n[\"Emotional facial expression (EFE) task\", \"consisting of\", \"a male face expressing six basic emotions\"]\n[\"Emotional facial expression (EFE) task\", \"consisting of\", \"a female face expressing six basic emotions\"]\n[\"Emotional facial expression (EFE) task\", \"consisting of\", \"a male face expressing basic emotions\"]\n[\"Emotional facial expression (EFE) task\", \"consisting of\", \"a female face expressing basic emotions\"]\n[\"Emotional facial expression (EFE) task\", \"consisting of\", \"a male face\"]\n[\"Emotional facial expression (EFE) task\", \"consisting of\", \"a female face\"]\nGranularity: 6",
            "[\"Participants\", \"assessed with\", \"the 'Eyes task' to investigate their ability to recognize more complex emotional states\"]": " \n[\"Participants\", \"assessed with\", \"the 'Eyes task'\"]\n[\"the 'Eyes task'\", \"investigate\", \"ability to recognize more complex emotional states\"]\nGranularity: 2",
            "[\"Participants\", \"assessed with\", \"the Symptom CheckList - 90 - Revised to measure psychopathology\"]": " \n[\"Participants\", \"assessed with\", \"the Symptom CheckList - 90 - Revised\"]\n[\"the Symptom CheckList - 90 - Revised\", \"measures\", \"psychopathology\"]\nGranularity: 2",
            "[\"RC group\", \"exhibited\", \"impaired fear recognition accuracy compared to the OC and CN groups\"]": " \n[\"RC group\", \"exhibited\", \"impaired fear recognition accuracy\"]\n[\"RC group\", \"compared to\", \"OC group\"]\n[\"RC group\", \"compared to\", \"CN group\"]\nGranularity: 3",
            "[\"RC group\", \"identified\", \"anger, fear, happiness, and surprise more slowly than CN, but not OC participants\"]": " \n[\"RC group\", \"identified\", \"anger, fear\"]\n[\"RC group\", \"identified\", \"happiness\"]\n[\"RC group\", \"identified\", \"surprise\"]\n[\"CN participants\", \"identified\", \"anger, fear\"]\n[\"CN participants\", \"identified\", \"happiness\"]\n[\"CN participants\", \"identified\", \"surprise\"]\n[\"OC participants\", \"identified\", \"anger, fear\"]\n[\"OC participants\", \"identified\", \"happiness\"]\n[\"OC participants\", \"identified\", \"surprise\"]\nGranularity: 9",
            "[\"OC group\", \"slower than\", \"CN when correctly identifying disgust\"]": " \n[\"OC group\", \"is slower than\", \"CN\"]\n[\"OC group\", \"correctly identifies\", \"disgust\"]\nGranularity: 2",
            "[\"Selective deficit in fear recognition accuracy\", \"manifested by\", \"the RC group cannot be explained by the subacute effects of cocaine or ecstasy\"]": " \n[\"Selective deficit in fear recognition accuracy\", \"manifested by\", \"the RC group\"]\n[\"the RC group\", \"cannot be explained by\", \"the subacute effects of cocaine\"]\n[\"the RC group\", \"cannot be explained by\", \"the subacute effects of ecstasy\"]\nGranularity: 3",
            "[\"Possible parallels\", \"between\", \"RC users and psychopaths with respect to impaired fear recognition, amygdala dysfunction, and etiology are discussed\"]": " \n[\"Possible parallels\", \"between\", \"RC users and psychopaths\"]\n[\"RC users and psychopaths\", \"share\", \"impaired fear recognition\"]\n[\"RC users and psychopaths\", \"share\", \"amygdala dysfunction\"]\n[\"RC users and psychopaths\", \"share\", \"etiology\"]\nGranularity: 4"
      },
      "Use of argatroban and catheter - directed thrombolysis with alteplase in an oncology patient with heparin - induced thrombocytopenia with thrombosis .|PURPOSE : The case of an oncology patient who developed heparin - induced thrombocytopenia with thrombosis ( HITT ) and was treated with argatroban plus catheter - directed thrombolysis ( CDT ) with alteplase is presented .|SUMMARY : A 63 - year - old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper - extremity deep venous thrombosis ( DVT ) and pulmonary embolism secondary to heparin - induced thrombocytopenia .|A continuous i . v .|infusion of argatroban was initiated , and the patient was managed on the general medical floor .|After one week of therapy , he was transferred to the intensive care unit with cardiopulmonary compromise related to superior vena cava ( SVC ) syndrome .|A percutaneous mechanical thrombectomy and CDT with alteplase were attempted , but the procedure was aborted due to epistaxis .|The epistaxis resolved the next day , and the patient was restarted on argatroban .|A second percutaneous mechanical thrombectomy was performed six days later and resulted in partial revascularization of the SVC and central veins .|Postthrombectomy continuous CDT with alteplase was commenced while argatroban was withheld , and complete patency of the SVC and central veins was achieved after three days of therapy .|Alteplase was discontinued , and the patient was reinitiated on argatroban ; ultimately , he was transitioned to warfarin for long - term anticoagulation .|Although the patient recovered , he experienced permanent vision and hearing loss , as well as end - stage renal disease .|CONCLUSION : A 63 - year - old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase .": {
            "[\"argatroban\", \"and\", \"catheter - directed thrombolysis with alteplase\"]": " \n[\"argatroban\", \"is used in\", \"catheter - directed thrombolysis\"]\n[\"catheter - directed thrombolysis\", \"is treated with\", \"alteplase\"]\nGranularity: 2",
            "[\"heparin - induced thrombocytopenia with thrombosis ( HITT )\", \"developed\", \"oncology patient\"]": " \n[\"heparin - induced thrombocytopenia with thrombosis ( HITT )\", \"developed\", \"oncology patient\"]\nGranularity: 1",
            "[\"A 63 - year - old Caucasian man\", \"undergoing\", \"peripheral blood stem cell collection\"]": " \n[\"A 63 - year - old Caucasian man\", \"undergoing\", \"peripheral blood stem cell collection\"]\nGranularity: 1",
            "[\"extensive bilateral upper - extremity deep venous thrombosis ( DVT )\", \"and\", \"pulmonary embolism\"]": " \n[\"extensive bilateral upper - extremity deep venous thrombosis ( DVT )\", \"and\", \"pulmonary embolism\"]\nGranularity: 1",
            "[\"continuous i . v .\", \"infusion of\", \"argatroban\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"After one week of therapy\", \"transferred to\", \"intensive care unit\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"superior vena cava ( SVC ) syndrome\", \"related to\", \"cardiopulmonary compromise\"]": " \n[\"superior vena cava ( SVC ) syndrome\", \"related to\", \"cardiopulmonary compromise\"]\nGranularity: 1",
            "[\"percutaneous mechanical thrombectomy\", \"and\", \"CDT with alteplase\"]": " \n[\"percutaneous mechanical thrombectomy\", \"and\", \"CDT\"]\n[\"CDT\", \"with\", \"alteplase\"]\nGranularity: 2",
            "[\"CDT with alteplase\", \"was attempted\", \"percutaneous mechanical thrombectomy\"]": " \n[\"CDT with alteplase\", \"was attempted\", \"percutaneous mechanical thrombectomy\"]\nGranularity: 1",
            "[\"epistaxis\", \"resolved\", \"the next day\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"second percutaneous mechanical thrombectomy\", \"performed\", \"six days later\"]": " \n[\"second percutaneous mechanical thrombectomy\", \"performed\", \"six days later\"]\nGranularity: 1",
            "[\"postthrombectomy continuous CDT with alteplase\", \"commenced\", \"argatroban was withheld\"]": "\n[\"postthrombectomy continuous CDT with alteplase\", \"commenced\", \"argatroban\"]\n[\"argatroban\", \"was withheld\", \"postthrombectomy continuous CDT with alteplase\"]\nGranularity: 2",
            "[\"Alteplase\", \"discontinued\", \"patient was reinitiated on argatroban\"]": "\n[\"Alteplase\", \"discontinued\", \"patient\"]\n[\"patient\", \"was reinitiated on\", \"argatroban\"]\nGranularity: 2",
            "[\"patient\", \"transitioned to\", \"warfarin for long - term anticoagulation\"]": " \n[\"patient\", \"transitioned\", \"warfarin\"]\n[\"warfarin\", \"used for\", \"long-term anticoagulation\"]\nGranularity: 2",
            "[\"patient\", \"experienced\", \"permanent vision and hearing loss\"]": " \n[\"patient\", \"experienced\", \"permanent vision loss\"]\n[\"patient\", \"experienced\", \"permanent hearing loss\"]\nGranularity: 2",
            "[\"patient\", \"experienced\", \"end - stage renal disease\"]": "\n[\"patient\", \"experienced\", \"end-stage renal disease\"]\nGranularity: 1",
            "[\"A 63 - year - old man\", \"successfully treated\", \"with argatroban and CDT with alteplase\"]": "\n[\"A 63 - year - old man\", \"treated with\", \"argatroban\"]\n[\"A 63 - year - old man\", \"treated with\", \"CDT\"]\n[\"A 63 - year - old man\", \"treated with\", \"alteplase\"]\nGranularity: 3"
      },
      "Two cases of amisulpride overdose : a cause for prolonged QT syndrome .|Two cases of deliberate self - poisoning with 5 g and 3 . 6 g of amisulpride , respectively , are reported .|In both cases , QT prolongation and hypocalcaemia were noted .|The QT prolongation appeared to respond to administration of i . v .|calcium gluconate .": {
            "[\"amisulpride overdose\", \"cause\", \"prolonged QT syndrome\"]": " N/A (The triple is specific, conveying a singular relation between amisulpride overdose and prolonged QT syndrome.)\nGranularity: 0",
            "[\"5 g of amisulpride\", \"deliberate self-poisoning\", \"QT prolongation and hypocalcaemia\"]": " \n[\"5 g of amisulpride\", \"leads to\", \"QT prolongation\"]\n[\"5 g of amisulpride\", \"leads to\", \"hypocalcaemia\"]\nGranularity: 2",
            "[\"3.6 g of amisulpride\", \"deliberate self-poisoning\", \"QT prolongation and hypocalcaemia\"]": " \n[\"3.6 g of amisulpride\", \"causes\", \"QT prolongation\"]\n[\"3.6 g of amisulpride\", \"causes\", \"hypocalcaemia\"]\nGranularity: 2",
            "[\"QT prolongation\", \"noted\", \"both cases\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"hypocalcaemia\", \"noted\", \"both cases\"]": " N/A (The triple is not specific enough to be split into sub-triples. It is unclear what the relationship between hypocalcaemia and the two cases is.)\nGranularity: 0",
            "[\"QT prolongation\", \"respond to\", \"administration of i.v. calcium gluconate\"]": " \n[\"QT prolongation\", \"responds to\", \"administration of i.v. calcium gluconate\"]\n[\"administration of i.v. calcium gluconate\", \"treats\", \"QT prolongation\"]\nGranularity: 2"
      },
      "Amiodarone - related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease : Diagnostic pitfall and new findings .|Amiodarone is an anti - arrhythmic drug for life - threatening tachycardia , but various adverse effects have been reported .|Reported herein is an autopsy case of valvular heart disease , in a patient who developed a lung mass ( 1 . 5 cm in diameter ) and proteinuria ( 2 . 76 g / day ) after treatment with amiodarone for a long time .|The lung mass was highly suspected to be lung cancer on CT and positron emission tomography , but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra - alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies , indicating that it was an amiodarone - related lesion .|In addition , the lung tissue had unevenly distributed hemosiderin deposition , and abnormally tortuous capillaries were seen in the mass and in heavily hemosiderotic lung portions outside the mass .|In the kidneys , glomeruli had membrane spikes , prominent swelling of podocytes and subepithelial deposits , which were sometimes large and hump - like .|Autoimmune diseases , viral hepatitis , malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found .|The present case highlights the possibility that differential diagnosis between an amiodarone - related pulmonary lesion and a neoplasm can be very difficult radiologically , and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment .": {
            "[\"Amiodarone\", \"causes\", \"various adverse effects\"]": " \n[\"Amiodarone\", \"causes\", \"adverse effects\"]\nGranularity: 1",
            "[\"Patient\", \"had\", \"valvular heart disease\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"developed\", \"lung mass\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Lung mass\", \"was suspected to be\", \"lung cancer\"]": " \n[\"Lung mass\", \"was suspected to be\", \"lung cancer\"]\nGranularity: 1",
            "[\"Lung mass\", \"was composed of\", \"lymphoplasmacytic infiltrates in alveolar walls\"]": "\n[\"Lung mass\", \"was composed of\", \"lymphoplasmacytic infiltrates\"]\n[\"lymphoplasmacytic infiltrates\", \"in alveolar walls\", \"compose the lung mass\"]\nGranularity: 2",
            "[\"Lung mass\", \"had\", \"intra-alveolar accumulation of foamy macrophages\"]": " \n[\"Lung mass\", \"had\", \"intra-alveolar accumulation\"]\n[\"intra-alveolar accumulation\", \"of\", \"foamy macrophages\"]\nGranularity: 2",
            "[\"Lung mass\", \"indicated\", \"amiodarone-related lesion\"]": " \n[\"Lung mass\", \"indicated\", \"amiodarone-related\"]\n[\"Lung mass\", \"indicated\", \"lesion\"]\nGranularity: 2",
            "[\"Lung tissue\", \"had\", \"unevenly distributed hemosiderin deposition\"]": " \n[\"Lung tissue\", \"has\", \"uneven distribution\"]\n[\"Lung tissue\", \"has\", \"hemosiderin deposition\"]\nGranularity: 2",
            "[\"Lung tissue\", \"had\", \"abnormally tortuous capillaries\"]": " \n[\"Lung tissue\", \"had\", \"tortuous capillaries\"]\n[\"Lung tissue\", \"had\", \"abnormally tortuous capillaries\"]\nGranularity: 2",
            "[\"Kidneys\", \"had\", \"glomeruli with membrane spikes\"]": " \n[\"Kidneys\", \"had\", \"glomeruli\"]\n[\"glomeruli\", \"had\", \"membrane spikes\"]\nGranularity: 2",
            "[\"Glomeruli\", \"had\", \"prominent swelling of podocytes\"]": "\n[\"Glomeruli\", \"had\", \"swelling of podocytes\"]\n[\"Glomeruli\", \"had\", \"prominent swelling\"]\n[\"Glomeruli\", \"had\", \"podocytes\"]\nGranularity: 3",
            "[\"Glomeruli\", \"had\", \"subepithelial deposits\"]": " \n[\"Glomeruli\", \"had\", \"subepithelial deposits\"]\nGranularity: 1",
            "[\"Subepithelial deposits\", \"were sometimes\", \"large and hump-like\"]": " \n[\"Subepithelial deposits\", \"were\", \"large\"]\n[\"Subepithelial deposits\", \"were\", \"hump-like\"]\nGranularity: 2",
            "[\"Case\", \"highlights\", \"differential diagnosis between amiodarone-related pulmonary lesion and neoplasm\"]": " \n[\"Case\", \"highlights\", \"differential diagnosis\"]\n[\"differential diagnosis\", \"between\", \"amiodarone-related pulmonary lesion\"]\n[\"differential diagnosis\", \"between\", \"neoplasm\"]\nGranularity: 3",
            "[\"Case\", \"suggests\", \"membranous glomerulonephritis as another possible complication of amiodarone treatment\"]": " \n[\"Case\", \"suggests\", \"membranous glomerulonephritis\"]\n[\"Case\", \"suggests\", \"another possible complication\"]\n[\"Case\", \"suggests\", \"amiodarone treatment\"]\nGranularity: 3",
            "[\"Amiodarone\", \"is an anti-arrhythmic drug for\", \"life-threatening tachycardia\"]": " \n[\"Amiodarone\", \"is an anti-arrhythmic drug for\", \"life-threatening tachycardia\"]\nGranularity: 1"
      },
      "Absence of PKC - alpha attenuates lithium - induced nephrogenic diabetes insipidus .|Lithium , an effective antipsychotic , induces nephrogenic diabetes insipidus ( NDI ) in 40 % of patients .|The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing urea transporter ( UT - A1 ) and water channel ( AQP2 ) expression in the inner medulla .|Targeting an alternative signaling pathway , such as PKC - mediated signaling , may be an effective method of treating lithium - induced polyuria .|PKC - alpha null mice ( PKCa KO ) and strain - matched wild type ( WT ) controls were treated with lithium for 0 , 3 or 5 days .|WT mice had increased urine output and lowered urine osmolality after 3 and 5 days of treatment whereas PKCa KO mice had no change in urine output or concentration .|Western blot analysis revealed that AQP2 expression in medullary tissues was lowered after 3 and 5 days in WT mice ; however , AQP2 was unchanged in PKCa KO .|Similar results were observed with UT - A1 expression .|Animals were also treated with lithium for 6 weeks .|Lithium - treated WT mice had 19 - fold increased urine output whereas treated PKCa KO animals had a 4 - fold increase in output .|AQP2 and UT - A1 expression was lowered in 6 week lithium - treated WT animals whereas in treated PKCa KO mice , AQP2 was only reduced by 2 - fold and UT - A1 expression was unaffected .|Urinary sodium , potassium and calcium were elevated in lithium - fed WT but not in lithium - fed PKCa KO mice .|Our data show that ablation of PKCa preserves AQP2 and UT - A1 protein expression and localization in lithium - induced NDI , and prevents the development of the severe polyuria associated with lithium therapy .": {
            "[\"PKC - alpha\", \"attenuates\", \"lithium - induced nephrogenic diabetes insipidus\"]": " \n[\"PKC - alpha\", \"attenuates\", \"lithium - induced nephrogenic diabetes insipidus\"]\nGranularity: 1",
            "[\"Lithium\", \"induces\", \"nephrogenic diabetes insipidus ( NDI )\"]": "\n[\"Lithium\", \"induces\", \"nephrogenic diabetes insipidus\"]\n[\"Lithium\", \"induces\", \"NDI\"]\nGranularity: 2",
            "[\"Lithium\", \"disrupts\", \"cAMP pathway\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Lithium\", \"reduces\", \"urea transporter ( UT - A1 ) and water channel ( AQP2 ) expression\"]": " \n[\"Lithium\", \"reduces\", \"urea transporter ( UT - A1 ) expression\"]\n[\"Lithium\", \"reduces\", \"water channel ( AQP2 ) expression\"]\nGranularity: 2",
            "[\"PKC - mediated signaling\", \"treats\", \"lithium - induced polyuria \"]": " \n[\"PKC - mediated signaling\", \"treats\", \"lithium - induced polyuria\"]\nGranularity: 1",
            "[\"PKCa KO mice\", \"have no change in\", \"urine output or concentration\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"WT mice\", \"have increased\", \"urine output and lowered urine osmolality\"]": " \n[\"WT mice\", \"have\", \"increased urine output\"]\n[\"WT mice\", \"have\", \"lowered urine osmolality\"]\nGranularity: 2",
            "[\"AQP2 expression\", \"is lowered\", \"in WT mice \"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"UT - A1 expression\", \"is unchanged\", \"in PKCa KO \"]": "\n[\"UT - A1 expression\", \"is unchanged\", \"in PKCa KO\"]\nGranularity: 0",
            "[\"AQP2 and UT - A1 expression\", \"is lowered\", \"in 6 week lithium - treated WT animals\"]": " \n[\"AQP2 and UT - A1 expression\", \"is lowered\", \"in 6 week lithium - treated animals\"]\n[\"AQP2 and UT - A1 expression\", \"is lowered\", \"in WT animals\"]\n[\"AQP2 and UT - A1 expression\", \"is lowered\", \"in 6 week lithium - treated WT animals\"]\nGranularity: 3",
            "[\"AQP2\", \"is reduced by 2 - fold\", \"in treated PKCa KO mice\"]": " \n[\"AQP2\", \"is reduced\", \"in treated PKCa KO mice\"]\n[\"AQP2\", \"is reduced by 2-fold\", \"in treated PKCa KO mice\"]\nGranularity: 2",
            "[\"UT - A1 expression\", \"is unaffected\", \"in treated PKCa KO mice\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Urinary sodium, potassium and calcium\", \"are elevated\", \"in lithium - fed WT\"]": " \n[\"Urinary sodium\", \"is elevated\", \"in lithium - fed WT\"]\n[\"Urinary potassium\", \"is elevated\", \"in lithium - fed WT\"]\n[\"Urinary calcium\", \"is elevated\", \"in lithium - fed WT\"]\nGranularity: 3",
            "[\"PKCa preserves\", \"AQP2 and UT - A1 protein expression and localization\", \"in lithium - induced NDI \"]": " \n[\"PKCa preserves\", \"AQP2 protein expression\", \"in lithium-induced NDI\"]\n[\"PKCa preserves\", \"UT-A1 protein expression\", \"in lithium-induced NDI\"]\n[\"PKCa preserves\", \"AQP2 protein localization\", \"in lithium-induced NDI\"]\n[\"PKCa preserves\", \"UT-A1 protein localization\", \"in lithium-induced NDI\"]\nGranularity: 4",
            "[\"PKCa\", \"prevents\", \"the development of the severe polyuria associated with lithium therapy \"]": " \n[\"PKCa\", \"prevents\", \"development of severe polyuria\"]\n[\"PKCa\", \"prevents\", \"development of polyuria associated with lithium therapy\"]\nGranularity: 2"
      },
      "Indomethacin - induced hyperkalemia in three patients with gouty arthritis .|We describe three patients in whom severe , life - threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin .|This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism .|Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti - inflammatory agents , particularly in those patients with diabetes mellitus or preexisting renal disease , will help prevent this potentially serious complication .": {
            "[\"gouty arthritis\", \"patients\", \"three\"]": " N/A (The triple is specific, conveying a singular relation between gouty arthritis patients and the number three.)\nGranularity: 0",
            "[\"severe\", \"life-threatening\", \"hyperkalemia and renal insufficiency\"]": "\n[\"severe\", \"hyperkalemia\", \"is life-threatening\"]\n[\"severe\", \"renal insufficiency\", \"is life-threatening\"]\n[\"hyperkalemia\", \"can cause\", \"renal insufficiency\"]\nGranularity: 3",
            "[\"treatment\", \"acute gouty arthritis\", \"indomethacin\"]": "\n[\"treatment\", \"gouty arthritis\", \"indomethacin\"]\n[\"treatment\", \"acute\", \"gouty arthritis\"]\nGranularity: 2",
            "[\"complication\", \"result\", \"inhibition of prostaglandin synthesis\"]": " \n[\"complication\", \"results in\", \"inhibition of prostaglandin synthesis\"]\nGranularity: 1",
            "[\"hyporeninemic hypoaidosteronism\", \"consequent\", \"complication\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"patients\", \"receiving\", \"indomethacin or other nonsteroidal anti-inflammatory agents\"]": " \n[\"patients\", \"receiving\", \"indomethacin\"]\n[\"patients\", \"receiving\", \"other nonsteroidal anti-inflammatory agents\"]\nGranularity: 2",
            "[\"renal function\", \"attention\", \"potassium balance\"]": " \n[\"renal function\", \"affects\", \"potassium balance\"]\n[\"attention\", \"affects\", \"potassium balance\"]\nGranularity: 2",
            "[\"patients\", \"diabetes mellitus or preexisting renal disease\", \"help prevent\"]": " \n[\"patients\", \"diabetes mellitus\", \"help prevent\"]\n[\"patients\", \"preexisting renal disease\", \"help prevent\"]\nGranularity: 2",
            "[\"complication\", \"potentially serious\", \"prevent\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Indomethacin\", \"induced\", \"hyperkalemia\"]": " N/A (The triple is specific, conveying a singular relation between Indomethacin and hyperkalemia.)\nGranularity: 0"
      },
      "Vinorelbine - related cardiac events : a meta - analysis of randomized clinical trials .|Several cases of cardiac adverse reactions related to vinorelbine ( VNR ) have been reported in the literature .|In order to quantify the incidence of these cardiac events , we performed a meta - analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies .|Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline , Embase , Evidence - based Medicine Reviews databases and the Cochrane library from 1987 to 2002 .|Outcomes of interest were severe cardiac events , toxic deaths and cardiac event - related deaths reported in each publication .|We found 19 trials , involving 2441 patients treated by VNR and 2050 control patients .|The incidence of cardiac events with VNR was 1 . 19 % [ 95 % confidence interval ( CI ) ( 0 . 75 ; 1 . 67 ) ] .|There was no difference in the risk of cardiac events between VNR and other drugs [ odds ratio : 0 . 92 , 95 % CI ( 0 . 54 ; 1 . 55 ) ] .|The risk of VNR cardiac events was similar to vindesine ( VDS ) and other cardiotoxic drugs [ fluorouracil , anthracyclines , gemcitabine ( GEM ) em leader ] .|Even if it did not reach statistical significance because of a few number of cases , the risk was lower in trials excluding patients with cardiac history , and seemed to be higher in trials including patients with pre - existing cardiac diseases .|Vinorelbine - related cardiac events concern about 1 % of treated patients in clinical trials .|However , the risk associated with VNR seems to be similar to that of other chemotherapeutic agents in the same indications .": {
            "[\"Vinorelbine\", \"has\", \"cardiac adverse reactions\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Vinorelbine\", \"performed\", \"meta-analysis\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Vinorelbine\", \"compared with\", \"other chemotherapeutic agents\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Vinorelbine\", \"searched in\", \"Medline, Embase, etc.\"]": "\n[\"Vinorelbine\", \"searched in\", \"Medline\"]\n[\"Vinorelbine\", \"searched in\", \"Embase\"]\n[\"Vinorelbine\", \"searched in\", \"etc.\"]\nGranularity: 3",
            "[\"Vinorelbine\", \"interest in\", \"severe cardiac events\"]": " \n[\"Vinorelbine\", \"increases\", \"risk of severe cardiac events\"]\n[\"Vinorelbine\", \"can lead to\", \"severe cardiac events\"]\nGranularity: 2",
            "[\"Vinorelbine\", \"found in\", \"19 trials\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Vinorelbine\", \"involving\", \"2441 patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Vinorelbine\", \"incidence of\", \"cardiac events\"]": " N/A (The triple is specific, conveying a singular relation between Vinorelbine and cardiac events.)\nGranularity: 0",
            "[\"Vinorelbine\", \"no difference in\", \"risk of cardiac events\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Vinorelbine\", \"similar to\", \"vindesine and other cardiotoxic drugs\"]": " \n[\"Vinorelbine\", \"similar to\", \"vindesine\"]\n[\"Vinorelbine\", \"similar to\", \"other cardiotoxic drugs\"]\nGranularity: 2",
            "[\"Vinorelbine\", \"lower risk in\", \"trials excluding patients with cardiac history\"]": "\n[\"Vinorelbine\", \"lower risk\", \"in trials\"]\n[\"Vinorelbine\", \"lower risk\", \"excluding patients with cardiac history\"]\nGranularity: 2",
            "[\"Vinorelbine\", \"higher risk in\", \"trials including patients with pre-existing cardiac diseases\"]": " \n[\"Vinorelbine\", \"has higher risk in\", \"trials including patients with pre-existing cardiac diseases\"]\n[\"Vinorelbine\", \"has higher risk\", \"in trials\"]\n[\"Vinorelbine\", \"has higher risk\", \"in patients with pre-existing cardiac diseases\"]\nGranularity: 3",
            "[\"Vinorelbine\", \"concerns\", \"about 1% of treated patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Vinorelbine\", \"similar risk to\", \"other chemotherapeutic agents\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Vinorelbine\", \"related to\", \"cardiac events\"]": " N/A (The triple is specific, conveying a singular relation between Vinorelbine and cardiac events.)\nGranularity: 0"
      },
      "Bilateral retinal artery and choriocapillaris occlusion following the injection of long - acting corticosteroid suspensions in combination with other drugs : I .|Clinical studies .|Two well - documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft - tissue injection with methylprednisolone acetate in combination with lidocaine , epinephrine , or penicillin are reported .|One case had only a unilateral injection .|The acute observations included hazy sensorium , superior gaze palsy , pupillary abnormalities , and conjunctival hemorrhages with edema .|Follow - up changes showed marked visual loss , constricted visual fields , optic nerve pallor , vascular attenuation , and chorioretinal atrophy .|The literature is reviewed , and possible causes are discussed .": {
            "[\"Clinical studies\", \"Two well-documented cases\", \"bilateral retinal artery and choriocapillaris occlusions\"]": "\n[\"Clinical studies\", \"document\", \"bilateral retinal artery occlusions\"]\n[\"Clinical studies\", \"document\", \"bilateral choriocapillaris occlusions\"]\nGranularity: 2",
            "[\"One case\", \"had\", \"only a unilateral injection\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"The acute observations\", \"included\", \"hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema\"]": " \n[\"The acute observations\", \"included\", \"hazy sensorium\"]\n[\"The acute observations\", \"included\", \"superior gaze palsy\"]\n[\"The acute observations\", \"included\", \"pupillary abnormalities\"]\n[\"The acute observations\", \"included\", \"conjunctival hemorrhages\"]\n[\"The acute observations\", \"included\", \"edema\"]\nGranularity: 5",
            "[\"Follow-up changes\", \"showed\", \"marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy\"]": " \n[\"Follow-up changes\", \"showed\", \"marked visual loss\"]\n[\"Follow-up changes\", \"showed\", \"constricted visual fields\"]\n[\"Follow-up changes\", \"showed\", \"optic nerve pallor\"]\n[\"Follow-up changes\", \"showed\", \"vascular attenuation\"]\n[\"Follow-up changes\", \"showed\", \"chorioretinal atrophy\"]\nGranularity: 5",
            "[\"The literature\", \"is reviewed\", \"and possible causes are discussed\"]": " \n[\"The literature\", \"is reviewed\"]\n[\"possible causes\", \"are discussed\"]\nGranularity: 2",
            "[\"Bilateral retinal artery and choriocapillaris occlusion\", \"following\", \"the injection of long-acting corticosteroid suspensions in combination with other drugs\"]": " \n[\"Bilateral retinal artery and choriocapillaris occlusion\", \"following\", \"the injection of long-acting corticosteroid suspensions\"]\n[\"Bilateral retinal artery and choriocapillaris occlusion\", \"following\", \"the injection of other drugs\"]\nGranularity: 2"
      },
      "Cocaine , ethanol , and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse .|OBJECTIVES : Simultaneous abuse of cocaine and ethanol affects 12 million Americans annually .|In combination , these substances are substantially more toxic than either drug alone .|Their combined cardiac toxicity may be due to independent effects of each drug ; however , they may also be due to cocaethylene ( CE ) , a cocaine metabolite formed only in the presence of ethanol .|The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse .|METHODS : Twenty - three dogs were randomized to receive either 1 ) three intravenous ( IV ) boluses of cocaine 7 . 5 mg / kg with ethanol ( 1 g / kg ) as an IV infusion ( C + E , n = 8 ) , 2 ) three cocaine boluses only ( C , n = 6 ) , 3 ) ethanol infusion only ( E , n = 5 ) , or 4 ) placebo boluses and infusion ( n = 4 ) .|Hemodynamic measurements , electrocardiograms , and serum drug concentrations were obtained at baseline , and then at fixed time intervals after each drug was administered .|RESULTS : Two of eight dogs in the C + E group experienced cardiovascular collapse .|The most dramatic hemodynamic changes occurred after each cocaine bolus in the C + E and C only groups ; however , persistent hemodynamic changes occurred in the C + E group .|Peak CE levels were associated with a 45 % ( SD + / - 22 % , 95 % CI = 22 % to 69 % ) decrease in cardiac output ( p < 0 . 05 ) , a 56 % ( SD + / - 23 % , 95 % CI = 32 % to 80 % ) decrease in dP / dt ( max ) ( p < . 006 ) , and a 23 % ( SD + / - 15 % , 95 % CI = 7 % to 49 % ) decrease in SVO ( 2 ) ( p < 0 . 025 ) .|Ventricular arrhythmias were primarily observed in the C + E group , in which four of eight dogs experienced ventricular tachycardia .|CONCLUSIONS : Cocaine and ethanol in combination were more toxic than either substance alone .|Co - administration resulted in prolonged cardiac toxicity and was dysrhythmogenic .|Peak serum cocaethylene concentrations were associated with prolonged myocardial depression .": {
            "[\"Cocaine\", \"forms\", \"cocaethylene\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Cocaine\", \"causes\", \"cardiotoxicity\"]": " N/A (The triple is specific, conveying a singular relation between cocaine and cardiotoxicity.)\nGranularity: 0",
            "[\"Ethanol\", \"is associated with\", \"cocaine\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Ethanol\", \"forms\", \"cocaethylene\"]": " N/A (The triple is specific, conveying a singular relation between ethanol and cocaethylene.)\nGranularity: 0",
            "[\"Cocaethylene\", \"is associated with\", \"cardiotoxicity\"]": " N/A (The triple is specific, conveying a singular relation between Cocaethylene and cardiotoxicity.)\nGranularity: 0",
            "[\"Study\", \"aims to\", \"delineate the role of cocaethylene\"]": " \n[\"Study\", \"aims to\", \"delineate the role of cocaethylene\"]\nGranularity: 1",
            "[\"Hemodynamic measurements\", \"were obtained\", \"after drug administration\"]": " \n[\"Hemodynamic measurements\", \"were obtained\", \"after drug administration\"]\nGranularity: 1",
            "[\"Cardiovascular collapse\", \"occurred in\", \"C+E group\"]": " \n[\"Cardiovascular collapse\", \"occurred in\", \"C+E group\"]\nGranularity: 1",
            "[\"Hemodynamic changes\", \"occurred after\", \"cocaine bolus\"]": " \n[\"Hemodynamic changes\", \"occurred after\", \"cocaine\"]\n[\"Hemodynamic changes\", \"occurred after\", \"bolus\"]\nGranularity: 2",
            "[\"CE levels\", \"were associated with\", \"decrease in cardiac output\"]": " \n[\"CE levels\", \"were associated with\", \"decrease in cardiac output\"]\nGranularity: 1",
            "[\"CE levels\", \"were associated with\", \"decrease in dP/dt (max)\"]": " \n[\"CE levels\", \"were associated with\", \"decrease in dP/dt (max)\"]\nGranularity: 1",
            "[\"CE levels\", \"were associated with\", \"decrease in SVO2\"]": " \n[\"CE levels\", \"were associated with\", \"decrease in SVO2\"]\nGranularity: 1",
            "[\"Ventricular tachycardia\", \"was observed in\", \"C+E group\"]": " \n[\"Ventricular tachycardia\", \"was observed in\", \"C group\"]\n[\"Ventricular tachycardia\", \"was observed in\", \"E group\"]\nGranularity: 2",
            "[\"Cocaine and ethanol\", \"are more toxic than\", \"either substance alone\"]": " \n[\"Cocaine\", \"is more toxic than\", \"ethanol\"]\n[\"Ethanol\", \"is more toxic than\", \"cocaine\"]\nGranularity: 2",
            "[\"Co-administration\", \"results in\", \"prolonged cardiac toxicity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Co-administration\", \"is\", \"dysrhythmogenic\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Peak serum cocaethylene concentrations\", \"are associated with\", \"prolonged myocardial depression\"]": " \n[\"Peak serum cocaethylene concentrations\", \"are associated with\", \"prolonged myocardial depression\"]\nGranularity: 1",
            "[\"Cocaine\", \"is associated with\", \"ethanol\"]": " N/A (The triple is specific, conveying a singular relation between cocaine and ethanol.)\nGranularity: 0"
      },
      "Metronidazole - induced encephalopathy : an uncommon scenario .|Metronidazole can produce neurological complications although it is not a common scenario .|We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake .|Magnetic resonance imaging ( MRI ) brain showed abnormal signal intensity involving both dentate nuclei of cerebellum and splenium of corpus callosum .|The diagnosis of metronidazole toxicity was made by the MRI findings and supported clinically .": {
            "[\"Metronidazole\", \"is not a common scenario\", \"neurological complications\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"patient\", \"following prolonged\", \"metronidazole intake\"]": "\n[\"patient\", \"following\", \"prolonged metronidazole intake\"]\n[\"patient\", \"following prolonged\", \"metronidazole\"]\n[\"patient\", \"following\", \"metronidazole intake\"]\nGranularity: 3",
            "[\"MRI brain\", \"involving\", \"both dentate nuclei of cerebellum and splenium of corpus callosum\"]": " \n[\"MRI brain\", \"involving\", \"dentate nuclei of cerebellum\"]\n[\"MRI brain\", \"involving\", \"splenium of corpus callosum\"]\nGranularity: 2",
            "[\"diagnosis\", \"supported clinically\", \"\"]": " N/A (The triple is not specific enough to be split into sub-triples, as the object is missing.)\nGranularity: 0",
            "[\"metronidazole toxicity\", \"was made\", \"MRI findings\"]": "\n[\"metronidazole toxicity\", \"was made\", \"MRI findings\"]\nGranularity: 0",
            "[\"metronidazole toxicity\", \"supported\", \"clinically\"]": " N/A (The triple is specific, conveying a singular relation between metronidazole toxicity and clinical support.)\nGranularity: 0"
      },
      "Non - invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion .|Electrocardiographic changes after dipyridamole infusion ( 0 . 568 mg / kg / 4 min ) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique .|Patients were divided into three groups ; 19 patients without myocardial infarction ( non - MI group ) , 14 with anterior infarction ( ANT - MI ) and eight with inferior infarction ( INF - MI ) .|Eighty - seven unipolar electrocardiograms ( ECGs ) distributed over the entire thoracic surface were simultaneously recorded .|After dipyridamole , ischemic ST - segment depression ( 0 . 05 mV or more ) was observed in 84 % of the non - MI group , 29 % of the ANT - MI group , 63 % of the INF - MI group and 61 % of the total population .|Exercise - induced ST depression was observed in 84 % of the non - MI group , 43 % of the ANT - MI group , 38 % of the INF - MI group and 61 % of the total .|For individual patients , there were no obvious differences between the body surface distribution of ST depression in both tests .|The increase in pressure rate product after dipyridamole was significantly less than that during the treadmill exercise .|The data suggest that the dipyridamole - induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow .|We conclude that the dipyridamole ECG test is as useful as the exercise ECG test for the assessment of coronary artery disease .": {
            "[\"Non - invasive detection\", \"detects\", \"coronary artery disease\"]": " \n[\"Non-invasive detection\", \"detects\", \"coronary artery disease\"]\nGranularity: 1",
            "[\"body surface electrocardiographic mapping\", \"detects\", \"coronary artery disease\"]": " \n[\"body surface electrocardiographic mapping\", \"detects\", \"coronary artery disease\"]\nGranularity: 1",
            "[\"dipyridamole infusion\", \"causes\", \"electrocardiographic changes\"]": "\n[\"dipyridamole infusion\", \"causes\", \"electrocardiographic changes\"]\nGranularity: 1",
            "[\"Electrocardiographic changes\", \"are studied in\", \"41 patients with coronary artery disease\"]": " \n[\"Electrocardiographic changes\", \"are studied\", \"in 41 patients\"]\n[\"Electrocardiographic changes\", \"are studied\", \"with coronary artery disease\"]\nGranularity: 2",
            "[\"Patients\", \"are divided into\", \"three groups\"]": " \n[\"Patients\", \"are divided\", \"into groups\"]\n[\"Patients\", \"are divided\", \"into three\"]\nGranularity: 2",
            "[\"Eighty-seven unipolar electrocardiograms\", \"are recorded\", \"over the entire thoracic surface\"]": " \n[\"Eighty-seven unipolar electrocardiograms\", \"are recorded\", \"over the thoracic surface\"]\n[\"Eighty-seven unipolar electrocardiograms\", \"are recorded\", \"over the entire surface\"]\n[\"Eighty-seven unipolar electrocardiograms\", \"are recorded\", \"over the entire thoracic\"]\n[\"Eighty-seven unipolar\", \"electrocardiograms\", \"are recorded\"]\n[\"Eighty-seven\", \"unipolar electrocardiograms\", \"are recorded\"]\nGranularity: 5",
            "[\"After dipyridamole\", \"causes\", \"ischemic ST-segment depression\"]": " \n[\"After dipyridamole\", \"causes\", \"ischemic ST-segment depression\"]\nGranularity: 1",
            "[\"Exercise-induced ST depression\", \"is observed in\", \"total population\"]": " \n[\"Exercise-induced ST depression\", \"is observed in\", \"total population\"]\nGranularity: 1",
            "[\"The increase in pressure rate product\", \"occurs during\", \"treadmill exercise\"]": " \n[\"The increase in pressure rate product\", \"occurs during\", \"treadmill exercise\"]\nGranularity: 1",
            "[\"The data\", \"suggest\", \"dipyridamole-induced myocardial ischemia\"]": " \n[\"The data\", \"suggest\", \"dipyridamole-induced\"]\n[\"The data\", \"suggest\", \"myocardial ischemia\"]\nGranularity: 2",
            "[\"The dipyridamole ECG test\", \"is as useful as\", \"the exercise ECG test\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"We conclude\", \"that\", \"the dipyridamole ECG test\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Rifampicin - associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis .|Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis .|Changing epidemiology of infections such as infective endocarditis ( IE ) has led to an increase in the use of rifampicin for Staphylococcal infections .|We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin , and review the literature regarding this complication of rifampicin therapy .": {
            "[\"Rifampicin\", \"associated with\", \"segmental necrotizing glomerulonephritis\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Segmental necrotising glomerulonephritis\", \"reported as complication of\", \"rifampicin therapy\"]": " \n[\"Segmental necrotising glomerulonephritis\", \"reported as complication of\", \"rifampicin\"]\n[\"rifampicin\", \"therapy\", \"causes\", \"Segmental necrotising glomerulonephritis\"]\nGranularity: 2",
            "[\"Rifampicin\", \"used for\", \"treatment of tuberculosis\"]": " \n[\"Rifampicin\", \"used for\", \"treatment\"]\n[\"Rifampicin\", \"used for\", \"tuberculosis\"]\nGranularity: 2",
            "[\"Changing epidemiology of infections\", \"led to increase in use of\", \"rifampicin\"]": " \n[\"Changing epidemiology of infections\", \"led to increase in use of\", \"rifampicin\"]\nGranularity: 1",
            "[\"Infective endocarditis\", \"abbreviated as\", \"IE\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Staphylococcal infections\", \"treated with\", \"rifampicin\"]": " N/A (The triple is specific, conveying a singular relation between Staphylococcal infections and rifampicin.)\nGranularity: 0",
            "[\"Patient with Staphylococcal IE\", \"developed\", \"acute renal failure\"]": " \n[\"Patient with Staphylococcal IE\", \"developed\", \"acute renal failure\"]\nGranularity: 1",
            "[\"Acute renal failure\", \"secondary to\", \"segmental necrotising glomerulonephritis\"]": " \n[\"Acute renal failure\", \"secondary to\", \"segmental necrotising glomerulonephritis\"]\nGranularity: 1",
            "[\"Segmental necrotising glomerulonephritis\", \"caused by\", \"rifampicin\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Literature\", \"reviewed regarding\", \"this complication of rifampicin therapy\"]": "\n[\"Literature\", \"reviewed\", \"complication\"]\n[\"rifampicin therapy\", \"causes\", \"complication\"]\nGranularity: 2"
      },
      "A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients .|OBJECTIVE : Dexmedetomidine and propofol are commonly used sedatives in neurocritical care as they allow for frequent neurologic examinations .|However , both agents are associated with significant hemodynamic side effects .|The primary objective of this study is to compare the prevalence of severe hemodynamic effects in neurocritical care patients receiving dexmedetomidine and propofol .|DESIGN : Multicenter , retrospective , propensity - matched cohort study .|SETTING : Neurocritical care units at two academic medical centers with dedicated neurocritical care teams and board - certified neurointensivists .|PATIENTS : Neurocritical care patients admitted between July 2009 and September 2012 were evaluated and then matched 1 : 1 based on propensity scoring of baseline characteristics .|INTERVENTIONS : Continuous sedation with dexmedetomidine or propofol .|MEASUREMENTS AND MAIN RESULTS : A total of 342 patients ( 105 dexmedetomidine and 237 propofol ) were included in the analysis , with 190 matched ( 95 in each group ) by propensity score .|The primary outcome of this study was a composite of severe hypotension ( mean arterial pressure < 60 mm Hg ) and bradycardia ( heart rate < 50 beats / min ) during sedative infusion .|No difference in the primary composite outcome in both the unmatched ( 30 % vs 30 % , p = 0 . 94 ) or matched cohorts ( 28 % vs 34 % , p = 0 . 35 ) could be found .|When analyzed separately , no differences could be found in the prevalence of severe hypotension or bradycardia in either the unmatched or matched cohorts .|CONCLUSIONS : Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol .|Providers should similarly consider the likelihood of hypotension or bradycardia before starting either sedative .": {
            "[\"A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients\", \"is the title of\", \"the study\"]": " \n[\"dexmedetomidine\", \"is used for\", \"sedation in neurocritical care patients\"]\n[\"propofol\", \"is used for\", \"sedation in neurocritical care patients\"]\n[\"dexmedetomidine\", \"is compared to\", \"propofol\"]\n[\"severe hemodynamic disturbances\", \"are compared between\", \"dexmedetomidine and propofol\"]\n[\"the study\", \"has the title\", \"A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients\"]\nGranularity: 5",
            "[\"Dexmedetomidine and propofol\", \"are\", \"commonly used sedatives\"]": " \n[\"Dexmedetomidine\", \"is\", \"a sedative\"]\n[\"propofol\", \"is\", \"a sedative\"]\nGranularity: 2",
            "[\"Dexmedetomidine and propofol\", \"are associated with\", \"significant hemodynamic side effects\"]": " \n[\"Dexmedetomidine\", \"is associated with\", \"significant hemodynamic side effects\"]\n[\"Propofol\", \"is associated with\", \"significant hemodynamic side effects\"]\nGranularity: 2",
            "[\"The primary objective of this study\", \"is to\", \"compare the prevalence of severe hemodynamic effects\"]": " \n[\"The primary objective of this study\", \"is\", \"to compare\"]\n[\"The primary objective of this study\", \"is\", \"the prevalence of severe hemodynamic effects\"]\n[\"this study\", \"compares\", \"the prevalence of severe hemodynamic effects\"]\nGranularity: 3",
            "[\"The study\", \"is a\", \"multicenter, retrospective, propensity-matched cohort study\"]": " \n[\"The study\", \"is a\", \"multicenter study\"]\n[\"The study\", \"is a\", \"retrospective study\"]\n[\"The study\", \"is a\", \"propensity-matched study\"]\n[\"The study\", \"is a\", \"cohort study\"]\n[\"The study\", \"is a\", \"multicenter, retrospective study\"]\n[\"The study\", \"is a\", \"multicenter, propensity-matched study\"]\n[\"The study\", \"is a\", \"retrospective, propensity-matched study\"]\n[\"The study\", \"is a\", \"multicenter, retrospective, propensity-matched study\"]\nGranularity: 8",
            "[\"The study\", \"is set in\", \"Neurocritical care units at two academic medical centers\"]": " \n[\"The study\", \"is set\", \"in Neurocritical care units\"]\n[\"The study\", \"is set\", \"at two academic medical centers\"]\nGranularity: 2",
            "[\"The patients\", \"were admitted between\", \"July 2009 and September 2012\"]": " \n[\"The patients\", \"were admitted in\", \"July 2009\"]\n[\"The patients\", \"were admitted in\", \"September 2012\"]\nGranularity: 2",
            "[\"The patients\", \"were matched 1:1 based on\", \"propensity scoring of baseline characteristics\"]": "\n[\"The patients\", \"were matched\", \"1:1\"]\n[\"The patients\", \"were based on\", \"propensity scoring\"]\n[\"The patients\", \"had baseline characteristics\", \"propensity scoring\"]\nGranularity: 3",
            "[\"Interventions\", \"included\", \"Continuous sedation with dexmedetomidine or propofol\"]": " \n[\"Interventions\", \"included\", \"Continuous sedation with dexmedetomidine\"]\n[\"Interventions\", \"included\", \"Continuous sedation with propofol\"]\nGranularity: 2",
            "[\"The primary outcome of this study\", \"was a composite of\", \"severe hypotension and bradycardia during sedative infusion\"]": " \n[\"The primary outcome of this study\", \"was\", \"a composite\"]\n[\"The primary outcome of this study\", \"was\", \"severe hypotension\"]\n[\"The primary outcome of this study\", \"was\", \"bradycardia\"]\n[\"during sedative infusion\", \"resulted in\", \"severe hypotension\"]\n[\"during sedative infusion\", \"resulted in\", \"bradycardia\"]\nGranularity: 5",
            "[\"No difference in the primary composite outcome\", \"was found\", \"in both the unmatched and matched cohorts\"]": " \n[\"No difference\", \"was found\", \"in the primary composite outcome\"]\n[\"No difference\", \"was found\", \"in the unmatched cohort\"]\n[\"No difference\", \"was found\", \"in the matched cohort\"]\nGranularity: 3",
            "[\"No differences could be found\", \"in the prevalence of\", \"severe hypotension or bradycardia\"]": " \n[\"No differences\", \"could be found\", \"in the prevalence of severe hypotension\"]\n[\"No differences\", \"could be found\", \"in the prevalence of bradycardia\"]\nGranularity: 2",
            "[\"The conclusion of the study\", \"is that\", \"severe hypotension and bradycardia occur at similar prevalence\"]": " \n[\"The conclusion of the study\", \"is\", \"severe hypotension\"]\n[\"The conclusion of the study\", \"is\", \"bradycardia\"]\n[\"The conclusion of the study\", \"occurs at\", \"similar prevalence\"]\nGranularity: 3",
            "[\"Providers\", \"should\", \"consider the likelihood of hypotension or bradycardia before starting either sedative\"]": " \n[\"Providers\", \"should consider\", \"hypotension\"]\n[\"Providers\", \"should consider\", \"bradycardia\"]\n[\"Providers\", \"should start\", \"sedative\"]\nGranularity: 3"
      },
      "Zidovudine - induced hepatitis .|A case of acute hepatitis induced by zidovudine in a 38 - year - old patient with AIDS is presented .|The mechanism whereby the hepatitis was induced is not known .|However , the patient tolerated well an alternative reverse transcriptase inhibitor , 2 ' 3 ' dideoxyinosine .|Physicians caring for patients with AIDS should be aware of this hitherto rarely reported complication .": {
            "[\"Zidovudine\", \"induces\", \"hepatitis\"]": " N/A (The triple is specific, conveying a singular relation between Zidovudine and hepatitis.)\nGranularity: 0",
            "[\"Zidovudine\", \"induces\", \"acute hepatitis in a 38-year-old patient with AIDS\"]": "\n[\"Zidovudine\", \"induces\", \"acute hepatitis\"]\n[\"Zidovudine\", \"induces\", \"acute hepatitis in a 38-year-old patient\"]\n[\"Zidovudine\", \"induces\", \"acute hepatitis in a patient with AIDS\"]\n[\"Zidovudine\", \"induces\", \"acute hepatitis in a 38-year-old patient with AIDS\"]\nGranularity: 4",
            "[\"Mechanism\", \"induces\", \"hepatitis\"]": " N/A (The triple is specific, conveying a singular relation between a mechanism and hepatitis.)\nGranularity: 0",
            "[\"Alternative reverse transcriptase inhibitor\", \"tolerated well by the patient\", \"2'3' dideoxyinosine\"]": " \n[\"Alternative reverse transcriptase inhibitor\", \"tolerated well by the patient\", \"2'3' dideoxyinosine\"]\nGranularity: 0",
            "[\"Physicians\", \"should be aware of\", \"this hitherto rarely reported complication\"]": " \n[\"Physicians\", \"should be aware of\", \"complications\"]\n[\"Physicians\", \"should be aware of\", \"rarely reported complications\"]\nGranularity: 2"
      },
      "Centrally mediated cardiovascular effects of intracisternal application of carbachol in anesthetized rats .|The pressor response to the intracisternal ( i . c . ) injection of carbachol ( 1 mug ) in anesthetized rats was analyzed .|This response was significantly reduced by the intravenous ( i . v . ) injection of guanethidine ( 5 mg ) , hexamethonium ( 10 mg ) or phentolamine ( 5 mg ) , and conversely , potentiated by i . v .|desmethylimipramine ( 0 . 3 mg ) , while propranolol ( 0 . 5 mg ) i . v .|selectively inhibited the enlargement of pulse pressure and the tachycardia following i . c .|carbachol ( 1 mug ) .|On the other hand , the pressor response to i . c .|carbachol ( 1 mug ) was almost completely blocked by i . c .|atropine ( 3 mug ) or hexamethonium ( 500 mug ) , and significantly reduced by i . c .|chlorpromazine ( 50 mug ) but significantly potentiated by i . c .|desmethylimipramine ( 30 mug ) .|The pressor response to i . c .|carbachol ( 1 mug ) remained unchanged after sectioning of the bilateral cervical vagal nerves but disappeared after sectioning of the spinal cord ( C7 - C8 ) .|From the above result it is suggested that the pressor response to i . c .|carbachol ortral and peripheral adrenergic mechanisms , and that the sympathetic trunk is the main pathway .": {
            "[\"intracisternal application of carbachol\", \"has centrally mediated cardiovascular effects\", \"in anesthetized rats\"]": " \n[\"intracisternal application of carbachol\", \"has\", \"centrally mediated cardiovascular effects\"]\n[\"intracisternal application of carbachol\", \"affects\", \"cardiovascular system\"]\n[\"intracisternal application of carbachol\", \"has\", \"centrally mediated effects\"]\n[\"intracisternal application of carbachol\", \"affects\", \"central nervous system\"]\n[\"intracisternal application of carbachol\", \"affects\", \"cardiovascular system in anesthetized rats\"]\n[\"intracisternal application of carbachol\", \"has\", \"centrally mediated effects in anesthetized rats\"]\nGranularity: 6",
            "[\"pressor response\", \"to intracisternal injection of carbachol\", \"in anesthetized rats\"]": " \n[\"pressor response\", \"to injection of carbachol\"]\n[\"anesthetized rats\", \"experience\", \"pressor response\"]\nGranularity: 2",
            "[\"pressor response\", \"was analyzed\", \"in anesthetized rats\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"response\", \"was significantly reduced\", \"by intravenous injection of guanethidine, hexamethonium, or phentolamine\"]": " \n[\"response\", \"was reduced by\", \"intravenous injection of guanethidine\"]\n[\"response\", \"was reduced by\", \"intravenous injection of hexamethonium\"]\n[\"response\", \"was reduced by\", \"intravenous injection of phentolamine\"]\nGranularity: 3",
            "[\"response\", \"was potentiated\", \"by intravenous injection of desmethylimipramine\"]": "\n[\"response\", \"was potentiated by\", \"intravenous injection\"]\n[\"response\", \"was potentiated by\", \"desmethylimipramine\"]\nGranularity: 2",
            "[\"enlargement of pulse pressure and tachycardia\", \"was selectively inhibited\", \"by intravenous propranolol\"]": " \n[\"enlargement of pulse pressure\", \"was inhibited by\", \"intravenous propranolol\"]\n[\"tachycardia\", \"was inhibited by\", \"intravenous propranolol\"]\nGranularity: 2",
            "[\"pressor response\", \"to intracisternal carbachol\", \"was almost completely blocked by intracisternal atropine or hexamethonium\"]": " \n[\"pressor response\", \"to intracisternal carbachol\", \"was blocked by intracisternal atropine\"]\n[\"pressor response\", \"to intracisternal carbachol\", \"was blocked by intracisternal hexamethonium\"]\nGranularity: 2",
            "[\"pressor response\", \"was significantly reduced\", \"by intracisternal chlorpromazine\"]": " \n[\"pressor response\", \"was reduced by\", \"intracisternal chlorpromazine\"]\n[\"intracisternal chlorpromazine\", \"reduced\", \"pressor response\"]\nGranularity: 2",
            "[\"pressor response\", \"was significantly potentiated\", \"by intracisternal desmethylimipramine\"]": " \n[\"pressor response\", \"was potentiated by\", \"intracisternal desmethylimipramine\"]\n[\"pressor response\", \"was significantly potentiated\", \"by intracisternal\"]\n[\"pressor response\", \"was significantly potentiated\", \"by desmethylimipramine\"]\nGranularity: 3",
            "[\"pressor response\", \"remained unchanged\", \"after sectioning of bilateral cervical vagal nerves\"]": " \n[\"pressor response\", \"remained unchanged\", \"after sectioning of bilateral cervical vagal nerves\"]\nGranularity: 0",
            "[\"pressor response\", \"disappeared\", \"after sectioning of spinal cord (C7-C8)\"]": " \n[\"pressor response\", \"disappeared\", \"after sectioning of spinal cord\"]\n[\"pressor response\", \"disappeared\", \"after sectioning of spinal cord (C7-C8)\"]\nGranularity: 2",
            "[\"pressor response\", \"involves central and peripheral adrenergic mechanisms\", \"sugested from the above results\"]": "\n[\"pressor response\", \"involves\", \"central adrenergic mechanisms\"]\n[\"pressor response\", \"involves\", \"peripheral adrenergic mechanisms\"]\nGranularity: 2",
            "[\"sympathetic trunk\", \"is the main pathway\", \"suggested from the above results\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Antiandrogenic therapy can cause coronary arterial disease .|AIM : To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer .|MATERIALS AND METHODS : We studied with a 2 . 5 years follow - up the changes in plasma cholesterols ( C ) , triglycerides ( TG ) , lipoproteins ( LP ) , and apolipoproteins ( Apo ) B - 100 , A - I , and A - II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer ( stage : T1cN0M0 , Gleason score : 2 - 5 ) during treatment with cyproterone acetate ( CPA ) without surgical management or radiation therapy .|RESULTS : Significant decreases of HDL - C , Apo A - I and Apo A - II and an increase of triglyceride levels in VLDL were induced by CPA .|After a period of 2 . 5 years on CPA treatment , four patients out of twenty - four were found to be affected by coronary heart disease .|CONCLUSIONS : Ischaemic coronary arteriosclerosis with an incidence rate of 16 . 6 % as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol , Apo A - I and Apo A - II pro fi les , other than the well - known hyperglyceridemic effect caused by estrogen .": {
            "[\"Antiandrogenic therapy\", \"can cause\", \"coronary arterial disease\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"AIM\", \"To study\", \"change of lipid metabolism by antiandrogen therapy\"]": " \n[\"AIM\", \"To study\", \"change of lipid metabolism\"]\n[\"AIM\", \"To study\", \"antiandrogen therapy\"]\nGranularity: 2",
            "[\"MATERIALS AND METHODS\", \"studied\", \"changes in plasma cholesterols, triglycerides, lipoproteins, and apolipoproteins\"]": " \n[\"MATERIALS AND METHODS\", \"studied\", \"changes in plasma cholesterols\"]\n[\"MATERIALS AND METHODS\", \"studied\", \"changes in triglycerides\"]\n[\"MATERIALS AND METHODS\", \"studied\", \"changes in lipoproteins\"]\n[\"MATERIALS AND METHODS\", \"studied\", \"changes in apolipoproteins\"]\nGranularity: 4",
            "[\"24 patients\", \"with\", \"low risk prostate cancer\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"cyproterone acetate (CPA)\", \"induced\", \"significant decreases of HDL-C, Apo A-I and Apo A-II\"]": " \n[\"cyproterone acetate (CPA)\", \"induced\", \"decreases of HDL-C\"]\n[\"cyproterone acetate (CPA)\", \"induced\", \"decreases of Apo A-I\"]\n[\"cyproterone acetate (CPA)\", \"induced\", \"decreases of Apo A-II\"]\nGranularity: 3",
            "[\"CPA\", \"increase\", \"triglyceride levels in VLDL\"]": " \n[\"CPA\", \"increases\", \"triglyceride levels\"]\n[\"CPA\", \"increases\", \"VLDL\"]\nGranularity: 2",
            "[\"four patients\", \"found to be affected by\", \"coronary heart disease\"]": "\n[\"four patients\", \"have\", \"coronary heart disease\"]\n[\"four patients\", \"were found to be affected by\", \"coronary heart disease\"]\nGranularity: 2",
            "[\"Ischaemic coronary arteriosclerosis\", \"caused by\", \"prolonged CPA therapy\"]": " \n[\"Ischaemic coronary arteriosclerosis\", \"caused by\", \"prolonged CPA therapy\"]\nGranularity: 1",
            "[\"changes in HDL cholesterol, Apo A-I and Apo A-II profiles\", \"mediated through\", \"Ischaemic coronary arteriosclerosis\"]": " \n[\"changes in HDL cholesterol\", \"mediated through\", \"Ischaemic coronary arteriosclerosis\"]\n[\"changes in Apo A-I profiles\", \"mediated through\", \"Ischaemic coronary arteriosclerosis\"]\n[\"changes in Apo A-II profiles\", \"mediated through\", \"Ischaemic coronary arteriosclerosis\"]\nGranularity: 3",
            "[\"hyperglyceridemic effect\", \"caused by\", \"estrogen\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Curcumin prevents maleate - induced nephrotoxicity : relation to hemodynamic alterations , oxidative stress , mitochondrial oxygen consumption and activity of respiratory complex I .|The potential protective effect of the dietary antioxidant curcumin ( 120 mg / Kg / day for 6 days ) against the renal injury induced by maleate was evaluated .|Tubular proteinuria and oxidative stress were induced by a single injection of maleate ( 400 mg / kg ) in rats .|Maleate - induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein , glucose , sodium , neutrophil gelatinase - associated lipocalin ( NGAL ) and N - acetyl b - D - glucosaminidase ( NAG ) , upregulation of kidney injury molecule ( KIM ) - 1 , decrease in renal blood flow and claudin - 2 expression besides of necrosis and apoptosis of tubular cells on 24 h .|Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels .|Studies were also conducted in renal epithelial LLC - PK1 cells and in mitochondria isolated from kidneys of all the experimental groups .|Maleate induced cell damage and reactive oxygen species ( ROS ) production in LLC - PK1 cells in culture .|In addition , maleate treatment reduced oxygen consumption in ADP - stimulated mitochondria and diminished respiratory control index when using malate / glutamate as substrate .|The activities of both complex I and aconitase were also diminished .|All the above - described alterations were prevented by curcumin .|It is concluded that curcumin is able to attenuate in vivo maleate - induced nephropathy and in vitro cell damage .|The in vivo protection was associated to the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I , and the in vitro protection was associated to the prevention of ROS production .": {
            "[\"Curcumin\", \"prevents\", \"maleate-induced nephrotoxicity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Curcumin\", \"relates to\", \"hemodynamic alterations\"]": " N/A (The triple is specific, conveying a singular relation between Curcumin and hemodynamic alterations.)\nGranularity: 0",
            "[\"Curcumin\", \"relates to\", \"oxidative stress\"]": " N/A (The triple is specific, conveying a singular relation between curcumin and oxidative stress.)\nGranularity: 0",
            "[\"Curcumin\", \"relates to\", \"mitochondrial oxygen consumption\"]": " \n[\"Curcumin\", \"relates to\", \"mitochondrial function\"]\n[\"Curcumin\", \"relates to\", \"oxygen consumption\"]\nGranularity: 2",
            "[\"Curcumin\", \"relates to\", \"activity of respiratory complex I\"]": " \n[\"Curcumin\", \"relates to\", \"activity of respiratory complex I\"]\nGranularity: 1",
            "[\"Curcumin\", \"has a potential protective effect against\", \"renal injury induced by maleate\"]": " \n[\"Curcumin\", \"has a potential protective effect against\", \"renal injury\"]\n[\"Curcumin\", \"has a potential protective effect against\", \"maleate\"]\nGranularity: 2",
            "[\"Maleate\", \"induces\", \"tubular proteinuria and oxidative stress\"]": " \n[\"Maleate\", \"induces\", \"tubular proteinuria\"]\n[\"Maleate\", \"induces\", \"oxidative stress\"]\nGranularity: 2",
            "[\"Maleate\", \"induces\", \"renal injury\"]": " N/A (The triple is specific, conveying a singular relation between Maleate and renal injury.)\nGranularity: 0",
            "[\"Maleate-induced renal injury\", \"includes\", \"increase in renal vascular resistance\"]": " \n[\"Maleate-induced renal injury\", \"includes\", \"increase in renal vascular resistance\"]\nGranularity: 1",
            "[\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of total protein, glucose, sodium, NGAL, and NAG\"]": " \n[\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of total protein\"]\n[\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of glucose\"]\n[\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of sodium\"]\n[\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of NGAL\"]\n[\"Maleate-induced renal injury\", \"includes\", \"increase in urinary excretion of NAG\"]\nGranularity: 5",
            "[\"Maleate-induced renal injury\", \"includes\", \"upregulation of kidney injury molecule (KIM)-1\"]": " \n[\"Maleate-induced renal injury\", \"includes\", \"upregulation of KIM-1\"]\nGranularity: 1",
            "[\"Maleate-induced renal injury\", \"includes\", \"decrease in renal blood flow and claudin-2 expression\"]": " \n[\"Maleate-induced renal injury\", \"includes\", \"decrease in renal blood flow\"]\n[\"Maleate-induced renal injury\", \"includes\", \"claudin-2 expression\"]\nGranularity: 2",
            "[\"Maleate-induced renal injury\", \"includes\", \"necrosis and apoptosis of tubular cells\"]": " \n[\"Maleate-induced renal injury\", \"includes\", \"necrosis of tubular cells\"]\n[\"Maleate-induced renal injury\", \"includes\", \"apoptosis of tubular cells\"]\nGranularity: 2",
            "[\"Oxidative stress\", \"is determined by\", \"measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels\"]": " \n[\"Oxidative stress\", \"is determined by\", \"measuring the oxidation of lipids\"]\n[\"Oxidative stress\", \"is determined by\", \"measuring the oxidation of proteins\"]\n[\"Oxidative stress\", \"is determined by\", \"diminution in renal Nrf2 levels\"]\nGranularity: 3",
            "[\"Studies\", \"were conducted in\", \"renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups\"]": " \n[\"Studies\", \"were conducted in\", \"renal epithelial LLC-PK1 cells\"]\n[\"Studies\", \"were conducted in\", \"mitochondria isolated from kidneys\"]\n[\"mitochondria isolated from kidneys\", \"were isolated from\", \"experimental groups\"]\nGranularity: 3",
            "[\"Maleate\", \"induces\", \"cell damage and ROS production in LLC-PK1 cells in culture\"]": " \n[\"Maleate\", \"induces\", \"cell damage\"]\n[\"Maleate\", \"induces\", \"ROS production\"]\n[\"Maleate\", \"induces\", \"cell damage and ROS production\"]\nGranularity: 3",
            "[\"Maleate treatment\", \"reduces\", \"oxygen consumption in ADP-stimulated mitochondria\"]": "\n[\"Maleate treatment\", \"reduces\", \"oxygen consumption\"]\n[\"Maleate treatment\", \"reduces\", \"ADP-stimulated mitochondria\"]\nGranularity: 2",
            "[\"Maleate treatment\", \"diminishes\", \"respiratory control index when using malate/glutamate as substrate\"]": " \n[\"Maleate treatment\", \"diminishes\", \"respiratory control index\"]\n[\"Maleate treatment\", \"uses\", \"malate/glutamate as substrate\"]\nGranularity: 2",
            "[\"Maleate treatment\", \"diminishes\", \"the activities of both complex I and aconitase\"]": " \n[\"Maleate treatment\", \"diminishes\", \"complex I\"]\n[\"Maleate treatment\", \"diminishes\", \"aconitase\"]\nGranularity: 2",
            "[\"Curcumin\", \"prevents\", \"all the above-described alterations\"]": " N/A (The triple is specific, conveying a singular relation between curcumin and the prevention of alterations.)\nGranularity: 0",
            "[\"Curcumin\", \"is able to\", \"attenuate in vivo maleate-induced nephropathy and in vitro cell damage\"]": " \n[\"Curcumin\", \"is able to\", \"attenuate in vivo maleate-induced nephropathy\"]\n[\"Curcumin\", \"is able to\", \"attenuate in vitro cell damage\"]\nGranularity: 2",
            "[\"In vivo protection by curcumin\", \"is associated with\", \"the prevention of oxidative stress and preservation of mitochondrial oxygen consumption and activity of respiratory complex I\"]": " \n[\"In vivo protection by curcumin\", \"is associated with\", \"prevention of oxidative stress\"]\n[\"In vivo protection by curcumin\", \"is associated with\", \"preservation of mitochondrial oxygen consumption\"]\n[\"In vivo protection by curcumin\", \"is associated with\", \"activity of respiratory complex I\"]\nGranularity: 3",
            "[\"In vitro protection by curcumin\", \"is associated with\", \"the prevention of ROS production\"]": " \n[\"In vitro protection\", \"is associated with\", \"prevention of ROS production\"]\n[\"curcumin\", \"is associated with\", \"prevention of ROS production\"]\nGranularity: 2"
      },
      "Linezolid - induced optic neuropathy .|Many systemic antimicrobials have been implicated to cause ocular adverse effects .|This is especially relevant in multidrug therapy where more than one drug can cause a similar ocular adverse effect .|We describe a case of progressive loss of vision associated with linezolid therapy .|A 45 - year - old male patient who was on treatment with multiple second - line anti - tuberculous drugs including linezolid and ethambutol for extensively drug - resistant tuberculosis ( XDR - TB ) presented to us with painless progressive loss of vision in both eyes .|Color vision was defective and fundus examination revealed optic disc edema in both eyes .|Ethambutol - induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn .|Deterioration of vision occurred despite withdrawal of ethambutol .|Discontinuation of linezolid resulted in marked improvement of vision .|Our report emphasizes the need for monitoring of visual function in patients on long - term linezolid treatment .": {
            "[\"Antimicrobials\", \"cause\", \"ocular adverse effects\"]": "\n[\"Antimicrobials\", \"cause\", \"ocular effects\"]\n[\"Antimicrobials\", \"cause\", \"adverse effects\"]\nGranularity: 2",
            "[\"Multidrug therapy\", \"causes\", \"similar ocular adverse effect\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Patient\", \"presented with\", \"progressive loss of vision\"]": " \n[\"Patient\", \"presented with\", \"progressive loss\"]\n[\"Patient\", \"presented with\", \"vision\"]\nGranularity: 2",
            "[\"Color vision\", \"was\", \"defective\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Fundus examination\", \"revealed\", \"optic disc edema\"]": " \n[\"Fundus examination\", \"revealed\", \"optic disc edema\"]\nGranularity: 1",
            "[\"Ethambutol\", \"induced\", \"toxic optic neuropathy\"]": " \n[\"Ethambutol\", \"causes\", \"toxic optic neuropathy\"]\n[\"Ethambutol\", \"leads to\", \"toxic optic neuropathy\"]\nGranularity: 2",
            "[\"Withdrawal of ethambutol\", \"led to\", \"deterioration of vision\"]": " \n[\"Withdrawal of ethambutol\", \"led to\", \"deterioration of vision\"]\nGranularity: 1",
            "[\"Discontinuation of linezolid\", \"resulted in\", \"improvement of vision\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Report\", \"emphasizes\", \"need for monitoring of visual function\"]": " \n[\"Report\", \"emphasizes\", \"need for monitoring\"]\n[\"Report\", \"emphasizes\", \"visual function\"]\nGranularity: 2",
            "[\"Linezolid\", \"induced\", \"optic neuropathy\"]": " N/A (The triple is specific, conveying a singular relation between Linezolid and optic neuropathy.)\nGranularity: 0"
      },
      "Indomethacin induced hypotension in sodium and volume depleted rats .|After a single oral dose of 4 mg / kg indomethacin ( IDM ) to sodium and volume depleted rats plasma renin activity ( PRA ) and systolic blood pressure fell significantly within four hours .|In sodium repleted animals indomethacin did not change systolic blood pressure ( BP ) although plasma renin activity was decreased .|Thus , indomethacin by inhibition of prostaglandin synthesis may diminish the blood pressure maintaining effect of the stimulated renin - angiotensin system in sodium and volume depletion .": {
            "[\"hypotension\", \"in\", \"sodium and volume depleted rats\"]": " \n[\"hypotension\", \"in\", \"sodium depleted rats\"]\n[\"hypotension\", \"in\", \"volume depleted rats\"]\nGranularity: 2",
            "[\"dose\", \"led to\", \"plasma renin activity ( PRA ) and systolic blood pressure fell significantly within four hours\"]": "\n[\"dose\", \"led to\", \"plasma renin activity ( PRA )\"]\n[\"dose\", \"led to\", \"systolic blood pressure fell significantly\"]\nGranularity: 2",
            "[\"blood pressure\", \"in\", \"sodium repleted animals\"]": " \n[\"blood pressure\", \"in\", \"sodium repleted animals\"]\nGranularity: 1",
            "[\"plasma renin activity\", \"in\", \"sodium repleted animals\"]": " \n[\"plasma renin activity\", \"in\", \"sodium repleted animals\"]\nGranularity: 1",
            "[\"prostaglandin synthesis\", \"may diminish\", \"the blood pressure maintaining effect of the stimulated renin - angiotensin system\"]": " \n[\"prostaglandin synthesis\", \"may diminish\", \"blood pressure maintaining effect\"]\n[\"prostaglandin synthesis\", \"may diminish\", \"stimulated renin - angiotensin system\"]\nGranularity: 2",
            "[\"Indomethacin\", \"induced\", \"hypotension\"]": " N/A (The triple is specific, conveying a singular relation between Indomethacin and hypotension.)\nGranularity: 0",
            "[\"Indomethacin\", \"given as\", \"single oral dose of 4 mg / kg\"]": " \n[\"Indomethacin\", \"given as\", \"single oral dose\"]\n[\"Indomethacin\", \"given as\", \"4 mg / kg\"]\nGranularity: 2",
            "[\"Indomethacin\", \"did not change\", \"systolic blood pressure\"]": " N/A (The triple is specific, conveying a singular relation between Indomethacin and systolic blood pressure.)\nGranularity: 0",
            "[\"Indomethacin\", \"led to\", \"decreased plasma renin activity\"]": " N/A (The triple is specific, conveying a singular relation between Indomethacin and decreased plasma renin activity.)\nGranularity: 0",
            "[\"Indomethacin\", \"by inhibition of\", \"prostaglandin synthesis\"]": " \n[\"Indomethacin\", \"inhibits\", \"prostaglandin synthesis\"]\nGranularity: 1",
            "[\"the blood pressure maintaining effect of the stimulated renin - angiotensin system\", \"in\", \"sodium and volume depletion\"]": " \n[\"the blood pressure maintaining effect\", \"of the stimulated renin - angiotensin system\", \"in sodium depletion\"]\n[\"the blood pressure maintaining effect\", \"of the stimulated renin - angiotensin system\", \"in volume depletion\"]\nGranularity: 2"
      },
      "Worsening of Parkinsonism after the use of veralipride for treatment of menopause : case report .|We describe a female patient with stable Parkinson 's disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride , as well as the improvement of her symptoms back to baseline after discontinuation of the drug .|We emphasize the anti - dopaminergic effect of veralipride .": {
            "[\"Worsening of Parkinsonism\", \"after the use of\", \"veralipride\"]": " \n[\"Worsening of Parkinsonism\", \"after the use of\", \"veralipride\"]\nGranularity: 1",
            "[\"veralipride\", \"for treatment of\", \"menopause\"]": " N/A (The triple is specific, conveying a singular relation between veralipride and menopause.)\nGranularity: 0",
            "[\"veralipride\", \"causes\", \"worsening of motor functions in Parkinson's disease\"]": " \n[\"veralipride\", \"causes\", \"worsening of motor functions\"]\n[\"veralipride\", \"causes\", \"Parkinson's disease\"]\nGranularity: 2",
            "[\"veralipride\", \"improvement of symptoms back to baseline after\", \"discontinuation\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"veralipride\", \"has\", \"anti-dopaminergic effect\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Mitochondrial impairment contributes to cocaine - induced cardiac dysfunction : Prevention by the targeted antioxidant MitoQ .|The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine - induced cardiac dysfunction .|We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction .|Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers , specifically through complex I and complex III .|ROS levels were increased , specifically in interfibrillar mitochondria .|In parallel there was a decrease in ATP synthesis , whereas no difference was observed in subsarcolemmal mitochondria .|This uncoupling effect on oxidative phosphorylation was not detectable after short - term exposure to cocaine , suggesting that these mitochondrial abnormalities were a late rather than a primary event in the pathological response to cocaine .|MitoQ , a mitochondrial - targeted antioxidant , was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure - volume data .|Taken together , these results extend previous studies and demonstrate that cocaine - induced cardiac dysfunction may be due to a mitochondrial defect .": {
            "[\"Mitochondrial impairment\", \"contributes to\", \"cocaine-induced cardiac dysfunction\"]": "\n[\"Mitochondrial impairment\", \"contributes to\", \"cocaine-induced dysfunction\"]\n[\"Mitochondrial impairment\", \"contributes to\", \"cardiac dysfunction\"]\nGranularity: 2",
            "[\"Mitochondrial impairment\", \"linked to\", \"ROS production\"]": " \n[\"Mitochondrial impairment\", \"linked to\", \"ROS production\"]\nGranularity: 1",
            "[\"Mitochondrial impairment\", \"linked to\", \"altered mitochondrial function\"]": " \n[\"Mitochondrial impairment\", \"linked to\", \"altered function\"]\n[\"Mitochondrial impairment\", \"linked to\", \"mitochondrial function\"]\nGranularity: 2",
            "[\"Cocaine abuse\", \"may lead to\", \"altered mitochondrial function\"]": "\n[\"Cocaine abuse\", \"may lead to\", \"altered function of mitochondria\"]\n[\"Cocaine abuse\", \"may lead to\", \"changes in mitochondrial function\"]\nGranularity: 2",
            "[\"Cocaine administration\", \"led to\", \"increased oxygen consumption\"]": "\n[\"Cocaine administration\", \"led to\", \"increased oxygen consumption\"]\nGranularity: 0",
            "[\"Cocaine administration\", \"led to\", \"increased ROS levels\"]": " \n[\"Cocaine administration\", \"caused\", \"increased ROS levels\"]\n[\"Cocaine administration\", \"resulted in\", \"increased ROS levels\"]\nGranularity: 2",
            "[\"Cocaine administration\", \"led to\", \"decreased ATP synthesis\"]": " \n[\"Cocaine administration\", \"led to\", \"decreased ATP synthesis\"]\nGranularity: 1",
            "[\"MitoQ\", \"prevents\", \"mitochondrial abnormalities and cardiac dysfunction\"]": " \n[\"MitoQ\", \"prevents\", \"mitochondrial abnormalities\"]\n[\"MitoQ\", \"prevents\", \"cardiac dysfunction\"]\nGranularity: 2",
            "[\"Mitochondrial abnormalities\", \"linked to\", \"diastolic dysfunction\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Cocaine-induced cardiac dysfunction\", \"may be due to\", \"a mitochondrial defect\"]": "\n[\"Cocaine-induced cardiac dysfunction\", \"may be due to\", \"mitochondrial defect\"]\nGranularity: 1"
      },
      "The enhancement of aminonucleoside nephrosis by the co - administration of protamine .|An experimental model of focal segmental glomerular sclerosis ( FSGS ) was developed in rats by the combined administration of puromycin - aminonucleoside ( AMNS ) and protamine sulfate ( PS ) .|Male Sprague - Dawley rats , uninephrectomized three weeks before , received daily injections of subcutaneous AMNS ( 1 mg / 100 g body wt ) and intravenous PS ( 2 separated doses of 2 . 5 mg / 100 g body wt ) for four days .|The series of injections were repeated another three times at 10 day intervals .|The animals were sacrificed on days 24 , 52 , and 80 .|They developed nephrotic syndrome and finally renal failure .|The time - course curve of creatinine clearance dropped and showed significant difference ( P less than 0 . 01 ) from that of each control group , such as , AMNS alone , PS alone or saline injected .|Their glomeruli showed changes of progressive FSGS .|The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm .|Therefore , it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end - stage renal disease .": {
            "[\"The enhancement of aminonucleoside nephrosis\", \"by\", \"the co-administration of protamine\"]": " \n[\"The enhancement of aminonucleoside nephrosis\", \"by\", \"co-administration\"]\n[\"co-administration\", \"of\", \"protamine\"]\nGranularity: 2",
            "[\"An experimental model of focal segmental glomerular sclerosis (FSGS)\", \"was developed in rats by\", \"the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS)\"]": " \n[\"experimental model\", \"of FSGS\", \"developed in rats\"]\n[\"experimental model\", \"of FSGS\", \"combined administration\"]\n[\"combined administration\", \"of puromycin-aminonucleoside\", \"and protamine sulfate\"]\nGranularity: 3",
            "[\"Male Sprague-Dawley rats\", \"received\", \"daily injections of subcutaneous AMNS and intravenous PS\"]": " \n[\"Male Sprague-Dawley rats\", \"received\", \"daily injections of subcutaneous AMNS\"]\n[\"Male Sprague-Dawley rats\", \"received\", \"intravenous PS\"]\nGranularity: 2",
            "[\"The series of injections\", \"were repeated\", \"another three times at 10 day intervals\"]": " \n[\"The series of injections\", \"were repeated\", \"three times\"]\n[\"The series of injections\", \"were repeated\", \"at 10 day intervals\"]\n[\"The series of injections\", \"were repeated\", \"another three times\"]\n[\"The series of injections\", \"were repeated\", \"another three times at 10 day intervals\"]\nGranularity: 4",
            "[\"The animals\", \"were sacrificed\", \"on days 24, 52, and 80\"]": " \n[\"The animals\", \"were sacrificed\", \"on day 24\"]\n[\"The animals\", \"were sacrificed\", \"on day 52\"]\n[\"The animals\", \"were sacrificed\", \"on day 80\"]\nGranularity: 3",
            "[\"The animals\", \"developed\", \"nephrotic syndrome and finally renal failure\"]": "\n[\"The animals\", \"developed\", \"nephrotic syndrome\"]\n[\"The animals\", \"developed\", \"renal failure\"]\nGranularity: 2",
            "[\"The time-course curve of creatinine clearance\", \"showed significant difference\", \"from that of each control group\"]": " \n[\"The time-course curve\", \"of creatinine clearance\", \"showed significant difference\"]\n[\"The time-course curve\", \"showed\", \"significant difference\"]\n[\"creatinine clearance\", \"showed\", \"significant difference\"]\n[\"control group\", \"showed\", \"significant difference\"]\nGranularity: 4",
            "[\"Their glomeruli\", \"showed\", \"changes of progressive FSGS\"]": " \n[\"Their glomeruli\", \"showed\", \"changes\"]\n[\"changes\", \"of\", \"progressive FSGS\"]\nGranularity: 2",
            "[\"The ultrastructural studies\", \"revealed\", \"significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm\"]": " \n[\"The ultrastructural studies\", \"revealed\", \"significant lack of particles of perfused ruthenium red on the lamina rara externa\"]\n[\"The ultrastructural studies\", \"revealed\", \"marked changes in epithelial cell cytoplasm\"]\nGranularity: 2",
            "[\"It is suggested\", \"that\", \"the administration of PS enhances the toxicity of AMNS on the glomerulus\"]": " \n[\"the administration of PS\", \"enhances\", \"the toxicity of AMNS\"]\n[\"the administration of PS\", \"on\", \"the glomerulus\"]\nGranularity: 2",
            "[\"The administration of PS\", \"readily produces\", \"progressive FSGS in rats resulting in the end-stage renal disease\"]": " \n[\"The administration of PS\", \"produces\", \"progressive FSGS in rats\"]\n[\"Progressive FSGS\", \"results in\", \"end-stage renal disease\"]\nGranularity: 2"
      },
      "Pharmacological studies on a new dihydrothienopyridine calcium antagonist , S - 312 - d .|5th communication : anticonvulsant effects in mice .|S - 312 , S - 312 - d , but not S - 312 - l , L - type calcium channel antagonists , showed anticonvulsant effects on the audiogenic tonic convulsions in DBA / 2 mice ; and their ED50 values were 18 . 4 ( 12 . 8 - 27 . 1 ) mg / kg , p . o .|and 15 . 0 ( 10 . 2 - 23 . 7 ) mg / kg , p . o . , respectively , while that of flunarizine was 34 . 0 ( 26 . 0 - 44 . 8 ) mg / kg , p . o .|Although moderate anticonvulsant effects of S - 312 - d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole ( 85 mg / kg , s . c . ) or bemegride ( 40 mg / kg , s . c . ) , no effects were observed in convulsions induced by N - methyl - D - aspartate , picrotoxin , or electroshock in Slc : ddY mice .|S - 312 - d may be useful in the therapy of certain types of human epilepsy .": {
            "[\"Penicillin\", \"treats\", \"bacterial infections\"]": " N/A (The triple is specific, conveying a singular relation between Penicillin and bacterial infections.)\nGranularity: 0",
            "[\"Penicillin\", \"discovered by\", \"Alexander Fleming\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Metformin\", \"helps by\", \"lowering glucose production in the liver\"]": " \n[\"Metformin\", \"helps\", \"lowering glucose production\"]\n[\"Metformin\", \"helps\", \"in the liver\"]\nGranularity: 2",
            "[\"Metformin\", \"increases\", \"body's sensitivity to insulin\"]": " \n[\"Metformin\", \"increases\", \"body's sensitivity\"]\n[\"Metformin\", \"increases\", \"insulin\"]\nGranularity: 2",
            "[\"S - 312 - d\", \"is a type of\", \"L-type calcium channel antagonist\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"S - 312 - d\", \"shows\", \"anticonvulsant effects\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"S - 312 - d\", \"induces\", \"moderate anticonvulsant effects\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"S - 312 - d\", \"may be useful in\", \"therapy of certain types of human epilepsy\"]": " \n[\"S - 312 - d\", \"may be useful in\", \"therapy\"]\n[\"S - 312 - d\", \"may be useful in\", \"certain types of human epilepsy\"]\nGranularity: 2",
            "[\"Metformin\", \"is prescribed for\", \"managing type 2 diabetes\"]": " \n[\"Metformin\", \"is prescribed for\", \"managing\"]\n[\"Metformin\", \"is prescribed for\", \"type 2 diabetes\"]\nGranularity: 2",
            "[\"Pharmacological studies\", \"investigate\", \"new dihydrothienopyridine calcium antagonist\"]": " \n[\"Pharmacological studies\", \"investigate\", \"new dihydrothienopyridine\"]\n[\"Pharmacological studies\", \"investigate\", \"calcium antagonist\"]\nGranularity: 2"
      },
      "Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix .|BACKGROUND : The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma .|METHODS : The combination of carboplatin ( area under the concentration curve [ AUC ] , 5 ) and liposomal doxorubicin ( Doxil ; starting dose , 40 mg / m ( 2 ) ) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile .|RESULTS : Twenty - nine patients were assessable for response , and 35 patients were assessable for toxicity .|The overall response rate was 38 % , the median time to response was 10 weeks , the median duration of response was 26 weeks , and the median survival was 37 weeks .|The main toxic effect was myelosuppression , with Grade 3 and 4 neutropenia in 16 patients , anemia in 12 patients , thrombocytopenia in 11 patients , and neutropenic fever in 3 patients .|Four patients had five infusion - related reactions during the infusion of liposomal doxorubicin , leading to treatment discontinuation in three patients .|Grade > or = 2 nonhematologic toxicity included nausea in 17 patients , emesis in 14 patients , fatigue in 9 patients , mucositis and / or stomatitis in 8 patients , constipation in 6 patients , weight loss in 5 patients , hand - foot syndrome in 2 patients , and skin reactions in 3 patients .|CONCLUSIONS : The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma .": {
            "[\"carboplatin\", \"and\", \"liposomal doxorubicin\"]": " \n[\"carboplatin\", \"and\", \"liposomal doxorubicin\"]\nGranularity: 1",
            "[\"Phase II study\", \"tested\", \"combination\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"combination\", \"administered\", \"intravenously\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"combination\", \"determine\", \"antitumor activity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"combination\", \"determine\", \"toxicity profile\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Twenty-nine patients\", \"assessable for\", \"response\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Thirty-five patients\", \"assessable for\", \"toxicity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Overall response rate\", \"was\", \"38%\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Median time to response\", \"was\", \"10 weeks\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Median duration of response\", \"was\", \"26 weeks\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Median survival\", \"was\", \"37 weeks\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Main toxic effect\", \"was\", \"myelosuppression\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Grade 3 and 4 neutropenia\", \"in\", \"16 patients\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Anemia\", \"in\", \"12 patients\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Thrombocytopenia\", \"in\", \"11 patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Neutropenic fever\", \"in\", \"3 patients\"]": " \n[\"Neutropenic fever\", \"occurs in\", \"3 patients\"]\n[\"Neutropenic fever\", \"affects\", \"3 patients\"]\n[\"Neutropenic fever\", \"is experienced by\", \"3 patients\"]\nGranularity: 3",
            "[\"Five infusion-related reactions\", \"during\", \"infusion of liposomal doxorubicin\"]": " \n[\"Five infusion-related reactions\", \"during\", \"infusion of liposomal doxorubicin\"]\nGranularity: 1",
            "[\"Treatment discontinuation\", \"in\", \"three patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"nausea in 17 patients\"]": " \n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"nausea\"]\n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"17 patients\"]\nGranularity: 2",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"emesis in 14 patients\"]": " \n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"emesis\"]\n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"14 patients\"]\nGranularity: 2",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"fatigue in 9 patients\"]": " \n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"fatigue\"]\n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"9 patients\"]\nGranularity: 2",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"mucositis and / or stomatitis in 8 patients\"]": " \n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"mucositis\"]\n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"stomatitis\"]\nGranularity: 2",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"constipation in 6 patients\"]": " \n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"constipation\"]\n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"6 patients\"]\nGranularity: 2",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"weight loss in 5 patients\"]": "\n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"weight loss\"]\n[\"weight loss\", \"in 5 patients\", \"due to\"]\nGranularity: 2",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"hand-foot syndrome in 2 patients\"]": " \n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"hand-foot syndrome\"]\n[\"hand-foot syndrome\", \"occurred in\", \"2 patients\"]\nGranularity: 2",
            "[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"skin reactions in 3 patients\"]": " \n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"skin reactions\"]\n[\"Grade > or = 2 nonhematologic toxicity\", \"included\", \"3 patients\"]\nGranularity: 2",
            "[\"Combination of carboplatin\", \"has\", \"modest activity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Combination of carboplatin\", \"in\", \"patients with recurrent cervical carcinoma\"]": " \n[\"Combination of carboplatin\", \"in\", \"patients with recurrent cervical carcinoma\"]\nGranularity: 1"
      },
      "Electron microscopic investigations of the cyclophosphamide - induced lesions of the urinary bladder of the rat and their prevention by mesna .|Fully developed cyclophosphamide - induced cystitis is characterized by nearly complete detachment of the urothelium , severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses .|The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the luminal membrane .|This damages the cellular barrier against the hypertonic urine .|Subsequent breaks in the lateral cell membranes of the superficial cells and in all the plasma membranes of the intermediate and basal cells , intercellular and intracellular edema and disintegration of the desmosomes and hemidesmosomes lead to progressive degeneration and detachment of the epithelial cells with exposure and splitting of the basal membrane .|The morphological changes of the endothelial cells , which become more pronounced in the later stages of the experiment , the involvement of blood vessels regardless of their diameter and the location - dependent extent of the damage indicate a direct type of damage which is preceded by a mediator - induced increase in permeability , the morphological correlate of which is the formation of gaps in the interendothelial cell connections on the venules .|These changes can be effectively prevented by mesna .|The only sign of a possible involvement is the increase in the number of specific granules with a presumed lysosomal function in the superficial cells .": {
            "[\"Electron microscopic investigations\", \"investigate\", \"cyclophosphamide-induced lesions of the urinary bladder of the rat\"]": " \n[\"Electron microscopic investigations\", \"investigate\", \"cyclophosphamide-induced lesions\"]\n[\"cyclophosphamide-induced lesions\", \"of\", \"the urinary bladder of the rat\"]\nGranularity: 2",
            "[\"Cyclophosphamide\", \"induces\", \"lesions of the urinary bladder\"]": " \n[\"Cyclophosphamide\", \"induces\", \"lesions\"]\n[\"Cyclophosphamide\", \"induces\", \"urinary bladder\"]\nGranularity: 2",
            "[\"Mesna\", \"prevents\", \"cyclophosphamide-induced lesions\"]": " \n[\"Mesna\", \"prevents\", \"cyclophosphamide-induced lesions\"]\nGranularity: 1",
            "[\"Fully developed cyclophosphamide-induced cystitis\", \"is characterized by\", \"nearly complete detachment of the urothelium\"]": " \n[\"Fully developed cyclophosphamide-induced cystitis\", \"is characterized by\", \"detachment of the urothelium\"]\n[\"Fully developed cyclophosphamide-induced cystitis\", \"is characterized by\", \"complete detachment\"]\nGranularity: 2",
            "[\"Fully developed cyclophosphamide-induced cystitis\", \"causes\", \"severe submucosal edema\"]": "\n[\"Fully developed cyclophosphamide-induced cystitis\", \"causes\", \"severe edema\"]\n[\"Fully developed cyclophosphamide-induced cystitis\", \"causes\", \"submucosal edema\"]\nGranularity: 2",
            "[\"Fully developed cyclophosphamide-induced cystitis\", \"causes\", \"focal muscle necroses\"]": " \n[\"Fully developed cyclophosphamide-induced cystitis\", \"causes\", \"focal muscle necroses\"]\nGranularity: 1",
            "[\"The initial response to the primary attack by the cyclophosphamide metabolites\", \"seems to be\", \"fragmentation of the luminal membrane\"]": " \n[\"The initial response to the primary attack\", \"by the cyclophosphamide metabolites\", \"seems to be\", \"fragmentation of the luminal membrane\"]\n[\"The initial response\", \"to the primary attack\", \"by the cyclophosphamide metabolites\"]\n[\"The initial response\", \"to the primary attack\", \"fragmentation of the luminal membrane\"]\n[\"The initial response\", \"by the cyclophosphamide metabolites\", \"fragmentation of the luminal membrane\"]\n[\"The primary attack\", \"by the cyclophosphamide metabolites\", \"seems to be\", \"fragmentation of the luminal membrane\"]\n[\"The primary attack\", \"by the cyclophosphamide metabolites\"]\n[\"The primary attack\", \"seems to be\", \"fragmentation of the luminal membrane\"]\n[\"The cyclophosphamide metabolites\", \"seems to be\", \"fragmentation of the luminal membrane\"]\nGranularity: 8",
            "[\"The initial response to the primary attack by the cyclophosphamide metabolites\", \"damages\", \"the cellular barrier against the hypertonic urine\"]": " \n[\"The initial response to the primary attack\", \"damages\", \"the cellular barrier\"]\n[\"The initial response to the primary attack\", \"damages\", \"the hypertonic urine\"]\n[\"The cyclophosphamide metabolites\", \"attack\", \"the cellular barrier\"]\n[\"The cyclophosphamide metabolites\", \"attack\", \"the hypertonic urine\"]\n[\"The cellular barrier\", \"protects against\", \"the hypertonic urine\"]\nGranularity: 5",
            "[\"Subsequent breaks\", \"occur\", \"in the lateral cell membranes of the superficial cells\"]": " \n[\"Subsequent breaks\", \"occur\", \"in the lateral cell membranes\"]\n[\"lateral cell membranes\", \"are broken in\", \"superficial cells\"]\nGranularity: 2",
            "[\"Subsequent breaks\", \"occur\", \"in all the plasma membranes of the intermediate and basal cells\"]": " \n[\"Subsequent breaks\", \"occur\", \"in plasma membranes of intermediate cells\"]\n[\"Subsequent breaks\", \"occur\", \"in plasma membranes of basal cells\"]\nGranularity: 2",
            "[\"Subsequent breaks\", \"lead to\", \"progressive degeneration and detachment of the epithelial cells\"]": " \n[\"Subsequent breaks\", \"lead to\", \"progressive degeneration of epithelial cells\"]\n[\"Subsequent breaks\", \"lead to\", \"detachment of epithelial cells\"]\nGranularity: 2",
            "[\"Subsequent breaks\", \"expose and split\", \"the basal membrane\"]": " \n[\"Subsequent breaks\", \"expose\", \"the basal membrane\"]\n[\"Subsequent breaks\", \"split\", \"the basal membrane\"]\nGranularity: 2",
            "[\"The morphological changes of the endothelial cells\", \"become more pronounced\", \"in the later stages of the experiment\"]": " \n[\"The morphological changes\", \"are pronounced in\", \"later stages\"]\n[\"The endothelial cells\", \"undergo morphological changes in\", \"later stages\"]\n[\"The morphological changes\", \"occur in\", \"endothelial cells\"]\n[\"The endothelial cells\", \"undergo changes in\", \"morphology\"]\nGranularity: 4",
            "[\"The morphological changes of the endothelial cells\", \"involve\", \"blood vessels regardless of their diameter\"]": " \n[\"The morphological changes\", \"involve\", \"endothelial cells\"]\n[\"endothelial cells\", \"involve\", \"blood vessels\"]\n[\"blood vessels\", \"have\", \"diameter\"]\nGranularity: 3",
            "[\"The morphological changes of the endothelial cells\", \"indicate\", \"a direct type of damage\"]": " \n[\"The morphological changes\", \"indicate\", \"endothelial cell damage\"]\n[\"endothelial cells\", \"undergo\", \"morphological changes\"]\nGranularity: 2",
            "[\"The morphological changes of the endothelial cells\", \"are preceded by\", \"a mediator-induced increase in permeability\"]": " \n[\"The morphological changes\", \"are preceded by\", \"a mediator-induced increase in permeability\"]\n[\"endothelial cells\", \"are preceded by\", \"a mediator-induced increase in permeability\"]\n[\"a mediator-induced increase in permeability\", \"precedes\", \"morphological changes\"]\nGranularity: 3",
            "[\"The morphological changes of the endothelial cells\", \"have a morphological correlate\", \"the formation of gaps in the interendothelial cell connections on the venules\"]": " \n[\"The morphological changes of the endothelial cells\", \"have a morphological correlate\", \"the formation of gaps\"]\n[\"The morphological changes of the endothelial cells\", \"have a morphological correlate\", \"interendothelial cell connections on the venules\"]\n[\"The formation of gaps\", \"is a morphological correlate\", \"interendothelial cell connections on the venules\"]\nGranularity: 3",
            "[\"These changes\", \"can be effectively prevented by\", \"mesna\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"The only sign of a possible involvement\", \"is\", \"the increase in the number of specific granules with a presumed lysosomal function in the superficial cells\"]": "\n[\"The only sign\", \"of\", \"possible involvement\"]\n[\"increase\", \"in\", \"number of specific granules\"]\n[\"specific granules\", \"have\", \"presumed lysosomal function\"]\n[\"superficial cells\", \"have\", \"presumed lysosomal function\"]\nGranularity: 4"
      },
      "Vasopressin as a possible contributor to hypertension .|The role of vasopressin as a pressor agent to the hypertensive process was examined .|Vasopressin plays a major role in the pathogenesis of DOCA - salt hypertension , since the elevation of blood pressure was not substantial in the rats with lithium - treated diabetes insipidus after DOCA - salt treatment .|Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP .|Furthermore , the pressor action of vasopressin appears to be important in the development of this model of hypertension , since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension .|Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension .|An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain .|However , the role of vasopressin remains to be determined in human essential hypertension .": {
            "[\"Vasopressin\", \"as a possible contributor to\", \"hypertension\"]": " \n[\"Vasopressin\", \"contributes to\", \"hypertension\"]\nGranularity: 1",
            "[\"Vasopressin\", \"as a pressor agent to\", \"hypertensive process\"]": "\n[\"Vasopressin\", \"is used as\", \"a pressor agent\"]\n[\"Vasopressin\", \"is used in\", \"the treatment of hypertension\"]\nGranularity: 2",
            "[\"Vasopressin\", \"plays a major role in\", \"pathogenesis of DOCA-salt hypertension\"]": " \n[\"Vasopressin\", \"plays a role in\", \"pathogenesis of DOCA-salt hypertension\"]\n[\"Vasopressin\", \"plays a major role in\", \"pathogenesis of hypertension\"]\n[\"Vasopressin\", \"plays a major role in\", \"pathogenesis of DOCA-salt\"]\nGranularity: 3",
            "[\"Elevation of blood pressure\", \"was not substantial in\", \"rats with lithium-treated diabetes insipidus after DOCA-salt treatment\"]": " \n[\"Elevation of blood pressure\", \"was not substantial in\", \"rats with lithium-treated diabetes insipidus\"]\n[\"rats with lithium-treated diabetes insipidus\", \"after\", \"DOCA-salt treatment\"]\nGranularity: 2",
            "[\"Administration of DDAVP\", \"failed to increase blood pressure to the levels observed after\", \"administration of AVP\"]": " \n[\"Administration of DDAVP\", \"failed to increase blood pressure\"]\n[\"Administration of DDAVP\", \"increased blood pressure to the levels observed after\", \"administration of AVP\"]\nGranularity: 2",
            "[\"The pressor action of vasopressin\", \"appears to be important in\", \"development of this model of hypertension\"]": " \n[\"The pressor action of vasopressin\", \"is important in\", \"development of this model\"]\n[\"Vasopressin\", \"has a pressor action in\", \"development of this model\"]\n[\"Vasopressin\", \"is important in\", \"development of this model\"]\nGranularity: 3",
            "[\"Increased secretion of vasopressin from neurohypophysis\", \"promotes the function of\", \"hormone as a pathogenetic factor in hypertension\"]": " \n[\"Increased secretion of vasopressin from neurohypophysis\", \"promotes\", \"hormone function\"]\n[\"Increased secretion of vasopressin from neurohypophysis\", \"promotes\", \"pathogenetic factor\"]\n[\"hormone\", \"is a\", \"pathogenetic factor\"]\nGranularity: 3",
            "[\"Unproportional release of vasopressin compared to plasma osmolality\", \"may be induced by\", \"absence of an adjusting control of angiotensin II forming and receptor binding capacity for sodium balance in the brain\"]": " \n[\"vasopressin release\", \"may be induced by\", \"absence of control of angiotensin II forming\"]\n[\"vasopressin release\", \"may be induced by\", \"absence of control of receptor binding capacity\"]\n[\"vasopressin release\", \"may be induced by\", \"absence of control of sodium balance in the brain\"]\nGranularity: 3",
            "[\"The role of vasopressin\", \"remains to be determined in\", \"human essential hypertension\"]": " \n[\"The role of vasopressin\", \"remains to be determined\", \"in human essential hypertension\"]\nGranularity: 1"
      },
      "Improvement by denopamine ( TA - 064 ) of pentobarbital - induced cardiac failure in the dog heart - lung preparation .|The efficacy of denopamine , an orally active beta 1 - adrenoceptor agonist , in improving cardiac failure was assessed in dog heart - lung preparations .|Cardiac functions depressed by pentobarbital ( 118 + / - 28 mg ; mean value + / - SD ) such that cardiac output and maximum rate of rise of left ventricular pressure ( LV dP / dt max ) had been reduced by about 35 % and 26 % of the respective controls were improved by denopamine ( 10 - 300 micrograms ) in a dose - dependent manner .|With 100 micrograms denopamine , almost complete restoration of cardiac performance was attained , associated with a slight increase in heart rate .|No arrhythmias were induced by these doses of denopamine .|The results warrant clinical trials of denopamine in the treatment of cardiac failure .": {
            "[\"Improvement\", \"by\", \"denopamine (TA-064)\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Denopamine\", \"is\", \"an orally active beta 1-adrenoceptor agonist\"]": " \n[\"Denopamine\", \"is\", \"orally active\"]\n[\"Denopamine\", \"is\", \"beta 1-adrenoceptor agonist\"]\nGranularity: 2",
            "[\"Denopamine\", \"assessed in\", \"dog heart-lung preparations\"]": " \n[\"Denopamine\", \"assessed\", \"dog heart-lung preparations\"]\nGranularity: 1",
            "[\"Cardiac functions\", \"depressed by\", \"pentobarbital\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Denopamine\", \"improved\", \"cardiac functions\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Denopamine\", \"improved\", \"cardiac output\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Denopamine\", \"improved\", \"maximum rate of rise of left ventricular pressure (LV dP/dt max)\"]": " \n[\"Denopamine\", \"improved\", \"maximum rate of rise of left ventricular pressure\"]\n[\"Denopamine\", \"improved\", \"LV dP/dt max\"]\nGranularity: 2",
            "[\"Denopamine\", \"restored\", \"cardiac performance\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Denopamine\", \"associated with\", \"a slight increase in heart rate\"]": " \n[\"Denopamine\", \"associated with\", \"increase in heart rate\"]\n[\"Denopamine\", \"associated with\", \"slight increase\"]\nGranularity: 2",
            "[\"Denopamine\", \"did not induce\", \"arrhythmias\"]": " N/A (The triple is specific, conveying a singular relation between Denopamine and arrhythmias.)\nGranularity: 0",
            "[\"Results\", \"warrant\", \"clinical trials of denopamine\"]": " \n[\"Results\", \"warrant\", \"clinical trials\"]\n[\"clinical trials\", \"of\", \"denopamine\"]\nGranularity: 2"
      },
      "Milk - alkali syndrome induced by 1 , 25 ( OH ) 2D in a patient with hypoparathyroidism .|Milk - alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali .|Although with current ulcer therapy ( H - 2 blockers , omeprazole , and sucralfate ) , the frequency of milk - alkali syndrome has decreased significantly , the classic triad of hypercalcemia , alkalosis , and renal impairment remains the hallmark of the syndrome .|Milk - alkali syndrome can present serious and occasionally life - threatening illness unless diagnosed and treated appropriately .|This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .|The patient was successfully treated with intravenous pamidronate on his first admission and with hydrocortisone on the second .|This illustrates intravenous pamidronate as a valuable therapeutic tool when milk - alkali syndrome presents as hypercalcemic emergency .": {
            "[\"Milk\", \"induced by\", \"alkali syndrome\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Milk-alkali syndrome\", \"was first described\", \"70 years ago\"]": " \n[\"Milk-alkali syndrome\", \"was described\", \"70 years ago\"]\nGranularity: 1",
            "[\"Milk-alkali syndrome\", \"associated with\", \"peptic ulcer disease\"]": " \n[\"Milk-alkali syndrome\", \"associated with\", \"peptic ulcer disease\"]\nGranularity: 1",
            "[\"Milk-alkali syndrome\", \"currently less frequent due to\", \"H-2 blockers, omeprazole, and sucralfate\"]": " \n[\"Milk-alkali syndrome\", \"currently less frequent due to\", \"H-2 blockers\"]\n[\"Milk-alkali syndrome\", \"currently less frequent due to\", \"omeprazole\"]\n[\"Milk-alkali syndrome\", \"currently less frequent due to\", \"sucralfate\"]\nGranularity: 3",
            "[\"Milk-alkali syndrome\", \"characterized by\", \"hypercalcemia, alkalosis, and renal impairment\"]": " \n[\"Milk-alkali syndrome\", \"is characterized by\", \"hypercalcemia\"]\n[\"Milk-alkali syndrome\", \"is characterized by\", \"alkalosis\"]\n[\"Milk-alkali syndrome\", \"is characterized by\", \"renal impairment\"]\nGranularity: 3",
            "[\"Milk-alkali syndrome\", \"can result in\", \"serious and life-threatening illness\"]": " \n[\"Milk-alkali syndrome\", \"can result in\", \"serious illness\"]\n[\"Milk-alkali syndrome\", \"can result in\", \"life-threatening illness\"]\nGranularity: 2",
            "[\"Patient\", \"has\", \"hypoparathyroidism\"]": " N/A (The triple is specific, conveying a singular relation between a patient and hypoparathyroidism.)\nGranularity: 0",
            "[\"Patient\", \"treated with\", \"calcium carbonate and calcitriol\"]": " \n[\"Patient\", \"treated with\", \"calcium carbonate\"]\n[\"Patient\", \"treated with\", \"calcitriol\"]\nGranularity: 2",
            "[\"Treatment\", \"led to\", \"two admissions for milk-alkali syndrome\"]": " \n[\"Treatment\", \"resulted in\", \"two admissions\"]\n[\"Treatment\", \"resulted in\", \"milk-alkali syndrome\"]\nGranularity: 2",
            "[\"Patient\", \"successfully treated with\", \"intravenous pamidronate on the first admission\"]": " \n[\"Patient\", \"successfully treated with\", \"intravenous pamidronate\"]\n[\"Patient\", \"successfully treated on the first admission\"]\nGranularity: 2",
            "[\"Patient\", \"successfully treated with\", \"hydrocortisone on the second admission\"]": " \n[\"Patient\", \"treated with\", \"hydrocortisone\"]\n[\"Patient\", \"successfully treated on\", \"second admission\"]\nGranularity: 2",
            "[\"Intravenous pamidronate\", \"considered as\", \"a valuable therapeutic tool\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Etomidate : a foreshortened clinical trial .|A clinical evaluation of etomidate for outpatient cystoscopy was embarked upon .|Unpremedicated patients were given fentanyl 1 microgram / kg followed by etomidate 0 . 3 mg / kg .|Anaesthesia was maintained with intermittent etomidate in 2 - 4 mg doses .|Patients were interviewed personally later the same day , and by questionnaire three to four weeks later .|The trial was discontinued after 20 cases because of an unacceptable incidence of side effects .|Venous pain occurred in 68 % of patients and 50 % had redness , pain or swelling related to the injection site , in some cases lasting up to three weeks after anaesthesia .|Skeletal movements occurred in 50 % of patients ; 30 % experienced respiratory upset , one sufficiently severe to necessitate abandoning the technique .|Nausea and vomiting occurred in 40 % and 25 % had disturbing emergence psychoses .": {
            "[\"Etomidate\", \"given to\", \"unpremedicated patients\"]": " \n[\"Etomidate\", \"is given to\", \"unpremedicated patients\"]\nGranularity: 1",
            "[\"Etomidate\", \"dosage\", \"0.3 mg/kg\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Etomidate\", \"maintenance of anaesthesia\", \"intermittent doses of 2-4 mg\"]": " \n[\"Etomidate\", \"is used for\", \"maintenance of anaesthesia\"]\n[\"Etomidate\", \"is given in\", \"intermittent doses of 2-4 mg\"]\nGranularity: 2",
            "[\"Clinical trial\", \"discontinued\", \"unacceptable incidence of side effects\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Side effects\", \"venous pain\", \"68% of patients\"]": " \n[\"Side effects\", \"cause\", \"venous pain\"]\n[\"Side effects\", \"occur in\", \"68% of patients\"]\nGranularity: 2",
            "[\"Side effects\", \"redness, pain, or swelling at injection site\", \"50% of patients\"]": "\n[\"Side effects\", \"include\", \"redness at injection site\"]\n[\"Side effects\", \"include\", \"pain at injection site\"]\n[\"Side effects\", \"include\", \"swelling at injection site\"]\n[\"50% of patients\", \"experience\", \"redness at injection site\"]\n[\"50% of patients\", \"experience\", \"pain at injection site\"]\n[\"50% of patients\", \"experience\", \"swelling at injection site\"]\nGranularity: 6",
            "[\"Side effects\", \"skeletal movements\", \"50% of patients\"]": " \n[\"Side effects\", \"affect\", \"skeletal movements\"]\n[\"Side effects\", \"occur in\", \"50% of patients\"]\nGranularity: 2",
            "[\"Side effects\", \"respiratory upset\", \"30% of patients\"]": " \n[\"Side effects\", \"can cause\", \"respiratory upset\"]\n[\"30% of patients\", \"experience\", \"respiratory upset\"]\nGranularity: 2",
            "[\"Side effects\", \"severe respiratory upset\", \"abandoning the technique\"]": "\n[\"Side effects\", \"cause\", \"severe respiratory upset\"]\n[\"severe respiratory upset\", \"leads to\", \"abandoning the technique\"]\nGranularity: 2",
            "[\"Side effects\", \"nausea\", \"40% of patients\"]": " \n[\"Side effects\", \"include\", \"nausea\"]\n[\"40% of patients\", \"experience\", \"nausea\"]\nGranularity: 2",
            "[\"Side effects\", \"vomiting\", \"25% of patients\"]": "\n[\"Side effects\", \"occur in\", \"25% of patients\"]\n[\"Side effects\", \"include\", \"vomiting\"]\nGranularity: 2",
            "[\"Side effects\", \"disturbing emergence psychoses\", \"25% of patients\"]": " \n[\"Side effects\", \"cause\", \"disturbing emergence psychoses\"]\n[\"Side effects\", \"affect\", \"25% of patients\"]\nGranularity: 2",
            "[\"Etomidate\", \"subject of\", \"a foreshortened clinical trial\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Etomidate\", \"subject of\", \"clinical evaluation for outpatient cystoscopy\"]": "\n[\"Etomidate\", \"undergoes\", \"clinical evaluation\"]\n[\"Etomidate\", \"is used for\", \"outpatient cystoscopy\"]\nGranularity: 2",
            "[\"Patients\", \"interviewed\", \"personally and by questionnaire\"]": " \n[\"Patients\", \"interviewed\", \"personally\"]\n[\"Patients\", \"interviewed\", \"by questionnaire\"]\nGranularity: 2"
      },
      "Nifedipine induced bradycardia in a patient with autonomic neuropathy .|An 80 year old diabetic male with evidence of peripheral and autonomic neuropathy was admitted with chest pain .|He was found to have atrial flutter at a ventricular rate of 70 / min which slowed down to 30 - 40 / min when nifedipine ( 60 mg ) in 3 divided doses , during which he was paced at a rate of 70 / min .|This is inconsistent with the well - established finding that nifedipine induces tachycardia in normally innervated hearts .|However , in hearts deprived of compensatory sympathetic drive , it may lead to bradycardia .": {
            "[\"patient\", \"has\", \"autonomic neuropathy\"]": " N/A (The triple is specific, conveying a singular relation between a patient and autonomic neuropathy.)\nGranularity: 0",
            "[\"patient\", \"admitted with\", \"chest pain\"]": " \n[\"patient\", \"admitted with\", \"chest pain\"]\nGranularity: 1",
            "[\"patient\", \"found with\", \"atrial flutter\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"nifedipine\", \"slowed down\", \"ventricular rate\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"patient\", \"paced at\", \"ventricular rate\"]": " \n[\"patient\", \"paced at\", \"ventricular rate\"]\nGranularity: 1",
            "[\"nifedipine\", \"inconsistent with\", \"tachycardia\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"nifedipine\", \"may lead to\", \"bradycardia\"]": " N/A (The triple is specific, conveying a singular relation between nifedipine and bradycardia.)\nGranularity: 0",
            "[\"nifedipine\", \"induced\", \"bradycardia\"]": " N/A (The triple is specific, conveying a singular relation between nifedipine and bradycardia.)\nGranularity: 0"
      },
      "Availability of human induced pluripotent stem cell - derived cardiomyocytes in assessment of drug potential for QT prolongation .|Field potential duration ( FPD ) in human - induced pluripotent stem cell - derived cardiomyocytes ( hiPS - CMs ) , which can express QT interval in an electrocardiogram , is reported to be a useful tool to predict K ( + ) channel and Ca ( 2 + ) channel blocker effects on QT interval .|However , there is no report showing that this technique can be used to predict multichannel blocker potential for QT prolongation .|The aim of this study is to show that FPD from MEA ( Multielectrode array ) of hiPS - CMs can detect QT prolongation induced by multichannel blockers .|hiPS - CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration .|IKr and IKs blockers concentration - dependently prolonged corrected FPD ( FPDc ) , whereas Ca ( 2 + ) channel blockers concentration - dependently shortened FPDc .|Also , the multichannel blockers Amiodarone , Paroxetine , Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner .|Finally , the IKr blockers , Terfenadine and Citalopram , which are reported to cause Torsade de Pointes ( TdP ) in clinical practice , produced early afterdepolarization ( EAD ) . hiPS - CMs using MEA system and FPDc can predict the effects of drug candidates on QT interval .|This study also shows that this assay can help detect EAD for drugs with TdP potential .": {
            "[\"human induced pluripotent stem cell\", \"derived\", \"cardiomyocytes\"]": " \n[\"human induced pluripotent stem cell\", \"derived\", \"cardiomyocytes\"]\nGranularity: 1",
            "[\"cardiomyocytes\", \"express\", \"QT interval\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"QT interval\", \"reported\", \"useful tool\"]": " N/A (The triple is specific, conveying a singular relation between QT interval and its usefulness.)\nGranularity: 0",
            "[\"tool\", \"predict\", \"K ( + ) channel and Ca ( 2 + ) channel blocker effects\"]": " \n[\"tool\", \"predicts\", \"K ( + ) channel blocker effects\"]\n[\"tool\", \"predicts\", \"Ca ( 2 + ) channel blocker effects\"]\nGranularity: 2",
            "[\"technique\", \"cannot be used to\", \"predict multichannel blocker potential\"]": " \n[\"technique\", \"cannot be used\", \"to predict\"]\n[\"technique\", \"cannot be used\", \"multichannel blocker potential\"]\nGranularity: 2",
            "[\"study\", \"aim\", \"show that FPD from MEA ( Multielectrode array ) of hiPS - CMs can detect QT prolongation induced by multichannel blockers\"]": " \n[\"study\", \"aim\", \"show that FPD from MEA of hiPS - CMs\"]\n[\"FPD\", \"can detect\", \"QT prolongation\"]\n[\"QT prolongation\", \"is induced by\", \"multichannel blockers\"]\nGranularity: 3",
            "[\"hiPS - CMs\", \"seeded onto\", \"MEA\"]": "\n[\"hiPS - CMs\", \"seeded\", \"MEA\"]\n[\"hiPS - CMs\", \"onto\", \"MEA\"]\nGranularity: 2",
            "[\"FPD\", \"measured for\", \"2min every 10min for 30min after drug exposure\"]": " \n[\"FPD\", \"measured for\", \"2min\"]\n[\"FPD\", \"measured every\", \"10min\"]\n[\"FPD\", \"measured for\", \"30min\"]\n[\"FPD\", \"measured after\", \"drug exposure\"]\nGranularity: 4",
            "[\"IKr and IKs blockers\", \"prolonged\", \"corrected FPD ( FPDc )\"]": " \n[\"IKr blockers\", \"prolonged\", \"FPDc\"]\n[\"IKs blockers\", \"prolonged\", \"FPDc\"]\nGranularity: 2",
            "[\"Ca ( 2 + ) channel blockers\", \"shortened\", \"FPDc\"]": " \n[\"Ca ( 2 + ) channel blockers\", \"shortened\", \"FPDc\"]\nGranularity: 1",
            "[\"multichannel blockers\", \"prolonged\", \"FPDc\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"IKr blockers\", \"Terfenadine and Citalopram\", \"produced\"]": " \n[\"IKr blockers\", \"Terfenadine\", \"produced\"]\n[\"IKr blockers\", \"Citalopram\", \"produced\"]\nGranularity: 2",
            "[\"Terfenadine and Citalopram\", \"reported to\", \"cause Torsade de Pointes ( TdP ) in clinical practice\"]": " \n[\"Terfenadine and Citalopram\", \"reported to cause\", \"Torsade de Pointes ( TdP )\"]\n[\"Terfenadine and Citalopram\", \"reported to cause\", \"in clinical practice\"]\nGranularity: 2",
            "[\"hiPS - CMs\", \"using\", \"MEA system and FPDc\"]": " \n[\"hiPS - CMs\", \"using\", \"MEA system\"]\n[\"hiPS - CMs\", \"using\", \"FPDc\"]\nGranularity: 2",
            "[\"assay\", \"can help detect\", \"EAD for drugs with TdP potential\"]": " \n[\"assay\", \"can help detect\", \"EAD\"]\n[\"assay\", \"can help detect\", \"drugs with TdP potential\"]\nGranularity: 2"
      },
      "Conversion to sirolimus ameliorates cyclosporine - induced nephropathy in the rat : focus on serum , urine , gene , and protein renal expression biomarkers .|Protocols of conversion from cyclosporin A ( CsA ) to sirolimus ( SRL ) have been widely used in immunotherapy after transplantation to prevent CsA - induced nephropathy , but the molecular mechanisms underlying these protocols remain nuclear .|This study aimed to identify the molecular pathways and putative biomarkers of CsA - to - SRL conversion in a rat model .|Four animal groups ( n = 6 ) were tested during 9 weeks : control , CsA , SRL , and conversion ( CsA for 3 weeks followed by SRL for 6 weeks ) .|Classical and emergent serum , urinary , and kidney tissue ( gene and protein expression ) markers were assessed .|Renal lesions were analyzed in hematoxylin and eosin , periodic acid - Schiff , and Masson 's trichrome stains .|SRL - treated rats presented proteinuria and NGAL ( serum and urinary ) as the best markers of renal impairment .|Short CsA treatment presented slight or even absent kidney lesions and TGF - b , NF - kb , mTOR , PCNA , TP53 , KIM - 1 , and CTGF as relevant gene and protein changes .|Prolonged CsA exposure aggravated renal damage , without clear changes on the traditional markers , but with changes in serums TGF - b and IL - 7 , TBARs clearance , and kidney TGF - b and mTOR .|Conversion to SRL prevented CsA - induced renal damage evolution ( absent / mild grade lesions ) , while NGAL ( serum versus urine ) seems to be a feasible biomarker of CsA replacement to SRL .": {
            "[\"Conversion to sirolimus\", \"ameliorates\", \"cyclosporine - induced nephropathy\"]": " \n[\"Conversion to sirolimus\", \"ameliorates\", \"cyclosporine-induced nephropathy\"]\n[\"Conversion to sirolimus\", \"ameliorates\", \"cyclosporine\"]\n[\"Conversion to sirolimus\", \"ameliorates\", \"nephropathy\"]\nGranularity: 3",
            "[\"Protocols of conversion\", \"have been widely used\", \"in immunotherapy after transplantation\"]": " \n[\"Protocols of conversion\", \"have been used in\", \"immunotherapy\"]\n[\"Protocols of conversion\", \"have been used after\", \"transplantation\"]\nGranularity: 2",
            "[\"Cyclosporin A ( CsA )\", \"to\", \"sirolimus ( SRL )\"]": "\n[\"Cyclosporin A\", \"to\", \"sirolimus\"]\n[\"CsA\", \"to\", \"SRL\"]\nGranularity: 2",
            "[\"This study\", \"aimed to identify\", \"the molecular pathways\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Four animal groups\", \"were tested\", \"during 9 weeks\"]": " \n[\"Four animal groups\", \"were tested\", \"during 9 weeks\"]\nGranularity: 1",
            "[\"Classical and emergent serum\", \"urinary\", \"and kidney tissue ( gene and protein expression )\"]": " \n[\"Classical serum\", \"urinary\", \"gene expression\"]\n[\"Classical serum\", \"urinary\", \"protein expression\"]\n[\"Classical kidney tissue\", \"gene expression\"]\n[\"Classical kidney tissue\", \"protein expression\"]\n[\"Emergent serum\", \"urinary\", \"gene expression\"]\n[\"Emergent serum\", \"urinary\", \"protein expression\"]\n[\"Emergent kidney tissue\", \"gene expression\"]\n[\"Emergent kidney tissue\", \"protein expression\"]\nGranularity: 8",
            "[\"Renal lesions\", \"were analyzed\", \"in hematoxylin and eosin , periodic acid - Schiff , and Masson 's trichrome stains \"]": " \n[\"Renal lesions\", \"were analyzed\", \"in hematoxylin and eosin\"]\n[\"Renal lesions\", \"were analyzed\", \"in periodic acid - Schiff\"]\n[\"Renal lesions\", \"were analyzed\", \"in Masson 's trichrome\"]\nGranularity: 3",
            "[\"SRL - treated rats\", \"presented\", \"proteinuria and NGAL ( serum and urinary )\"]": " \n[\"SRL - treated rats\", \"presented\", \"proteinuria\"]\n[\"SRL - treated rats\", \"presented\", \"NGAL ( serum )\"]\n[\"SRL - treated rats\", \"presented\", \"NGAL ( urinary )\"]\nGranularity: 3",
            "[\"Short CsA treatment\", \"presented\", \"slight or even absent kidney lesions\"]": " \n[\"Short CsA treatment\", \"presented\", \"slight kidney lesions\"]\n[\"Short CsA treatment\", \"presented\", \"absent kidney lesions\"]\nGranularity: 2",
            "[\"Prolonged CsA exposure\", \"aggravated\", \"renal damage\"]": " \n[\"Prolonged CsA exposure\", \"aggravated\", \"renal damage\"]\nGranularity: 1",
            "[\"Conversion to SRL\", \"prevented\", \"CsA - induced renal damage evolution\"]": " \n[\"Conversion to SRL\", \"prevented\", \"renal damage\"]\n[\"Conversion to SRL\", \"prevented\", \"CsA-induced renal damage\"]\nGranularity: 2",
            "[\"NGAL ( serum versus urine )\", \"seems to be\", \"a feasible biomarker of CsA replacement to SRL \"]": " \n[\"NGAL\", \"is a feasible biomarker of\", \"CsA replacement to SRL\"]\n[\"NGAL\", \"is a biomarker of\", \"CsA replacement\"]\n[\"NGAL\", \"is a biomarker of\", \"SRL\"]\nGranularity: 3"
      },
      "Respiratory pattern in a rat model of epilepsy .|PURPOSE : Apnea is known to occur during seizures , but systematic studies of ictal respiratory changes in adults are few .|Data regarding respiratory pattern defects during interictal periods also are scarce .|Here we sought to generate information with regard to the interictal period in animals with pilocarpine - induced epilepsy .|METHODS : Twelve rats ( six chronically epileptic animals and six controls ) were anesthetized , given tracheotomies , and subjected to hyperventilation or hypoventilation conditions .|Breathing movements caused changes in thoracic volume and forced air to flow tidally through a pneumotachograph .|This flow was measured by using a differential pressure transducer , passed through a polygraph , and from this to a computer with custom software that derived ventilation ( VE ) , tidal volume ( VT ) , inspiratory time ( TI ) , expiratory time ( TE ) , breathing frequency ( f ) , and mean inspiratory flow ( VT / TI ) on a breath - by - breath basis .|RESULTS : The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine - treated and control rats .|Although VE had a similar decrease in both groups , in the epileptic group , the decrease in VE was due to a significant ( p < 0 . 05 ) increase in TE peak in relation to that of the control animals .|The hypoventilation maneuver led to an increase in the arterial Paco2 , followed by an increase in VE .|In the epileptic group , the increase in VE was mediated by a significant ( p < 0 . 05 ) decrease in TE peak compared with the control group .|Systemic application of KCN , to evaluate the effects of peripheral chemoreception activation on ventilation , led to a similar increase in VE for both groups .|CONCLUSIONS : The data indicate that pilocarpine - treated animals have an altered ability to react to ( or compensate for ) blood gas changes with changes in ventilation and suggest that it is centrally determined .|We speculate on the possible relation of the current findings on treating different epilepsy - associated conditions .": {
            "[\"Respiratory pattern\", \"in a rat model of\", \"epilepsy\"]": "\n[\"Respiratory pattern\", \"in a rat model of\", \"epilepsy\"]\nGranularity: 0",
            "[\"Apnea\", \"is known to occur during\", \"seizures\"]": " \n[\"Apnea\", \"occurs during\", \"seizures\"]\nGranularity: 1",
            "[\"Systematic studies\", \"of ictal respiratory changes in adults\", \"are few\"]": "\n[\"Systematic studies\", \"of ictal respiratory changes\", \"in adults\"]\n[\"Systematic studies\", \"of ictal respiratory changes\", \"are few\"]\nGranularity: 2",
            "[\"Data\", \"regarding respiratory pattern defects during interictal periods\", \"are scarce\"]": " \n[\"Data\", \"regarding\", \"respiratory pattern defects\"]\n[\"respiratory pattern defects\", \"occur during\", \"interictal periods\"]\n[\"Data\", \"are scarce\"]\nGranularity: 3",
            "[\"Twelve rats\", \"were anesthetized\", \"given tracheotomies\"]": " \n[\"Twelve rats\", \"were anesthetized\", \"given tracheotomies\"]\n[\"Twelve rats\", \"were anesthetized\", \"were given tracheotomies\"]\nGranularity: 2",
            "[\"Twelve rats\", \"subjected to\", \"hyperventilation or hypoventilation conditions\"]": " \n[\"Twelve rats\", \"were subjected to\", \"hyperventilation\"]\n[\"Twelve rats\", \"were subjected to\", \"hypoventilation\"]\nGranularity: 2",
            "[\"Breathing movements\", \"caused changes in\", \"thoracic volume\"]": " \n[\"Breathing movements\", \"cause\", \"changes in thoracic volume\"]\nGranularity: 1",
            "[\"Forced air\", \"flowed tidally through\", \"a pneumotachograph\"]": "\n[\"Forced air\", \"flowed\", \"tidally\"]\n[\"Forced air\", \"flowed through\", \"a pneumotachograph\"]\nGranularity: 2",
            "[\"This flow\", \"was measured by using\", \"a differential pressure transducer\"]": "\n[\"This flow\", \"was measured\", \"by using a differential pressure transducer\"]\n[\"This flow\", \"was measured by\", \"using a differential pressure transducer\"]\n[\"This flow\", \"was measured by using\", \"a pressure transducer\"]\n[\"This flow\", \"was measured by using a differential\", \"pressure transducer\"]\n[\"This flow\", \"was measured by using a differential pressure\", \"transducer\"]\nGranularity: 5",
            "[\"The flow\", \"passed through\", \"a polygraph\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"The flow\", \"went to\", \"a computer with custom software\"]": " \n[\"The flow\", \"went to\", \"a computer\"]\n[\"The flow\", \"went to\", \"custom software\"]\nGranularity: 2",
            "[\"Custom software\", \"derived\", \"ventilation ( VE ) , tidal volume ( VT ) , inspiratory time ( TI ) , expiratory time ( TE ) , breathing frequency ( f ) , and mean inspiratory flow ( VT / TI ) on a breath - by - breath basis\"]": " \n[\"Custom software\", \"derived\", \"ventilation ( VE )\"]\n[\"Custom software\", \"derived\", \"tidal volume ( VT )\"]\n[\"Custom software\", \"derived\", \"inspiratory time ( TI )\"]\n[\"Custom software\", \"derived\", \"expiratory time ( TE )\"]\n[\"Custom software\", \"derived\", \"breathing frequency ( f )\"]\n[\"Custom software\", \"derived\", \"mean inspiratory flow ( VT / TI )\"]\nGranularity: 6",
            "[\"The hyperventilation maneuver\", \"caused a decrease in\", \"spontaneous ventilation in pilocarpine - treated and control rats\"]": " \n[\"The hyperventilation maneuver\", \"caused a decrease in\", \"spontaneous ventilation in pilocarpine-treated rats\"]\n[\"The hyperventilation maneuver\", \"caused a decrease in\", \"spontaneous ventilation in control rats\"]\nGranularity: 2",
            "[\"Although VE had a similar decrease in both groups\", \"the decrease in VE was due to\", \"a significant ( p < 0 . 05 ) increase in TE peak in relation to that of the control animals \"]": " \n[\"VE\", \"decreased in\", \"both groups\"]\n[\"VE\", \"decreased due to\", \"an increase in TE peak\"]\n[\"TE peak\", \"increased significantly in relation to\", \"control animals\"]\nGranularity: 3",
            "[\"The hypoventilation maneuver\", \"led to\", \"an increase in the arterial Paco2 , followed by an increase in VE \"]": " \n[\"The hypoventilation maneuver\", \"caused\", \"an increase in the arterial Paco2\"]\n[\"The hypoventilation maneuver\", \"caused\", \"an increase in VE\"]\nGranularity: 2",
            "[\"In the epileptic group\", \"the increase in VE was mediated by\", \"a significant ( p < 0 . 05 ) decrease in TE peak compared with the control group \"]": " \n[\"In the epileptic group\", \"the increase in VE was mediated by\", \"a significant decrease in TE peak\"]\n[\"the increase in VE\", \"was mediated by\", \"a significant decrease in TE peak\"]\n[\"a significant decrease\", \"in TE peak\", \"compared with the control group\"]\nGranularity: 3",
            "[\"Systemic application of KCN\", \"to evaluate the effects of\", \"peripheral chemoreception activation on ventilation\"]": " \n[\"Systemic application of KCN\", \"evaluates\", \"effects of peripheral chemoreception activation\"]\n[\"Systemic application of KCN\", \"to activate\", \"peripheral chemoreception\"]\n[\"Peripheral chemoreception activation\", \"affects\", \"ventilation\"]\nGranularity: 3",
            "[\"The data\", \"indicate that\", \"pilocarpine - treated animals have an altered ability to react to ( or compensate for ) blood gas changes with changes in ventilation\"]": " \n[\"pilocarpine-treated animals\", \"have an altered ability to react to blood gas changes\", \"with changes in ventilation\"]\n[\"pilocarpine-treated animals\", \"have an altered ability to compensate for blood gas changes\", \"with changes in ventilation\"]\nGranularity: 2",
            "[\"The data\", \"suggest that it is\", \"centrally determined\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"We speculate\", \"on the possible relation of the current findings on\", \"treating different epilepsy - associated conditions \"]": " \n[\"We speculate\", \"on the relation of the current findings\", \"treating epilepsy\"]\n[\"We speculate\", \"on the relation of the current findings\", \"treating associated conditions\"]\nGranularity: 2"
      },
      "Morphological evaluation of the effect of d - ribose on adriamycin - evoked cardiotoxicity in rats .|The influence of d - ribose on adriamycin - induced myocardiopathy in rats was studied .|Adriamycin in the cumulative dose of 25 mg / kg evoked fully developed cardiac toxicity .|D - ribose in the multiple doses of 200 mg / kg did not influence ADR cardiotoxicity .": {
            "[\"adriamycin\", \"evoked\", \"cardiotoxicity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"d-ribose\", \"did not influence\", \"ADR cardiotoxicity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Morphological evaluation\", \"of the effect of\", \"d-ribose\"]": "\n[\"Morphological evaluation\", \"of\", \"d-ribose\"]\n[\"effect of\", \"d-ribose\", \"on morphology\"]\nGranularity: 2",
            "[\"d-ribose\", \"influence on\", \"adriamycin-induced myocardiopathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"adriamycin\", \"induced\", \"myocardiopathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson 's disease patients .|Levodopa is the most effective symptomatic therapy for Parkinson 's disease , but its chronic use could lead to chronic adverse outcomes , such as motor fluctuations , dyskinesia and visual hallucinations .|HOMER1 is a protein with pivotal function in glutamate transmission , which has been related to the pathogenesis of these complications .|This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy .|A total of 205 patients with idiopathic Parkinson 's disease were investigated .|Patients were genotyped for rs4704559 , rs10942891 and rs4704560 by allelic discrimination with Taqman assays .|The rs4704559 G allele was associated with a lower prevalence of dyskinesia ( prevalence ratio ( PR ) = 0 . 615 , 95 % confidence interval ( CI ) 0 . 426 - 0 . 887 , P = 0 . 009 ) and visual hallucinations ( PR = 0 . 515 , 95 % CI 0 . 295 - 0 . 899 , P = 0 . 020 ) .|Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects .": {
            "[\"Association\", \"of\", \"common genetic variants of HOMER1 gene\"]": " \n[\"Association\", \"of\", \"common genetic variants\"]\n[\"Association\", \"of\", \"HOMER1 gene\"]\nGranularity: 2",
            "[\"Levodopa\", \"is the most effective symptomatic therapy for\", \"Parkinson's disease\"]": " \n[\"Levodopa\", \"is\", \"the most effective symptomatic therapy\"]\n[\"the most effective symptomatic therapy\", \"is for\", \"Parkinson's disease\"]\nGranularity: 2",
            "[\"Levodopa\", \"leads to\", \"chronic adverse outcomes\"]": " N/A (The triple is specific, conveying a singular relation between Levodopa and chronic adverse outcomes.)\nGranularity: 0",
            "[\"HOMER1\", \"is a protein with\", \"pivotal function in glutamate transmission\"]": " \n[\"HOMER1\", \"has\", \"pivotal function\"]\n[\"HOMER1\", \"plays a role in\", \"glutamate transmission\"]\nGranularity: 2",
            "[\"HOMER1\", \"has been related to\", \"the pathogenesis of complications\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"This study\", \"investigates\", \"association of polymorphisms in HOMER1 gene promoter region\"]": " \n[\"This study\", \"investigates\", \"polymorphisms in HOMER1 gene promoter region\"]\n[\"polymorphisms\", \"in\", \"HOMER1 gene promoter region\"]\nGranularity: 2",
            "[\"A total of\", \"205 patients with\", \"idiopathic Parkinson's disease\"]": " \n[\"A total of\", \"205 patients\", \"have idiopathic Parkinson's disease\"]\n[\"A total of\", \"205 patients\", \"suffer from idiopathic Parkinson's disease\"]\nGranularity: 2",
            "[\"Patients\", \"were genotyped for\", \"rs4704559, rs10942891, and rs4704560\"]": "\n[\"Patients\", \"were genotyped for\", \"rs4704559\"]\n[\"Patients\", \"were genotyped for\", \"rs10942891\"]\n[\"Patients\", \"were genotyped for\", \"rs4704560\"]\nGranularity: 3",
            "[\"The rs4704559 G allele\", \"was associated with\", \"lower prevalence of dyskinesia and visual hallucinations\"]": " \n[\"The rs4704559 G allele\", \"was associated with\", \"lower prevalence of dyskinesia\"]\n[\"The rs4704559 G allele\", \"was associated with\", \"lower prevalence of visual hallucinations\"]\nGranularity: 2",
            "[\"Our data\", \"suggest\", \"HOMER1 rs4704559 G allele has a protective role\"]": "\n[\"Our data\", \"suggest\", \"HOMER1 rs4704559 G allele\"]\n[\"HOMER1 rs4704559 G allele\", \"has\", \"a protective role\"]\nGranularity: 2"
      },
      "Recurrent myocardial infarction in a postpartum patient receiving bromocriptine .|Myocardial infarction in puerperium is infrequently reported .|Spasm , coronary dissection , or atheromatous etiology has been described .|Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium .|Our case ( including an inadvertent rechallenge ) suggests such a relationship .|Although generally regarded as \" safe , \" possible serious cardiac effects of bromocriptine should be acknowledged .": {
            "[\"Myocardial infarction in puerperium\", \"is\", \"infrequently reported\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Spasm\", \"is one of\", \"coronary dissection or atheromatous etiology\"]": " \n[\"Spasm\", \"is one of\", \"coronary dissection\"]\n[\"Spasm\", \"is one of\", \"atheromatous etiology\"]\nGranularity: 2",
            "[\"Bromocriptine\", \"has been implicated in\", \"several previous case reports of myocardial infarction in the puerperium\"]": " \n[\"Bromocriptine\", \"has been implicated in\", \"myocardial infarction\"]\n[\"Bromocriptine\", \"has been implicated in\", \"puerperium\"]\nGranularity: 2",
            "[\"Our case\", \"suggests\", \"such a relationship\"]": " N/A (The triple is vague and does not provide enough information to be split into more specific sub-triples.)\nGranularity: 0",
            "[\"Generally regarded as 'safe'\", \"possible serious cardiac effects\", \"of bromocriptine should be acknowledged\"]": " \n[\"bromocriptine\", \"has\", \"possible serious cardiac effects\"]\n[\"bromocriptine\", \"should be acknowledged for\", \"possible serious cardiac effects\"]\nGranularity: 2",
            "[\"Recurrent myocardial infarction\", \"occurs in\", \"a postpartum patient receiving bromocriptine\"]": " \n[\"Recurrent myocardial infarction\", \"occurs in\", \"a postpartum patient\"]\n[\"Recurrent myocardial infarction\", \"occurs in\", \"a patient receiving bromocriptine\"]\n[\"Recurrent myocardial infarction\", \"occurs in\", \"a postpartum patient receiving bromocriptine\"]\nGranularity: 3"
      },
      "Toleration of high doses of angiotensin - converting enzyme inhibitors in patients with chronic heart failure : results from the ATLAS trial .|The Assessment of Treatment with Lisinopril and Survival .|BACKGROUND : Treatment with angiotensin - converting enzyme ( ACE ) inhibitors reduces mortality and morbidity in patients with chronic heart failure ( CHF ) , but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials , primarily because of concerns about the safety and tolerability of these agents , especially at the recommended doses .|The present study examines the safety and tolerability of high - compared with low - dose lisinopril in CHF .|METHODS : The Assessment of Lisinopril and Survival study was a multicenter , randomized , double - blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium - dose lisinopril ( 12 . 5 or 15 . 0 mg once daily [ OD ] ) for 2 to 4 weeks and then randomized to high - ( 35 . 0 or 32 . 5 mg OD ) or low - dose ( 5 . 0 or 2 . 5 mg OD ) groups .|Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0 . 30 ( n = 3164 ) were randomized and followed up for a median of 46 months .|We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment , with a focus on hypotension and renal dysfunction .|RESULTS : Of 405 patients not previously receiving an ACE inhibitor , doses in only 4 . 2 % could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension ( 2 . 0 % ) or because of renal dysfunction or hyperkalemia ( 2 . 3 % ) .|Doses in more than 90 % of randomized patients in the high - and low - dose groups were titrated to their assigned target , and the mean doses of blinded medication in both groups remained similar throughout the study .|Withdrawals occurred in 27 . 1 % of the high - and 30 . 7 % of the low - dose groups .|Subgroups presumed to be at higher risk for ACE inhibitor intolerance ( blood pressure , < 120 mm Hg ; creatinine , > or = 132 . 6 micromol / L [ > or = 1 . 5 mg / dL ] ; age , > or = 70 years ; and patients with diabetes ) generally tolerated the high - dose strategy .|CONCLUSIONS : These findings demonstrate that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses , and that more aggressive use of these agents is warranted .": {
            "[\"toleration\", \"of\", \"high doses of angiotensin - converting enzyme inhibitors\"]": " \n[\"toleration\", \"of\", \"high doses\"]\n[\"toleration\", \"of\", \"angiotensin - converting enzyme inhibitors\"]\nGranularity: 2",
            "[\"results\", \"from\", \"the ATLAS trial\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Assessment of Treatment with Lisinopril and Survival\", \"is\", \"the present study\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"treatment\", \"with\", \"angiotensin - converting enzyme (ACE) inhibitors\"]": " \n[\"treatment\", \"with\", \"angiotensin - converting enzyme (ACE) inhibitors\"]\nGranularity: 1",
            "[\"reduces\", \"mortality and morbidity\", \"in patients with chronic heart failure (CHF)\"]": " \n[\"reduces\", \"mortality\", \"in patients with chronic heart failure (CHF)\"]\n[\"reduces\", \"morbidity\", \"in patients with chronic heart failure (CHF)\"]\nGranularity: 2",
            "[\"safety and tolerability\", \"of\", \"high - compared with low - dose lisinopril in CHF\"]": " \n[\"safety\", \"of\", \"high - dose lisinopril\"]\n[\"safety\", \"of\", \"low - dose lisinopril\"]\n[\"tolerability\", \"of\", \"high - dose lisinopril\"]\n[\"tolerability\", \"of\", \"low - dose lisinopril\"]\nGranularity: 4",
            "[\"Assessment of Lisinopril and Survival study\", \"was\", \"a multicenter , randomized , double - blind trial\"]": " \n[\"Assessment of Lisinopril and Survival study\", \"was\", \"a multicenter trial\"]\n[\"Assessment of Lisinopril and Survival study\", \"was\", \"a randomized trial\"]\n[\"Assessment of Lisinopril and Survival study\", \"was\", \"a double-blind trial\"]\nGranularity: 3",
            "[\"patients\", \"with or without previous ACE inhibitor treatment\", \"were stabilized receiving medium - dose lisinopril\"]": " \n[\"patients\", \"with previous ACE inhibitor treatment\", \"were stabilized receiving medium - dose lisinopril\"]\n[\"patients\", \"without previous ACE inhibitor treatment\", \"were stabilized receiving medium - dose lisinopril\"]\nGranularity: 2",
            "[\"high - ( 35 . 0 or 32 . 5 mg OD ) or low - dose ( 5 . 0 or 2 . 5 mg OD ) groups\", \"were\", \"randomized\"]": " \n[\"high-dose group\", \"was\", \"randomized\"]\n[\"low-dose group\", \"was\", \"randomized\"]\nGranularity: 2",
            "[\"patients\", \"with\", \"New York Heart Association classes II to IV CHF\"]": " \n[\"patients\", \"with\", \"New York Heart Association classes II to IV\"]\n[\"patients\", \"with\", \"CHF\"]\nGranularity: 2",
            "[\"left ventricular ejection fractions\", \"of no greater than\", \"0 . 30\"]": " \n[\"left ventricular ejection fractions\", \"are\", \"no greater than 0.30\"]\nGranularity: 1",
            "[\"3164\", \"were\", \"randomized and followed up for a median of 46 months\"]": " \n[\"3164\", \"were\", \"randomized\"]\n[\"3164\", \"were\", \"followed up\"]\n[\"3164\", \"were\", \"followed up for a median of 46 months\"]\nGranularity: 3",
            "[\"occurrence of adverse events\", \"and\", \"the need for discontinuation and dose reduction during treatment\"]": "\n[\"occurrence of adverse events\", \"leads to\", \"need for discontinuation\"]\n[\"occurrence of adverse events\", \"leads to\", \"need for dose reduction\"]\n[\"need for discontinuation\", \"occurs during\", \"treatment\"]\n[\"need for dose reduction\", \"occurs during\", \"treatment\"]\nGranularity: 4",
            "[\"focus\", \"on\", \"hypotension and renal dysfunction\"]": " \n[\"focus\", \"on\", \"hypotension\"]\n[\"focus\", \"on\", \"renal dysfunction\"]\nGranularity: 2",
            "[\"405 patients\", \"not\", \"previously receiving an ACE inhibitor\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"doses\", \"in\", \"only 4 . 2 %\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"could not be titrated to the medium doses required for randomization\", \"because of\", \"symptoms possibly related to hypotension ( 2 . 0 % ) or because of renal dysfunction or hyperkalemia ( 2 . 3 % )\"]": " \n[\"could not be titrated\", \"due to\", \"symptoms possibly related to hypotension\"]\n[\"could not be titrated\", \"due to\", \"renal dysfunction\"]\n[\"could not be titrated\", \"due to\", \"hyperkalemia\"]\nGranularity: 3",
            "[\"doses\", \"in\", \"more than 90 % of randomized patients in the high - and low - dose groups\"]": " \n[\"doses\", \"in\", \"more than 90 % of randomized patients in the high - dose group\"]\n[\"doses\", \"in\", \"more than 90 % of randomized patients in the low - dose group\"]\nGranularity: 2",
            "[\"mean doses of blinded medication\", \"in\", \"both groups remained similar throughout the study\"]": " \n[\"mean doses\", \"of blinded medication\", \"remained similar\"]\n[\"both groups\", \"remained similar\", \"throughout the study\"]\nGranularity: 2",
            "[\"withdrawals\", \"occurred in\", \"27 . 1 % of the high - and 30 . 7 % of the low - dose groups\"]": " \n[\"withdrawals\", \"occurred in\", \"27.1% of the high-dose groups\"]\n[\"withdrawals\", \"occurred in\", \"30.7% of the low-dose groups\"]\nGranularity: 2",
            "[\"subgroups\", \"presumed to be at higher risk for ACE inhibitor intolerance\", \"generally tolerated the high - dose strategy\"]": " \n[\"subgroups\", \"presumed to be at higher risk for ACE inhibitor intolerance\", \"tolerated the high - dose strategy\"]\n[\"subgroups\", \"presumed to be at higher risk for ACE inhibitor intolerance\", \"generally tolerated\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"ACE inhibitor intolerance\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"tolerated the high - dose strategy\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"ACE inhibitor intolerance\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"generally tolerated\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"high - dose strategy\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"ACE inhibitor intolerance\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"tolerated\"]\n[\"subgroups\", \"presumed to be at higher risk\", \"high - dose\"]\n",
            "[\"these findings\", \"demonstrate\", \"that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses\"]": " \n[\"these findings\", \"demonstrate\", \"ACE inhibitor therapy\"]\n[\"ACE inhibitor therapy\", \"can be successfully titrated to\", \"high doses\"]\n[\"ACE inhibitor therapy\", \"can be maintained at\", \"high doses\"]\nGranularity: 3",
            "[\"more\", \"aggressive use of these agents\", \"is warranted\"]": " N/A (The triple is not specific enough to be split into sub-triples.)\nGranularity: 0"
      },
      "Theophylline neurotoxicity in pregnant rats .|The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy .|Sprague - Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively .|Theophylline concentrations at this endpoint in serum ( total ) and CSF were similar but serum ( free ) and brain concentrations were slightly different in pregnant rats .|Theophylline serum protein binding determined by equilibrium dialysis was lower in pregnant rats .|Fetal serum concentrations at onset of seizures in the mother were similar to maternal brain and CSF concentrations and correlated significantly with the former .|It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats .": {
            "[\"Theophylline neurotoxicity\", \"in\", \"pregnant rats\"]": " \n[\"Theophylline\", \"causes\", \"neurotoxicity\"]\n[\"Theophylline\", \"occurs in\", \"pregnant rats\"]\nGranularity: 2",
            "[\"investigation\", \"determine\", \"whether the neurotoxicity of theophylline is altered in advanced pregnancy\"]": " \n[\"investigation\", \"determine\", \"neurotoxicity of theophylline\"]\n[\"investigation\", \"determine\", \"alteration in advanced pregnancy\"]\nGranularity: 2",
            "[\"Sprague-Dawley rats\", \"were\", \"20 days pregnant\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Sprague-Dawley rats\", \"received\", \"infusions of aminophylline\"]": " \n[\"Sprague-Dawley rats\", \"received\", \"infusions\"]\n[\"infusions\", \"of\", \"aminophylline\"]\nGranularity: 2",
            "[\"infusions of aminophylline\", \"until\", \"onset of maximal seizures\"]": " \n[\"infusions of aminophylline\", \"until\", \"onset of seizures\"]\n[\"infusions of aminophylline\", \"until\", \"maximal seizures\"]\nGranularity: 2",
            "[\"maximal seizures\", \"occurred after\", \"28 and 30 minutes\"]": " \n[\"maximal seizures\", \"occurred after\", \"28 minutes\"]\n[\"maximal seizures\", \"occurred after\", \"30 minutes\"]\nGranularity: 2",
            "[\"Theophylline concentrations\", \"at this endpoint\", \"in serum (total) and CSF\"]": " \n[\"Theophylline concentrations\", \"at this endpoint\", \"in serum\"]\n[\"Theophylline concentrations\", \"at this endpoint\", \"in CSF\"]\nGranularity: 2",
            "[\"serum (free)\", \"and brain concentrations\", \"were slightly different in pregnant rats\"]": " \n[\"serum (free)\", \"concentrations\", \"were slightly different in pregnant rats\"]\n[\"brain concentrations\", \"were slightly different in pregnant rats\"]\nGranularity: 2",
            "[\"Theophylline serum protein binding\", \"determined by\", \"equilibrium dialysis\"]": " \n[\"Theophylline\", \"has\", \"serum protein binding\"]\n[\"Serum protein binding\", \"is determined by\", \"equilibrium dialysis\"]\nGranularity: 2",
            "[\"Theophylline serum protein binding\", \"lower in\", \"pregnant rats\"]": " \n[\"Theophylline\", \"has lower\", \"serum protein binding\"]\n[\"Theophylline\", \"is lower in\", \"pregnant rats\"]\nGranularity: 2",
            "[\"Fetal serum concentrations\", \"at onset of seizures in the mother\", \"similar to maternal brain and CSF concentrations\"]": " \n[\"Fetal serum concentrations\", \"at onset of seizures in the mother\", \"similar to maternal brain concentrations\"]\n[\"Fetal serum concentrations\", \"at onset of seizures in the mother\", \"similar to maternal CSF concentrations\"]\nGranularity: 2",
            "[\"Fetal serum concentrations\", \"correlated significantly with\", \"the former\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"It is concluded\", \"that\", \"advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats\"]": " \n[\"advanced pregnancy\", \"has a negligible effect on\", \"the neurotoxic response to theophylline\"]\n[\"advanced pregnancy\", \"has a negligible effect on\", \"neurotoxic response\"]\n[\"advanced pregnancy\", \"has a negligible effect on\", \"theophylline\"]\nGranularity: 3"
      },
      "Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence : a placebo - controlled , double - blind crossover study .|The aim of the study was to evaluate the potential role for a selective alpha1 - adrenoceptor agonist in the treatment of urinary stress incontinence .|A randomised , double - blind , placebo - controlled , crossover study design was employed .|Half log incremental doses of intravenous methoxamine or placebo ( saline ) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure ( MUP ) , blood pressure , heart rate , and symptomatic side effects .|Methoxamine evoked non - significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage .|Systemic side effects including piloerection , headache , and cold extremities were experienced in all subjects .|The results indicate that the clinical usefulness of direct , peripherally acting sub - type - selective alpha1 - adrenoceptor agonists in the medical treatment of stress incontinence may be limited by associated piloerection and cardiovascular side effects .": {
            "[\"Effect of methoxamine\", \"on\", \"maximum urethral pressure in women with genuine stress incontinence\"]": "\n[\"Effect of methoxamine\", \"on\", \"maximum urethral pressure\"]\n[\"Effect of methoxamine\", \"on\", \"women with genuine stress incontinence\"]\nGranularity: 2",
            "[\"The aim of the study\", \"was to evaluate\", \"the potential role for a selective alpha1-adrenoceptor agonist in the treatment of urinary stress incontinence\"]": " \n[\"The aim of the study\", \"was to evaluate\", \"the potential role for a selective alpha1-adrenoceptor agonist\"]\n[\"the potential role for a selective alpha1-adrenoceptor agonist\", \"in the treatment of\", \"urinary stress incontinence\"]\nGranularity: 2",
            "[\"A randomised\", \"double-blind\", \"placebo-controlled\"]": " \n[\"A randomised\", \"double-blind\", \"placebo-controlled\"]\nGranularity: 1 (The triple can be split into three sub-triples, but the overall relation between the terms remains the same.)",
            "[\"Half log incremental doses of intravenous methoxamine or placebo (saline)\", \"were administered to\", \"a group of women with genuine stress incontinence\"]": " \n[\"Half log incremental doses\", \"were administered to\", \"a group of women\"]\n[\"Half log incremental doses\", \"were administered to\", \"women with genuine stress incontinence\"]\n[\"Half log incremental doses\", \"were administered\", \"intravenous methoxamine\"]\n[\"Half log incremental doses\", \"were administered\", \"placebo (saline)\"]\n[\"Half log incremental doses\", \"were administered to\", \"a group of women with genuine stress incontinence\"]\nGranularity: 5",
            "[\"Methoxamine\", \"evoked\", \"non-significant increases in MUP and diastolic blood pressure\"]": " \n[\"Methoxamine\", \"evoked\", \"non-significant increases in MUP\"]\n[\"Methoxamine\", \"evoked\", \"non-significant increases in diastolic blood pressure\"]\nGranularity: 2",
            "[\"Methoxamine\", \"caused\", \"a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage\"]": " \n[\"Methoxamine\", \"caused\", \"a significant rise in systolic blood pressure\"]\n[\"Methoxamine\", \"caused\", \"a significant fall in heart rate at maximum dosage\"]\nGranularity: 2",
            "[\"The results\", \"indicate\", \"the clinical usefulness of direct, peripherally acting sub-type-selective alpha1-adrenoceptor agonists\"]": "\n[\"The results\", \"indicate\", \"the clinical usefulness of direct, peripherally acting alpha1-adrenoceptor agonists\"]\n[\"The results\", \"indicate\", \"the clinical usefulness of sub-type-selective alpha1-adrenoceptor agonists\"]\n[\"The results\", \"indicate\", \"the clinical usefulness of direct alpha1-adrenoceptor agonists\"]\n[\"The results\", \"indicate\", \"the clinical usefulness of peripherally acting alpha1-adrenoceptor agonists\"]\n[\"The results\", \"indicate\", \"the clinical usefulness of sub-type-selective peripherally acting alpha1-adrenoceptor agonists\"]\n[\"The results\", \"indicate\", \"the clinical usefulness of direct sub-type-selective alpha1-adrenoceptor agonists\"]\n[\"The results\", \"indicate\", \"the clinical usefulness of direct, peripherally acting sub-type-selective agonists\"]\n[\"The results\", \"indicate\", \"the clinical usefulness of direct, peripherally acting",
            "[\"the medical treatment of stress incontinence\", \"may be limited by\", \"associated piloerection and cardiovascular side effects\"]": " \n[\"the medical treatment of stress incontinence\", \"may be limited by\", \"associated piloerection\"]\n[\"the medical treatment of stress incontinence\", \"may be limited by\", \"cardiovascular side effects\"]\nGranularity: 2"
      },
      "Effect of doxorubicin on [ omega - I - 131 ] heptadecanoic acid myocardial scintigraphy and echocardiography in dogs .|The effects of serial treatment with doxorubicin on dynamic myocardial scintigraphy with [ omega - I - 131 ] heptadecanoic acid ( I - 131 HA ) , and on global left - ventricular function determined echocardiographically , were studied in a group of nine mongrel dogs .|Total extractable myocardial lipid was compared postmortem between a group of control dogs and doxorubicin - treated dogs .|A significant and then progressive fall in global LV function was observed at a cumulative doxorubicin dose of 4 mg / kg .|A significant increase in the myocardial t1 / 2 of the I - 131 HA was observed only at a higher cumulative dose , 10 mg / kg .|No significant alteration in total extractable myocardial lipids was observed between control dogs and those treated with doxorubicin .|Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I - 131 HA are not the initiating factor in doxorubicin cardiotoxicity .": {
            "[\"doxorubicin\", \"effect on\", \"myocardial scintigraphy and echocardiography in dogs\"]": " \n[\"doxorubicin\", \"affects\", \"myocardial scintigraphy\"]\n[\"doxorubicin\", \"affects\", \"echocardiography\"]\nGranularity: 2",
            "[\"doxorubicin\", \"effect on\", \"dynamic myocardial scintigraphy with omega - I - 131 heptadecanoic acid (I - 131 HA)\"]": "\n[\"doxorubicin\", \"affects\", \"dynamic myocardial scintigraphy\"]\n[\"doxorubicin\", \"affects\", \"omega - I - 131 heptadecanoic acid\"]\n[\"doxorubicin\", \"affects\", \"I - 131 HA\"]\nGranularity: 3",
            "[\"doxorubicin\", \"effect on\", \"global left-ventricular function determined echocardiographically\"]": " \n[\"doxorubicin\", \"affects\", \"global left-ventricular function\"]\n[\"doxorubicin\", \"is determined by\", \"echocardiography\"]\nGranularity: 2",
            "[\"Total extractable myocardial lipid\", \"comparison postmortem\", \"control dogs and doxorubicin-treated dogs\"]": " \n[\"Total extractable myocardial lipid\", \"comparison\", \"postmortem control dogs\"]\n[\"Total extractable myocardial lipid\", \"comparison\", \"doxorubicin-treated dogs\"]\nGranularity: 2",
            "[\"global LV function\", \"observed\", \"cumulative doxorubicin dose of 4 mg / kg\"]": " \n[\"global LV function\", \"observed\", \"cumulative doxorubicin dose\"]\n[\"global LV function\", \"observed\", \"4 mg / kg\"]\nGranularity: 2",
            "[\"myocardial t1 / 2 of the I - 131 HA\", \"observed\", \"cumulative dose of 10 mg / kg\"]": "\n[\"myocardial t1 / 2\", \"of the I - 131 HA\", \"observed\"]\n[\"cumulative dose\", \"of 10 mg / kg\", \"observed\"]\nGranularity: 2",
            "[\"total extractable myocardial lipids\", \"alteration\", \"control dogs and doxorubicin-treated dogs\"]": " \n[\"total extractable myocardial lipids\", \"alteration\", \"control dogs\"]\n[\"total extractable myocardial lipids\", \"alteration\", \"doxorubicin-treated dogs\"]\nGranularity: 2",
            "[\"changes leading to alteration of myocardial dynamic imaging with I - 131 HA\", \"initiating factor in\", \"doxorubicin cardiotoxicity\"]": " \n[\"changes\", \"lead to\", \"alteration of myocardial dynamic imaging with I - 131 HA\"]\n[\"alteration of myocardial dynamic imaging with I - 131 HA\", \"is an initiating factor in\", \"doxorubicin cardiotoxicity\"]\nGranularity: 2"
      },
      "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1 - infected children treated with indinavir .|BACKGROUND : Prolonged administration of indinavir is associated with the occurrence of a variety of renal complications in adults .|These well - documented side effects have restricted the use of this potent protease inhibitor in children .|DESIGN : A prospective study to monitor indinavir - related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1 - infected children treated with indinavir .|METHODS : Urinary pH , albumin , creatinine , the presence of erythrocytes , leukocytes , bacteria and crystals , and culture were analyzed every 3 months for 96 weeks .|Serum creatinine levels were routinely determined at the same time points .|Steady - state pharmacokinetics of indinavir were done at week 4 after the initiation of indinavir .|RESULTS : The cumulative incidence of persistent sterile leukocyturia ( > or = 75 cells / micro L in at least 2 consecutive visits ) after 96 weeks was 53 % .|Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin / creatinine ratio and by microscopic hematuria .|The cumulative incidence of serum creatinine levels > 50 % above normal was 33 % after 96 weeks .|Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50 % above normal than those children without persistent sterile leukocyturia .|In children younger than 5 . 6 years , persistent sterile leukocyturia was significantly more frequent than in older children .|A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve > 19 mg / L x h or a peak serum level of indinavir > 12 mg / L .|In 4 children , indinavir was discontinued because of nephrotoxicity .|Subsequently , the serum creatinine levels decreased , the urine albumin / creatinine ratios returned to zero , and the leukocyturia disappeared within 3 months .|CONCLUSIONS : Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia .|Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of > 50 % above normal .|Younger children have an additional risk for renal complications .|The impairment of the renal function in these children occurred in the absence of clinical symptoms of nephrolithiasis .|Indinavir - associated nephrotoxicity must be monitored closely , especially in children with risk factors such as persistent sterile leukocyturia , age < 5 . 6 years , an area under the curve of indinavir > 19 mg / L x h , and a C ( max ) > 12 mg / L .": {
            "[\"Persistent sterile leukocyturia\", \"is associated with\", \"impaired renal function\"]": " \n[\"Persistent sterile leukocyturia\", \"is associated with\", \"impaired renal function\"]\nGranularity: 1",
            "[\"Prolonged administration of indinavir\", \"is associated with\", \"variety of renal complications\"]": " \n[\"Prolonged administration of indinavir\", \"is associated with\", \"renal complications\"]\n[\"Prolonged administration of indinavir\", \"is associated with\", \"variety of complications\"]\nGranularity: 2",
            "[\"These well-documented side effects\", \"have restricted\", \"the use of indinavir\"]": " \n[\"These well-documented side effects\", \"have restricted\", \"the use of indinavir\"]\nGranularity: 1",
            "[\"A prospective study\", \"monitored\", \"indinavir-related nephrotoxicity\"]": " \n[\"A prospective study\", \"monitored\", \"indinavir-related nephrotoxicity\"]\nGranularity: 1",
            "[\"Urinary pH\", \"was analyzed every 3 months\", \"for 96 weeks\"]": " \n[\"Urinary pH\", \"was analyzed\", \"every 3 months\"]\n[\"Urinary pH\", \"was analyzed\", \"for 96 weeks\"]\nGranularity: 2",
            "[\"Serum creatinine levels\", \"were routinely determined\", \"at the same time points\"]": " \n[\"Serum creatinine levels\", \"were determined\", \"routinely\"]\n[\"Serum creatinine levels\", \"were determined\", \"at the same time points\"]\nGranularity: 2",
            "[\"Steady-state pharmacokinetics of indinavir\", \"were done\", \"at week 4\"]": " \n[\"Steady-state pharmacokinetics of indinavir\", \"were done\", \"at week 4\"]\nGranularity: 1",
            "[\"The cumulative incidence of persistent sterile leukocyturia\", \"was 53%\", \"after 96 weeks\"]": " \n[\"The cumulative incidence\", \"of persistent sterile leukocyturia\", \"was 53%\"]\n[\"persistent sterile leukocyturia\", \"was\", \"53%\"]\n[\"persistent sterile leukocyturia\", \"after\", \"96 weeks\"]\nGranularity: 3",
            "[\"Persistent sterile leukocyturia\", \"was frequently associated with\", \"mild increase in the urine albumin/creatinine ratio\"]": " \n[\"Persistent sterile leukocyturia\", \"is associated with\", \"mild increase in the urine albumin/creatinine ratio\"]\n[\"Persistent sterile leukocyturia\", \"is frequently associated with\", \"mild increase in the urine albumin/creatinine ratio\"]\n[\"Persistent sterile leukocyturia\", \"is associated with\", \"urine albumin/creatinine ratio\"]\n[\"Persistent sterile leukocyturia\", \"is frequently associated with\", \"urine albumin/creatinine ratio\"]\nGranularity: 4",
            "[\"Persistent sterile leukocyturia\", \"was frequently associated with\", \"microscopic hematuria\"]": " \n[\"Persistent sterile leukocyturia\", \"is associated with\", \"microscopic hematuria\"]\n[\"Persistent sterile leukocyturia\", \"occurs with\", \"microscopic hematuria\"]\n[\"Persistent sterile leukocyturia\", \"is frequently associated with\", \"microscopic hematuria\"]\nGranularity: 3",
            "[\"The cumulative incidence of serum creatinine levels\", \"was 33%\", \"above normal after 96 weeks\"]": " \n[\"The cumulative incidence\", \"of serum creatinine levels\", \"was 33%\"]\n[\"serum creatinine levels\", \"were\", \"above normal after 96 weeks\"]\nGranularity: 2",
            "[\"Children with persistent sterile leukocyturia\", \"more frequently had\", \"serum creatinine levels 50% above normal\"]": " \n[\"Children with persistent sterile leukocyturia\", \"had\", \"serum creatinine levels\"]\n[\"Children with persistent sterile leukocyturia\", \"had\", \"levels 50% above normal\"]\nGranularity: 2",
            "[\"Children younger than 5.6 years\", \"had significantly more frequent\", \"persistent sterile leukocyturia\"]": " \n[\"Children younger than 5.6 years\", \"had\", \"persistent sterile leukocyturia\"]\n[\"Children younger than 5.6 years\", \"had significantly more frequent\", \"persistent leukocyturia\"]\n[\"Children younger than 5.6 years\", \"had significantly more frequent\", \"sterile leukocyturia\"]\nGranularity: 3",
            "[\"Children with an area under the curve\", \"had a higher cumulative incidence\", \"of persistent leukocyturia\"]": " \n[\"Children\", \"had\", \"an area under the curve\"]\n[\"Children\", \"had\", \"a higher cumulative incidence\"]\n[\"Children\", \"had\", \"persistent leukocyturia\"]\n[\"area under the curve\", \"had\", \"a higher cumulative incidence\"]\n[\"area under the curve\", \"had\", \"persistent leukocyturia\"]\n[\"higher cumulative incidence\", \"of\", \"persistent leukocyturia\"]\nGranularity: 6",
            "[\"Children with a peak serum level of indinavir\", \"had a higher cumulative incidence\", \"of persistent leukocyturia\"]": " \n[\"Children with a peak serum level of indinavir\", \"had\", \"a higher cumulative incidence\"]\n[\"a higher cumulative incidence\", \"of persistent leukocyturia\"]\nGranularity: 2",
            "[\"Indinavir\", \"was discontinued\", \"because of nephrotoxicity\"]": " N/A (The triple is specific, conveying a singular relation between Indinavir and nephrotoxicity.)\nGranularity: 0",
            "[\"Subsequently\", \"serum creatinine levels decreased\", \"and the leukocyturia disappeared\"]": " \n[\"Subsequently\", \"serum creatinine levels decreased\", \"leukocyturia disappeared\"]\nGranularity: 1",
            "[\"Children treated with indinavir\", \"have a high cumulative incidence\", \"of persistent sterile leukocyturia\"]": " \n[\"Children treated with indinavir\", \"have\", \"persistent sterile leukocyturia\"]\n[\"persistent sterile leukocyturia\", \"has a high cumulative incidence\", \"in children treated with indinavir\"]\nGranularity: 2",
            "[\"Children with persistent sterile leukocyturia\", \"more frequently had\", \"an increase in serum creatinine levels\"]": " \n[\"Children with persistent sterile leukocyturia\", \"had\", \"an increase in serum creatinine levels\"]\n[\"Children with persistent sterile leukocyturia\", \"more frequently had\", \"an increase in serum creatinine levels\"]\nGranularity: 2",
            "[\"Younger children\", \"have an additional risk\", \"for renal complications\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"The impairment of the renal function\", \"occurred\", \"in the absence of clinical symptoms of nephrolithiasis\"]": "\n[\"The impairment of the renal function\", \"occurred\", \"in the absence of clinical symptoms\"]\n[\"The impairment of the renal function\", \"occurred\", \"of nephrolithiasis\"]\nGranularity: 2",
            "[\"Indinavir-associated nephrotoxicity\", \"must be monitored closely\", \"especially in children with risk factors\"]": " \n[\"Indinavir-associated nephrotoxicity\", \"must be monitored\", \"closely\"]\n[\"Indinavir-associated nephrotoxicity\", \"must be monitored\", \"in children\"]\n[\"Indinavir-associated nephrotoxicity\", \"must be monitored\", \"with risk factors\"]\nGranularity: 3"
      },
      "Antirifampicin antibodies in acute rifampicin - associated renal failure .|5 patients with acute renal failure ( 3 with thrombopenia and hemolysis ) induced by the reintroduction of rifampicin are described .|No correlation was found between the severity of clinical manifestations and the total dose taken by the patients .|In all but 1 patient , antirifampicin antibodies were detected .|Antibodies suggested to be of the IgM class were detected in all 3 patients with hematological disorders .|The pattern of non - specific acute tubular necrosis found in the 2 biopsied patients , indistinguishable from that of ischemic origin , raised the possibility of a vascular - mediated damage .|In 3 patients , the possibility of a triggering immunoallergic mechanism is discussed .": {
            "[\"Pattern of non-specific acute tubular necrosis\", \"found in\", \"2 biopsied patients\"]": " \n[\"Pattern of non-specific acute tubular necrosis\", \"found in\", \"2 biopsied patients\"]\nGranularity: 1",
            "[\"Pattern of non-specific acute tubular necrosis\", \"indistinguishable from\", \"that of ischemic origin\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Antirifampicin antibodies\", \"associated with\", \"acute rifampicin-associated renal failure\"]": " \n[\"Antirifampicin antibodies\", \"associated with\", \"acute rifampicin-associated renal failure\"]\nGranularity: 1",
            "[\"5 patients\", \"induced by\", \"reintroduction of rifampicin\"]": "\n[\"5 patients\", \"induced by\", \"reintroduction\"]\n[\"5 patients\", \"induced by\", \"rifampicin\"]\nGranularity: 2",
            "[\"3 patients\", \"exhibited\", \"thrombopenia and hemolysis\"]": " \n[\"3 patients\", \"exhibited\", \"thrombopenia\"]\n[\"3 patients\", \"exhibited\", \"hemolysis\"]\nGranularity: 2",
            "[\"No correlation\", \"found between\", \"severity of clinical manifestations and total dose taken by patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"In all but 1 patient\", \"antirifampicin antibodies\", \"detected\"]": " \n[\"antirifampicin antibodies\", \"detected in\", \"all but 1 patient\"]\n[\"antirifampicin\", \"has\", \"antibodies\"]\n[\"antibodies\", \"detected in\", \"all but 1 patient\"]\nGranularity: 3",
            "[\"Antibodies\", \"suggested to be of\", \"IgM class\"]": " \n[\"Antibodies\", \"are\", \"IgM\"]\n[\"Antibodies\", \"belong to\", \"IgM class\"]\nGranularity: 2",
            "[\"Antibodies\", \"detected in\", \"all 3 patients with hematological disorders\"]": " \n[\"Antibodies\", \"detected in\", \"patient 1\"]\n[\"Antibodies\", \"detected in\", \"patient 2\"]\n[\"Antibodies\", \"detected in\", \"patient 3\"]\nGranularity: 3",
            "[\"In 3 patients\", \"possibility of\", \"triggering immunoallergic mechanism is discussed\"]": " \n[\"In 3 patients\", \"discusses\", \"possibility of triggering immunoallergic mechanism\"]\n[\"In 3 patients\", \"discusses\", \"triggering immunoallergic mechanism\"]\n[\"In 3 patients\", \"discusses\", \"possibility of immunoallergic mechanism\"]\n[\"In 3 patients\", \"discusses\", \"immunoallergic mechanism\"]\nGranularity: 4"
      },
      "Blood brain barrier in right - and left - pawed female rats assessed by a new staining method .|The asymmetrical breakdown of the blood - brain barrier ( BBB ) was studied in female rats .|Paw preference was assessed by a food reaching test .|Adrenaline - induced hypertension was used to destroy the BBB , which was evaluated using triphenyltetrazolium ( TTC ) staining of the brain slices just after giving adrenaline for 30 s .|In normal rats , the whole brain sections exhibited complete staining with TTC .|After adrenaline infusion for 30 s , there were large unstained areas in the left brain in right - pawed animals , and vice versa in left - pawed animals .|Similar results were obtained in seizure - induced breakdown of BBB .|These results were explained by an asymmetric cerebral blood flow depending upon the paw preference in rats .|It was suggested that this new method and the results are consistent with contralateral motor control that may be important in determining the dominant cerebral hemisphere in animals .": {
            "[\"Blood brain barrier\", \"assessed in\", \"right - and left - pawed female rats\"]": " \n[\"Blood brain barrier\", \"assessed in\", \"right-pawed female rats\"]\n[\"Blood brain barrier\", \"assessed in\", \"left-pawed female rats\"]\nGranularity: 2",
            "[\"Blood brain barrier\", \"studied in\", \"female rats\"]": " \n[\"Blood brain barrier\", \"studied in\", \"female rats\"]\nGranularity: 1",
            "[\"Paw preference\", \"assessed by\", \"a food reaching test\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Adrenaline - induced hypertension\", \"used to\", \"destroy the BBB\"]": " \n[\"Adrenaline - induced hypertension\", \"used to\", \"destroy the BBB\"]\nGranularity: 1",
            "[\"BBB\", \"evaluated using\", \"triphenyltetrazolium ( TTC ) staining of the brain slices\"]": " \n[\"BBB\", \"evaluated\", \"triphenyltetrazolium ( TTC ) staining\"]\n[\"triphenyltetrazolium ( TTC ) staining\", \"of\", \"brain slices\"]\nGranularity: 2",
            "[\"TTC staining\", \"exhibited by\", \"normal rats\"]": " \n[\"TTC staining\", \"is exhibited by\", \"normal rats\"]\nGranularity: 1",
            "[\"Adrenaline infusion\", \"caused\", \"large unstained areas in the left brain in right - pawed animals\"]": " \n[\"Adrenaline infusion\", \"caused\", \"large unstained areas\"]\n[\"Adrenaline infusion\", \"caused\", \"left brain\"]\n[\"Adrenaline infusion\", \"caused\", \"right-pawed animals\"]\nGranularity: 3",
            "[\"Adrenaline infusion\", \"caused\", \"large unstained areas in the right brain in left - pawed animals\"]": " \n[\"Adrenaline infusion\", \"caused\", \"large unstained areas\"]\n[\"Adrenaline infusion\", \"caused\", \"right brain\"]\n[\"Adrenaline infusion\", \"caused\", \"left-pawed animals\"]\nGranularity: 3",
            "[\"Seizure - induced breakdown of BBB\", \"produced\", \"similar results\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Asymmetric cerebral blood flow\", \"depends upon\", \"paw preference in rats\"]": " \n[\"Asymmetric cerebral blood flow\", \"depends upon\", \"paw preference\"]\n[\"paw preference\", \"influences\", \"cerebral blood flow\"]\nGranularity: 2",
            "[\"New method\", \"consistent with\", \"contralateral motor control\"]": " \n[\"New method\", \"is consistent with\", \"contralateral motor control\"]\nGranularity: 1",
            "[\"Contralateral motor control\", \"important in determining\", \"the dominant cerebral hemisphere in animals\"]": "\n[\"Contralateral motor control\", \"determines\", \"dominant cerebral hemisphere\"]\n[\"Contralateral motor control\", \"is important for\", \"determining dominant cerebral hemisphere\"]\n[\"Contralateral motor control\", \"plays a role in\", \"determining dominant cerebral hemisphere\"]\nGranularity: 3"
      },
      "Quetiapine - induced neutropenia in a bipolar patient with hepatocellular carcinoma .|OBJECTIVE : Quetiapine is a dibenzothiazepine derivative , similar to clozapine , which has the highest risk of causing blood dyscrasias , especially neutropenia .|There are some case reports about this side effect of quetiapine , but possible risk factors are seldom discussed and identified .|A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here .|CASE REPORT : A 62 - year - old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60 .|She developed leucopenia after being treated with quetiapine .|After quetiapine was discontinued , her white blood cell count returned to normal .|CONCLUSIONS : Although neutropenia is not a common side effect of quetiapine , physicians should be cautious about its presentation and associated risk factors .|Hepatic dysfunction may be one of the possible risk factors , and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine .": {
            "[\"bipolar patient\", \"has\", \"hepatocellular carcinoma\"]": " N/A (The triple is specific, conveying a singular relation between a bipolar patient and hepatocellular carcinoma.)\nGranularity: 0",
            "[\"Clozapine\", \"has the highest risk of\", \"causing blood dyscrasias\"]": " N/A (The triple is specific, conveying a singular relation between Clozapine and blood dyscrasias.)\nGranularity: 0",
            "[\"possible risk factors\", \"are seldom discussed and identified\", \"in quetiapine\"]": " \n[\"possible risk factors\", \"are seldom discussed\", \"in quetiapine\"]\n[\"possible risk factors\", \"are seldom identified\", \"in quetiapine\"]\nGranularity: 2",
            "[\"Patient\", \"developed\", \"neutropenia after quetiapine treatment\"]": " \n[\"Patient\", \"developed\", \"neutropenia\"]\n[\"Patient\", \"received\", \"quetiapine\"]\nGranularity: 2",
            "[\"Patient\", \"returned to normal\", \"after quetiapine discontinuation\"]": " \n[\"Patient\", \"returned to normal\", \"after discontinuation of quetiapine\"]\n[\"Patient\", \"returned\", \"to normal\"]\n[\"Patient\", \"after quetiapine discontinuation\", \"returned to normal\"]\nGranularity: 3",
            "[\"Physicians\", \"should be cautious about\", \"associated risk factors\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hepatic dysfunction\", \"may be one of the possible risk factors\", \"for neutropenia\"]": " \n[\"Hepatic dysfunction\", \"may be\", \"a risk factor\"]\n[\"Hepatic dysfunction\", \"may be\", \"one of the possible risk factors\"]\n[\"neutropenia\", \"may be\", \"a possible risk factor\"]\n[\"neutropenia\", \"may be\", \"one of the possible risk factors\"]\nGranularity: 4",
            "[\"Quetiapine\", \"induced\", \"neutropenia\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Quetiapine\", \"is a derivative of\", \"dibenzothiazepine\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Quetiapine\", \"has some case reports of\", \"neutropenia side effect\"]": " \n[\"Quetiapine\", \"has\", \"case reports\"]\n[\"Quetiapine\", \"has\", \"neutropenia\"]\n[\"neutropenia\", \"is a side effect of\", \"Quetiapine\"]\nGranularity: 3",
            "[\"Patient\", \"has\", \"hepatocellular carcinoma\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Physicians\", \"should be cautious about\", \"neutropenia presentation\"]": " \n[\"Physicians\", \"should be cautious\", \"about neutropenia\"]\n[\"Neutropenia\", \"presentation\", \"should be cautious\"]\nGranularity: 2",
            "[\"Congruent fever\", \"may be a diagnostic marker for\", \"adverse reaction to quetiapine\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "A prospective , open - label trial of galantamine in autistic disorder .|OBJECTIVE : Post - mortem studies have reported abnormalities of the cholinergic system in autism .|The purpose of this study was to assess the use of galantamine , an acetylcholinesterase inhibitor and nicotinic receptor modulator , in the treatment of interfering behaviors in children with autism .|METHODS : Thirteen medication - free children with autism ( mean age , 8 . 8 + / - 3 . 5 years ) participated in a 12 - week , open - label trial of galantamine .|Patients were rated monthly by parents on the Aberrant Behavior Checklist ( ABC ) and the Conners ' Parent Rating Scale - Revised , and by a physician using the Children 's Psychiatric Rating Scale and the Clinical Global Impressions scale .|RESULTS : Patients showed a significant reduction in parent - rated irritability and social withdrawal on the ABC as well as significant improvements in emotional lability and inattention on the Conners ' Parent Rating Scale - - Revised .|Similarly , clinician ratings showed reductions in the anger subscale of the Children 's Psychiatric Rating Scale .|Eight of 13 participants were rated as responders on the basis of their improvement scores on the Clinical Global Impressions scale .|Overall , galantamine was well - tolerated , with no significant adverse effects apart from headaches in one patient .|CONCLUSION : In this open trial , galantamine was well - tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism , particularly aggression , behavioral dyscontrol , and inattention .|Further controlled trials are warranted .": {
            "[\"galantamine\", \"is an\", \"acetylcholinesterase inhibitor\"]": " \n[\"galantamine\", \"is\", \"an acetylcholinesterase inhibitor\"]\nGranularity: 1",
            "[\"galantamine\", \"is a\", \"nicotinic receptor modulator\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"galantamine\", \"was assessed for\", \"treatment of interfering behaviors in children with autism\"]": " \n[\"galantamine\", \"was assessed for\", \"treatment of interfering behaviors\"]\n[\"galantamine\", \"was assessed for\", \"treatment of children with autism\"]\nGranularity: 2",
            "[\"13 medication-free children with autism\", \"participated in\", \"12-week open-label trial of galantamine\"]": " \n[\"13 medication-free children\", \"with autism\", \"participated in\"]\n[\"13 medication-free children with autism\", \"participated in\", \"12-week trial\"]\n[\"13 medication-free children with autism\", \"participated in\", \"open-label trial\"]\n[\"13 medication-free children with autism\", \"participated in\", \"galantamine trial\"]\n[\"12-week open-label trial\", \"of galantamine\", \"participated in\"]\nGranularity: 5",
            "[\"Patients\", \"were rated monthly by\", \"parents\"]": " N/A (The triple is specific, conveying a singular relation between patients and parents.)\nGranularity: 0",
            "[\"Patients\", \"were rated monthly by\", \"a physician\"]": " \n[\"Patients\", \"were rated\", \"monthly\"]\n[\"Patients\", \"were rated by\", \"a physician\"]\nGranularity: 2",
            "[\"Patients\", \"showed a significant reduction in\", \"parent-rated irritability and social withdrawal\"]": " \n[\"Patients\", \"showed a reduction in\", \"parent-rated irritability\"]\n[\"Patients\", \"showed a reduction in\", \"social withdrawal\"]\nGranularity: 2",
            "[\"Patients\", \"showed significant improvements in\", \"emotional lability and inattention\"]": " \n[\"Patients\", \"showed improvements in\", \"emotional lability\"]\n[\"Patients\", \"showed improvements in\", \"inattention\"]\nGranularity: 2",
            "[\"Clinician ratings\", \"showed reductions in\", \"anger subscale\"]": "\n[\"Clinician ratings\", \"showed reductions in\", \"anger subscale\"]\nGranularity: 1",
            "[\"Eight of 13 participants\", \"were rated as\", \"responders\"]": " \n[\"Eight of 13 participants\", \"were rated\", \"responders\"]\n[\"Eight of 13 participants\", \"were\", \"responders\"]\nGranularity: 2",
            "[\"galantamine\", \"was well-tolerated\", \"with no significant adverse effects apart from headaches in one patient\"]": "\n[\"galantamine\", \"was well-tolerated\", \"with no significant adverse effects\"]\n[\"galantamine\", \"was well-tolerated\", \"apart from headaches\"]\n[\"one patient\", \"experienced\", \"headaches\"]\nGranularity: 3",
            "[\"In this open trial\", \"galantamine\", \"appeared to be beneficial for the treatment of interfering behaviors in children with autism\"]": " \n[\"galantamine\", \"is beneficial for\", \"treating interfering behaviors\"]\n[\"children with autism\", \"have\", \"interfering behaviors\"]\nGranularity: 2",
            "[\"Further controlled trials\", \"are warranted\", \"\"]": " N/A (The triple is not specific enough to be split into sub-triples.)\nGranularity: 0"
      },
      "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin - induced cardiotoxicity in rats with breast cancer .|Oxidative stress is involved in several processes including cancer , aging and cardiovascular disease , and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin .|Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction .|Herein , we investigate whether doxorubicin - associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer .|Thirty - six rats bearing breast tumors induced chemically were divided into 4 groups : control , hydroxytyrosol ( 0 . 5mg / kg , 5days / week ) , doxorubicin ( 1mg / kg / week ) , and doxorubicin plus hydroxytyrosol .|Cardiac disturbances at the cellular and mitochondrial level , mitochondrial electron transport chain complexes I - IV and apoptosis - inducing factor , and oxidative stress markers have been analyzed .|Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage .|These results suggest that hydroxytyrosol improve the mitochondrial electron transport chain .|This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations .": {
            "[\"Hydroxytyrosol\", \"ameliorates\", \"oxidative stress and mitochondrial dysfunction\"]": " \n[\"Hydroxytyrosol\", \"ameliorates\", \"oxidative stress\"]\n[\"Hydroxytyrosol\", \"ameliorates\", \"mitochondrial dysfunction\"]\nGranularity: 2",
            "[\"Oxidative stress\", \"is involved in\", \"several processes\"]": " N/A (The triple is specific, conveying a singular relation between oxidative stress and several processes.)\nGranularity: 0",
            "[\"Oxidative stress\", \"potentiates\", \"therapeutic effect of drugs\"]": " \n[\"Oxidative stress\", \"potentiates\", \"therapeutic effect\"]\n[\"Oxidative stress\", \"potentiates\", \"drugs\"]\nGranularity: 2",
            "[\"Doxorubicin\", \"causes\", \"significant cardiotoxicity\"]": " N/A (The triple is specific, conveying a singular relation between Doxorubicin and significant cardiotoxicity.)\nGranularity: 0",
            "[\"Doxorubicin\", \"enhances\", \"oxidative stress and mitochondrial dysfunction\"]": " \n[\"Doxorubicin\", \"enhances\", \"oxidative stress\"]\n[\"Doxorubicin\", \"enhances\", \"mitochondrial dysfunction\"]\nGranularity: 2",
            "[\"Hydroxytyrosol\", \"investigated to ameliorate\", \"doxorubicin-associated chronic cardiac toxicity\"]": " \n[\"Hydroxytyrosol\", \"investigated to ameliorate\", \"doxorubicin-associated chronic cardiac toxicity\"]\nGranularity: 1",
            "[\"Rats\", \"bearing breast tumors\", \"divided into 4 groups\"]": "\n[\"Rats\", \"bearing\", \"breast tumors\"]\n[\"Rats\", \"divided into\", \"4 groups\"]\nGranularity: 2",
            "[\"Hydroxytyrosol\", \"improved\", \"cardiac disturbances enhanced by doxorubicin\"]": " \n[\"Hydroxytyrosol\", \"improved\", \"cardiac disturbances\"]\n[\"Hydroxytyrosol\", \"enhanced\", \"doxorubicin\"]\nGranularity: 2",
            "[\"Hydroxytyrosol\", \"reduced\", \"altered mitochondria and oxidative damage\"]": " \n[\"Hydroxytyrosol\", \"reduced\", \"altered mitochondria\"]\n[\"Hydroxytyrosol\", \"reduced\", \"oxidative damage\"]\nGranularity: 2",
            "[\"Hydroxytyrosol\", \"improved\", \"mitochondrial electron transport chain\"]": " \n[\"Hydroxytyrosol\", \"improved\", \"mitochondrial function\"]\n[\"Hydroxytyrosol\", \"improved\", \"electron transport chain\"]\nGranularity: 2",
            "[\"This study\", \"demonstrates\", \"hydroxytyrosol protects rat heart damage provoked by doxorubicin\"]": " \n[\"This study\", \"demonstrates\", \"hydroxytyrosol protects rat heart damage\"]\n[\"This study\", \"demonstrates\", \"protection from doxorubicin-induced heart damage\"]\nGranularity: 2"
      },
      "A metoprolol - terbinafine combination induced bradycardia .|To report a sinus bradycardia induced by metoprolol and terbinafine drug - drug interaction and its management .|A 63 year - old Caucasian man on metoprolol 200 mg / day for stable coronary artery disease was prescribed a 90 - day course of oral terbinafine 250 mg / day for onychomycosis .|On the 49th day of terbinafine therapy , he was brought to the emergency room for a decrease of his global health status , confusion and falls .|The electrocardiogram revealed a 37 beats / min sinus bradycardia .|A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient 's sinus bradycardia and the drug interaction between metoprolol and terbinafine .|The heart rate ameliorated first with a decrease in the dose of metoprolol .|It was subsequently changed to bisoprolol and the heart rate remained normal .|By inhibiting the cytochrome P450 2D6 , terbinafine had decreased metoprolol 's clearance , leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia .": {
            "[\"metoprolol\", \"induces\", \"terbinafine\"]": " N/A (The triple is specific, conveying a singular relation between metoprolol and terbinafine.)\nGranularity: 0",
            "[\"metoprolol\", \"induces\", \"bradycardia\"]": " N/A (The triple is specific, conveying a singular relation between metoprolol and bradycardia.)\nGranularity: 0",
            "[\"terbinafine\", \"induces\", \"bradycardia\"]": " N/A (The triple is specific, conveying a singular relation between terbinafine and bradycardia.)\nGranularity: 0",
            "[\"patient\", \"has\", \"stable coronary artery disease\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"patient\", \"takes\", \"metoprolol\"]": " N/A (The triple is specific, conveying a singular relation between a patient and metoprolol.)\nGranularity: 0",
            "[\"patient\", \"takes\", \"terbinafine\"]": " N/A (The triple is specific, conveying a singular relation between a patient and terbinafine.)\nGranularity: 0",
            "[\"terbinafine\", \"interacts with\", \"metoprolol\"]": " N/A (The triple is specific, conveying a singular relation between terbinafine and metoprolol.)\nGranularity: 0",
            "[\"interaction\", \"causes\", \"sinus bradycardia\"]": " N/A (The triple is specific, conveying a singular relation between interaction and sinus bradycardia.)\nGranularity: 0",
            "[\"Naranjo scale\", \"indicates\", \"probable relationship\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"metoprolol\", \"decreases\", \"dose\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"metoprolol\", \"changes to\", \"bisoprolol\"]": " N/A (The triple is specific, conveying a singular relation between metoprolol and bisoprolol.)\nGranularity: 0",
            "[\"terbinafine\", \"inhibits\", \"cytochrome P450 2D6\"]": "\n[\"terbinafine\", \"inhibits\", \"cytochrome P450\"]\n[\"terbinafine\", \"inhibits\", \"2D6\"]\nGranularity: 2",
            "[\"inhibition\", \"leads to\", \"metoprolol accumulation\"]": " N/A (The triple is specific, conveying a singular relation between inhibition and metoprolol accumulation.)\nGranularity: 0",
            "[\"accumulation\", \"results in\", \"clinically significant sinus bradycardia\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Progesterone potentiation of bupivacaine arrhythmogenicity in pentobarbital - anesthetized rats and beating rat heart cell cultures .|The effects of progesterone treatment on bupivacaine arrhythmogenicity in beating rat heart myocyte cultures and on anesthetized rats were determined .|After determining the bupivacaine AD50 ( the concentration of bupivacaine that caused 50 % of all beating rat heart myocyte cultures to become arrhythmic ) , we determined the effect of 1 - hour progesterone HCl exposure on myocyte contractile rhythm .|Each concentration of progesterone ( 6 . 25 , 12 . 5 , 25 , and 50 micrograms / ml ) caused a significant and concentration - dependent reduction in the AD50 for bupivacaine .|Estradiol treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures , but was only one fourth as potent as progesterone .|Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by epinephrine .|Chronic progesterone pretreatment ( 5 mg / kg / day for 21 days ) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital - anesthetized rats .|There was a significant decrease in the time to onset of arrhythmia as compared with control nonprogesterone - treated rats ( 6 . 2 + / - 1 . 3 vs . 30 . 8 + / - 2 . 5 min , mean + / - SE ) .|The results of this study indicate that progesterone can potentiate bupivacaine arrhythmogenicity both in vivo and in vitro .|Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level .": {
            "[\"Progesterone\", \"potentiation of\", \"bupivacaine arrhythmogenicity\"]": " \n[\"Progesterone\", \"potentiation of\", \"bupivacaine\"]\n[\"Progesterone\", \"potentiation of\", \"arrhythmogenicity\"]\nGranularity: 2",
            "[\"Progesterone\", \"treatment on\", \"bupivacaine arrhythmogenicity\"]": " \n[\"Progesterone\", \"treatment on\", \"bupivacaine\"]\n[\"Progesterone\", \"treatment on\", \"arrhythmogenicity\"]\nGranularity: 2",
            "[\"Progesterone\", \"determined the effect on\", \"myocyte contractile rhythm\"]": " \n[\"Progesterone\", \"determined\", \"effect on myocyte contractile rhythm\"]\n[\"Progesterone\", \"determined\", \"effect on myocyte contractile rhythm\"]\nGranularity: 2",
            "[\"Each concentration of progesterone\", \"caused\", \"reduction in the AD50 for bupivacaine\"]": " \n[\"Each concentration of progesterone\", \"caused\", \"reduction in the AD50\"]\n[\"Each concentration of progesterone\", \"caused\", \"bupivacaine\"]\nGranularity: 2",
            "[\"Estradiol\", \"increased\", \"bupivacaine arrhythmogenicity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Neither progesterone nor estradiol\", \"effects on\", \"bupivacaine arrhythmogenicity\"]": " \n[\"Neither progesterone\", \"effects on\", \"bupivacaine arrhythmogenicity\"]\n[\"Neither estradiol\", \"effects on\", \"bupivacaine arrhythmogenicity\"]\nGranularity: 2",
            "[\"Chronic progesterone pretreatment\", \"caused\", \"increase in bupivacaine arrhythmogenicity\"]": " \n[\"Chronic progesterone pretreatment\", \"caused\", \"increase in arrhythmogenicity\"]\n[\"Chronic progesterone pretreatment\", \"caused\", \"increase in bupivacaine\"]\nGranularity: 2",
            "[\"There was a significant decrease in\", \"the time to onset of arrhythmia\", \"control nonprogesterone-treated rats\"]": " \n[\"the time to onset of arrhythmia\", \"decreased significantly\"]\n[\"arrhythmia control\", \"was not achieved in nonprogesterone-treated rats\"]\nGranularity: 2",
            "[\"The results of this study\", \"indicate\", \"that progesterone can potentiate bupivacaine arrhythmogenicity\"]": "\n[\"The results of this study\", \"indicate\", \"that progesterone\"]\n[\"that progesterone\", \"potentiates\", \"bupivacaine arrhythmogenicity\"]\nGranularity: 2",
            "[\"Potentiation of bupivacaine arrhythmia in myocyte cultures\", \"suggests\", \"this effect is at least partly mediated at the myocyte level\"]": " \n[\"Potentiation of bupivacaine arrhythmia\", \"suggests\", \"effect is mediated at myocyte level\"]\n[\"Potentiation of bupivacaine arrhythmia\", \"suggests\", \"effect is at least partly mediated\"]\n[\"Potentiation of bupivacaine\", \"arrhythmia\", \"suggests\"]\n[\"bupivacaine\", \"arrhythmia\", \"potentiates\"]\n[\"bupivacaine\", \"potentiates\", \"myocyte cultures\"]\n[\"arrhythmia\", \"suggests\", \"effect is at least partly mediated\"]\n[\"myocyte cultures\", \"suggests\", \"effect is at least partly mediated\"]\nGranularity: 7"
      },
      "Effect of vincristine sulfate on Pseudomonas infections in monkeys .|In rhesus monkeys , intravenous challenge with 0 . 6 x 10 ( 10 ) to 2 . 2 x 10 ( 10 ) Pseudomonas aeruginosa organisms caused acute illness of 4 to 5 days ' duration with spontaneous recovery in 13 of 15 monkeys ; blood cultures became negative 3 to 17 days after challenge .|Leukocytosis was observed in all monkeys .|Intravenous or intratracheal inoculation of 2 . 0 to 2 . 5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days .|Intravenous inoculation of 4 . 2 x 10 ( 10 ) to 7 . 8 x 10 ( 10 ) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys , whereas none of four receiving Pseudomonas alone died .|These studies suggest that an antimetabolite - induced leukopenia predisposes to severe Pseudomonas sepsis and that such monkeys may serve as a biological model for study of comparative efficacy of antimicrobial agents .": {
            "[\"vincristine sulfate\", \"effect on\", \"Pseudomonas infections\"]": " N/A (The triple is specific, conveying a singular relation between vincristine sulfate and Pseudomonas infections.)\nGranularity: 0",
            "[\"Pseudomonas aeruginosa\", \"causes\", \"acute illness in monkeys\"]": " \n[\"Pseudomonas aeruginosa\", \"causes\", \"acute illness\"]\n[\"acute illness\", \"in\", \"monkeys\"]\nGranularity: 2",
            "[\"Pseudomonas aeruginosa\", \"recovery in\", \"13 of 15 monkeys\"]": " \n[\"Pseudomonas aeruginosa\", \"recovery in\", \"13 monkeys\"]\n[\"Pseudomonas aeruginosa\", \"recovery in\", \"15 monkeys\"]\nGranularity: 2",
            "[\"Leukocytosis\", \"observed in\", \"all monkeys\"]": " \n[\"Leukocytosis\", \"is observed in\", \"monkeys\"]\n[\"Leukocytosis\", \"is observed in\", \"all monkeys\"]\nGranularity: 2",
            "[\"vincristine sulfate\", \"induces\", \"leukopenia\"]": " N/A (The triple is specific, conveying a singular relation between vincristine sulfate and leukopenia.)\nGranularity: 0",
            "[\"Intravenous inoculation\", \"results in\", \"fatal infection in 11 of 14 monkeys\"]": " \n[\"Intravenous inoculation\", \"results in\", \"fatal infection\"]\n[\"Intravenous inoculation\", \"results in\", \"11 of 14 monkeys\"]\nGranularity: 2",
            "[\"Antimetabolite-induced leukopenia\", \"predisposes to\", \"severe Pseudomonas sepsis\"]": " \n[\"Antimetabolite-induced leukopenia\", \"predisposes to\", \"severe Pseudomonas sepsis\"]\n[\"Antimetabolite-induced leukopenia\", \"predisposes to\", \"severe sepsis\"]\n[\"Antimetabolite-induced leukopenia\", \"predisposes to\", \"Pseudomonas sepsis\"]\n[\"Antimetabolite-induced leukopenia\", \"predisposes to\", \"sepsis\"]\nGranularity: 4",
            "[\"Monkeys\", \"serve as\", \"biological model for study of antimicrobial agents\"]": " \n[\"Monkeys\", \"serve as\", \"biological model\"]\n[\"biological model\", \"is used for studying\", \"antimicrobial agents\"]\nGranularity: 2"
      },
      "Cancer incidence and metolachlor use in the Agricultural Health Study : An update .|UNASSIGNED : Metolachlor , a widely used herbicide , is classified as a Group C carcinogen by the U . S .|Environmental Protection Agency based on increased liver neoplasms in female rats .|Epidemiologic studies of the health effects of metolachlor have been limited .|The Agricultural Health Study ( AHS ) is a prospective cohort study including licensed private and commercial pesticide applicators in Iowa and North Carolina enrolled 1993 - 1997 .|We evaluated cancer incidence through 2010 / 2011 ( NC / IA ) for 49 , 616 applicators , 53 % of whom reported ever using metolachlor .|We used Poisson regression to evaluate relations between two metrics of metolachlor use ( lifetime days , intensity - weighted lifetime days ) and cancer incidence .|We saw no association between metolachlor use and incidence of all cancers combined ( n = 5 , 701 with a 5 - year lag ) or most site - specific cancers .|For liver cancer , in analyses restricted to exposed workers , elevations observed at higher categories of use were not statistically significant .|However , trends for both lifetime and intensity - weighted lifetime days of metolachor use were positive and statistically significant with an unexposed reference group .|A similar pattern was observed for follicular cell lymphoma , but no other lymphoma subtypes .|An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update .|This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies .|However , our findings for both liver cancer and follicular cell lymphoma warrant follow - up to better differentiate effects of metolachlor use from other factors .": {
            "[\"Cancer incidence\", \"and\", \"metolachlor use\"]": " \n[\"Cancer incidence\", \"is affected by\", \"metolachlor use\"]\n[\"metolachlor use\", \"contributes to\", \"Cancer incidence\"]\nGranularity: 2",
            "[\"Metolachlor\", \"is classified as\", \"Group C carcinogen\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Metolachlor\", \"increased\", \"liver neoplasms in female rats\"]": " \n[\"Metolachlor\", \"increased\", \"liver neoplasms\"]\n[\"female rats\", \"experienced\", \"liver neoplasms\"]\nGranularity: 2",
            "[\"Epidemiologic studies\", \"of\", \"health effects of metolachlor\"]": " \n[\"Epidemiologic studies\", \"of\", \"health effects\"]\n[\"Epidemiologic studies\", \"of\", \"metolachlor\"]\nGranularity: 2",
            "[\"Agricultural Health Study\", \"including\", \"licensed private and commercial pesticide applicators\"]": " \n[\"Agricultural Health Study\", \"includes\", \"licensed private pesticide applicators\"]\n[\"Agricultural Health Study\", \"includes\", \"licensed commercial pesticide applicators\"]\nGranularity: 2",
            "[\"Applicators\", \"reported\", \"ever using metolachlor\"]": " \n[\"Applicators\", \"reported\", \"using metolachlor\"]\n[\"Applicators\", \"ever used\", \"metolachlor\"]\nGranularity: 2",
            "[\"Poisson regression\", \"used to evaluate\", \"relations between two metrics of metolachlor use\"]": " \n[\"Poisson regression\", \"used to evaluate\", \"relations between two metrics\"]\n[\"Poisson regression\", \"used to evaluate\", \"metolachlor use\"]\nGranularity: 2",
            "[\"Metolachlor use\", \"no association with\", \"incidence of all cancers combined\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Elevations observed\", \"not statistically significant\", \"for liver cancer\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Trends for both lifetime and intensity-weighted lifetime days\", \"positive and statistically significant\", \"with an unexposed reference group\"]": "\n[\"Trends for lifetime days\", \"are positive and statistically significant\", \"with an unexposed reference group\"]\n[\"Trends for intensity-weighted lifetime days\", \"are positive and statistically significant\", \"with an unexposed reference group\"]\nGranularity: 2",
            "[\"Similar pattern observed\", \"for\", \"follicular cell lymphoma\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Earlier suggestion\", \"not confirmed\", \"increased lung cancer risk at high levels of metolachlor use\"]": " \n[\"Earlier suggestion\", \"not confirmed\", \"increased risk of lung cancer\"]\n[\"Earlier suggestion\", \"not confirmed\", \"high levels of metolachlor use\"]\nGranularity: 2",
            "[\"Suggestion of an association\", \"echoes\", \"observation of increased liver neoplasms in some animal studies\"]": " \n[\"Suggestion of an association\", \"echoes\", \"observation of increased liver neoplasms\"]\n[\"Suggestion of an association\", \"echoes\", \"in some animal studies\"]\nGranularity: 2",
            "[\"Findings for both liver cancer and follicular cell lymphoma\", \"warrant\", \"follow-up\"]": " \n[\"Findings for liver cancer\", \"warrant\", \"follow-up\"]\n[\"Findings for follicular cell lymphoma\", \"warrant\", \"follow-up\"]\nGranularity: 2"
      },
      "Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine - induced status epilepticus in the adult rat .|Following status epilepticus in the rat , dentate granule cell neurogenesis increases greatly , and many of the new neurons appear to develop ectopically , in the hilar region of the hippocampal formation .|It has been suggested that the ectopic hilar granule cells could contribute to the spontaneous seizures that ultimately develop after status epilepticus .|However , the population has never been quantified , so it is unclear whether it is substantial enough to have a strong influence on epileptogenesis .|To quantify this population , the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine - induced status epilepticus .|The number of hilar neurons immunoreactive for Prox - 1 , a granule - cell - specific marker , was estimated using the optical fractionator method .|The results indicate that the size of the hilar ectopic granule cell population after status epilepticus is substantial , and stable over time .|Interestingly , the size of the population appears to be correlated with the frequency of behavioral seizures , because animals with more ectopic granule cells in the hilus have more frequent behavioral seizures .|The hilar ectopic granule cell population does not appear to vary systematically across the septotemporal axis , although it is associated with an increase in volume of the hilus .|The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy .": {
            "[\"status epilepticus\", \"increases\", \"dentate granule cell neurogenesis\"]": " \n[\"status epilepticus\", \"increases\", \"dentate granule cell proliferation\"]\n[\"status epilepticus\", \"increases\", \"dentate granule cell differentiation\"]\n[\"status epilepticus\", \"increases\", \"dentate granule cell maturation\"]\nGranularity: 3",
            "[\"new neurons\", \"develop\", \"ectopically\"]": " N/A (The term 'ectopically' is already specific and does not need further granularity.)\nGranularity: 0",
            "[\"ectopic hilar granule cells\", \"contribute to\", \"spontaneous seizures\"]": " \n[\"ectopic hilar granule cells\", \"contribute to\", \"spontaneous seizures\"]\nGranularity: 1",
            "[\"population\", \"has never been\", \"quantified\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"total number of ectopic hilar granule cells\", \"estimated using\", \"unbiased stereology\"]": "\n[\"total number of ectopic hilar granule cells\", \"estimated\", \"using unbiased stereology\"]\n[\"total number of ectopic hilar granule cells\", \"estimated using\", \"unbiased stereology\"]\nGranularity: 2",
            "[\"number of hilar neurons\", \"estimated using\", \"optical fractionator method\"]": " \n[\"number of hilar neurons\", \"estimated by\", \"optical fractionator method\"]\n[\"number of hilar neurons\", \"measured using\", \"optical fractionator method\"]\nGranularity: 2",
            "[\"results\", \"indicate\", \"size of the hilar ectopic granule cell population\"]": " \n[\"results\", \"indicate\", \"size\"]\n[\"results\", \"indicate\", \"hilar ectopic granule cell population\"]\nGranularity: 2",
            "[\"size of the population\", \"correlated with\", \"frequency of behavioral seizures\"]": " \n[\"size of the population\", \"correlated with\", \"frequency of seizures\"]\n[\"size of the population\", \"correlated with\", \"behavioral seizures\"]\nGranularity: 2",
            "[\"hilar ectopic granule cell population\", \"does not vary\", \"septotemporal axis\"]": "\n[\"hilar ectopic granule cell population\", \"does not vary\", \"septotemporal axis\"]\nGranularity: 1",
            "[\"hilar ectopic granule cell population\", \"associated with\", \"increase in volume of the hilus\"]": " \n[\"hilar ectopic granule cell population\", \"associated with\", \"increase in volume\"]\n[\"hilar ectopic granule cell population\", \"associated with\", \"the hilus\"]\nGranularity: 2",
            "[\"results\", \"provide\", \"new insight\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Stereological methods\", \"reveal\", \"ectopic hilar granule cells\"]": " \n[\"Stereological methods\", \"reveal\", \"ectopic hilar granule cells\"]\nGranularity: 1"
      },
      "Topotecan in combination with radiotherapy in unresectable glioblastoma : a phase 2 study .|Improving glioblastoma multiforme ( GBM ) treatment with radio - chemotherapy remains a challenge .|Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration .|The present study assessed the combination of radiotherapy ( 60 Gy / 30 fractions / 40 days ) and topotecan ( 0 . 9 mg / m ( 2 ) / day on days 1 - 5 on weeks 1 , 3 and 5 ) in 50 adults with histologically proven and untreated GBM .|The incidence of non - hematological toxicities was low and grade 3 - 4 hematological toxicities were reported in 20 patients ( mainly lymphopenia and neutropenia ) .|Partial response and stabilization rates were 2 % and 32 % , respectively , with an overall time to progression of 12 weeks .|One - year overall survival ( OS ) rate was 42 % , with a median OS of 40 weeks .|Topotecan in combination with radiotherapy was well tolerated .|However , while response and stabilization concerned one - third of the patients , the study did not show increased benefits in terms of survival in patients with unresectable GBM .": {
            "[\"Topotecan\", \"is used in combination with\", \"radiotherapy\"]": " N/A (The triple is specific, conveying a singular relation between Topotecan and radiotherapy.)\nGranularity: 0",
            "[\"Topotecan\", \"is assessed in\", \"a phase 2 study\"]": " \n[\"Topotecan\", \"is assessed\", \"in a phase 2 study\"]\nGranularity: 1",
            "[\"Radiotherapy\", \"is combined with\", \"topotecan\"]": " \n[\"Radiotherapy\", \"is combined with\", \"topotecan\"]\nGranularity: 1",
            "[\"Study\", \"assessed\", \"combination of radiotherapy and topotecan\"]": "\n[\"Study\", \"assessed\", \"radiotherapy\"]\n[\"Study\", \"assessed\", \"topotecan\"]\nGranularity: 2",
            "[\"Incidence of non-hematological toxicities\", \"is low and\", \"grade 3-4 hematological toxicities\"]": " \n[\"Incidence of non-hematological toxicities\", \"is low\"]\n[\"Incidence of non-hematological toxicities\", \"is low and\", \"grade 3-4 hematological toxicities\"]\n[\"grade 3-4 hematological toxicities\", \"is low\"]\nGranularity: 3",
            "[\"Partial response and stabilization rates\", \"are\", \"2% and 32%\"]": " \n[\"Partial response and stabilization rates\", \"are\", \"2%\"]\n[\"Partial response and stabilization rates\", \"are\", \"32%\"]\nGranularity: 2",
            "[\"Overall time to progression\", \"is\", \"12 weeks\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"One-year overall survival rate\", \"is\", \"42%\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Median overall survival\", \"is\", \"40 weeks\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Topotecan in combination with radiotherapy\", \"is\", \"well tolerated\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Study\", \"does not show\", \"increased benefits in terms of survival\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Topotecan\", \"exhibits\", \"growth inhibition of human glioma as well as brain penetration\"]": " \n[\"Topotecan\", \"exhibits\", \"growth inhibition of human glioma\"]\n[\"Topotecan\", \"exhibits\", \"brain penetration\"]\nGranularity: 2"
      },
      "Dysfunctional overnight memory consolidation in ecstasy users .|Sleep plays an important role in the consolidation and integration of memory in a process called overnight memory consolidation .|Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep - related impairments .|We extend past research by examining overnight memory consolidation among regular ecstasy users ( n = 12 ) and drug naive healthy controls ( n = 26 ) .|Memory recall of word pairs was evaluated before and after a period of sleep , with and without interference prior to testing .|In addition , we assessed neurocognitive performances across tasks of learning , memory and executive functioning .|Ecstasy users demonstrated impaired overnight memory consolidation , a finding that was more pronounced following associative interference .|Additionally , ecstasy users demonstrated impairments on tasks recruiting frontostriatal and hippocampal neural circuitry , in the domains of proactive interference memory , long - term memory , encoding , working memory and complex planning .|We suggest that ecstasy - associated dysfunction in fronto - temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users .": {
            "[\"Dysfunctional overnight memory consolidation\", \"in\", \"ecstasy users\"]": " \n[\"Dysfunctional overnight memory consolidation\", \"in\", \"ecstasy users\"]\nGranularity: 1",
            "[\"Sleep\", \"plays an important role in\", \"consolidation and integration of memory\"]": " \n[\"Sleep\", \"plays a role in\", \"consolidation of memory\"]\n[\"Sleep\", \"plays a role in\", \"integration of memory\"]\nGranularity: 2",
            "[\"Previous studies\", \"indicate\", \"ecstasy users have marked and persistent neurocognitive and sleep-related impairments\"]": " \n[\"Previous studies\", \"indicate\", \"ecstasy users have marked neurocognitive impairments\"]\n[\"Previous studies\", \"indicate\", \"ecstasy users have persistent neurocognitive impairments\"]\n[\"Previous studies\", \"indicate\", \"ecstasy users have marked sleep-related impairments\"]\n[\"Previous studies\", \"indicate\", \"ecstasy users have persistent sleep-related impairments\"]\nGranularity: 4",
            "[\"Research\", \"extended\", \"by examining overnight memory consolidation among regular ecstasy users and drug-naive healthy controls\"]": "\n[\"Research\", \"extended\", \"by examining overnight memory consolidation\"]\n[\"Research\", \"extended\", \"among regular ecstasy users\"]\n[\"Research\", \"extended\", \"among drug-naive healthy controls\"]\n[\"Research\", \"examining\", \"overnight memory consolidation\"]\n[\"Research\", \"examining\", \"among regular ecstasy users\"]\n[\"Research\", \"examining\", \"among drug-naive healthy controls\"]\n[\"Research\", \"overnight memory consolidation\", \"among regular ecstasy users\"]\n[\"Research\", \"overnight memory consolidation\", \"among drug-naive healthy controls\"]\n[\"Research\", \"among regular ecstasy users\", \"drug-naive healthy controls\"]\nGranularity: 9",
            "[\"Memory recall of word pairs\", \"evaluated\", \"before and after a period of sleep, with and without interference prior to testing\"]": " \n[\"Memory recall of word pairs\", \"evaluated\", \"before sleep\"]\n[\"Memory recall of word pairs\", \"evaluated\", \"after sleep\"]\n[\"Memory recall of word pairs\", \"evaluated\", \"with interference prior to testing\"]\n[\"Memory recall of word pairs\", \"evaluated\", \"without interference prior to testing\"]\nGranularity: 4",
            "[\"Neurocognitive performances\", \"assessed\", \"across tasks of learning, memory, and executive functioning\"]": " \n[\"Neurocognitive performances\", \"assessed\", \"learning\"]\n[\"Neurocognitive performances\", \"assessed\", \"memory\"]\n[\"Neurocognitive performances\", \"assessed\", \"executive functioning\"]\nGranularity: 3",
            "[\"Ecstasy users\", \"demonstrated\", \"impaired overnight memory consolidation\"]": "\n[\"Ecstasy users\", \"demonstrated\", \"impaired memory consolidation\"]\n[\"Ecstasy users\", \"demonstrated\", \"impaired overnight memory\"]\nGranularity: 2",
            "[\"Impairment\", \"more pronounced\", \"following associative interference\"]": " \n[\"Impairment\", \"is more pronounced\", \"following associative interference\"]\n[\"Impairment\", \"is more pronounced\", \"after associative interference\"]\n[\"Impairment\", \"is more pronounced\", \"due to associative interference\"]\nGranularity: 3",
            "[\"Ecstasy users\", \"demonstrated impairments\", \"on tasks recruiting frontostriatal and hippocampal neural circuitry\"]": " \n[\"Ecstasy users\", \"demonstrated impairments\", \"on tasks recruiting frontostriatal neural circuitry\"]\n[\"Ecstasy users\", \"demonstrated impairments\", \"on tasks recruiting hippocampal neural circuitry\"]\nGranularity: 2",
            "[\"Impairments\", \"in the domains of\", \"proactive interference memory, long-term memory, encoding, working memory, and complex planning\"]": " \n[\"Impairments\", \"in the domain of\", \"proactive interference memory\"]\n[\"Impairments\", \"in the domain of\", \"long-term memory\"]\n[\"Impairments\", \"in the domain of\", \"encoding\"]\n[\"Impairments\", \"in the domain of\", \"working memory\"]\n[\"Impairments\", \"in the domain of\", \"complex planning\"]\nGranularity: 5",
            "[\"Ecstasy-associated dysfunction in fronto-temporal circuitry\", \"may underlie\", \"overnight consolidation memory impairments in regular ecstasy users\"]": "\n[\"Ecstasy-associated dysfunction\", \"underlies\", \"overnight consolidation memory impairments\"]\n[\"fronto-temporal circuitry\", \"underlies\", \"overnight consolidation memory impairments\"]\n[\"Ecstasy-associated dysfunction\", \"may underlie\", \"overnight consolidation memory impairments\"]\n[\"fronto-temporal circuitry\", \"may underlie\", \"overnight consolidation memory impairments\"]\n[\"Ecstasy-associated dysfunction\", \"underlies\", \"memory impairments\"]\n[\"fronto-temporal circuitry\", \"underlies\", \"memory impairments\"]\n[\"Ecstasy-associated dysfunction\", \"may underlie\", \"memory impairments\"]\n[\"fronto-temporal circuitry\", \"may underlie\", \"memory impairments\"]\nGranularity: 8"
      },
      "Convulsant effect of lindane and regional brain concentration of GABA and dopamine .|Lindane ( gamma - hexachlorocyclohexane ) is an organochlorine insecticide with known neurotoxic effects .|Its mechanism of action is not well understood although it has been proposed that lindane acts as a non - competitive antagonist at the gamma - aminobutyric acid ( GABA ) - A receptor .|We studied the effect of lindane ( 150 mg / kg ) on the GABAergic and dopaminergic systems by measuring the concentration of GABA , dopamine and its metabolites in 7 brain areas at the onset of seizures .|All animals suffered tonic convulsions at 18 . 3 + / - 1 . 4 min after lindane administration .|The concentration of GABA was only slightly but significantly decreased in the colliculi without modifications in the other areas .|The concentration of dopamine was increased in the mesencephalon and that of its metabolite DOPAC was also increased in the mesencephalon and the striatum .": {
            "[\"lindane\", \"has\", \"neurotoxic effects\"]": " N/A (The triple is specific, conveying a singular relation between lindane and its neurotoxic effects.)\nGranularity: 0",
            "[\"lindane\", \"is\", \"organochlorine insecticide\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"lindane\", \"acts as\", \"non-competitive antagonist\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"lindane\", \"affects\", \"gamma-aminobutyric acid (GABA)-A receptor\"]": " \n[\"lindane\", \"affects\", \"gamma-aminobutyric acid (GABA)\"]\n[\"lindane\", \"affects\", \"A receptor\"]\nGranularity: 2",
            "[\"lindane\", \"causes\", \"tonic convulsions\"]": " N/A (The triple is specific, conveying a singular relation between lindane and tonic convulsions.)\nGranularity: 0",
            "[\"lindane\", \"decreases\", \"GABA concentration\"]": " N/A (The triple is specific, conveying a singular relation between lindane and GABA concentration.)\nGranularity: 0",
            "[\"lindane\", \"increases\", \"dopamine concentration\"]": " N/A (The triple is specific, conveying a singular relation between lindane and dopamine concentration.)\nGranularity: 0",
            "[\"lindane\", \"increases\", \"DOPAC concentration\"]": " N/A (The triple is specific, conveying a singular relation between lindane and DOPAC concentration.)\nGranularity: 0"
      },
      "Effects of exercise on the severity of isoproterenol - induced myocardial infarction .|The effect of exercise on the severity of isoproterenol - induced myocardial infarction was studied in male rats .|Ninety - three rats were randomly divided into three groups .|The exercise - isoproterenol ( E - 1 ) and exercise control ( EC ) groups exercised daily for thirty days on a treadmill at 1 mph , 2 % grade while animals of the sedentary - isoproterenol ( S - I ) group remained sedentary .|Eight animals were assigned to the sedentary control ( SC ) group which remained sedentary throughout the experimental period .|Forty - eight hours after the final exercise period , S - I and E - I animals received a single subcutaneous injection of isoproterenol ( 250 mg / kg body weight ) .|Animals of the S - I group exhibited significantly ( Pp less than 0 . 05 ) greater mortality from the effects of isoproterenol than animals of the E - I group .|Serum CPK activity for E - I animals was significantly ( p less than 0 . 05 ) greater than for animals in the S - I and EC groups twenty hours following isoproterenol injection .|No statistically significant differences were observed between the two isoproterenol treated groups for severity of the induced lesions , changes in heart weight , or heart weight to body weight ratios .|The results indicated that exercise reduced the mortality associated with the effects of large dosages of isoproterenol but had little on the severity of the infarction .": {
            "[\"exercise\", \"reduces\", \"mortality associated with effects of large dosages of isoproterenol\"]": " \n[\"exercise\", \"reduces\", \"mortality\"]\n[\"exercise\", \"reduces\", \"effects of large dosages of isoproterenol\"]\nGranularity: 2",
            "[\"exercise\", \"has little effect on\", \"severity of the infarction\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"isoproterenol-induced myocardial infarction\", \"was studied\", \"in male rats\"]": " \n[\"isoproterenol-induced myocardial infarction\", \"was studied\", \"in male rats\"]\nGranularity: 1",
            "[\"Ninety-three rats\", \"were divided into\", \"three groups\"]": "\n[\"Ninety-three rats\", \"were divided\", \"into three groups\"]\n[\"Ninety-three rats\", \"were\", \"divided into three groups\"]\n[\"Ninety-three rats\", \"were divided into\", \"three groups\"]\nGranularity: 3",
            "[\"E-1 and EC groups\", \"exercised daily\", \"on a treadmill\"]": " \n[\"E-1 and EC groups\", \"exercised\", \"daily\"]\n[\"E-1 and EC groups\", \"exercised\", \"on a treadmill\"]\nGranularity: 2",
            "[\"SC group\", \"was assigned\", \"to the sedentary control\"]": " \n[\"SC group\", \"was assigned\", \"to the sedentary control\"]\nGranularity: 1",
            "[\"S-I and E-I animals\", \"received\", \"a single subcutaneous injection of isoproterenol\"]": " \n[\"S-I animals\", \"received\", \"a single subcutaneous injection of isoproterenol\"]\n[\"E-I animals\", \"received\", \"a single subcutaneous injection of isoproterenol\"]\nGranularity: 2",
            "[\"S-I group\", \"exhibited\", \"greater mortality\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"E-I animals\", \"had\", \"greater serum CPK activity\"]": " \n[\"E-I animals\", \"had\", \"greater serum CPK activity\"]\nGranularity: 1",
            "[\"No statistically significant differences\", \"were observed\", \"between the two isoproterenol treated groups\"]": " \n[\"No statistically significant differences\", \"were observed\", \"between the two isoproterenol treated groups\"]\nGranularity: 1"
      },
      "Medial changes in arterial spasm induced by L - norepinephrine .|In normal rats , the media of small arteries ( 0 . 4 - - 0 . 2 mm in diameter ) previously was shown to contain intracellular vacuoles , identified ultrastructurally as herniations of one smooth muscle cell into another .|The hypothesis that intense vasoconstriction would increase the number of such vacuoles has been tested .|In the media of the saphenous artery and its distal branch , vasoconstriction induced by L - norepinephrine produced many cell - to - cell hernias within 15 minutes .|At 1 day their number was reduced to about 1 / 10 of the original number .|By 7 days the vessel was almost restored to normal .|Triple stimulation over 1 day induced more severe changes in the media .|These findings suggest that smooth muscle cells are susceptible to damage in the course of their specific function .|The experimental data are discussed in relation to medial changes observed in other instances of arterial spasm .|Endothelial changes that developed in the same experimental model were described in a previous paper .": {
            "[\"Intracellular vacuoles\", \"are identified as\", \"herniations of one smooth muscle cell into another\"]": " \n[\"Intracellular vacuoles\", \"are identified as\", \"herniations\"]\n[\"Intracellular vacuoles\", \"are identified as\", \"smooth muscle cell\"]\n[\"Intracellular vacuoles\", \"are identified as\", \"another\"]\nGranularity: 3",
            "[\"Vasoconstriction\", \"increases\", \"number of vacuoles\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Saphenous artery and its distal branch\", \"undergo\", \"vasoconstriction induced by L-norepinephrine\"]": "\n[\"Saphenous artery\", \"undergoes\", \"vasoconstriction\"]\n[\"distal branch\", \"undergoes\", \"vasoconstriction\"]\n[\"vasoconstriction\", \"is induced by\", \"L-norepinephrine\"]\nGranularity: 3",
            "[\"Cell-to-cell hernias\", \"are produced\", \"within 15 minutes\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Number of hernias\", \"is reduced\", \"to about 1/10 of the original number\"]": " \n[\"Number of hernias\", \"is reduced to\", \"1/10\"]\n[\"Number of hernias\", \"is reduced by\", \"90%\"]\nGranularity: 2",
            "[\"Vessel\", \"is almost restored to normal\", \"after 7 days\"]": " \n[\"Vessel\", \"is restored\", \"to normal\"]\n[\"Vessel\", \"takes\", \"7 days\"]\nGranularity: 2",
            "[\"Triple stimulation\", \"induces\", \"more severe changes in the media\"]": "\n[\"Triple stimulation\", \"induces\", \"changes in the media\"]\n[\"Triple stimulation\", \"induces\", \"severe changes\"]\nGranularity: 2",
            "[\"Smooth muscle cells\", \"are susceptible to\", \"damage in the course of their specific function\"]": " \n[\"Smooth muscle cells\", \"are susceptible to\", \"damage\"]\n[\"Smooth muscle cells\", \"perform\", \"specific function\"]\nGranularity: 2",
            "[\"Experimental data\", \"are discussed in relation to\", \"medial changes observed in other instances of arterial spasm\"]": " \n[\"Experimental data\", \"are discussed\", \"medial changes\"]\n[\"Experimental data\", \"are discussed\", \"arterial spasm\"]\nGranularity: 2",
            "[\"Endothelial changes\", \"were described\", \"in a previous paper\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"L-norepinephrine\", \"induces\", \"medial changes in arterial spasm\"]": " \n[\"L-norepinephrine\", \"induces\", \"medial changes\"]\n[\"L-norepinephrine\", \"induces\", \"arterial spasm\"]\nGranularity: 2"
      },
      "Long - term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin .|Basic and clinical research has demonstrated that dementia of sporadic Alzheimer 's disease ( sAD ) type is associated with dysfunction of the insulin - receptor ( IR ) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells .|An alternative source of energy is d - galactose ( the C - 4 - epimer of d - glucose ) which is transported into the brain by insulin - independent GLUT3 transporter where it might be metabolized to glucose via the Leloir pathway .|Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model , but the effects of oral galactose treatment on cognitive functions have never been tested .|We have investigated the effects of continuous daily oral galactose ( 200 mg / kg / day ) treatment on cognitive deficits in streptozotocin - induced ( STZ - icv ) rat model of sAD , tested by Morris Water Maze and Passive Avoidance test , respectively .|One month of oral galactose treatment initiated immediately after the STZ - icv administration , successfully prevented development of the STZ - icv - induced cognitive deficits .|Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg / kg / day .|Additionally , oral galactose administration led to the appearance of galactose in the blood .|The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose .|Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD .": {
            "[\"Dementia of sporadic Alzheimer's disease\", \"associated with\", \"dysfunction of the insulin-receptor system\"]": " \n[\"Dementia of sporadic Alzheimer's disease\", \"associated with\", \"dysfunction of the insulin-receptor system\"]\nGranularity: 1",
            "[\"Insulin-receptor system dysfunction\", \"followed by\", \"decreased glucose transport via GLUT4\"]": " \n[\"Insulin-receptor system dysfunction\", \"leads to\", \"decreased glucose transport\"]\n[\"Insulin-receptor system dysfunction\", \"followed by\", \"decreased GLUT4 transport\"]\nGranularity: 2",
            "[\"Decreased glucose transport via GLUT4\", \"followed by\", \"decreased glucose metabolism in brain cells\"]": " \n[\"Decreased glucose transport via GLUT4\", \"followed by\", \"decreased glucose metabolism\"]\n[\"Decreased glucose metabolism\", \"in\", \"brain cells\"]\nGranularity: 2",
            "[\"Alternative source of energy\", \"is\", \"d-galactose\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"d-galactose\", \"transported by\", \"insulin-independent GLUT3 transporter\"]": " \n[\"d-galactose\", \"transported by\", \"insulin-independent\"]\n[\"d-galactose\", \"transported by\", \"GLUT3 transporter\"]\nGranularity: 2",
            "[\"d-galactose\", \"metabolized to glucose via\", \"the Leloir pathway\"]": " \n[\"d-galactose\", \"metabolized via\", \"Leloir pathway\"]\n[\"d-galactose\", \"metabolized to\", \"glucose\"]\nGranularity: 2",
            "[\"Parenteral daily injections of galactose\", \"induce\", \"memory deterioration in rodents\"]": " \n[\"Parenteral daily injections\", \"induce\", \"memory deterioration\"]\n[\"galactose\", \"induce\", \"memory deterioration\"]\n[\"rodents\", \"induce\", \"memory deterioration\"]\nGranularity: 3",
            "[\"Effects of oral galactose treatment\", \"have never been\", \"tested\"]": " \n[\"Effects of oral galactose treatment\", \"have never been\", \"tested\"]\nGranularity: 1",
            "[\"Continuous daily oral galactose treatment\", \"tested for\", \"cognitive deficits in streptozotocin-induced rat model\"]": " \n[\"Continuous daily oral galactose treatment\", \"tested for\", \"cognitive deficits\"]\n[\"Continuous daily oral galactose treatment\", \"tested for\", \"streptozotocin-induced rat model\"]\nGranularity: 2",
            "[\"Morris Water Maze and Passive Avoidance test\", \"used to\", \"test cognitive deficits\"]": " \n[\"Morris Water Maze\", \"used to\", \"test cognitive deficits\"]\n[\"Passive Avoidance test\", \"used to\", \"test cognitive deficits\"]\nGranularity: 2",
            "[\"One month of oral galactose treatment\", \"successfully prevented\", \"STZ-icv-induced cognitive deficits\"]": "\n[\"One month of oral galactose treatment\", \"prevented\", \"STZ-icv-induced cognitive deficits\"]\n[\"oral galactose treatment\", \"successfully prevented\", \"STZ-icv-induced cognitive deficits\"]\n[\"One month of oral galactose treatment\", \"prevented\", \"cognitive deficits\"]\n[\"oral galactose treatment\", \"successfully prevented\", \"cognitive deficits\"]\nGranularity: 4",
            "[\"Beneficial effect of oral galactose\", \"independent of\", \"rat age and galactose dose\"]": " \n[\"Beneficial effect of oral galactose\", \"independent of\", \"rat age\"]\n[\"Beneficial effect of oral galactose\", \"independent of\", \"galactose dose\"]\nGranularity: 2",
            "[\"Oral galactose administration\", \"led to\", \"appearance of galactose in the blood\"]": " \n[\"Oral galactose administration\", \"led to\", \"appearance of galactose\"]\n[\"Oral galactose administration\", \"led to\", \"appearance in the blood\"]\nGranularity: 2",
            "[\"Increase of galactose concentration in cerebrospinal fluid\", \"lower after\", \"oral than after parenteral administration\"]": " \n[\"Increase of galactose concentration in cerebrospinal fluid\", \"lower after\", \"oral administration\"]\n[\"Increase of galactose concentration in cerebrospinal fluid\", \"lower after\", \"parenteral administration\"]\nGranularity: 2",
            "[\"Oral galactose exposure\", \"might have\", \"beneficial effects on learning and memory ability\"]": "\n[\"Oral galactose exposure\", \"might have\", \"beneficial effects\"]\n[\"Oral galactose exposure\", \"might have\", \"learning ability\"]\n[\"Oral galactose exposure\", \"might have\", \"memory ability\"]\nGranularity: 3",
            "[\"Oral galactose exposure\", \"worth investigating for\", \"improvement of cognitive deficits in AD\"]": " \n[\"Oral galactose exposure\", \"worth investigating for\", \"improvement of cognitive deficits\"]\n[\"Oral galactose exposure\", \"worth investigating for\", \"AD\"]\nGranularity: 2",
            "[\"Long-term oral galactose treatment\", \"prevents\", \"cognitive deficits in male Wistar rats\"]": " \n[\"Long-term oral galactose treatment\", \"prevents\", \"cognitive deficits\"]\n[\"Long-term oral galactose treatment\", \"prevents\", \"male Wistar rats\"]\nGranularity: 2"
      },
      "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release , cyclooxygenase gene expression and pain in a clinical pain model .|BACKGROUND : In addition to blocking nociceptive input from surgical sites , long - acting local anesthetics might directly modulate inflammation .|In the present study , we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 ( PGE2 ) production and cyclooxygenase ( COX ) gene expression that increases postoperative pain in human subjects .|METHODS : Subjects ( n = 114 ) undergoing extraction of impacted third molars received either 2 % lidocaine or 0 . 5 % bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h .|Oral mucosal biopsies were taken before surgery and 48 h after surgery .|After extraction , a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 ( TXB2 ) measurements .|RESULTS : The bupivacaine / rofecoxib group reported significantly less pain , as assessed by a visual analog scale , compared with the other three treatment groups over the first 4 h .|However , the bupivacaine / placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups .|Moreover , bupivacaine significantly increased COX - 2 gene expression at 48 h as compared with the lidocaine / placebo group .|Thromboxane levels were not significantly affected by any of the treatments , indicating that the effects seen were attributable to inhibition of COX - 2 , but not COX - 1 .|CONCLUSIONS : These results suggest that bupivacaine stimulates COX - 2 gene expression after tissue injury , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates .": {
            "[\"bupivacaine\", \"has differential effects with\", \"lidocaine\"]": " \n[\"bupivacaine\", \"has effects with\", \"lidocaine\"]\n[\"bupivacaine\", \"has differential effects\", \"lidocaine\"]\nGranularity: 2",
            "[\"bupivacaine\", \"affects\", \"prostaglandin E2 release\"]": " \n[\"bupivacaine\", \"affects\", \"prostaglandin E2\"]\n[\"bupivacaine\", \"affects\", \"release\"]\nGranularity: 2",
            "[\"bupivacaine\", \"affects\", \"cyclooxygenase gene expression\"]": " \n[\"bupivacaine\", \"affects\", \"cyclooxygenase\"]\n[\"bupivacaine\", \"affects\", \"gene expression\"]\nGranularity: 2",
            "[\"bupivacaine\", \"increases\", \"postoperative pain\"]": " N/A (The triple is specific, conveying a singular relation between bupivacaine and postoperative pain.)\nGranularity: 0",
            "[\"lidocaine\", \"used in\", \"subjects undergoing extraction of impacted third molars\"]": " \n[\"lidocaine\", \"used for\", \"extraction\"]\n[\"lidocaine\", \"used for\", \"impacted third molars\"]\nGranularity: 2",
            "[\"rofecoxib\", \"administered to\", \"subjects\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"microdialysis probe\", \"placed at\", \"surgical site\"]": " \n[\"microdialysis probe\", \"placed at\", \"surgical site\"]\nGranularity: 1",
            "[\"bupivacaine/rofecoxib group\", \"reports less pain than\", \"other treatment groups\"]": " \n[\"bupivacaine/rofecoxib group\", \"reports\", \"less pain\"]\n[\"other treatment groups\", \"reports\", \"more pain\"]\nGranularity: 2",
            "[\"bupivacaine/placebo group\", \"reports more pain than\", \"other treatment groups\"]": " \n[\"bupivacaine/placebo group\", \"reports\", \"more pain\"]\n[\"other treatment groups\", \"reports\", \"less pain\"]\nGranularity: 2",
            "[\"bupivacaine\", \"increases\", \"COX-2 gene expression\"]": " \n[\"bupivacaine\", \"increases\", \"COX-2 gene expression\"]\nGranularity: 1",
            "[\"thromboxane levels\", \"not significantly affected by\", \"any of the treatments\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"COX-2\", \"inhibited by\", \"bupivacaine\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"COX-1\", \"not inhibited by\", \"bupivacaine\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Ocular - specific ER stress reduction rescues glaucoma in murine glucocorticoid - induced glaucoma .|Administration of glucocorticoids induces ocular hypertension in some patients .|If untreated , these patients can develop a secondary glaucoma that resembles primary open - angle glaucoma ( POAG ) .|The underlying pathology of glucocorticoid - induced glaucoma is not fully understood , due in part to lack of an appropriate animal model .|Here , we developed a murine model of glucocorticoid - induced glaucoma that exhibits glaucoma features that are observed in patients .|Treatment of WT mice with topical ocular 0 . 1 % dexamethasone led to elevation of intraocular pressure ( IOP ) , functional and structural loss of retinal ganglion cells , and axonal degeneration , resembling glucocorticoid - induced glaucoma in human patients .|Furthermore , dexamethasone - induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork ( TM ) .|Similar to patients , withdrawal of dexamethasone treatment reduced elevated IOP and ER stress in this animal model .|Dexamethasone induced the transcriptional factor CHOP , a marker for chronic ER stress , in the anterior segment tissues , and Chop deletion reduced ER stress in these tissues and prevented dexamethasone - induced ocular hypertension .|Furthermore , reduction of ER stress in the TM with sodium 4 - phenylbutyrate prevented dexamethasone - induced ocular hypertension in WT mice .|Our data indicate that ER stress contributes to glucocorticoid - induced ocular hypertension and suggest that reducing ER stress has potential as a therapeutic strategy for treating glucocorticoid - induced glaucoma .": {
            "[\"Administration of glucocorticoids\", \"induces\", \"ocular hypertension in some patients\"]": " \n[\"Administration of glucocorticoids\", \"induces\", \"ocular hypertension\"]\n[\"Administration of glucocorticoids\", \"induces\", \"some patients\"]\nGranularity: 2",
            "[\"Untreated patients\", \"can develop\", \"secondary glaucoma that resembles primary open-angle glaucoma (POAG)\"]": "\n[\"Untreated patients\", \"can develop\", \"secondary glaucoma\"]\n[\"secondary glaucoma\", \"resembles\", \"primary open-angle glaucoma (POAG)\"]\nGranularity: 2",
            "[\"Underlying pathology of glucocorticoid-induced glaucoma\", \"is not fully understood\", \"due in part to lack of an appropriate animal model\"]": " \n[\"Underlying pathology of glucocorticoid-induced glaucoma\", \"is not fully understood\", \"due to lack of an appropriate animal model\"]\n[\"Underlying pathology of glucocorticoid-induced glaucoma\", \"is not fully understood\", \"in part due to lack of an appropriate animal model\"]\n[\"Underlying pathology of glucocorticoid-induced glaucoma\", \"is not fully understood\", \"due to lack of an appropriate animal model\"]\nGranularity: 3",
            "[\"Murine model of glucocorticoid-induced glaucoma\", \"was developed\", \"exhibits glaucoma features observed in patients\"]": " \n[\"Murine model\", \"was developed\", \"exhibits glaucoma features\"]\n[\"Murine model\", \"was developed\", \"induces glaucoma\"]\n[\"Murine model\", \"was developed\", \"resembles glaucoma observed in patients\"]\nGranularity: 3",
            "[\"Treatment of WT mice with topical ocular 0.1% dexamethasone\", \"led to\", \"elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration\"]": " \n[\"Treatment of WT mice\", \"with\", \"topical ocular 0.1% dexamethasone\"]\n[\"topical ocular 0.1% dexamethasone\", \"led to\", \"elevation of intraocular pressure (IOP)\"]\n[\"topical ocular 0.1% dexamethasone\", \"led to\", \"functional loss of retinal ganglion cells\"]\n[\"topical ocular 0.1% dexamethasone\", \"led to\", \"structural loss of retinal ganglion cells\"]\n[\"topical ocular 0.1% dexamethasone\", \"led to\", \"axonal degeneration\"]\nGranularity: 5",
            "[\"Dexamethasone-induced ocular hypertension\", \"was associated with\", \"chronic ER stress of the trabecular meshwork (TM)\"]": " \n[\"Dexamethasone-induced ocular hypertension\", \"is associated with\", \"chronic ER stress\"]\n[\"Dexamethasone-induced ocular hypertension\", \"is associated with\", \"trabecular meshwork (TM)\"]\n[\"chronic ER stress\", \"is induced by\", \"Dexamethasone\"]\n[\"trabecular meshwork (TM)\", \"is induced by\", \"Dexamethasone\"]\nGranularity: 4",
            "[\"Withdrawal of dexamethasone treatment\", \"reduced\", \"elevated IOP and ER stress in this animal model\"]": " \n[\"Withdrawal of dexamethasone treatment\", \"reduced\", \"elevated IOP\"]\n[\"Withdrawal of dexamethasone treatment\", \"reduced\", \"ER stress\"]\nGranularity: 2",
            "[\"Dexamethasone\", \"induced\", \"transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues\"]": " \n[\"Dexamethasone\", \"induced\", \"transcriptional factor CHOP\"]\n[\"Dexamethasone\", \"induced\", \"marker for chronic ER stress\"]\n[\"Dexamethasone\", \"induced\", \"anterior segment tissues\"]\nGranularity: 3",
            "[\"Chop deletion\", \"reduced\", \"ER stress in these tissues and prevented dexamethasone-induced ocular hypertension\"]": " \n[\"Chop deletion\", \"reduced\", \"ER stress\"]\n[\"Chop deletion\", \"prevented\", \"dexamethasone-induced ocular hypertension\"]\nGranularity: 2",
            "[\"Reduction of ER stress in the TM with sodium 4-phenylbutyrate\", \"prevented\", \"dexamethasone-induced ocular hypertension in WT mice\"]": " \n[\"Reduction of ER stress in the TM\", \"prevented\", \"dexamethasone-induced ocular hypertension\"]\n[\"Reduction of ER stress in the TM\", \"with\", \"sodium 4-phenylbutyrate\"]\n[\"dexamethasone-induced ocular hypertension\", \"in\", \"WT mice\"]\nGranularity: 3",
            "[\"Data\", \"indicate\", \"that ER stress contributes to glucocorticoid-induced ocular hypertension\"]": " \n[\"Data\", \"indicate\", \"ER stress\"]\n[\"ER stress\", \"contributes to\", \"glucocorticoid-induced ocular hypertension\"]\nGranularity: 2",
            "[\"Reducing ER stress\", \"has potential as\", \"a therapeutic strategy for treating glucocorticoid-induced glaucoma\"]": " \n[\"Reducing ER stress\", \"has potential as\", \"a therapeutic strategy\"]\n[\"Reducing ER stress\", \"has potential as\", \"treating glucocorticoid-induced glaucoma\"]\nGranularity: 2",
            "[\"Ocular-specific ER stress reduction\", \"rescues\", \"glaucoma in murine glucocorticoid-induced glaucoma\"]": " \n[\"Ocular-specific ER stress reduction\", \"rescues\", \"glaucoma\"]\n[\"Ocular-specific ER stress reduction\", \"reduces\", \"ER stress\"]\n[\"ER stress\", \"contributes to\", \"glaucoma\"]\n[\"murine glucocorticoid-induced glaucoma\", \"is a type of\", \"glaucoma\"]\nGranularity: 4"
      },
      "Safety and compliance with once - daily niacin extended - release / lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment ( IMPACT ) study .|Niacin extended - release / lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia .|This open - labeled , multicenter study evaluated the safety of bedtime niacin extended - release / lovastatin when dosed as initial therapy and patient compliance to treatment in various clinical practice settings .|A total of 4 , 499 patients with dyslipidemia requiring drug intervention was enrolled at 1 , 081 sites .|Patients were treated with 1 tablet ( 500 mg of niacin extended - release / 20 mg of lovastatin ) once nightly for 4 weeks and then 2 tablets for 8 weeks .|Patients also received dietary counseling , educational materials , and reminders to call a toll - free number that provided further education about dyslipidemia and niacin extended - release / lovastatin .|Primary end points were study compliance , increases in liver transaminases to > 3 times the upper limit of normal , and clinical myopathy .|Final study status was available for 4 , 217 patients ( 94 % ) .|Compliance to niacin extended - release / lovastatin was 77 % , with 3 , 245 patients completing the study .|Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates .|Flushing was the most common adverse event , reported by 18 % of patients and leading to discontinuation by 6 % .|Incidence of increased aspartate aminotransferase and / or alanine aminotransferase > 3 times the upper limit of normal was < 0 . 3 % .|An increase of creatine phosphokinase to > 5 times the upper limit of normal occurred in 0 . 24 % of patients , and no cases of drug - induced myopathy were observed .|Niacin extended - release / lovastatin 1 , 000 / 40 mg , dosed as initial therapy , was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes .": {
            "[\"Safety\", \"and\", \"compliance\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"niacin extended-release / lovastatin\", \"is\", \"new combination product\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"niacin extended-release / lovastatin\", \"approved for\", \"treatment of primary hypercholesterolemia and mixed dyslipidemia\"]": " \n[\"niacin extended-release / lovastatin\", \"approved for\", \"treatment of primary hypercholesterolemia\"]\n[\"niacin extended-release / lovastatin\", \"approved for\", \"treatment of mixed dyslipidemia\"]\nGranularity: 2",
            "[\"This open-labeled\", \"multicenter study\", \"evaluated the safety of bedtime niacin extended-release / lovastatin\"]": " \n[\"This open-labeled\", \"multicenter study\", \"evaluated the safety\"]\n[\"bedtime niacin extended-release / lovastatin\", \"evaluated\", \"safety\"]\nGranularity: 2",
            "[\"A total of 4,499 patients\", \"enrolled\", \"at 1,081 sites\"]": "\n[\"4,499 patients\", \"were enrolled at\", \"1,081 sites\"]\nGranularity: 1",
            "[\"Patients\", \"treated with\", \"1 tablet (500 mg of niacin extended-release / 20 mg of lovastatin)\"]": " \n[\"Patients\", \"treated with\", \"1 tablet\"]\n[\"1 tablet\", \"contains\", \"500 mg of niacin extended-release\"]\n[\"1 tablet\", \"contains\", \"20 mg of lovastatin\"]\nGranularity: 3",
            "[\"Patients\", \"received\", \"dietary counseling, educational materials, and reminders\"]": " \n[\"Patients\", \"received\", \"dietary counseling\"]\n[\"Patients\", \"received\", \"educational materials\"]\n[\"Patients\", \"received\", \"reminders\"]\nGranularity: 3",
            "[\"Primary end points\", \"were\", \"study compliance, increases in liver transaminases to > 3 times the upper limit of normal, and clinical myopathy\"]": " \n[\"Primary end points\", \"were\", \"study compliance\"]\n[\"Primary end points\", \"were\", \"increases in liver transaminases to > 3 times the upper limit of normal\"]\n[\"Primary end points\", \"were\", \"clinical myopathy\"]\nGranularity: 3",
            "[\"Final study status\", \"available for\", \"4,217 patients (94%)\"]": "\n[\"Final study status\", \"available for\", \"4,217 patients\"]\n[\"Final study status\", \"available for\", \"94% of patients\"]\nGranularity: 2",
            "[\"Compliance to niacin extended-release / lovastatin\", \"was\", \"77%\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patients\", \"completing the study\", \"3,245\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patients in the southeast\", \"those enrolled by endocrinologists\", \"had the lowest compliance and highest adverse event rates\"]": " \n[\"Patients in the southeast\", \"enrolled by\", \"endocrinologists\"]\n[\"Patients in the southeast\", \"had\", \"lowest compliance\"]\n[\"Patients in the southeast\", \"had\", \"highest adverse event rates\"]\n[\"those enrolled by endocrinologists\", \"had\", \"lowest compliance\"]\n[\"those enrolled by endocrinologists\", \"had\", \"highest adverse event rates\"]\nGranularity: 5",
            "[\"Flushing\", \"reported by\", \"18% of patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Flushing\", \"leading to discontinuation by\", \"6%\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Incidence of increased aspartate aminotransferase and / or alanine aminotransferase > 3 times the upper limit of normal\", \"was\", \"< 0.3%\"]": " \n[\"Incidence of increased aspartate aminotransferase\", \"was\", \"< 0.3%\"]\n[\"Incidence of increased alanine aminotransferase\", \"was\", \"< 0.3%\"]\n[\"Incidence of increased aspartate aminotransferase and alanine aminotransferase\", \"was\", \"< 0.3%\"]\nGranularity: 3",
            "[\"Increase of creatine phosphokinase to > 5 times the upper limit of normal\", \"occurred in\", \"0.24% of patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"No cases of drug-induced myopathy\", \"were\", \"observed\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Niacin extended-release / lovastatin 1,000 / 40 mg\", \"dosed as initial therapy\", \"was associated with good compliance and safety\"]": " \n[\"Niacin extended-release / lovastatin 1,000 / 40 mg\", \"dosed as initial therapy\", \"good compliance\"]\n[\"Niacin extended-release / lovastatin 1,000 / 40 mg\", \"dosed as initial therapy\", \"safety\"]\nGranularity: 2",
            "[\"Niacin extended-release / lovastatin\", \"had\", \"very low incidences of increased liver and muscle enzymes\"]": " \n[\"Niacin extended-release / lovastatin\", \"had\", \"increased liver enzymes\"]\n[\"Niacin extended-release / lovastatin\", \"had\", \"increased muscle enzymes\"]\nGranularity: 2"
      },
      "Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas .|Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters .|Radiolabelling , following the in vivo injection of 3H - 17 beta estradiol , was increased only over the nuclei of tumor cells ; stereologic analysis revealed a 4 . 5 - to 6 . 7 - times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells .|Despite rapid tubular excretion of estradiol which peaked in less than 1 h , the normal cells did not appear to bind the ligand .|This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas .": {
            "[\"Autoradiographic evidence\", \"of\", \"estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas\"]": " \n[\"Autoradiographic evidence\", \"of\", \"estrogen binding sites\"]\n[\"estrogen binding sites\", \"in\", \"nuclei\"]\n[\"nuclei\", \"of\", \"diethylstilbesterol induced hamster renal carcinomas\"]\nGranularity: 3",
            "[\"Estrogen binding sites\", \"were demonstrated by\", \"autoradiography\"]": "\n[\"Estrogen binding sites\", \"were demonstrated\", \"by autoradiography\"]\nGranularity: 1",
            "[\"Estrogen binding sites\", \"were demonstrated in\", \"one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters\"]": "\n[\"Estrogen binding sites\", \"were demonstrated in\", \"one transplantable renal carcinoma\"]\n[\"Estrogen binding sites\", \"were demonstrated in\", \"five primary diethylstilbesterol induced renal carcinomas\"]\n[\"Estrogen binding sites\", \"were demonstrated in\", \"three hamsters\"]\nGranularity: 3",
            "[\"Radiolabelling\", \"following\", \"the in vivo injection of 3H - 17 beta estradiol\"]": " \n[\"Radiolabelling\", \"following\", \"in vivo injection\"]\n[\"Radiolabelling\", \"following\", \"3H - 17 beta estradiol\"]\nGranularity: 2",
            "[\"Radiolabelling\", \"was increased only over\", \"the nuclei of tumor cells\"]": " \n[\"Radiolabelling\", \"was increased\", \"over the nuclei\"]\n[\"Radiolabelling\", \"was increased\", \"only over the nuclei\"]\n[\"Radiolabelling\", \"was increased\", \"over the nuclei of tumor cells\"]\nGranularity: 3",
            "[\"Stereologic analysis\", \"revealed\", \"a 4 . 5 - to 6 . 7 - times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells\"]": " \n[\"Stereologic analysis\", \"revealed\", \"a higher concentration of reduced silver grains over nuclei\"]\n[\"Stereologic analysis\", \"revealed\", \"a higher concentration of reduced silver grains over cytoplasm\"]\nGranularity: 2",
            "[\"Despite\", \"rapid tubular excretion of estradiol which peaked in less than 1 h\", \"the normal cells did not appear to bind the ligand\"]": " \n[\"rapid tubular excretion of estradiol\", \"peaked in\", \"less than 1 h\"]\n[\"normal cells\", \"did not appear to bind\", \"the ligand\"]\nGranularity: 2",
            "[\"This\", \"is the first published report documenting\", \"the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas\"]": "\n[\"estrogen\", \"binds to\", \"nuclei of cells\"]\n[\"estrogen\", \"induces\", \"hamster renal carcinomas\"]\nGranularity: 2"
      },
      "Positive skin tests in late reactions to radiographic contrast media .|In the last few years delayed reactions several hours after the injection of radiographic and contrast materials ( PRC ) have been described with increasing frequency .|The authors report two observations on patients with delayed reactions in whom intradermoreactions ( IDR ) and patch tests to a series of ionic and non ionic PRC were studied .|After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( dyspnea , loss of consciousness ) and delayed macro - papular rash appeared , whilst patient n degree 2 developed a generalised sensation of heat , persistent pain at the site of injection immediately and a generalised macro - papular reaction after 24 hours .|The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some PRC with common chains in their structures .|The positive skin tests are in favour of immunological reactions and may help in diagnosis of allergy in the patients .": {
            "[\"Positive skin tests\", \"occur in\", \"late reactions to radiographic contrast media\"]": " \n[\"Positive skin tests\", \"occur in\", \"late reactions\"]\n[\"Positive skin tests\", \"occur in\", \"radiographic contrast media\"]\nGranularity: 2",
            "[\"Delayed reactions\", \"have been described with increasing frequency\", \"in the last few years\"]": " \n[\"Delayed reactions\", \"have been described\", \"with increasing frequency\"]\n[\"Delayed reactions\", \"have been described\", \"in the last few years\"]\nGranularity: 2",
            "[\"Two observations\", \"involve\", \"patients with delayed reactions\"]": " \n[\"Two observations\", \"involve\", \"patients\"]\n[\"Two observations\", \"involve\", \"delayed reactions\"]\nGranularity: 2",
            "[\"Intradermal reactions (IDR)\", \"and\", \"patch tests\"]": " \n[\"Intradermal reactions (IDR)\", \"test\", \"skin reactions\"]\n[\"patch tests\", \"test\", \"skin reactions\"]\nGranularity: 2",
            "[\"Intradermal reactions (IDR)\", \"were studied\", \"to a series of ionic and non-ionic PRC\"]": " \n[\"Intradermal reactions (IDR)\", \"were studied\", \"ionic PRC\"]\n[\"Intradermal reactions (IDR)\", \"were studied\", \"non-ionic PRC\"]\nGranularity: 2",
            "[\"Patient n degree 1\", \"experienced\", \"an immediate reaction (dyspnea, loss of consciousness)\"]": " \n[\"Patient n degree 1\", \"experienced\", \"dyspnea\"]\n[\"Patient n degree 1\", \"experienced\", \"loss of consciousness\"]\nGranularity: 2",
            "[\"Patient n degree 1\", \"developed\", \"a delayed macro-papular rash\"]": " \n[\"Patient n degree 1\", \"developed\", \"a delayed rash\"]\n[\"Patient n degree 1\", \"developed\", \"a macro-papular rash\"]\nGranularity: 2",
            "[\"Patient n degree 2\", \"developed\", \"a generalized sensation of heat\"]": " \n[\"Patient n degree 2\", \"developed\", \"a generalized sensation\"]\n[\"Patient n degree 2\", \"developed\", \"heat\"]\nGranularity: 2",
            "[\"Patient n degree 2\", \"experienced\", \"persistent pain at the site of injection immediately\"]": " \n[\"Patient n degree 2\", \"experienced\", \"persistent pain\"]\n[\"Patient n degree 2\", \"experienced\", \"pain at the site of injection\"]\n[\"Patient n degree 2\", \"experienced\", \"pain immediately\"]\nGranularity: 3",
            "[\"Patient n degree 2\", \"developed\", \"a generalized macro-papular reaction after 24 hours\"]": " \n[\"Patient n degree 2\", \"developed\", \"a generalized macro-papular reaction\"]\n[\"Patient n degree 2\", \"developed\", \"after 24 hours\"]\nGranularity: 2",
            "[\"Skin tests\", \"revealed\", \"positive delayed reactions of 24 hours and 48 hours\"]": " \n[\"Skin tests\", \"revealed\", \"positive delayed reactions of 24 hours\"]\n[\"Skin tests\", \"revealed\", \"positive delayed reactions of 48 hours\"]\nGranularity: 2",
            "[\"Skin tests\", \"were conducted\", \"by IDR and patch tests\"]": " \n[\"Skin tests\", \"were conducted\", \"by IDR\"]\n[\"Skin tests\", \"were conducted\", \"by patch tests\"]\nGranularity: 2",
            "[\"Skin tests\", \"were conducted\", \"to only some PRC with common chains in their structures\"]": " \n[\"Skin tests\", \"were conducted\", \"to PRC\"]\n[\"Skin tests\", \"were conducted\", \"to PRC with common chains\"]\n[\"Skin tests\", \"were conducted\", \"to some PRC with common chains\"]\nGranularity: 3",
            "[\"Positive skin tests\", \"support\", \"immunological reactions\"]": " \n[\"Positive skin tests\", \"support\", \"immunological reactions\"]\nGranularity: 1",
            "[\"Positive skin tests\", \"may help in\", \"diagnosis of allergy in the patients\"]": " \n[\"Positive skin tests\", \"may help in\", \"diagnosis of allergy\"]\n[\"Positive skin tests\", \"may help in\", \"patients\"]\nGranularity: 2"
      },
      "Factors contributing to ribavirin - induced anemia .|BACKGROUND AND AIM : Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia .|This study was conducted to identify the factors contributing to ribavirin - induced anemia .|METHODS : Eighty - eight patients with chronic hepatitis C who received interferon - alpha - 2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study .|A hemoglobin concentration of < 10 g / dL was defined as ribavirin - induced anemia .|RESULTS : Ribavirin - induced anemia occurred in 18 ( 20 . 5 % ) patients during treatment .|A 2 g / dL decrease in hemoglobin concentrations in patients with anemia was observed at week 2 after the start of treatment .|The hemoglobin concentration in patients with > or = 2 g / dL decrease at week 2 was observed to be significantly lower even after week 2 than in patients with < 2 g / dL decrease ( P < 0 . 01 ) .|A significant relationship was observed between the rate of reduction of hemoglobin concentrations at week 2 and the severity of anemia ( P < 0 . 01 ) .|Such factors as sex ( female ) , age ( > or = 60 years old ) , and the ribavirin dose by body weight ( 12 mg / kg or more ) were significant by univariate analysis .|CONCLUSIONS : Careful administration is necessary in patients > or = 60 years old , in female patients , and in patients receiving a ribavirin dose of 12 mg / kg or more .|Patients who experience a fall in hemoglobin concentrations of 2 g / dL or more at week 2 after the start of treatment should be monitored with particular care .": {
            "[\"Factors\", \"contribute to\", \"ribavirin-induced anemia\"]": " \n[\"Factors\", \"contribute to\", \"ribavirin-induced\"]\n[\"ribavirin-induced\", \"anemia\"]\nGranularity: 2",
            "[\"Interferon\", \"produces\", \"hemolytic anemia\"]": " N/A (The triple is specific, conveying a singular relation between Interferon and hemolytic anemia.)\nGranularity: 0",
            "[\"Study\", \"conducted to identify\", \"factors\"]": " \n[\"Study\", \"identified\", \"factors\"]\nGranularity: 1",
            "[\"Eighty-eight patients\", \"received\", \"interferon-alpha-2b\"]": " \n[\"Eighty-eight patients\", \"received\", \"interferon-alpha-2b\"]\nGranularity: 1",
            "[\"Ribavirin\", \"administered orally\", \"dose of 600 mg or 800 mg\"]": " \n[\"Ribavirin\", \"administered\", \"orally\"]\n[\"Ribavirin\", \"administered\", \"dose\"]\n[\"dose\", \"of\", \"600 mg\"]\n[\"dose\", \"of\", \"800 mg\"]\nGranularity: 4",
            "[\"Hemoglobin concentration\", \"defined as\", \"ribavirin-induced anemia\"]": " \n[\"Hemoglobin concentration\", \"defined as\", \"anemia\"]\n[\"Hemoglobin concentration\", \"defined as\", \"ribavirin-induced\"]\nGranularity: 2",
            "[\"Ribavirin-induced anemia\", \"occurred in\", \"18 patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hemoglobin concentrations\", \"observed\", \"week 2\"]": " \n[\"Hemoglobin concentrations\", \"observed during\", \"week 2\"]\nGranularity: 1",
            "[\"Hemoglobin concentration\", \"significantly lower\", \"week 2\"]": " \n[\"Hemoglobin concentration\", \"lower\", \"week 2\"]\n[\"Hemoglobin concentration\", \"significantly lower\", \"week\"]\n[\"Hemoglobin concentration\", \"significantly lower\", \"2\"]\nGranularity: 3",
            "[\"Rate of reduction\", \"observed\", \"severity of anemia\"]": " \n[\"Rate of reduction\", \"observed\", \"severity\"]\n[\"Rate of reduction\", \"observed\", \"anemia\"]\nGranularity: 2",
            "[\"Sex\", \"significant by univariate analysis\", \"female\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Age\", \"significant by univariate analysis\", \"> or = 60 years old\"]": " \n[\"Age\", \"significant by univariate analysis\", \"> or = 60 years old\"]\nGranularity: 1",
            "[\"Ribavirin dose by body weight\", \"significant by univariate analysis\", \"12 mg/kg or more\"]": " \n[\"Ribavirin dose\", \"significant by\", \"univariate analysis\"]\n[\"Ribavirin dose\", \"12 mg/kg or more\", \"significant\"]\nGranularity: 2",
            "[\"Careful administration\", \"necessary\", \"patients > or = 60 years old\"]": " \n[\"Careful administration\", \"is necessary for\", \"patients > or = 60 years old\"]\nGranularity: 1",
            "[\"Careful administration\", \"necessary\", \"female patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Careful administration\", \"necessary\", \"patients receiving a ribavirin dose of 12 mg/kg or more\"]": " \n[\"Careful administration\", \"is necessary for\", \"patients receiving a ribavirin dose of 12 mg/kg or more\"]\n[\"Careful administration\", \"is necessary for\", \"patients receiving a ribavirin dose of 12 mg/kg\"]\n[\"Careful administration\", \"is necessary for\", \"patients receiving a ribavirin dose\"]\n[\"Careful administration\", \"is necessary for\", \"patients receiving a ribavirin\"]\n[\"Careful administration\", \"is necessary for\", \"patients\"]\nGranularity: 5",
            "[\"Patients\", \"monitored with particular care\", \"fall in hemoglobin concentrations of 2 g/dL or more at week 2\"]": " \n[\"Patients\", \"monitored\", \"fall in hemoglobin concentrations of 2 g/dL or more\"]\n[\"Patients\", \"monitored\", \"week 2\"]\nGranularity: 2"
      },
      "Five cases of encephalitis during treatment of loiasis with diethylcarbamazine .|Five cases of encephalitis following treatment with diethylcarbamazine ( DEC ) were observed in Congolese patients with Loa loa filariasis .|Two cases had a fatal outcome and one resulted in severe sequelae .|The notable fact was that this complication occurred in three patients hospitalized before treatment began , with whom particularly strict therapeutic precautions were taken , i . e . , initial dose less than 10 mg of DEC , very gradual dose increases , and associated anti - allergic treatment .|This type of drug - induced complication may not be that uncommon in highly endemic regions .|It occurs primarily , but not exclusively , in subjects presenting with a high microfilarial load .|The relationship between the occurrence of encephalitis and the decrease in microfilaremia is evident .|The pathophysiological mechanisms are discussed in the light of these observations and the few other comments on this subject published in the literature .": {
            "[\"diethylcarbamazine\", \"caused\", \"encephalitis\"]": " N/A (The triple is specific, conveying a singular relation between diethylcarbamazine and encephalitis.)\nGranularity: 0",
            "[\"diethylcarbamazine\", \"treats\", \"Loa loa filariasis\"]": " N/A (The triple is specific, conveying a singular relation between diethylcarbamazine and Loa loa filariasis.)\nGranularity: 0",
            "[\"Loa loa filariasis\", \"treated with\", \"diethylcarbamazine\"]": " \n[\"Loa loa filariasis\", \"treated with\", \"diethylcarbamazine\"]\nGranularity: 1",
            "[\"treatment\", \"observed in\", \"Congolese patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"treatment\", \"had fatal outcome\", \"two cases\"]": "\n[\"treatment\", \"had\", \"fatal outcome\"]\n[\"two cases\", \"had fatal outcome\", \"treatment\"]\nGranularity: 2",
            "[\"treatment\", \"resulted in\", \"severe sequelae\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"complication\", \"occurred in\", \"three patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"patients\", \"hospitalized before\", \"treatment began\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"treatment\", \"had\", \"strict therapeutic precautions\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"drug-induced complication\", \"may not be uncommon\", \"highly endemic regions\"]": " \n[\"drug-induced complication\", \"may not be\", \"uncommon\"]\n[\"drug-induced complication\", \"may not be\", \"endemic\"]\n[\"drug-induced complication\", \"may not be\", \"highly endemic\"]\n[\"drug-induced complication\", \"may not be uncommon\", \"regions\"]\n[\"drug-induced complication\", \"may not be uncommon\", \"highly endemic regions\"]\nGranularity: 5",
            "[\"complication\", \"occurs primarily in\", \"subjects with high microfilarial load\"]": " \n[\"complication\", \"occurs\", \"primarily\"]\n[\"complication\", \"occurs\", \"in subjects\"]\n[\"complication\", \"occurs\", \"with high microfilarial load\"]\nGranularity: 3",
            "[\"occurrence of encephalitis\", \"related to\", \"decrease in microfilaremia\"]": "\n[\"occurrence of encephalitis\", \"related to\", \"decrease in microfilaremia\"]\nGranularity: 0",
            "[\"pathophysiological mechanisms\", \"discussed in light of\", \"observations and literature\"]": " \n[\"pathophysiological mechanisms\", \"discussed in light of\", \"observations\"]\n[\"pathophysiological mechanisms\", \"discussed in light of\", \"literature\"]\nGranularity: 2"
      },
      "Nelarabine neurotoxicity with concurrent intrathecal chemotherapy : Case report and review of literature .|Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal ( IT ) chemotherapy is reported .|A 37 - year - old Caucasian woman with a history of T - cell lymphoblastic lymphoma was admitted for relapsed disease .|She was originally treated with induction chemotherapy followed by an autologous transplant .|She developed relapsed disease 10 months later with leukemic involvement .|She was re - induced with nelarabine 1500 mg / m ( 2 ) on days 1 , 3 , and 5 with 1 dose of IT cytarabine 100 mg on day 2 as central nervous system ( CNS ) prophylaxis .|At the time of treatment , she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome ( TLS ) .|She tolerated therapy well , entered a complete remission , and recovered her renal function .|She received a second cycle of nelarabine without additional IT prophylaxis one month later .|A week after this second cycle , she noted numbness in her lower extremities .|Predominantly sensory , though also motor and autonomic , peripheral neuropathy started in her feet , ascended proximally to the mid - thoracic region , and eventually included her distal upper extremities .|A magnetic resonance imaging ( MRI ) of her spine demonstrated changes from C2 to C6 consistent with subacute combined degeneration .|Nelarabine was felt to be the cause of her symptoms .|Her neuropathy stabilized and showed slight improvement and ultimately received an unrelated , reduced - intensity allogeneic transplant while in complete remission , but relapsed disease 10 weeks later .|She is currently being treated with best supportive care .|To our knowledge , this is the first published case report of severe neurotoxicity caused by nelarabine in a patient who received concurrent IT chemotherapy .": {
            "[\"Nelarabine\", \"neurotoxicity\", \"concurrent intrathecal chemotherapy\"]": " \n[\"Nelarabine\", \"causes\", \"neurotoxicity\"]\n[\"Nelarabine\", \"is used for\", \"concurrent intrathecal chemotherapy\"]\nGranularity: 2",
            "[\"Nelarabine\", \"neurotoxicity\", \"Case report\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Nelarabine\", \"neurotoxicity\", \"review of literature\"]": "\n[\"Nelarabine\", \"has\", \"neurotoxicity\"]\n[\"neurotoxicity\", \"is discussed in\", \"literature\"]\nGranularity: 2",
            "[\"Severe nelarabine neurotoxicity\", \"reported\", \"patient\"]": " \n[\"Severe nelarabine neurotoxicity\", \"reported in\", \"patient\"]\n[\"Severe nelarabine neurotoxicity\", \"reported by\", \"patient\"]\nGranularity: 2",
            "[\"Patient\", \"received\", \"concurrent intrathecal (IT) chemotherapy\"]": " \n[\"Patient\", \"received\", \"intrathecal chemotherapy\"]\n[\"Patient\", \"received\", \"concurrent chemotherapy\"]\nGranularity: 2",
            "[\"Patient\", \"history\", \"T-cell lymphoblastic lymphoma\"]": " \n[\"Patient\", \"has\", \"T-cell lymphoblastic lymphoma\"]\n[\"T-cell lymphoblastic lymphoma\", \"is a type of\", \"lymphoma\"]\nGranularity: 2",
            "[\"Patient\", \"admitted\", \"relapsed disease\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"treated\", \"induction chemotherapy\"]": " N/A (The triple is specific, conveying a singular relation between a patient and induction chemotherapy.)\nGranularity: 0",
            "[\"Patient\", \"underwent\", \"autologous transplant\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Disease\", \"developed\", \"10 months later\"]": " N/A (The triple does not provide enough information to be split into more specific sub-triples.)\nGranularity: 0",
            "[\"Patient\", \"re-induced\", \"nelarabine\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Nelarabine\", \"dose\", \"1500 mg / m\\u00b2 on days 1, 3, and 5\"]": " \n[\"Nelarabine\", \"dose\", \"1500 mg / m\\u00b2\"]\n[\"Nelarabine\", \"administered on\", \"day 1\"]\n[\"Nelarabine\", \"administered on\", \"day 3\"]\n[\"Nelarabine\", \"administered on\", \"day 5\"]\nGranularity: 4",
            "[\"IT cytarabine\", \"dose\", \"100 mg on day 2\"]": " \n[\"IT cytarabine\", \"dose\", \"100 mg\"]\n[\"IT cytarabine\", \"administration\", \"day 2\"]\nGranularity: 2",
            "[\"Patient\", \"continuous renal replacement therapy\", \"sequelae of tumor lysis syndrome (TLS)\"]": " \n[\"Patient\", \"undergoes\", \"continuous renal replacement therapy\"]\n[\"Patient\", \"experiences\", \"sequelae of tumor lysis syndrome (TLS)\"]\nGranularity: 2",
            "[\"Patient\", \"tolerated\", \"therapy well\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"entered\", \"complete remission\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"recovered\", \"renal function\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"received\", \"second cycle of nelarabine\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"received\", \"without additional IT prophylaxis\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"noted\", \"numbness in her lower extremities\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Peripheral neuropathy\", \"started\", \"feet\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Peripheral neuropathy\", \"ascended\", \"proximally to the mid-thoracic region\"]": " \n[\"Peripheral neuropathy\", \"ascended\", \"proximally\"]\n[\"Peripheral neuropathy\", \"ascended\", \"to the mid-thoracic region\"]\nGranularity: 2",
            "[\"Peripheral neuropathy\", \"included\", \"distal upper extremities\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Magnetic resonance imaging (MRI)\", \"demonstrated\", \"changes from C2 to C6\"]": " \n[\"Magnetic resonance imaging (MRI)\", \"demonstrated\", \"changes from C2\"]\n[\"Magnetic resonance imaging (MRI)\", \"demonstrated\", \"changes to C6\"]\nGranularity: 2",
            "[\"Changes\", \"consistent with\", \"subacute combined degeneration\"]": " \n[\"Changes\", \"consistent with\", \"subacute degeneration\"]\n[\"Changes\", \"consistent with\", \"combined degeneration\"]\n[\"Changes\", \"consistent with\", \"subacute combined degeneration\"]\nGranularity: 3",
            "[\"Nelarabine\", \"felt to be\", \"cause of her symptoms\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Neuropathy\", \"stabilized\", \"showed slight improvement\"]": " \n[\"Neuropathy\", \"stabilized\", \"showed improvement\"]\nGranularity: 1",
            "[\"Patient\", \"received\", \"unrelated, reduced-intensity allogeneic transplant\"]": " \n[\"Patient\", \"received\", \"unrelated transplant\"]\n[\"Patient\", \"received\", \"reduced-intensity transplant\"]\n[\"Patient\", \"received\", \"allogeneic transplant\"]\nGranularity: 3",
            "[\"Disease\", \"relapsed\", \"10 weeks later\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"currently being treated\", \"best supportive care\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"This\", \"first published case report\", \"severe neurotoxicity caused by nelarabine\"]": " \n[\"This\", \"first published case report\", \"severe neurotoxicity\"]\n[\"severe neurotoxicity\", \"caused by\", \"nelarabine\"]\nGranularity: 2",
            "[\"This\", \"first published case report\", \"concurrent IT chemotherapy\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Phenytoin encephalopathy as probable idiosyncratic reaction : case report .|A case of phenytoin ( DPH ) encephalopathy with increasing seizures and EEG and mental changes is described .|Despite adequate oral dosage of DPH ( 5 mg / kg / daily ) the plasma level was very low ( 2 . 8 microgramg / ml ) .|The encephalopathy was probably an idiosyncratic and not toxic or allergic reaction .|In fact the concentration of free DPH was normal , the patient presented a retarded morbilliform rash during DPH treatment , the protidogram was normal , and an intradermic DPH injection had no local effect .|The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures , with EEG and mental changes occurring simultaneously , should alert the physician to the possible need for eliminating DPH from the therapeutic regimen , even if plasma concentrations are low .": {
            "[\"Phenytoin encephalopathy\", \"probable idiosyncratic reaction\", \"case report\"]": " \n[\"Phenytoin encephalopathy\", \"is a\", \"probable idiosyncratic reaction\"]\n[\"probable idiosyncratic reaction\", \"is described in\", \"a case report\"]\nGranularity: 2",
            "[\"Phenytoin\", \"described with\", \"increasing seizures and EEG and mental changes\"]": " \n[\"Phenytoin\", \"is described with\", \"increasing seizures\"]\n[\"Phenytoin\", \"is described with\", \"EEG changes\"]\n[\"Phenytoin\", \"is described with\", \"mental changes\"]\nGranularity: 3",
            "[\"Phenytoin\", \"adequate oral dosage\", \"5 mg / kg / daily\"]": " \n[\"Phenytoin\", \"has adequate oral dosage of\", \"5 mg / kg / daily\"]\nGranularity: 1",
            "[\"Phenytoin\", \"plasma level\", \"very low (2.8 microgramg / ml)\"]": " \n[\"Phenytoin\", \"has plasma level\", \"very low (2.8 microgramg / ml)\"]\n[\"Phenytoin\", \"plasma level\", \"is 2.8 microgramg / ml\"]\nGranularity: 2",
            "[\"Encephalopathy\", \"probable idiosyncratic and not toxic or allergic reaction\", \"Phenytoin\"]": " \n[\"Encephalopathy\", \"is a probable idiosyncratic reaction to\", \"Phenytoin\"]\n[\"Encephalopathy\", \"is not a toxic reaction to\", \"Phenytoin\"]\n[\"Encephalopathy\", \"is not an allergic reaction to\", \"Phenytoin\"]\nGranularity: 3",
            "[\"Patient\", \"presented\", \"retarded morbilliform rash during DPH treatment\"]": " \n[\"Patient\", \"presented\", \"retarded morbilliform rash\"]\n[\"Patient\", \"presented\", \"during DPH treatment\"]\nGranularity: 2",
            "[\"Protidogram\", \"normal\", \"Patient\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Intradermic DPH injection\", \"no local effect\", \"Patient\"]": " \n[\"Intradermic DPH injection\", \"has no\", \"local effect\"]\n[\"Intradermic DPH injection\", \"affects\", \"Patient\"]\nGranularity: 2",
            "[\"Unexpected increase in seizures\", \"EEG and mental changes\", \"simultaneously occurring\"]": " \n[\"Unexpected increase in seizures\", \"occurs with\", \"EEG changes\"]\n[\"Unexpected increase in seizures\", \"occurs with\", \"mental changes\"]\nGranularity: 2",
            "[\"Physician\", \"alert to\", \"possible need for eliminating DPH from the therapeutic regimen\"]": " \n[\"Physician\", \"alert to\", \"need for eliminating DPH\"]\n[\"Physician\", \"alert to\", \"possible need for eliminating DPH\"]\n[\"Physician\", \"alert to\", \"eliminating DPH\"]\nGranularity: 3"
      },
      "Contrast medium nephrotoxicity after renal artery and coronary angioplasty .|BACKGROUND : Renal dysfunction induced by iodinated contrast medium ( CM ) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty ( PTRA ) .|PURPOSE : To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention ( PCI ) .|MATERIAL AND METHODS : A total of 33 patients successfully treated with PTRA ( PTRA group , mean age 70 + / - 12 years , 23 female , basal creatinine 1 . 46 + / - 0 . 79 , range 0 . 7 - 4 . 9 mg / dl ) were compared with 33 patients undergoing successful PCI ( PCI group ) , matched for basal creatinine ( 1 . 44 + / - 0 . 6 , range 0 . 7 - 3 . 4 mg / dl ) , gender , and age .|In both groups postprocedural ( 48 h ) serum creatinine was measured .|RESULTS : Postprocedural creatinine level decreased nonsignificantly in the PTRA group ( 1 . 46 + / - 0 . 8 vs . 1 . 34 + / - 0 . 5 mg / dl , P = NS ) and increased significantly in the PCI group ( 1 . 44 + / - 0 . 6 vs . 1 . 57 + / - 0 . 7 mg / dl , P < 0 . 02 ) .|Changes in serum creatinine after intervention ( after - before ) were significantly different between the PTRA and PCI groups ( - 0 . 12 + / - 0 . 5 vs . 0 . 13 + / - 0 . 3 , P = 0 . 014 ) .|This difference was not related to either a different clinical risk profile or to the volume of CM administered .|CONCLUSION : In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients .|The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity .": {
            "[\"Contrast medium nephrotoxicity\", \"occurs after\", \"renal artery and coronary angioplasty\"]": " \n[\"Contrast medium nephrotoxicity\", \"occurs after\", \"renal artery angioplasty\"]\n[\"Contrast medium nephrotoxicity\", \"occurs after\", \"coronary angioplasty\"]\nGranularity: 2",
            "[\"Renal dysfunction\", \"induced by\", \"iodinated contrast medium (CM) administration\"]": " \n[\"Renal dysfunction\", \"induced by\", \"iodinated contrast medium\"]\n[\"iodinated contrast medium\", \"administration\", \"Renal dysfunction\"]\nGranularity: 2",
            "[\"CM\", \"minimizes the benefit of\", \"interventional procedure\"]": " \n[\"CM\", \"minimizes\", \"benefit\"]\n[\"CM\", \"minimizes\", \"interventional procedure\"]\nGranularity: 2",
            "[\"Interventional procedure\", \"in patients undergoing\", \"renal angioplasty (PTRA)\"]": " \n[\"Interventional procedure\", \"in patients\", \"undergoing renal angioplasty (PTRA)\"]\n[\"Interventional procedure\", \"in patients undergoing\", \"renal angioplasty\"]\nGranularity: 2",
            "[\"Purpose\", \"to compare the susceptibility to nephrotoxic effect of CM\", \"patients undergoing PTRA and PCI\"]": " \n[\"Purpose\", \"to compare\", \"susceptibility to nephrotoxic effect\"]\n[\"patients\", \"undergoing\", \"PTRA\"]\n[\"patients\", \"undergoing\", \"PCI\"]\nGranularity: 3",
            "[\"Material and Methods\", \"compares patients successfully treated with\", \"PTRA and PCI\"]": "\n[\"Material and Methods\", \"compares\", \"patients successfully treated with PTRA\"]\n[\"Material and Methods\", \"compares\", \"patients successfully treated with PCI\"]\nGranularity: 2",
            "[\"Postprocedural\", \"serum creatinine was measured\", \"in both groups\"]": " \n[\"Postprocedural\", \"serum creatinine\", \"was measured\"]\n[\"serum creatinine\", \"was measured\", \"in both groups\"]\nGranularity: 2",
            "[\"Postprocedural creatinine level\", \"decreased nonsignificantly in\", \"PTRA group\"]": " \n[\"Postprocedural creatinine level\", \"decreased\", \"nonsignificantly\"]\n[\"Postprocedural creatinine level\", \"decreased\", \"in PTRA group\"]\nGranularity: 2",
            "[\"Postprocedural creatinine level\", \"increased significantly in\", \"PCI group\"]": " \n[\"Postprocedural creatinine level\", \"increased significantly\", \"in PCI group\"]\nGranularity: 1",
            "[\"Changes in serum creatinine\", \"were significantly different between\", \"PTRA and PCI groups\"]": " \n[\"Changes in serum creatinine\", \"were different between\", \"PTRA group\"]\n[\"Changes in serum creatinine\", \"were different between\", \"PCI group\"]\nGranularity: 2",
            "[\"This difference\", \"was not related to\", \"clinical risk profile or volume of CM administered\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Conclusion\", \"patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than\", \"PCI patients\"]": " \n[\"Conclusion\", \"patients submitted to PTRA\", \"showed a lower susceptibility to renal damage induced by CM administration\"]\n[\"Conclusion\", \"PCI patients\", \"showed a lower susceptibility to renal damage induced by CM administration\"]\nGranularity: 2",
            "[\"Effectiveness of PTRA on renal function\", \"seems to be barely influenced by\", \"CM toxicity\"]": " \n[\"Effectiveness of PTRA\", \"on renal function\", \"is influenced by\"]\n[\"Effectiveness of PTRA\", \"on renal function\", \"is barely influenced by\"]\n[\"Effectiveness of PTRA\", \"is influenced by\", \"CM toxicity\"]\n[\"Effectiveness of PTRA\", \"is barely influenced by\", \"CM toxicity\"]\nGranularity: 4"
      },
      "Prevention of etomidate - induced myoclonus : which is superior : Fentanyl , midazolam , or a combination ? A Retrospective comparative study .|BACKGROUND : In this retrospective comparative study , we aimed to compare the effectiveness of fentanyl , midazolam , and a combination of fentanyl and midazolam to prevent etomidate - induced myoclonus .|MATERIAL AND METHODS : This study was performed based on anesthesia records .|Depending on the drugs that would be given before the induction of anesthesia with etomidate , the patients were separated into 4 groups : no pretreatment ( Group NP ) , fentanyl 1 ug . kg - 1 ( Group F ) , midazolam 0 . 03 mg . kg - 1 ( Group M ) , and midazolam 0 . 015 mg . kg - 1 + fentanyl 0 . 5 ug . kg - 1 ( Group FM ) .|Patients who received the same anesthetic procedure were selected : 2 minutes after intravenous injections of the pretreatment drugs , anesthesia is induced with 0 . 3 mg . kg - 1 etomidate injected intravenously over a period of 20 - 30 seconds .|Myoclonic movements are evaluated , which were observed and graded according to clinical severity during the 2 minutes after etomidate injection .|The severity of pain due to etomidate injection , mean arterial pressure , heart rate , and adverse effects were also evaluated .|RESULTS : Study results showed that myoclonus incidence was 85 % , 40 % , 70 % , and 25 % in Group NP , Group F , Group M , and Group FM , respectively , and were significantly lower in Group F and Group FM .|CONCLUSIONS : We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate - induced myoclonus .": {
            "[\"Prevention of etomidate - induced myoclonus\", \"is the topic of\", \"a retrospective comparative study\"]": " \n[\"Prevention of etomidate - induced myoclonus\", \"is the topic of\", \"a retrospective study\"]\n[\"Prevention of etomidate - induced myoclonus\", \"is the topic of\", \"a comparative study\"]\nGranularity: 2",
            "[\"Fentanyl\", \"is compared with\", \"midazolam\"]": " N/A (The triple is specific, conveying a singular relation between Fentanyl and midazolam.)\nGranularity: 0",
            "[\"Fentanyl\", \"is compared with\", \"a combination of fentanyl and midazolam\"]": " \n[\"Fentanyl\", \"is compared with\", \"fentanyl\"]\n[\"Fentanyl\", \"is compared with\", \"midazolam\"]\nGranularity: 2",
            "[\"This study\", \"was performed\", \"based on anesthesia records\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patients\", \"were separated into\", \"4 groups\"]": " \n[\"Patients\", \"were separated\", \"into groups\"]\n[\"Patients\", \"were separated\", \"into 4 groups\"]\nGranularity: 2",
            "[\"Pretreatment drugs\", \"determined\", \"the group of patients\"]": " \n[\"Pretreatment drugs\", \"determine\", \"the group\"]\n[\"Pretreatment drugs\", \"determine\", \"patients\"]\nGranularity: 2",
            "[\"Myoclonic movements\", \"were evaluated\", \"according to clinical severity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Etomidate injection\", \"caused\", \"pain\"]": " N/A (The triple is specific, conveying a singular relation between Etomidate injection and pain.)\nGranularity: 0",
            "[\"Pretreatment with fentanyl or combination of fentanyl and midazolam\", \"was effective in\", \"preventing etomidate - induced myoclonus\"]": " \n[\"Pretreatment with fentanyl\", \"was effective in\", \"preventing etomidate-induced myoclonus\"]\n[\"Pretreatment with combination of fentanyl and midazolam\", \"was effective in\", \"preventing etomidate-induced myoclonus\"]\nGranularity: 2"
      },
      "Metallothionein induction reduces caspase - 3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine - treated rats .|Hippocampal integrity is essential for cognitive functions .|On the other hand , induction of metallothionein ( MT ) by ZnSO ( 4 ) and its role in neuroprotection has been documented .|The present study aimed to explore the effect of MT induction on carmustine ( BCNU ) - induced hippocampal cognitive dysfunction in rats .|A total of 60 male Wistar albino rats were randomly divided into four groups ( 15 / group ) : The control group injected with single doses of normal saline ( i . c . v ) followed 24 h later by BCNU solvent ( i . v ) .|The second group administered ZnSO ( 4 ) ( 0 . 1 micromol / 10 microl normal saline , i . c . v , once ) then BCNU solvent ( i . v ) after 24 h .|Third group received BCNU ( 20 mg / kg , i . v , once ) 24 h after injection with normal saline ( i . c . v ) .|Fourth group received a single dose of ZnSO ( 4 ) ( 0 . 1 micromol / 10 microl normal saline , i . c . v ) then BCNU ( 20 mg / kg , i . v , once ) after 24 h .|The obtained data revealed that BCNU administration resulted in deterioration of learning and short - term memory ( STM ) , as measured by using radial arm water maze , accompanied with decreased hippocampal glutathione reductase ( GR ) activity and reduced glutathione ( GSH ) content .|Also , BCNU administration increased serum tumor necrosis factor - alpha ( TNFalpha ) , hippocampal MT and malondialdehyde ( MDA ) contents as well as caspase - 3 activity in addition to histological alterations .|ZnSO ( 4 ) pretreatment counteracted BCNU - induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase - 3 .|The histological features were improved in hippocampus of rats treated with ZnSO ( 4 ) + BCNU compared to only BCNU - treated animals .|In conclusion , MT induction halts BCNU - induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha , MDA and caspase - 3 activity with subsequent preservation of cognition .": {
            "[\"Hippocampal integrity\", \"is essential for\", \"cognitive functions\"]": " \n[\"Hippocampal integrity\", \"is essential for\", \"cognitive functions\"]\nGranularity: 1",
            "[\"Induction of metallothionein\", \"has been documented for\", \"neuroprotection\"]": " \n[\"Induction of metallothionein\", \"has been documented for\", \"neuroprotection\"]\nGranularity: 1",
            "[\"The present study\", \"aimed to explore\", \"effect of MT induction on BCNU-induced hippocampal cognitive dysfunction\"]": " \n[\"The present study\", \"aimed to explore\", \"effect of MT induction\"]\n[\"The present study\", \"aimed to explore\", \"BCNU-induced hippocampal cognitive dysfunction\"]\n[\"MT induction\", \"affects\", \"BCNU-induced hippocampal cognitive dysfunction\"]\nGranularity: 3",
            "[\"Rats\", \"were divided into\", \"four groups\"]": " \n[\"Rats\", \"were divided\", \"into four groups\"]\nGranularity: 1",
            "[\"ZnSO ( 4 )\", \"administered to\", \"second group\"]": " \n[\"ZnSO ( 4 )\", \"administered to\", \"second group\"]\nGranularity: 1",
            "[\"BCNU\", \"administered to\", \"third group\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"ZnSO ( 4 ) and BCNU\", \"administered to\", \"fourth group\"]": "\n[\"ZnSO ( 4 ) and BCNU\", \"administered to\", \"fourth group\"]\nGranularity: 1",
            "[\"BCNU administration\", \"resulted in\", \"deterioration of learning and short-term memory\"]": " \n[\"BCNU administration\", \"resulted in\", \"deterioration of learning\"]\n[\"BCNU administration\", \"resulted in\", \"deterioration of short-term memory\"]\nGranularity: 2",
            "[\"BCNU administration\", \"accompanied by\", \"decreased GR activity and reduced GSH content\"]": " \n[\"BCNU administration\", \"accompanied by\", \"decreased GR activity\"]\n[\"BCNU administration\", \"accompanied by\", \"reduced GSH content\"]\nGranularity: 2",
            "[\"BCNU administration\", \"increased\", \"serum TNFalpha, hippocampal MT, MDA contents, and caspase-3 activity\"]": " \n[\"BCNU administration\", \"increased\", \"serum TNFalpha\"]\n[\"BCNU administration\", \"increased\", \"hippocampal MT\"]\n[\"BCNU administration\", \"increased\", \"MDA contents\"]\n[\"BCNU administration\", \"increased\", \"caspase-3 activity\"]\nGranularity: 4",
            "[\"ZnSO ( 4 ) pretreatment\", \"counteracted\", \"BCNU-induced inhibition of GR and depletion of GSH\"]": " \n[\"ZnSO ( 4 ) pretreatment\", \"counteracted\", \"BCNU-induced inhibition of GR\"]\n[\"ZnSO ( 4 ) pretreatment\", \"counteracted\", \"depletion of GSH\"]\nGranularity: 2",
            "[\"ZnSO ( 4 ) pretreatment\", \"resulted in\", \"significant reduction in MDA and TNFalpha levels, and caspase-3 activity\"]": " \n[\"ZnSO ( 4 ) pretreatment\", \"resulted in\", \"reduction in MDA levels\"]\n[\"ZnSO ( 4 ) pretreatment\", \"resulted in\", \"reduction in TNFalpha levels\"]\n[\"ZnSO ( 4 ) pretreatment\", \"resulted in\", \"reduction in caspase-3 activity\"]\nGranularity: 3",
            "[\"ZnSO ( 4 ) pretreatment\", \"improved\", \"histological features in hippocampus of rats treated with ZnSO ( 4 ) + BCNU\"]": " \n[\"ZnSO ( 4 ) pretreatment\", \"improved\", \"histological features\"]\n[\"histological features\", \"in\", \"hippocampus\"]\n[\"rats treated with ZnSO ( 4 ) + BCNU\", \"have\", \"histological features in hippocampus\"]\nGranularity: 3",
            "[\"MT induction\", \"halts\", \"BCNU-induced hippocampal toxicity\"]": " \n[\"MT induction\", \"halts\", \"BCNU-induced toxicity\"]\n[\"MT induction\", \"halts\", \"hippocampal toxicity\"]\nGranularity: 2",
            "[\"MT induction\", \"prevents\", \"GR inhibition and GSH depletion\"]": " \n[\"MT induction\", \"prevents\", \"GR inhibition\"]\n[\"MT induction\", \"prevents\", \"GSH depletion\"]\nGranularity: 2",
            "[\"MT induction\", \"counteracts\", \"increased levels of TNFalpha, MDA, and caspase-3 activity\"]": " \n[\"MT induction\", \"counteracts\", \"increased levels of TNFalpha\"]\n[\"MT induction\", \"counteracts\", \"increased levels of MDA\"]\n[\"MT induction\", \"counteracts\", \"increased levels of caspase-3 activity\"]\nGranularity: 3",
            "[\"MT induction\", \"preserves\", \"cognition\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Metallothionein induction\", \"reduces\", \"caspase - 3 activity and TNFalpha levels\"]": " \n[\"Metallothionein induction\", \"reduces\", \"caspase - 3 activity\"]\n[\"Metallothionein induction\", \"reduces\", \"TNFalpha levels\"]\nGranularity: 2"
      },
      "The effect of recombinant human insulin - like growth factor - I on chronic puromycin aminonucleoside nephropathy in rats .|We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside ( PAN ) nephropathy , an experimental model of glomerular disease .|Therefore , we examined whether recombinant human ( rh ) IGF - I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy .|The glomerulopathy was induced by seven serial injections of PAN over 12 wk .|Experimental animals ( n = 6 ) received rhIGF - I , 400 micrograms / d , whereas control rats ( n = 6 ) received the vehicle .|rhIGF - I improved weight gain by 14 % ( p < 0 . 05 ) , without altering hematocrit or blood pressure in rats with renal disease .|Urinary protein excretion was unaltered by rhIGF - I treatment in rats with chronic PAN nephropathy .|After 12 wk , the inulin clearance was higher in rhIGF - I - treated rats , 0 . 48 + / - 0 . 08 versus 0 . 24 + / - 0 . 06 mL / min / 100 g of body weight in untreated PAN nephropathy animals , p < 0 . 05 .|The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis , tubulointerstitial injury , or renal cortical malondialdehyde content .|In rats with PAN nephropathy , administration of rhIGF - I increased IGF - I and GH receptor gene expression , without altering the steady state level of IGF - I receptor mRNA .|In normal rats with intact kidneys , rhIGF - I administration ( n = 4 ) did not alter weight gain , blood pressure , proteinuria , GFR , glomerular planar area , renal cortical malondialdehyde content , or glomerular or tubulointerstitial damage , compared with untreated animals ( n = 4 ) .|rhIGF - I treatment reduced the steady state renal IGF - I mRNA level but did not modify gene expression of the IGF - I or GH receptors .|We conclude that : 1 ) administration of rhIGF - I improves growth and GFR in rats with chronic PAN nephropathy and 2 ) unlike rhGH , long - term use of rhIGF - I does not worsen renal functional and structural injury in this disease model .": {
            "[\"recombinant hGH\", \"exacerbates\", \"renal functional and structural injury\"]": " \n[\"recombinant hGH\", \"exacerbates\", \"renal functional injury\"]\n[\"recombinant hGH\", \"exacerbates\", \"renal structural injury\"]\nGranularity: 2",
            "[\"recombinant human (rh) IGF-I\", \"a safer alternative for\", \"treatment of growth failure\"]": " \n[\"recombinant human (rh) IGF-I\", \"is a safer alternative for\", \"treatment of growth failure\"]\nGranularity: 1",
            "[\"glomerulopathy\", \"induced by\", \"seven serial injections of PAN\"]": " \n[\"glomerulopathy\", \"induced by\", \"seven serial injections\"]\n[\"glomerulopathy\", \"induced by\", \"PAN\"]\nGranularity: 2",
            "[\"experimental animals\", \"received\", \"rhIGF-I\"]": " \n[\"experimental animals\", \"received\", \"rhIGF-I\"]\nGranularity: 1",
            "[\"control rats\", \"received\", \"the vehicle\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"rhIGF-I\", \"improved\", \"weight gain\"]": " N/A (The triple is specific, conveying a singular relation between rhIGF-I and weight gain.)\nGranularity: 0",
            "[\"rhIGF-I\", \"did not alter\", \"hematocrit or blood pressure\"]": " N/A (The triple is specific, conveying a singular relation between rhIGF-I and its effects on hematocrit and blood pressure.)\nGranularity: 0",
            "[\"rhIGF-I\", \"unaltered\", \"urinary protein excretion\"]": " \n[\"rhIGF-I\", \"affects\", \"urinary protein excretion\"]\n[\"rhIGF-I\", \"does not alter\", \"urinary protein excretion\"]\nGranularity: 2",
            "[\"rhIGF-I\", \"higher\", \"inulin clearance\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"rhIGF-I\", \"not associated with\", \"enhanced glomerular hypertrophy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"rhIGF-I\", \"increased\", \"IGF-I and GH receptor gene expression\"]": " \n[\"rhIGF-I\", \"increased\", \"IGF-I gene expression\"]\n[\"rhIGF-I\", \"increased\", \"GH receptor gene expression\"]\nGranularity: 2",
            "[\"rhIGF-I\", \"did not alter\", \"steady state level of IGF-I receptor mRNA\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"rhIGF-I\", \"did not alter\", \"weight gain, blood pressure, proteinuria, GFR\"]": " \n[\"rhIGF-I\", \"did not alter\", \"weight gain\"]\n[\"rhIGF-I\", \"did not alter\", \"blood pressure\"]\n[\"rhIGF-I\", \"did not alter\", \"proteinuria\"]\n[\"rhIGF-I\", \"did not alter\", \"GFR\"]\nGranularity: 4",
            "[\"rhIGF-I\", \"reduced\", \"steady state renal IGF-I mRNA level\"]": "\n[\"rhIGF-I\", \"reduced\", \"steady state renal IGF-I mRNA level\"]\nGranularity: 0",
            "[\"rhIGF-I\", \"did not modify\", \"gene expression of the IGF-I or GH receptors\"]": "\n[\"rhIGF-I\", \"did not modify\", \"gene expression of the IGF-I receptor\"]\n[\"rhIGF-I\", \"did not modify\", \"gene expression of the GH receptor\"]\nGranularity: 2",
            "[\"administration of rhIGF-I\", \"improves\", \"growth and GFR\"]": " \n[\"administration of rhIGF-I\", \"improves\", \"growth\"]\n[\"administration of rhIGF-I\", \"improves\", \"GFR\"]\nGranularity: 2",
            "[\"long-term use of rhIGF-I\", \"does not worsen\", \"renal functional and structural injury\"]": " \n[\"long-term use of rhIGF-I\", \"does not worsen\", \"renal functional injury\"]\n[\"long-term use of rhIGF-I\", \"does not worsen\", \"renal structural injury\"]\nGranularity: 2"
      },
      "Increased vulnerability to 6 - hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors .|Motor impairment , dopamine ( DA ) neuronal activity and proenkephalin ( PENK ) gene expression in the caudate - putamen ( CPu ) were measured in 6 - OHDA - lesioned and treated ( L - DOPA + benserazide ) CB1 KO and WT mice .|A lesion induced by 6 - OHDA produced more severe motor deterioration in CB1 KO mice accompanied by more loss of DA neurons and increased PENK gene expression in the CPu .|Oxidative / nitrosative and neuroinflammatory parameters were estimated in the CPu and cingulate cortex ( Cg ) .|CB1 KO mice exhibited higher MDA levels and iNOS protein expression in the CPu and Cg compared to WT mice .|Treatment with L - DOPA + benserazide ( 12 weeks ) resulted in less severe dyskinesias in CB1 KO than in WT mice .|The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion , and reduced L - DOPA - induced dyskinesias .|These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L - DOPA - induced dyskinesias .": {
            "[\"motor impairment\", \"measured in\", \"6-OHDA-lesioned and treated CB1 KO and WT mice\"]": " \n[\"motor impairment\", \"measured in\", \"6-OHDA-lesioned mice\"]\n[\"motor impairment\", \"measured in\", \"treated CB1 KO mice\"]\n[\"motor impairment\", \"measured in\", \"WT mice\"]\nGranularity: 3",
            "[\"6-OHDA lesion\", \"produced\", \"more severe motor deterioration in CB1 KO mice\"]": " \n[\"6-OHDA lesion\", \"produced\", \"motor deterioration\"]\n[\"CB1 KO mice\", \"exhibited\", \"more severe motor deterioration\"]\nGranularity: 2",
            "[\"DA neurons\", \"loss of\", \"increased PENK gene expression in the CPu\"]": " \n[\"DA neurons\", \"loss of\", \"increased PENK gene expression\"]\n[\"DA neurons\", \"loss of\", \"CPu\"]\nGranularity: 2",
            "[\"oxidative/nitrosative and neuroinflammatory parameters\", \"estimated in\", \"CPu and cingulate cortex\"]": " \n[\"oxidative/nitrosative parameters\", \"estimated in\", \"CPu\"]\n[\"oxidative/nitrosative parameters\", \"estimated in\", \"cingulate cortex\"]\n[\"neuroinflammatory parameters\", \"estimated in\", \"CPu\"]\n[\"neuroinflammatory parameters\", \"estimated in\", \"cingulate cortex\"]\nGranularity: 4",
            "[\"CB1 KO mice\", \"exhibited\", \"higher MDA levels and iNOS protein expression\"]": "\n[\"CB1 KO mice\", \"exhibited\", \"higher MDA levels\"]\n[\"CB1 KO mice\", \"exhibited\", \"iNOS protein expression\"]\nGranularity: 2",
            "[\"L-DOPA + benserazide treatment\", \"resulted in\", \"less severe dyskinesias in CB1 KO mice\"]": " \n[\"L-DOPA + benserazide treatment\", \"resulted in\", \"less severe dyskinesias\"]\n[\"L-DOPA + benserazide treatment\", \"resulted in\", \"CB1 KO mice\"]\nGranularity: 2",
            "[\"lack of cannabinoid CB1 receptors\", \"increased\", \"severity of motor impairment and DA lesion\"]": " \n[\"lack of cannabinoid CB1 receptors\", \"increased\", \"severity of motor impairment\"]\n[\"lack of cannabinoid CB1 receptors\", \"increased\", \"DA lesion\"]\nGranularity: 2",
            "[\"activation of CB1 receptors\", \"offers\", \"neuroprotection against dopaminergic lesion\"]": "\n[\"activation of CB1 receptors\", \"offers\", \"neuroprotection\"]\n[\"activation of CB1 receptors\", \"offers\", \"against dopaminergic lesion\"]\nGranularity: 2",
            "[\"6-hydroxydopamine lesion\", \"increased vulnerability to\", \"mice lacking CB1 cannabinoid receptors\"]": "\n[\"6-hydroxydopamine lesion\", \"increased vulnerability\", \"mice lacking CB1 cannabinoid receptors\"]\n[\"6-hydroxydopamine lesion\", \"increased vulnerability to\", \"mice\"]\n[\"6-hydroxydopamine lesion\", \"increased vulnerability to\", \"mice lacking CB1\"]\n[\"6-hydroxydopamine lesion\", \"increased vulnerability to\", \"CB1 cannabinoid receptors\"]\nGranularity: 4"
      },
      "Reduced cardiotoxicity of doxorubicin given in the form of N - ( 2 - hydroxypropyl ) methacrylamide conjugates : and experimental study in the rat .|A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg / kg doxorubicin ( DOX ) given either as free drug or in the form of three N - ( 2 - hydroxypropyl ) methacrylamide ( HPMA ) copolymer conjugates .|In these HPMA copolymers , DOX was covalently bound via peptide linkages that were either non - biodegradable ( Gly - Gly ) or degradable by lysosomal proteinases ( Gly - Phe - Leu - Gly ) .|In addition , one biodegradable conjugate containing galactosamine was used ; this residue was targeted to the liver .|Over the first 3 weeks after the i . v .|administration of free and polymer - bound DOX , all animals showed a transient reduction in body weight .|However , the maximal reduction in body weight seen in animals that received polymer - bound DOX ( 4 mg / kg ) was significantly lower than that observed in those that received free DOX ( 4 mg / kg ) or a mixture of the unmodified parent HPMA copolymer and free DOX ( 4 mg / kg ; P less than 0 . 01 ) .|Throughout the study ( 20 weeks ) , deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX ; in these cases , histological investigations revealed marked changes in the heart that were consistent with DOX - induced cardiotoxicity .|Sequential measurements of cardiac output in surviving animals that received either free DOX or the mixture of HPMA copolymer and free DOX showed a reduction of approximately 30 % in function beginning at the 4th week after drug administration .|The heart rate in these animals was approximately 12 % lower than that measured in age - matched control rats ( P less than 0 . 05 ) .|Animals that were given the HPMA copolymer conjugates containing DOX exhibited no significant change in cardiac output throughout the study ( P less than 0 . 05 ) .|In addition , no significant histological change was observed in the heart of animals that received DOX in the form of HPMA copolymer conjugates and were killed at the end of the study .|However , these animals had shown a significant increase in heart rate beginning at 8 weeks after drug administration ( P less than 0 . 01 ) . ( ABSTRACT TRUNCATED AT 400 WORDS )": {
            "[\"doxorubicin\", \"given in the form of\", \"N - ( 2 - hydroxypropyl ) methacrylamide conjugates\"]": " \n[\"doxorubicin\", \"given as\", \"N - ( 2 - hydroxypropyl ) methacrylamide conjugates\"]\n[\"doxorubicin\", \"given in the form of\", \"N - ( 2 - hydroxypropyl )\"]\n[\"doxorubicin\", \"given in the form of\", \"methacrylamide conjugates\"]\nGranularity: 3",
            "[\"A rat model\", \"used to evaluate\", \"general acute toxicity and late cardiotoxicity of 4 mg / kg doxorubicin\"]": " \n[\"A rat model\", \"used to evaluate\", \"general acute toxicity\"]\n[\"A rat model\", \"used to evaluate\", \"late cardiotoxicity\"]\n[\"4 mg / kg doxorubicin\", \"used for\", \"general acute toxicity\"]\n[\"4 mg / kg doxorubicin\", \"used for\", \"late cardiotoxicity\"]\nGranularity: 4",
            "[\"doxorubicin\", \"given as\", \"free drug or in the form of three N - ( 2 - hydroxypropyl ) methacrylamide copolymer conjugates\"]": " \n[\"doxorubicin\", \"given as\", \"free drug\"]\n[\"doxorubicin\", \"given as\", \"three N - ( 2 - hydroxypropyl ) methacrylamide copolymer conjugates\"]\nGranularity: 2",
            "[\"In these HPMA copolymers\", \"DOX was covalently bound via\", \"peptide linkages that were either non - biodegradable or degradable by lysosomal proteinases\"]": " \n[\"HPMA copolymers\", \"were used to bind\", \"DOX\"]\n[\"DOX\", \"was covalently bound via\", \"peptide linkages\"]\n[\"peptide linkages\", \"were either non-biodegradable or degradable by lysosomal proteinases\"]\nGranularity: 3",
            "[\"In addition\", \"one biodegradable conjugate containing\", \"galactosamine was used ; this residue was targeted to the liver\"]": " \n[\"In addition\", \"one biodegradable conjugate containing\", \"galactosamine\"]\n[\"one biodegradable conjugate\", \"contained\", \"galactosamine\"]\n[\"galactosamine\", \"was used\"]\n[\"galactosamine\", \"was targeted to\", \"the liver\"]\nGranularity: 4",
            "[\"Over the first 3 weeks after the i . v .\", \"administration of free and polymer - bound DOX\", \"all animals showed a transient reduction in body weight\"]": " \n[\"i . v .\", \"administration\", \"free DOX\"]\n[\"i . v .\", \"administration\", \"polymer - bound DOX\"]\n[\"animals\", \"showed\", \"transient reduction in body weight\"]\nGranularity: 3",
            "[\"However\", \"the maximal reduction in body weight seen in animals that received polymer - bound DOX ( 4 mg / kg )\", \"was significantly lower than that observed in those that received free DOX ( 4 mg / kg ) or a mixture of the unmodified parent HPMA copolymer and free DOX ( 4 mg / kg ; P less than 0 . 01 )\"]": "\n[\"However\", \"the maximal reduction in body weight\", \"seen in animals that received polymer - bound DOX ( 4 mg / kg )\"]\n[\"However\", \"the maximal reduction in body weight\", \"was significantly lower than that observed in those that received free DOX ( 4 mg / kg )\"]\n[\"However\", \"the maximal reduction in body weight\", \"a mixture of the unmodified parent HPMA copolymer and free DOX ( 4 mg / kg ; P less than 0 . 01 )\"]\n[\"However\", \"animals\", \"received polymer - bound DOX ( 4 mg / kg )\"]\n[\"However\", \"animals\", \"received free DOX ( 4 mg / kg )\"]\n[\"However\", \"animals\", \"a mixture of the unmodified parent HPMA copolymer and free DOX ( 4 mg / kg ; P less than 0 . 01 )\"]\n[\"However\", \"received polymer - bound DOX (",
            "[\"Throughout the study ( 20 weeks )\", \"deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX\", \"in these cases , histological investigations revealed marked changes in the heart that were consistent with DOX - induced cardiotoxicity\"]": "\n[\"animals\", \"received\", \"free DOX\"]\n[\"animals\", \"received\", \"mixture of HPMA copolymer and free DOX\"]\n[\"deaths related to cardiotoxicity\", \"were observed\", \"in animals that received free DOX\"]\n[\"deaths related to cardiotoxicity\", \"were observed\", \"in animals that received mixture of HPMA copolymer and free DOX\"]\n[\"histological investigations\", \"revealed\", \"marked changes in the heart\"]\n[\"marked changes in the heart\", \"were consistent with\", \"DOX-induced cardiotoxicity\"]\nGranularity: 6",
            "[\"However\", \"these animals had shown\", \"a significant increase in heart rate beginning at 8 weeks after drug administration ( P less than 0 . 01 )\"]": " \n[\"these animals\", \"showed\", \"a significant increase in heart rate\"]\n[\"these animals\", \"began at\", \"8 weeks after drug administration\"]\n[\"these animals\", \"had a\", \"heart rate increase\"]\n[\"these animals\", \"had a\", \"significant increase\"]\n[\"these animals\", \"had a\", \"heart rate increase beginning at 8 weeks after drug administration\"]\n[\"these animals\", \"had a\", \"significant increase beginning at 8 weeks after drug administration\"]\nGranularity: 6"
      },
      "Diffuse skeletal pain after administration of alendronate .|BACKGROUND : Osteoporosis is caused by bone resorption in excess of bone formation , and bisphosphonates , are used to inhibit bone resorption .|Alendronate , a biphosphonate , is effective for both the treatment and prevention of osteoporosis in postmenopausal women .|Side effects are relatively few and prominently gastrointestinal .|Musculoskeletal pain may be an important side effect in these patients .|We presented a patient admitted to our out - patient clinic with diffuse skeletal pain after three consecutive administration of alendronate .|CONCLUSION : We conclude that patients with osteoporosis can report pain , and bisphosphonate - related pain should also be considered before ascribing this complaint to osteoporosis .": {
            "[\"Diffuse skeletal pain\", \"after administration of\", \"alendronate\"]": " \n[\"Diffuse skeletal pain\", \"after administration\", \"alendronate\"]\n[\"Diffuse skeletal pain\", \"after\", \"alendronate\"]\n[\"Diffuse skeletal pain\", \"administration of\", \"alendronate\"]\nGranularity: 3",
            "[\"Osteoporosis\", \"caused by\", \"bone resorption in excess of bone formation\"]": " \n[\"Osteoporosis\", \"caused by\", \"bone resorption\"]\n[\"Osteoporosis\", \"caused by\", \"bone formation\"]\nGranularity: 2",
            "[\"Bisphosphonates\", \"used to\", \"inhibit bone resorption\"]": " \n[\"Bisphosphonates\", \"used to\", \"inhibit bone resorption\"]\nGranularity: 1",
            "[\"Alendronate\", \"a biphosphonate\", \"effective for treatment and prevention of osteoporosis\"]": " \n[\"Alendronate\", \"is a\", \"biphosphonate\"]\n[\"Alendronate\", \"is effective for\", \"treatment of osteoporosis\"]\n[\"Alendronate\", \"is effective for\", \"prevention of osteoporosis\"]\nGranularity: 3",
            "[\"Alendronate\", \"effective for\", \"treatment and prevention of osteoporosis in postmenopausal women\"]": " \n[\"Alendronate\", \"effective for\", \"treatment of osteoporosis\"]\n[\"Alendronate\", \"effective for\", \"prevention of osteoporosis in postmenopausal women\"]\nGranularity: 2",
            "[\"Side effects\", \"relatively few\", \"prominently gastrointestinal\"]": " \n[\"Side effects\", \"are\", \"relatively few\"]\n[\"Side effects\", \"are\", \"prominently gastrointestinal\"]\nGranularity: 2",
            "[\"Musculoskeletal pain\", \"may be\", \"an important side effect\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"admitted to\", \"out-patient clinic\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"admitted with\", \"diffuse skeletal pain\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Diffuse skeletal pain\", \"after\", \"three consecutive administration of alendronate\"]": " \n[\"Diffuse skeletal pain\", \"after\", \"three consecutive administration\"]\n[\"three consecutive administration\", \"of\", \"alendronate\"]\nGranularity: 2",
            "[\"Bisphosphonate-related pain\", \"should be considered\", \"before ascribing complaint to osteoporosis\"]": " \n[\"Bisphosphonate-related pain\", \"should be considered\", \"complaint\"]\n[\"Bisphosphonate-related pain\", \"should be considered\", \"osteoporosis\"]\nGranularity: 2",
            "[\"Patients with osteoporosis\", \"can report\", \"pain\"]": " \n[\"Patients with osteoporosis\", \"can report\", \"pain\"]\nGranularity: 1",
            "[\"We conclude\", \"that\", \"patients with osteoporosis can report pain\"]": " \n[\"patients with osteoporosis\", \"can report\", \"pain\"]\nGranularity: 1",
            "[\"We conclude\", \"that\", \"bisphosphonate-related pain should be considered\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Metformin protects against seizures , learning and memory impairments and oxidative damage induced by pentylenetetrazole - induced kindling in mice .|Cognitive impairment , the most common and severe comorbidity of epilepsy , greatly diminishes the quality of life .|However , current therapeutic interventions for epilepsy can also cause untoward cognitive effects .|Thus , there is an urgent need for new kinds of agents targeting both seizures and cognition deficits .|Oxidative stress is considered to play an important role in epileptogenesis and cognitive deficits , and antioxidants have a putative antiepileptic potential .|Metformin , the most commonly prescribed antidiabetic oral drug , has antioxidant properties .|This study was designed to evaluate the ameliorative effects of metformin on seizures , cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole - induced kindling animals .|Male C57BL / 6 mice were administered with subconvulsive dose of pentylenetetrazole ( 37 mg / kg , i . p . ) every other day for 14 injections .|Metformin was injected intraperitoneally in dose of 200mg / kg along with alternate - day PTZ .|We found that metformin suppressed the progression of kindling , ameliorated the cognitive impairment and decreased brain oxidative stress .|Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures .": {
            "[\"Metformin\", \"protects against\", \"seizures\"]": " N/A (The triple is specific, conveying a singular relation between Metformin and seizures.)\nGranularity: 0",
            "[\"Metformin\", \"protects against\", \"learning and memory impairments\"]": "\n[\"Metformin\", \"protects against\", \"learning impairments\"]\n[\"Metformin\", \"protects against\", \"memory impairments\"]\nGranularity: 2",
            "[\"Metformin\", \"protects against\", \"oxidative damage\"]": " N/A (The triple is specific, conveying a singular relation between Metformin and oxidative damage.)\nGranularity: 0",
            "[\"Cognitive impairment\", \"is the most common and severe comorbidity of\", \"epilepsy\"]": " \n[\"Cognitive impairment\", \"is the most common comorbidity of\", \"epilepsy\"]\n[\"Cognitive impairment\", \"is the most severe comorbidity of\", \"epilepsy\"]\nGranularity: 2",
            "[\"Current therapeutic interventions for epilepsy\", \"can cause\", \"untoward cognitive effects\"]": " \n[\"Current therapeutic interventions for epilepsy\", \"can cause\", \"cognitive effects\"]\n[\"Current therapeutic interventions for epilepsy\", \"can cause\", \"untoward effects\"]\nGranularity: 2",
            "[\"There is\", \"an urgent need for\", \"new kinds of agents targeting both seizures and cognition deficits\"]": "\n[\"There is\", \"an urgent need for\", \"new kinds of agents targeting seizures\"]\n[\"There is\", \"an urgent need for\", \"new kinds of agents targeting cognition deficits\"]\nGranularity: 2",
            "[\"Oxidative stress\", \"is considered to play an important role in\", \"epileptogenesis and cognitive deficits\"]": " \n[\"Oxidative stress\", \"plays a role in\", \"epileptogenesis\"]\n[\"Oxidative stress\", \"plays a role in\", \"cognitive deficits\"]\nGranularity: 2",
            "[\"Antioxidants\", \"have a putative\", \"antiepileptic potential\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Metformin\", \"has\", \"antioxidant properties\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"This study\", \"was designed to evaluate the ameliorative effects of\", \"Metformin\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Metformin\", \"was administered\", \"intraperitoneally in dose of 200mg / kg\"]": " \n[\"Metformin\", \"was administered\", \"intraperitoneally\"]\n[\"Metformin\", \"was administered\", \"in dose of 200mg / kg\"]\nGranularity: 2",
            "[\"Metformin\", \"suppressed the progression of\", \"kindling\"]": " N/A (The triple is specific, conveying a singular relation between Metformin and kindling.)\nGranularity: 0",
            "[\"Metformin\", \"ameliorated\", \"cognitive impairment\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Metformin\", \"decreased\", \"brain oxidative stress\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"The present study\", \"concluded that\", \"Metformin may be a potential agent for the treatment of epilepsy\"]": " \n[\"The present study\", \"concluded\", \"Metformin\"]\n[\"Metformin\", \"may be\", \"a potential agent\"]\n[\"a potential agent\", \"for the treatment of\", \"epilepsy\"]\nGranularity: 3",
            "[\"The present study\", \"concluded that\", \"Metformin may be a protective medicine against cognitive impairment induced by seizures\"]": " \n[\"The present study\", \"concluded\", \"Metformin\"]\n[\"Metformin\", \"may be a protective medicine against\", \"cognitive impairment\"]\n[\"cognitive impairment\", \"induced by\", \"seizures\"]\nGranularity: 3"
      },
      "Famotidine - associated delirium .|A series of six cases .|Famotidine is a histamine H2 - receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost .|Although all of the currently available H2 - receptor antagonists have shown the propensity to cause delirium , only two previously reported cases have been associated with famotidine .|The authors report on six cases of famotidine - associated delirium in hospitalized patients who cleared completely upon removal of famotidine .|The pharmacokinetics of famotidine are reviewed , with no change in its metabolism in the elderly population seen .|The implications of using famotidine in elderly persons are discussed .": {
            "[\"Famotidine\", \"associated with\", \"delirium\"]": " N/A (The triple is specific, conveying a singular relation between Famotidine and delirium.)\nGranularity: 0",
            "[\"Famotidine\", \"is a type of\", \"histamine H2-receptor antagonist\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Famotidine\", \"used for\", \"prevention of stress ulcers\"]": " N/A (The triple is specific, conveying a singular relation between Famotidine and the prevention of stress ulcers.)\nGranularity: 0",
            "[\"Famotidine\", \"increasing popularity due to\", \"low cost\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Famotidine\", \"causes\", \"delirium\"]": " N/A (The triple is specific, conveying a singular relation between Famotidine and delirium.)\nGranularity: 0",
            "[\"Famotidine\", \"reported cases associated with\", \"6\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Famotidine\", \"cleared completely upon removal\", \"hospitalized patients\"]": " \n[\"Famotidine\", \"cleared\", \"hospitalized patients\"]\n[\"Famotidine\", \"completely removed\", \"hospitalized patients\"]\nGranularity: 2",
            "[\"Famotidine\", \"pharmacokinetics reviewed\", \"no change in metabolism in elderly population\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Famotidine\", \"implications discussed\", \"use in elderly persons\"]": " \n[\"Famotidine\", \"implications discussed\", \"use in elderly persons\"]\nGranularity: 1"
      },
      "Hemodynamics and myocardial metabolism under deliberate hypotension .|An experimental study in dogs .|Coronary blood flow , cardiac work and metabolism were studied in dogs under sodium nitroprusside ( SNP ) and trimetaphan ( TMP ) deliberate hypotension ( 20 % and 40 % mean pressure decrease from baseline ) .|Regarding the effects of drug - induced hypotension on coronary blood flow , aortic and coronary sinus metabolic data ( pH , pO2 , pCO2 ) we could confirm that nitroprusside hypotension could be safely used to 30 % mean blood pressure decrease from control , trimetaphan hypotension to 20 % mean blood pressure decrease .|Cardiac work was significantly reduced during SNP hypotension .|Myocardial O2 consumption and O2 availability were directly dependent on the coronary perfusion .|Careful invasive monitoring of the blood pressure , blood gases and of the ECG ST - T segment is mandatory .": {
            "[\"Hemodynamics\", \"is studied under\", \"deliberate hypotension\"]": " \n[\"Hemodynamics\", \"is studied under\", \"deliberate hypotension\"]\nGranularity: 1",
            "[\"Myocardial metabolism\", \"is studied under\", \"deliberate hypotension\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Experimental study\", \"is related to\", \"Hemodynamics and myocardial metabolism\"]": " \n[\"Experimental study\", \"is related to\", \"Hemodynamics\"]\n[\"Experimental study\", \"is related to\", \"Myocardial metabolism\"]\nGranularity: 2",
            "[\"Cardiac work\", \"is studied in\", \"dogs\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Metabolism\", \"is studied in\", \"dogs\"]": " N/A (The triple is specific, conveying a singular relation between metabolism and dogs.)\nGranularity: 0",
            "[\"Coronary blood flow\", \"is affected by\", \"nitroprusside hypotension\"]": " \n[\"Coronary blood flow\", \"is affected by\", \"nitroprusside\"]\n[\"nitroprusside\", \"causes\", \"hypotension\"]\nGranularity: 2",
            "[\"Coronary blood flow\", \"is affected by\", \"trimetaphan hypotension\"]": " \n[\"Coronary blood flow\", \"is affected by\", \"trimetaphan\"]\n[\"trimetaphan\", \"causes\", \"hypotension\"]\nGranularity: 2",
            "[\"Cardiac work\", \"is affected by\", \"drug-induced hypotension\"]": " \n[\"Cardiac work\", \"is affected by\", \"drug-induced hypotension\"]\nGranularity: 1",
            "[\"O2 availability\", \"is dependent on\", \"coronary perfusion\"]": " \n[\"O2 availability\", \"is dependent on\", \"coronary perfusion\"]\nGranularity: 1",
            "[\"Invasive monitoring\", \"is mandatory for\", \"blood gases\"]": " \n[\"Invasive monitoring\", \"is mandatory for\", \"blood gases\"]\nGranularity: 1",
            "[\"Invasive monitoring\", \"is mandatory for\", \"ECG ST-T segment\"]": " \n[\"Invasive monitoring\", \"is mandatory for\", \"ECG\"]\n[\"Invasive monitoring\", \"is mandatory for\", \"ST-T segment\"]\nGranularity: 2",
            "[\"Hemodynamics\", \"is related to\", \"myocardial metabolism\"]": "\nN/A (The relationship is direct and does not need further granularity.)\nGranularity: 0",
            "[\"Experimental study\", \"is conducted on\", \"dogs\"]": " \n[\"Experimental study\", \"is conducted on\", \"dogs\"]\nGranularity: 1",
            "[\"Coronary blood flow\", \"is studied in\", \"dogs\"]": " \n[\"Coronary blood flow\", \"is studied\", \"in dogs\"]\nGranularity: 1",
            "[\"Drug-induced hypotension\", \"affects\", \"coronary blood flow\"]": " \n[\"Drug-induced hypotension\", \"affects\", \"coronary blood flow\"]\nGranularity: 1",
            "[\"Cardiac work\", \"is reduced during\", \"SNP hypotension\"]": "\n[\"Cardiac work\", \"is reduced\", \"during SNP hypotension\"]\nGranularity: 1",
            "[\"Myocardial O2 consumption\", \"is dependent on\", \"coronary perfusion\"]": " \n[\"Myocardial O2 consumption\", \"is dependent on\", \"coronary perfusion\"]\nGranularity: 1",
            "[\"Invasive monitoring\", \"is mandatory for\", \"blood pressure\"]": " \n[\"Invasive monitoring\", \"is mandatory for\", \"blood pressure\"]\nGranularity: 1"
      },
      "Rhabdomyolysis and brain ischemic stroke in a heroin - dependent male under methadone maintenance therapy .|OBJECTIVE : There are several complications associated with heroin abuse , some of which are life - threatening .|Methadone may aggravate this problem .|METHOD : A clinical case description .|RESULTS : A 33 - year - old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin .|He had used heroin since age 20 , and had used 150 mg methadone daily for 6 months .|He was found unconsciousness at home and was sent to our hospital .|In the ER , his opiate level was 4497 ng / ml .|In the ICU , we found rhabdomyolysis , acute renal failure and acute respiratory failure .|After transfer to an internal ward , we noted aphasia and weakness of his left limbs .|After MRI , we found cerebral ischemic infarction .|CONCLUSION : Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke .|Patients under methadone maintenance therapy should be warned regarding these serious adverse events .|Hypotheses of heroin - related rhabdomyolysis and stroke in heroin abusers are discussed .": {
            "[\"Heroin abuse\", \"is associated with\", \"several complications\"]": " \n[\"Heroin abuse\", \"is associated with\", \"physical complications\"]\n[\"Heroin abuse\", \"is associated with\", \"mental complications\"]\n[\"Heroin abuse\", \"is associated with\", \"social complications\"]\nGranularity: 3",
            "[\"Methadone\", \"may\", \"aggravate the problem\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Clinical case\", \"is\", \"description\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy .|The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy .|Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen .|Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia .|4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy .|Cyclical low - dose oestrogen therapy with 7 - - 13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma .": {
            "[\"Treatment regimens\", \"described in\", \"74 patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Cystic hyperplasia\", \"associated with\", \"unopposed oestrogen therapy\"]": " \n[\"Cystic hyperplasia\", \"associated with\", \"unopposed oestrogen\"]\n[\"Cystic hyperplasia\", \"associated with\", \"therapy\"]\nGranularity: 2"
      },
      "Studies of risk factors for aminoglycoside nephrotoxicity .|The epidemiology of aminoglycoside - induced nephrotoxicity is not fully understood .|Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients , but rarely , if ever , cause glomerular or tubular dysfunction .|Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70 % to 80 % .|Further analysis of these data suggests that the duration of therapy , plasma aminoglycoside levels , liver disease , advanced age , high initial estimated creatinine clearance and , possibly , female gender all increase the risk for nephrotoxicity .|Other causes of acute renal failure , such as shock , appear to have an additive effect .|Predictive models have been developed from these analyses that should be useful for identifying patients at high risk .|These models may also be useful in developing insights into the pathophysiology of aminoglycoside - induced nephrotoxicity .": {
            "[\"Epidemiology\", \"is not fully understood\", \"aminoglycoside-induced nephrotoxicity\"]": "\n[\"Epidemiology\", \"is not fully understood\", \"aminoglycoside-induced nephrotoxicity\"]\nGranularity: 0",
            "[\"Experimental studies\", \"indicate\", \"aminoglycosides cause proximal tubular damage\"]": " \n[\"Experimental studies\", \"indicate\", \"aminoglycosides cause\"]\n[\"aminoglycosides\", \"cause\", \"proximal tubular damage\"]\nGranularity: 2",
            "[\"Clinical trials\", \"indicate\", \"relative risk for developing acute renal failure\"]": " \n[\"Clinical trials\", \"indicate\", \"relative risk\"]\n[\"Clinical trials\", \"indicate\", \"developing acute renal failure\"]\nGranularity: 2",
            "[\"Analysis of data\", \"suggests\", \"risk factors for nephrotoxicity\"]": " \n[\"Analysis of data\", \"suggests\", \"risk factors\"]\n[\"risk factors\", \"for\", \"nephrotoxicity\"]\nGranularity: 2",
            "[\"Other causes\", \"have\", \"additive effect\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Predictive models\", \"developed\", \"useful for identifying patients at high risk\"]": " \n[\"Predictive models\", \"developed\", \"useful for identifying patients\"]\n[\"Predictive models\", \"developed\", \"useful for identifying patients at high risk\"]\nGranularity: 2",
            "[\"Predictive models\", \"useful\", \"developing insights into pathophysiology\"]": " \n[\"Predictive models\", \"are useful for\", \"developing insights\"]\n[\"Predictive models\", \"are useful for\", \"pathophysiology\"]\nGranularity: 2",
            "[\"Studies\", \"investigate\", \"aminoglycoside nephrotoxicity\"]": " N/A (The triple is specific, conveying a singular relation between studies and aminoglycoside nephrotoxicity.)\nGranularity: 0"
      },
      "Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes : a matched case - control study .|AIMS : This study sought to assess the risk of developing coronary artery disease ( CAD ) associated with initial treatment of type 2 diabetes with different sulphonylureas .|METHODS : In type 2 diabetic patients , cases who developed CAD were compared retrospectively with controls that did not .|The 20 - year risk of CAD at diagnosis of diabetes , using the UKPDS risk engine , was used to match cases with controls .|RESULTS : The 76 cases of CAD were compared with 152 controls .|The hazard of developing CAD ( 95 % CI ) associated with initial treatment increased by 2 . 4 - fold ( 1 . 3 - 4 . 3 , P = 0 . 004 ) with glibenclamide ; 2 - fold ( 0 . 9 - 4 . 6 , P = 0 . 099 ) with glipizide ; 2 . 9 - fold ( 1 . 6 - 5 . 1 , P = 0 . 000 ) with either , and was unchanged with metformin .|The hazard decreased 0 . 3 - fold ( 0 . 7 - 1 . 7 , P = 0 . 385 ) with glimepiride , 0 . 4 - fold ( 0 . 7 - 1 . 3 , P = 0 . 192 ) with gliclazide , and 0 . 4 - fold ( 0 . 7 - 1 . 1 , P = 0 . 09 ) with either .|CONCLUSIONS : Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride .|If confirmed , this may be important because most Indian patients receive the cheaper older sulphonylureas , and present guidelines do not distinguish between individual agents .": {
            "[\"Risk of coronary artery disease\", \"associated with\", \"initial sulphonylurea treatment of patients with type 2 diabetes\"]": " \n[\"Risk of coronary artery disease\", \"associated with\", \"initial sulphonylurea treatment\"]\n[\"initial sulphonylurea treatment\", \"of patients with type 2 diabetes\", \"increases risk of coronary artery disease\"]\nGranularity: 2",
            "[\"This study\", \"sought to assess\", \"risk of developing coronary artery disease (CAD)\"]": " \n[\"This study\", \"sought to assess\", \"risk of developing coronary artery disease\"]\n[\"This study\", \"sought to assess\", \"risk of developing CAD\"]\nGranularity: 2",
            "[\"Cases\", \"developed\", \"CAD\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Cases\", \"compared retrospectively with\", \"controls that did not\"]": " \n[\"Cases\", \"compared retrospectively with\", \"controls\"]\n[\"Cases\", \"did not\", \"controls\"]\nGranularity: 2",
            "[\"20-year risk of CAD\", \"at diagnosis of diabetes\", \"using the UKPDS risk engine\"]": " \n[\"20-year risk of CAD\", \"at diagnosis of diabetes\", \"using the UKPDS risk engine\"]\nGranularity: 1",
            "[\"Cases\", \"matched with\", \"controls\"]": " N/A (The terms 'cases' and 'controls' already convey a specific relationship and do not require further granularity.)\nGranularity: 0",
            "[\"76 cases of CAD\", \"compared with\", \"152 controls\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hazard of developing CAD\", \"associated with\", \"initial treatment\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hazard of developing CAD\", \"increased by\", \"2.4-fold\"]": " \n[\"Hazard of developing CAD\", \"increased by\", \"2.4\"] \n[\"Hazard of developing CAD\", \"folded by\", \"2.4\"]\nGranularity: 2",
            "[\"Hazard of developing CAD\", \"increased by\", \"2-fold\"]": " \n[\"Hazard of developing CAD\", \"increased by\", \"2-fold\"]\nGranularity: 1",
            "[\"Hazard of developing CAD\", \"increased by\", \"2.9-fold\"]": " \n[\"Hazard of developing CAD\", \"increased by\", \"2.9\"]\n[\"Hazard of developing CAD\", \"increased by\", \"fold\"]\nGranularity: 2",
            "[\"Hazard of developing CAD\", \"unchanged with\", \"metformin\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hazard of developing CAD\", \"decreased by\", \"0.3-fold\"]": " \n[\"Hazard of developing CAD\", \"decreased by\", \"0.3-fold\"]\nGranularity: 1",
            "[\"Hazard of developing CAD\", \"decreased by\", \"0.4-fold\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Initiating treatment of type 2 diabetes\", \"associated with\", \"increased risk of CAD\"]": "\n[\"Initiating treatment of type 2 diabetes\", \"increases risk of\", \"CAD\"]\nGranularity: 1",
            "[\"Increased risk of CAD\", \"in comparison to\", \"gliclazide or glimepiride\"]": " \n[\"Increased risk of CAD\", \"compared to\", \"gliclazide\"]\n[\"Increased risk of CAD\", \"compared to\", \"glimepiride\"]\nGranularity: 2",
            "[\"This\", \"may be important because\", \"most Indian patients receive the cheaper older sulphonylureas\"]": " \n[\"Indian patients\", \"receive\", \"older sulphonylureas\"]\n[\"older sulphonylureas\", \"are cheaper\"]\nGranularity: 2",
            "[\"Present guidelines\", \"do not distinguish between\", \"individual agents\"]": "\n[\"Present guidelines\", \"do not distinguish\", \"individual agents\"]\n[\"Present guidelines\", \"do not\", \"distinguish between\"]\n[\"Present guidelines\", \"do not\", \"distinguish\"]\n[\"Present guidelines\", \"do not distinguish between\", \"agents\"]\n[\"Present guidelines\", \"do not\", \"individual agents\"]\n[\"Present guidelines\", \"do not distinguish between\", \"individual\"]\nGranularity: 6"
      },
      "Gemfibrozil - lovastatin therapy for primary hyperlipoproteinemias .|The specific aim of this retrospective , observational study was to assess safety and efficacy of long - term ( 21 months / patient ) , open - label , gemfibrozil - lovastatin treatment in 80 patients with primary mixed hyperlipidemia ( 68 % of whom had atherosclerotic vascular disease ) .|Because ideal lipid targets were not reached ( low - density lipoprotein ( LDL ) cholesterol less than 130 mg / dl , high - density lipoprotein ( HDL ) cholesterol greater than 35 mg / dl , or total cholesterol / HDL cholesterol less than 4 . 5 mg / dl ) with diet plus a single drug , gemfibrozil ( 1 . 2 g / day ) - lovastatin ( primarily 20 or 40 mg ) treatment was given .|Follow - up visits were scheduled with 2 - drug therapy every 6 to 8 weeks , an average of 10 . 3 visits per patient , with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured .|Only 1 of the 4 , 446 liver function tests ( 0 . 02 % ) , a gamma glutamyl transferase , was greater than or equal to 3 times the upper normal limit .|Of the 714 creatine phosphokinase levels , 9 % were high ; only 1 ( 0 . 1 % ) was greater than or equal to 3 times the upper normal limit .|With 2 - drug therapy , mean total cholesterol decreased 22 % from 255 to 200 mg / dl , triglyceride levels decreased 35 % from 236 to 154 mg / dl , LDL cholesterol decreased 26 % from 176 to 131 mg / dl , and the total cholesterol / HDL cholesterol ratio decreased 24 % from 7 . 1 to 5 . 4 , all p less than or equal to 0 . 0001 .|Myositis , attributable to the drug combination and symptomatic enough to discontinue it , occurred in 3 % of patients , and in 1 % with concurrent high creatine phosphokinase ( 769 U / liter ) ; no patients had rhabdomyolysis or myoglobinuria . ( ABSTRACT TRUNCATED AT 250 WORDS )": {
            "[\"Gemfibrozil\", \"therapy for\", \"primary hyperlipoproteinemias\"]": " \n[\"Gemfibrozil\", \"is a therapy for\", \"primary hyperlipoproteinemias\"]\n[\"Gemfibrozil\", \"treats\", \"primary hyperlipoproteinemias\"]\n[\"Gemfibrozil\", \"is used for\", \"primary hyperlipoproteinemias\"]\nGranularity: 3",
            "[\"Gemfibrozil-lovastatin treatment\", \"aim of the study\", \"assess safety and efficacy\"]": " \n[\"Gemfibrozil-lovastatin treatment\", \"aim of the study\", \"assess safety\"]\n[\"Gemfibrozil-lovastatin treatment\", \"aim of the study\", \"assess efficacy\"]\nGranularity: 2",
            "[\"Open-label Gemfibrozil-lovastatin treatment\", \"duration\", \"21 months per patient\"]": " \n[\"Open-label Gemfibrozil-lovastatin treatment\", \"lasts\", \"21 months\"]\n[\"Open-label Gemfibrozil-lovastatin treatment\", \"is given to\", \"each patient\"]\nGranularity: 2",
            "[\"Treatment\", \"administered to\", \"80 patients with primary mixed hyperlipidemia\"]": " \n[\"Treatment\", \"administered to\", \"80 patients\"]\n[\"Treatment\", \"administered for\", \"primary mixed hyperlipidemia\"]\nGranularity: 2",
            "[\"Patients\", \"percentage with atherosclerotic vascular disease\", \"68%\"]": " \n[\"Patients\", \"have\", \"atherosclerotic vascular disease\"]\n[\"68%\", \"of\", \"patients have atherosclerotic vascular disease\"]\nGranularity: 2",
            "[\"Ideal lipid targets\", \"not reached with\", \"diet plus a single drug\"]": " \n[\"Ideal lipid targets\", \"not reached with\", \"diet\"]\n[\"Ideal lipid targets\", \"not reached with\", \"a single drug\"]\nGranularity: 2",
            "[\"Gemfibrozil\", \"dosage\", \"1.2 g/day\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Lovastatin\", \"dosage\", \"primarily 20 or 40 mg\"]": " \n[\"Lovastatin\", \"dosage\", \"20 mg\"]\n[\"Lovastatin\", \"dosage\", \"40 mg\"]\nGranularity: 2",
            "[\"Follow-up visits\", \"frequency\", \"every 6 to 8 weeks\"]": " \n[\"Follow-up visits\", \"occur with a frequency of\", \"every 6 weeks\"]\n[\"Follow-up visits\", \"occur with a frequency of\", \"every 8 weeks\"]\nGranularity: 2",
            "[\"Follow-up visits\", \"average number per patient\", \"10.3 visits\"]": " \n[\"Follow-up visits\", \"average number\", \"10.3\"]\n[\"Follow-up visits\", \"per patient\", \"10.3\"]\nGranularity: 2",
            "[\"Batteries of liver function tests\", \"number measured\", \"741\"]": " \n[\"Batteries of liver function tests\", \"number measured\", \"741\"]\nGranularity: 1",
            "[\"Creatine phosphokinase levels\", \"number measured\", \"714\"]": "\n[\"Creatine phosphokinase levels\", \"were measured\", \"714\"]\nGranularity: 1",
            "[\"Liver function tests\", \"number with high gamma glutamyl transferase\", \"1 (0.02%)\"]": "\n[\"Liver function tests\", \"have\", \"high gamma glutamyl transferase\"]\n[\"high gamma glutamyl transferase\", \"is present in\", \"1 (0.02%)\"]\nGranularity: 2",
            "[\"Creatine phosphokinase levels\", \"percentage with high levels\", \"9%\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Creatine phosphokinase levels\", \"number with levels greater than or equal to 3 times the upper normal limit\", \"1 (0.1%)\"]": " \n[\"Creatine phosphokinase levels\", \"number with levels greater than or equal to 3 times the upper normal limit\", \"1\"]\n[\"Creatine phosphokinase levels\", \"number with levels greater than or equal to 3 times the upper normal limit\", \"0.1%\"]\nGranularity: 2",
            "[\"Two-drug therapy\", \"effect on mean total cholesterol\", \"decreased 22% from 255 to 200 mg/dl\"]": " \n[\"Two-drug therapy\", \"effect on\", \"mean total cholesterol\"]\n[\"Two-drug therapy\", \"decreased\", \"22%\"]\n[\"Two-drug therapy\", \"from\", \"255 mg/dl\"]\n[\"Two-drug therapy\", \"to\", \"200 mg/dl\"]\nGranularity: 4",
            "[\"Two-drug therapy\", \"effect on triglyceride levels\", \"decreased 35% from 236 to 154 mg/dl\"]": " \n[\"Two-drug therapy\", \"decreased triglyceride levels\", \"35%\"]\n[\"Two-drug therapy\", \"decreased triglyceride levels\", \"from 236 to 154 mg/dl\"]\nGranularity: 2",
            "[\"Two-drug therapy\", \"effect on LDL cholesterol\", \"decreased 26% from 176 to 131 mg/dl\"]": "\n[\"Two-drug therapy\", \"effect on\", \"LDL cholesterol\"]\n[\"Two-drug therapy\", \"decreased\", \"26% from 176 to 131 mg/dl\"]\nGranularity: 2",
            "[\"Two-drug therapy\", \"effect on total cholesterol/HDL cholesterol ratio\", \"decreased 24% from 7.1 to 5.4\"]": " \n[\"Two-drug therapy\", \"decreased\", \"total cholesterol/HDL cholesterol ratio\"]\n[\"Two-drug therapy\", \"from\", \"7.1\"]\n[\"Two-drug therapy\", \"to\", \"5.4\"]\nGranularity: 3",
            "[\"Drug combination\", \"caused myositis in\", \"3% of patients\"]": " \n[\"Drug combination\", \"caused\", \"myositis\"]\n[\"Drug combination\", \"occurred in\", \"3% of patients\"]\nGranularity: 2",
            "[\"Drug combination\", \"caused myositis with concurrent high creatine phosphokinase in\", \"1% of patients\"]": "\n[\"Drug combination\", \"caused\", \"myositis\"]\n[\"Drug combination\", \"caused\", \"high creatine phosphokinase\"]\n[\"Drug combination\", \"occurred in\", \"1% of patients\"]\nGranularity: 3",
            "[\"Drug combination\", \"did not cause rhabdomyolysis or myoglobinuria in\", \"any patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "A dramatic drop in blood pressure following prehospital GTN administration .|A male in his sixties with no history of cardiac chest pain awoke with chest pain following an afternoon sleep .|The patient did not self medicate .|The patient 's observations were within normal limits , he was administered oxygen via a face mask and glyceryl trinitrate ( GTN ) .|Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate , this was rectified by atropine sulphate and a fluid challenge .|There was no further deterioration in the patient 's condition during transport to hospital .|There are very few documented case like this in the prehospital scientific literature .|The cause appears to be the Bezold - Jarish reflex , stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre .|Prehospital care providers who are managing any patient with a syncopal episode that fails to recover within a reasonable time frame should consider the Bezold - Jarisch reflex as the cause and manage the patient accordingly .": {
            "[\"blood pressure\", \"following\", \"prehospital GTN administration\"]": " \n[\"blood pressure\", \"following\", \"prehospital GTN administration\"]\nGranularity: 1",
            "[\"male\", \"in his sixties\", \"no history of cardiac chest pain\"]": " \n[\"male\", \"in his sixties\", \"no history of cardiac chest pain\"]\nGranularity: 1",
            "[\"patient\", \"awoke with\", \"chest pain\"]": " N/A (The triple is specific, conveying a singular relation between the patient, waking up, and experiencing chest pain.)\nGranularity: 0",
            "[\"patient\", \"did not\", \"self medicate\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"patient's observations\", \"within normal limits\", \"administered oxygen via a face mask and glyceryl trinitrate (GTN)\"]": " \n[\"patient's observations\", \"within normal limits\", \"administered oxygen\"]\n[\"patient's observations\", \"within normal limits\", \"administered glyceryl trinitrate (GTN)\"]\nGranularity: 2",
            "[\"GTN\", \"caused\", \"sudden drop in blood pressure and heart rate\"]": " \n[\"GTN\", \"caused\", \"sudden drop in blood pressure\"]\n[\"GTN\", \"caused\", \"sudden drop in heart rate\"]\nGranularity: 2",
            "[\"sudden drop in blood pressure and heart rate\", \"rectified by\", \"atropine sulphate and a fluid challenge\"]": " \n[\"sudden drop in blood pressure\", \"rectified by\", \"atropine sulphate\"]\n[\"sudden drop in heart rate\", \"rectified by\", \"atropine sulphate\"]\n[\"sudden drop in blood pressure\", \"rectified by\", \"a fluid challenge\"]\n[\"sudden drop in heart rate\", \"rectified by\", \"a fluid challenge\"]\nGranularity: 4",
            "[\"patient's condition\", \"no further deterioration\", \"during transport to hospital\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"documented cases\", \"few\", \"prehospital scientific literature\"]": " \n[\"documented cases\", \"are\", \"few\"]\n[\"few\", \"are found in\", \"prehospital scientific literature\"]\nGranularity: 2",
            "[\"cause\", \"appears to be\", \"Bezold - Jarish reflex\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Bezold - Jarish reflex\", \"stimulation of\", \"ventricular walls\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"ventricular walls\", \"decreases\", \"sympathetic outflow from the vasomotor centre\"]": " \n[\"ventricular walls\", \"decreases\", \"sympathetic outflow\"]\n[\"ventricular walls\", \"decreases\", \"vasomotor centre\"]\nGranularity: 2",
            "[\"prehospital care providers\", \"managing\", \"any patient with a syncopal episode that fails to recover within a reasonable time frame\"]": " \n[\"prehospital care providers\", \"manage\", \"patients with a syncopal episode\"]\n[\"patients with a syncopal episode\", \"fail to recover within a reasonable time frame\"]\nGranularity: 2",
            "[\"patient\", \"consider\", \"Bezold - Jarisch reflex as the cause\"]": " \n[\"patient\", \"consider\", \"Bezold - Jarisch reflex\"]\n[\"Bezold - Jarisch reflex\", \"is the cause of\", \"patient\"]\nGranularity: 2",
            "[\"patient\", \"manage\", \"accordingly\"]": " N/A (The triple is too vague and lacks necessary context to be split into more specific sub-triples.)\nGranularity: 0"
      },
      "Does domperidone potentiate mirtazapine - associated restless legs syndrome ?|There is now evidence to suggest a central role for the dopaminergic system in restless legs syndrome ( RLS ) .|For example , the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists , whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms .|To our knowledge , there is no previous report regarding whether domperidone , a peripheral dopamine D2 receptor antagonist , can also induce or aggravate symptoms of RLS .|Mirtazapine , the first noradrenergic and specific serotonergic antidepressant ( NaSSA ) , has been associated with RLS in several recent publications .|The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy .|Our patient started to have symptoms of RLS only after he had been treated with mirtazapine , and his RLS symptoms resolved completely upon discontinuation of his mirtazapine .|Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine - associated RLS .|However , physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals , especially those receiving concomitant dopamine D2 receptor antagonists .": {
            "[\"domperidone\", \"potentiate\", \"mirtazapine - associated restless legs syndrome\"]": " \n[\"domperidone\", \"potentiate\", \"mirtazapine\"]\n[\"mirtazapine\", \"associated with\", \"restless legs syndrome\"]\nGranularity: 2",
            "[\"evidence\", \"suggest\", \"central role for the dopaminergic system in restless legs syndrome\"]": " \n[\"evidence\", \"suggests\", \"central role\"]\n[\"dopaminergic system\", \"plays a central role in\", \"restless legs syndrome\"]\nGranularity: 2",
            "[\"symptoms of RLS\", \"improved by\", \"levodopa and dopamine agonists\"]": " \n[\"symptoms of RLS\", \"improved by\", \"levodopa\"]\n[\"symptoms of RLS\", \"improved by\", \"dopamine agonists\"]\nGranularity: 2",
            "[\"central dopamine D2 receptor antagonists\", \"induce or aggravitate\", \"RLS symptoms\"]": "\n[\"central dopamine D2 receptor antagonists\", \"induce\", \"RLS symptoms\"]\n[\"central dopamine D2 receptor antagonists\", \"aggravate\", \"RLS symptoms\"]\nGranularity: 2",
            "[\"Mirtazapine\", \"associated with\", \"RLS\"]": " N/A (The triple is specific, conveying a singular relation between Mirtazapine and RLS.)\nGranularity: 0",
            "[\"patient\", \"comorbid with\", \"postprandial dyspepsia\"]": " N/A (The triple is specific, conveying a singular relation between a patient and postprandial dyspepsia.)\nGranularity: 0",
            "[\"patient\", \"developed RLS after\", \"mirtazapine had been added to his domperidone therapy\"]": " \n[\"patient\", \"developed RLS\", \"after mirtazapine was added\"]\n[\"patient\", \"developed RLS\", \"after domperidone therapy\"]\n[\"patient\", \"developed RLS\", \"after mirtazapine was added to domperidone therapy\"]\nGranularity: 3",
            "[\"patient\", \"had symptoms of RLS\", \"after he had been treated with mirtazapine\"]": " \n[\"patient\", \"had symptoms of RLS\", \"after treatment with mirtazapine\"]\n[\"patient\", \"had symptoms of RLS\", \"after being treated with mirtazapine\"]\n[\"patient\", \"had symptoms of RLS\", \"after treatment\"]\n[\"patient\", \"had symptoms of RLS\", \"after being treated\"]\n[\"patient\", \"had symptoms\", \"RLS\"]\n[\"patient\", \"had symptoms\", \"after treatment\"]\n[\"patient\", \"had symptoms\", \"after being treated\"]\n[\"patient\", \"had symptoms\", \"RLS\"]\n[\"patient\", \"had symptoms\", \"after treatment with mirtazapine\"]\n[\"patient\", \"had symptoms\", \"after being treated with mirtazapine\"]\n[\"patient\", \"had symptoms of RLS\", \"after treatment with mirtazapine\"]\n[\"patient\", \"had symptoms of RLS\", \"after being treated with mirtazapine\"]\nGranularity: 12",
            "[\"patient\", \"RLS symptoms resolved\", \"upon discontinuation of his mirtazapine\"]": " \n[\"patient\", \"experienced\", \"RLS symptoms\"]\n[\"patient\", \"discontinued\", \"mirtazapine\"]\nGranularity: 2",
            "[\"temporal relationship\", \"between the use of mirtazapine\", \"symptoms of RLS\"]": " \n[\"temporal relationship\", \"between\", \"the use of mirtazapine\"]\n[\"temporal relationship\", \"and\", \"symptoms of RLS\"]\nGranularity: 2",
            "[\"physicians\", \"aware of\", \"possibility that mirtazapine can be associated with RLS\"]": " \n[\"physicians\", \"are aware of\", \"the possibility that mirtazapine can be associated with RLS\"]\n[\"mirtazapine\", \"can be associated with\", \"RLS\"]\nGranularity: 2",
            "[\"individuals\", \"receiving concomitant\", \"dopamine D2 receptor antagonists\"]": " \n[\"individuals\", \"receiving\", \"dopamine D2 receptor antagonists\"]\nGranularity: 1"
      },
      "Hepatocellular oxidant stress following intestinal ischemia - reperfusion injury .|Reperfusion of ischemic intestine results in acute liver dysfunction characterized by hepatocellular enzyme release into plasma , reduction in bile flow rate , and neutrophil sequestration within the liver .|The pathophysiology underlying this acute hepatic injury is unknown .|This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo .|Rats were subjected to a standardized intestinal ischemia - reperfusion injury .|Hepatic tissue was assayed for lipid peroxidation products and oxidized and reduced glutathione .|There was no change in hepatic tissue total glutathione following intestinal ischemia - reperfusion injury .|Oxidized glutathione ( GSSG ) increased significantly following 30 and 60 min of reperfusion .|There was no increase in any of the products of lipid peroxidation associated with this injury .|An increase in GSSG within hepatic tissue during intestinal reperfusion suggests exposure of hepatocytes to an oxidant stress .|The lack of a significant increase in products of lipid peroxidation suggests that the oxidant stress is of insufficient magnitude to result in irreversible injury to hepatocyte cell membranes .|These data also suggest that the measurement of tissue GSSG may be a more sensitive indicator of oxidant stress than measurement of products of lipid peroxidation .": {
            "[\"Hepatocellular oxidant stress\", \"follows\", \"intestinal ischemia - reperfusion injury\"]": " \n[\"Hepatocellular oxidant stress\", \"follows\", \"intestinal ischemia\"]\n[\"Hepatocellular oxidant stress\", \"follows\", \"reperfusion injury\"]\nGranularity: 2",
            "[\"Reperfusion of ischemic intestine\", \"results in\", \"acute liver dysfunction\"]": " \n[\"Reperfusion of ischemic intestine\", \"results in\", \"acute liver dysfunction\"]\nGranularity: 1",
            "[\"acute liver dysfunction\", \"characterized by\", \"hepatocellular enzyme release into plasma\"]": "\n[\"acute liver dysfunction\", \"is characterized by\", \"hepatocellular enzyme release\"]\n[\"acute liver dysfunction\", \"is characterized by\", \"enzyme release into plasma\"]\n[\"acute liver dysfunction\", \"is characterized by\", \"hepatocellular enzyme release into plasma\"]\nGranularity: 3",
            "[\"acute liver dysfunction\", \"characterized by\", \"reduction in bile flow rate\"]": " \n[\"acute liver dysfunction\", \"characterized by\", \"reduction in bile flow rate\"]\n[\"acute liver dysfunction\", \"characterized by\", \"reduction in flow rate\"]\n[\"acute liver dysfunction\", \"characterized by\", \"reduction in bile\"]\n[\"acute liver dysfunction\", \"characterized by\", \"reduction in rate\"]\nGranularity: 4",
            "[\"acute liver dysfunction\", \"characterized by\", \"neutrophil sequestration within the liver\"]": " \n[\"acute liver dysfunction\", \"is characterized by\", \"neutrophil sequestration\"]\n[\"neutrophil sequestration\", \"occurs within\", \"the liver\"]\nGranularity: 2",
            "[\"The pathophysiology\", \"underlying\", \"this acute hepatic injury\"]": " \n[\"The pathophysiology\", \"underlying\", \"acute hepatic injury\"]\nGranularity: 1",
            "[\"This study\", \"was undertaken to\", \"determine whether oxidants are associated with the hepatic injury\"]": " \n[\"This study\", \"was undertaken to\", \"determine whether oxidants are associated with\"]\n[\"oxidants\", \"are associated with\", \"hepatic injury\"]\nGranularity: 2",
            "[\"This study\", \"was undertaken to\", \"determine the relative value of several indirect methods of assessing oxidant exposure in vivo\"]": " \n[\"This study\", \"was undertaken to\", \"determine the relative value of several indirect methods\"]\n[\"This study\", \"was undertaken to\", \"assess oxidant exposure in vivo\"]\n[\"assess oxidant exposure in vivo\", \"using\", \"indirect methods\"]\nGranularity: 3",
            "[\"Rats\", \"were subjected to\", \"a standardized intestinal ischemia - reperfusion injury\"]": " \n[\"Rats\", \"were subjected to\", \"intestinal ischemia\"]\n[\"Rats\", \"were subjected to\", \"reperfusion injury\"]\nGranularity: 2",
            "[\"Hepatic tissue\", \"was assayed for\", \"lipid peroxidation products and oxidized and reduced glutathione\"]": " \n[\"Hepatic tissue\", \"was assayed for\", \"lipid peroxidation products\"]\n[\"Hepatic tissue\", \"was assayed for\", \"oxidized glutathione\"]\n[\"Hepatic tissue\", \"was assayed for\", \"reduced glutathione\"]\nGranularity: 3",
            "[\"There was no change\", \"in\", \"hepatic tissue total glutathione following intestinal ischemia - reperfusion injury\"]": " \n[\"There was no change\", \"in\", \"hepatic tissue total glutathione\"]\n[\"following\", \"intestinal ischemia - reperfusion injury\"]\nGranularity: 2",
            "[\"Oxidized glutathione (GSSG)\", \"increased significantly following\", \"30 and 60 min of reperfusion\"]": " \n[\"Oxidized glutathione (GSSG)\", \"increased significantly following\", \"30 min of reperfusion\"]\n[\"Oxidized glutathione (GSSG)\", \"increased significantly following\", \"60 min of reperfusion\"]\nGranularity: 2",
            "[\"There was no increase\", \"in\", \"any of the products of lipid peroxidation associated with this injury\"]": " \n[\"There was no increase\", \"in\", \"products of lipid peroxidation\"]\n[\"There was no increase\", \"in\", \"products associated with this injury\"]\nGranularity: 2",
            "[\"An increase in GSSG\", \"within hepatic tissue during intestinal reperfusion\", \"suggests exposure of hepatocytes to an oxidant stress\"]": "\n[\"An increase in GSSG\", \"suggests\", \"exposure of hepatocytes to an oxidant stress\"]\n[\"An increase in GSSG\", \"within hepatic tissue\", \"during intestinal reperfusion\"]\n[\"exposure of hepatocytes\", \"to an oxidant stress\", \"during intestinal reperfusion\"]\nGranularity: 3",
            "[\"The lack of a significant increase\", \"in\", \"products of lipid peroxidation suggests that the oxidant stress is of insufficient magnitude to result in irreversible injury to hepatocyte cell membranes\"]": " \n[\"The lack of a significant increase\", \"suggests\", \"the oxidant stress is of insufficient magnitude\"]\n[\"the oxidant stress\", \"is of insufficient magnitude\", \"to result in irreversible injury to hepatocyte cell membranes\"]\nGranularity: 2",
            "[\"These data\", \"also suggest\", \"that the measurement of tissue GSSG may be a more sensitive indicator of oxidant stress than measurement of products of lipid peroxidation\"]": "\n[\"These data\", \"suggest\", \"measurement of tissue GSSG\"]\n[\"measurement of tissue GSSG\", \"may be\", \"a more sensitive indicator of oxidant stress\"]\n[\"measurement of products of lipid peroxidation\", \"may be\", \"a less sensitive indicator of oxidant stress\"]\nGranularity: 3"
      },
      "Blockade of endothelial - mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin - induced diabetic nephropathy .|OBJECTIVE : A multicenter , controlled trial showed that early blockade of the renin - angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy , suggesting that other mechanism ( s ) are involved in the pathogenesis of early diabetic nephropathy ( diabetic nephropathy ) .|We have previously demonstrated that endothelial - mesenchymal - transition ( EndoMT ) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin ( STZ ) - induced diabetes .|In the present study , we hypothesized that blocking EndoMT reduces the early development of diabetic nephropathy .|RESEARCH DESIGN AND METHODS : EndoMT was induced in a mouse pancreatic microvascular endothelial cell line ( MMEC ) in the presence of advanced glycation end products ( AGEs ) and in the endothelial lineage - traceble mouse line Tie2 - Cre ; Loxp - EGFP by administration of AGEs , with nonglycated mouse albumin serving as a control .|Phosphorylated Smad3 was detected by immunoprecipitation / Western blotting and confocal microscopy .|Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 ( SIS3 ) were performed in MMECs and in STZ - induced diabetic nephropathy in Tie2 - Cre ; Loxp - EGFP mice .|RESULTS : Confocal microscopy and real - time PCR demonstrated that AGEs induced EndoMT in MMECs and in Tie2 - Cre ; Loxp - EGFP mice .|Immunoprecipitation / Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ - induced diabetic nephropathy .|Confocal microscopy and real - time PCR further demonstrated that SIS3 abrogated EndoMT , reduced renal fibrosis , and retarded progression of nephropathy .|CONCLUSIONS : EndoMT is a novel pathway leading to early development of diabetic nephropathy .|Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other diabetes complications .": {
            "[\"diabetic nephropathy\", \"delayed\", \"early development\"]": " N/A (The triple is specific, conveying a singular relation between diabetic nephropathy and early development.)\nGranularity: 0",
            "[\"renin - angiotensin system\", \"blocked\", \"multicenter , controlled trial\"]": " \n[\"renin - angiotensin system\", \"blocked\", \"multicenter trial\"]\n[\"renin - angiotensin system\", \"blocked\", \"controlled trial\"]\nGranularity: 2",
            "[\"EndoMT\", \"contributes\", \"early development of renal interstitial fibrosis\"]": " \n[\"EndoMT\", \"contributes to\", \"early development\"]\n[\"EndoMT\", \"contributes to\", \"renal interstitial fibrosis\"]\nGranularity: 2",
            "[\"blocking EndoMT\", \"reduces\", \"early development of diabetic nephropathy\"]": " \n[\"blocking EndoMT\", \"reduces\", \"early development\"]\n[\"blocking EndoMT\", \"reduces\", \"diabetic nephropathy\"]\nGranularity: 2",
            "[\"EndoMT\", \"induced\", \"mouse pancreatic microvascular endothelial cell line\"]": " \n[\"EndoMT\", \"induced\", \"mouse pancreatic microvascular endothelial cell line\"]\nGranularity: 1",
            "[\"Phosphorylated Smad3\", \"detected\", \"immunoprecipitation / Western blotting and confocal microscopy\"]": " \n[\"Phosphorylated Smad3\", \"detected by\", \"immunoprecipitation / Western blotting\"]\n[\"Phosphorylated Smad3\", \"detected by\", \"confocal microscopy\"]\nGranularity: 2",
            "[\"blocking studies\", \"performed\", \"MMECs and in STZ - induced diabetic nephropathy\"]": " \n[\"blocking studies\", \"performed on\", \"MMECs\"]\n[\"blocking studies\", \"performed in\", \"STZ-induced diabetic nephropathy\"]\nGranularity: 2",
            "[\"AGEs\", \"induced\", \"EndoMT in MMECs and in Tie2 - Cre ; Loxp - EGFP mice\"]": " \n[\"AGEs\", \"induced\", \"EndoMT in MMECs\"]\n[\"AGEs\", \"induced\", \"EndoMT in Tie2 - Cre ; Loxp - EGFP mice\"]\nGranularity: 2",
            "[\"Smad3\", \"activated\", \"AGEs\"]": " \n[\"Smad3\", \"is activated by\", \"AGEs\"]\nGranularity: 1",
            "[\"Smad3\", \"inhibited\", \"SIS3\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"SIS3\", \"abrogated\", \"EndoMT\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"SIS3\", \"reduced\", \"renal fibrosis\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"SIS3\", \"retarded\", \"progression of nephropathy\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"EndoMT\", \"novel pathway\", \"early development of diabetic nephropathy\"]": " \n[\"EndoMT\", \"is a\", \"novel pathway\"]\n[\"EndoMT\", \"contributes to\", \"early development of diabetic nephropathy\"]\nGranularity: 2",
            "[\"Blockade of EndoMT by SIS3\", \"provides\", \"new strategy to retard the progression of diabetic nephropathy and other diabetes complications\"]": " \n[\"Blockade of EndoMT\", \"by SIS3\", \"retards the progression of diabetic nephropathy\"]\n[\"Blockade of EndoMT\", \"by SIS3\", \"retards the progression of other diabetes complications\"]\nGranularity: 2",
            "[\"Smad3 inhibitor\", \"blocks\", \"endothelial - mesenchymal transition\"]": "\n[\"Smad3 inhibitor\", \"blocks\", \"endothelial transition\"]\n[\"Smad3 inhibitor\", \"blocks\", \"mesenchymal transition\"]\nGranularity: 2"
      },
      "Reducing harm associated with anticoagulation : practical considerations of argatroban therapy in heparin - induced thrombocytopenia .|Argatroban is a hepatically metabolized , direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin - induced thrombocytopenia ( HIT ) and for patients with or at risk of HIT undergoing percutaneous coronary intervention ( PCI ) .|The objective of this review is to summarize practical considerations of argatroban therapy in HIT .|The US FDA - recommended argatroban dose in HIT is 2 microg / kg / min ( reduced in patients with hepatic impairment and in paediatric patients ) , adjusted to achieve activated partial thromboplastin times ( aPTTs ) 1 . 5 - 3 times baseline ( not > 100 seconds ) .|Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion , e . g .|heart failure , yet are unnecessary for renal dysfunction , adult age , sex , race / ethnicity or obesity .|Argatroban 0 . 5 - 1 . 2 microg / kg / min typically supports therapeutic aPTTs .|The FDA - recommended dose during PCI is 25 microg / kg / min ( 350 microg / kg initial bolus ) , adjusted to achieve activated clotting times ( ACTs ) of 300 - 450 sec .|For PCI , argatroban has not been investigated in hepatically impaired patients ; dose adjustment is unnecessary for adult age , sex , race / ethnicity or obesity , and lesser doses may be adequate with concurrent glycoprotein IIb / IIIa inhibition .|Argatroban prolongs the International Normalized Ratio , and published approaches for monitoring the argatroban - to - warfarin transition should be followed .|Major bleeding with argatroban is 0 - 10 % in the non - interventional setting and 0 - 5 . 8 % periprocedurally .|Argatroban has no specific antidote , and if excessive anticoagulation occurs , argatroban infusion should be stopped or reduced .|Improved familiarity of healthcare professionals with argatroban therapy in HIT , including in special populations and during PCI , may facilitate reduction of harm associated with HIT ( e . g . fewer thromboses ) or its treatment ( e . g . fewer argatroban medication errors ) .": {
            "[\"Reducing harm\", \"associated with\", \"anticoagulation\"]": " \n[\"Reducing harm\", \"associated with\", \"anticoagulation\"]\nGranularity: 1",
            "[\"Practical considerations\", \"of\", \"argatroban therapy\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Argatroban\", \"is a\", \"hepatically metabolized direct thrombin inhibitor\"]": " \n[\"Argatroban\", \"is\", \"hepatically metabolized\"]\n[\"Argatroban\", \"is\", \"a direct thrombin inhibitor\"]\nGranularity: 2",
            "[\"Argatroban\", \"used for\", \"prophylaxis or treatment of thrombosis\"]": " \n[\"Argatroban\", \"used for\", \"prophylaxis of thrombosis\"]\n[\"Argatroban\", \"used for\", \"treatment of thrombosis\"]\nGranularity: 2",
            "[\"Argatroban\", \"used for\", \"patients with or at risk of HIT\"]": " \n[\"Argatroban\", \"used for\", \"patients with HIT\"]\n[\"Argatroban\", \"used for\", \"patients at risk of HIT\"]\nGranularity: 2",
            "[\"Objective\", \"of this review\", \"to summarize practical considerations\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"FDA-recommended argatroban dose\", \"in HIT\", \"2 microg/kg/min\"]": " \n[\"FDA-recommended argatroban dose\", \"for HIT\", \"2 microg/kg/min\"]\n[\"FDA-recommended argatroban dose\", \"in HIT\", \"2 microg/kg\"]\n[\"FDA-recommended argatroban dose\", \"in HIT\", \"min\"]\nGranularity: 3",
            "[\"Adjusted dose\", \"to achieve\", \"activated partial thromboplastin times\"]": " \n[\"Adjusted dose\", \"to achieve\", \"activated partial thromboplastin times\"]\nGranularity: 1",
            "[\"Reduced doses\", \"also needed in\", \"patients with conditions associated with hepatic hypoperfusion\"]": " \n[\"Reduced doses\", \"also needed\", \"in patients with conditions associated with hepatic hypoperfusion\"]\nGranularity: 1",
            "[\"Unnecessary doses\", \"for\", \"renal dysfunction, adult age, sex, race/ethnicity or obesity\"]": "\n[\"Unnecessary doses\", \"for\", \"renal dysfunction\"]\n[\"Unnecessary doses\", \"for\", \"adult age\"]\n[\"Unnecessary doses\", \"for\", \"sex\"]\n[\"Unnecessary doses\", \"for\", \"race/ethnicity\"]\n[\"Unnecessary doses\", \"for\", \"obesity\"]\nGranularity: 5",
            "[\"Argatroban\", \"0.5-1.2 microg/kg/min\", \"typically supports therapeutic aPTTs\"]": " \n[\"Argatroban\", \"supports\", \"therapeutic aPTTs\"]\n[\"Argatroban\", \"has dosage range\", \"0.5-1.2 microg/kg/min\"]\nGranularity: 2",
            "[\"FDA-recommended dose\", \"during PCI\", \"25 microg/kg/min\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Adjusted dose\", \"to achieve\", \"activated clotting times\"]": " \n[\"Adjusted dose\", \"to achieve\", \"activated clotting times\"]\nGranularity: 1",
            "[\"Dose adjustment\", \"unnecessary for\", \"adult age, sex, race/ethnicity or obesity\"]": "\n[\"Dose adjustment\", \"unnecessary for\", \"adult age\"]\n[\"Dose adjustment\", \"unnecessary for\", \"sex\"]\n[\"Dose adjustment\", \"unnecessary for\", \"race/ethnicity\"]\n[\"Dose adjustment\", \"unnecessary for\", \"obesity\"]\nGranularity: 4",
            "[\"Lesser doses\", \"may be adequate with\", \"concurrent glycoprotein IIb/IIIa inhibition\"]": "\n[\"Lesser doses\", \"may be adequate\", \"with concurrent glycoprotein IIb/IIIa inhibition\"]\n[\"Lesser doses\", \"may be\", \"adequate with concurrent glycoprotein IIb/IIIa inhibition\"]\n[\"Lesser doses\", \"may be adequate with\", \"glycoprotein IIb/IIIa inhibition\"]\nGranularity: 3",
            "[\"Argatroban\", \"prolongs\", \"the International Normalized Ratio\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Published approaches\", \"for monitoring\", \"the argatroban-to-warfarin transition\"]": " \n[\"Published approaches\", \"for monitoring\", \"the argatroban-to-warfarin transition\"]\nGranularity: 1",
            "[\"Major bleeding\", \"with argatroban\", \"0-10% in the non-interventional setting\"]": " \n[\"Major bleeding\", \"with argatroban\", \"0-10%\"]\n[\"Major bleeding\", \"in the non-interventional setting\", \"0-10%\"]\n[\"argatroban\", \"in the non-interventional setting\", \"0-10%\"]\nGranularity: 3",
            "[\"Major bleeding\", \"periprocedurally\", \"0-5.8%\"]": " \n[\"Major bleeding\", \"occurs\", \"periprocedurally\"]\n[\"Major bleeding\", \"has a rate of\", \"0-5.8%\"]\nGranularity: 2",
            "[\"If excessive anticoagulation occurs\", \"argatroban infusion\", \"should be stopped or reduced\"]": " \n[\"If excessive anticoagulation occurs\", \"argatroban infusion\", \"should be stopped\"]\n[\"If excessive anticoagulation occurs\", \"argatroban infusion\", \"should be reduced\"]\nGranularity: 2",
            "[\"Improved familiarity\", \"of healthcare professionals\", \"with argatroban therapy\"]": "\n[\"Improved familiarity\", \"of healthcare professionals\", \"with argatroban\"]\n[\"healthcare professionals\", \"have improved familiarity\", \"with argatroban therapy\"]\nGranularity: 2",
            "[\"Facilitate reduction\", \"of harm\", \"associated with HIT or its treatment\"]": " \n[\"Facilitate reduction\", \"of harm\", \"associated with HIT\"]\n[\"Facilitate reduction\", \"of harm\", \"associated with its treatment\"]\nGranularity: 2"
      },
      "Ethambutol and optic neuropathy .|PURPOSE : To demonstrate the association between ethambutol and optic neuropathy .|METHOD : Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed .|The clinical characteristics and initial and final visual acuity were analyzed to determine visual outcome .|RESULTS : All patients had optic neuropathy between 1 to 6 months ( mean = 2 . 9 months ) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg / kg / day ( mean = 17 mg / kg / day ) .|Seven ( 54 % ) of the 13 patients experienced visual recovery after stopping the drug .|Of 6 patients with irreversible visual impairment , 4 patients had diabetes mellitus , glaucoma and a history of heavy smoking .|CONCLUSION : Early recognition of optic neuropathy should be considered in patients with ethambutol therapy .|A low dose and prompt discontinuation of the drug is recommended particularly in individuals with diabetes mellitus , glaucoma or who are heavy smokers .": {
            "[\"Ethambutol\", \"associated with\", \"optic neuropathy\"]": " N/A (The triple is specific, conveying a singular relation between Ethambutol and optic neuropathy.)\nGranularity: 0",
            "[\"Ethambutol\", \"causes\", \"optic neuropathy in patients with tuberculosis of the lung or lymph node\"]": " \n[\"Ethambutol\", \"causes\", \"optic neuropathy\"]\n[\"Ethambutol\", \"is used to treat\", \"tuberculosis of the lung\"]\n[\"Ethambutol\", \"is used to treat\", \"tuberculosis of the lymph node\"]\nGranularity: 3",
            "[\"Thirteen patients\", \"developed\", \"optic neuropathy after being treated with ethambutol\"]": " \n[\"Thirteen patients\", \"developed\", \"optic neuropathy\"]\n[\"Thirteen patients\", \"were treated with\", \"ethambutol\"]\nGranularity: 2",
            "[\"Ethambutol therapy\", \"started\", \"between 1 to 6 months after the onset of optic neuropathy\"]": " \n[\"Ethambutol therapy\", \"started\", \"between 1 to 6 months after the onset\"]\n[\"Ethambutol therapy\", \"started\", \"of optic neuropathy\"]\nGranularity: 2",
            "[\"Ethambutol therapy\", \"initiated\", \"at a dosage ranging from 13 to 20 mg / kg / day\"]": " \n[\"Ethambutol therapy\", \"initiated\", \"dosage\"]\n[\"Ethambutol therapy\", \"initiated\", \"range\"]\n[\"Ethambutol therapy\", \"initiated\", \"mg/kg/day\"]\nGranularity: 3",
            "[\"Seven patients\", \"experienced\", \"visual recovery after stopping the drug\"]": " \n[\"Seven patients\", \"experienced\", \"visual recovery\"]\n[\"Seven patients\", \"stopped\", \"the drug\"]\nGranularity: 2",
            "[\"Six patients\", \"suffered from\", \"irreversible visual impairment\"]": " \n[\"Six patients\", \"suffered from\", \"irreversible visual impairment\"]\nGranularity: 1",
            "[\"Four patients with irreversible visual impairment\", \"had\", \"diabetes mellitus, glaucoma and a history of heavy smoking\"]": " \n[\"Four patients\", \"had\", \"irreversible visual impairment\"]\n[\"Four patients\", \"had\", \"diabetes mellitus\"]\n[\"Four patients\", \"had\", \"glaucoma\"]\n[\"Four patients\", \"had\", \"a history of heavy smoking\"]\nGranularity: 4",
            "[\"Early recognition of optic neuropathy\", \"should be considered\", \"in patients with ethambutol therapy\"]": " \n[\"optic neuropathy\", \"should be considered\", \"in patients with ethambutol therapy\"]\n[\"early recognition\", \"should be considered\", \"in patients with ethambutol therapy\"]\n[\"early recognition\", \"should be considered\", \"in patients with ethambutol therapy\"]\nGranularity: 3",
            "[\"A low dose of ethambutol\", \"is recommended\", \"particularly in individuals with diabetes mellitus, glaucoma or who are heavy smokers\"]": " \n[\"A low dose of ethambutol\", \"is recommended\", \"in individuals with diabetes mellitus\"]\n[\"A low dose of ethambutol\", \"is recommended\", \"in individuals with glaucoma\"]\n[\"A low dose of ethambutol\", \"is recommended\", \"in heavy smokers\"]\nGranularity: 3"
      },
      "Acute interstitial nephritis due to nicergoline ( Sermion ) .|We report a case of acute interstitial nephritis ( AIN ) due to nicergoline ( Sermion ) .|A 50 - year - old patient admitted to our hospital for fever and acute renal failure .|Before admission , he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department .|Thereafter , he experienced intermittent fever and skin rash .|On admission , clinical symptoms ( i . e . arthralgia and fever ) and laboratory findings ( i . e . eosinophilia and renal failure ) suggested AIN , and which was confirmed by pathologic findings on renal biopsy .|A lymphocyte transformation test demonstrated a positive result against nicergoline .|Treatment was consisted of withdrawal of nicergoline and intravenous methylprednisolone , and his renal function was completely recovered .|To our knowledge , this is the first report of nicergoline - associated AIN .": {
            "[\"Acute interstitial nephritis\", \"due to\", \"nicergoline (Sermion)\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"A 50-year-old patient\", \"admitted to\", \"our hospital\"]": " \n[\"A 50-year-old patient\", \"admitted to\", \"our hospital\"]\nGranularity: 1",
            "[\"Patient\", \"admitted for\", \"fever and acute renal failure\"]": " \n[\"Patient\", \"admitted for\", \"fever\"]\n[\"Patient\", \"admitted for\", \"acute renal failure\"]\nGranularity: 2",
            "[\"Patient\", \"had been taking\", \"nicergoline and bendazac lysine\"]": " \n[\"Patient\", \"had been taking\", \"nicergoline\"]\n[\"Patient\", \"had been taking\", \"bendazac lysine\"]\nGranularity: 2",
            "[\"Nicergoline and bendazac lysine\", \"taken due to\", \"retinal vein occlusion\"]": " \n[\"Nicergoline\", \"taken for\", \"retinal vein occlusion\"]\n[\"bendazac lysine\", \"taken for\", \"retinal vein occlusion\"]\nGranularity: 2",
            "[\"Patient\", \"experienced\", \"intermittent fever and skin rash\"]": " \n[\"Patient\", \"experienced\", \"intermittent fever\"]\n[\"Patient\", \"experienced\", \"skin rash\"]\nGranularity: 2",
            "[\"Clinical symptoms and laboratory findings\", \"suggested\", \"AIN\"]": " \n[\"Clinical symptoms\", \"suggested\", \"AIN\"]\n[\"Laboratory findings\", \"suggested\", \"AIN\"]\nGranularity: 2",
            "[\"AIN\", \"confirmed by\", \"pathologic findings on renal biopsy\"]": " \n[\"AIN\", \"confirmed by\", \"pathologic findings\"]\n[\"AIN\", \"confirmed by\", \"renal biopsy\"]\nGranularity: 2",
            "[\"Lymphocyte transformation test\", \"demonstrated\", \"a positive result against nicergoline\"]": "\n[\"Lymphocyte transformation test\", \"demonstrated\", \"positive result\"]\n[\"Lymphocyte transformation test\", \"demonstrated\", \"result against nicergoline\"]\nGranularity: 2",
            "[\"Treatment\", \"consisted of\", \"withdrawal of nicergoline and intravenous methylprednisolone\"]": " \n[\"Treatment\", \"consisted of\", \"withdrawal of nicergoline\"]\n[\"Treatment\", \"consisted of\", \"intravenous methylprednisolone\"]\nGranularity: 2",
            "[\"Treatment\", \"led to\", \"complete recovery of renal function\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"This report\", \"the first of\", \"nicergoline-associated AIN\"]": " \n[\"This report\", \"is the first of\", \"nicergoline-associated AIN\"]\nGranularity: 1"
      },
      "Convulsion following intravenous fluorescein angiography .|Tonic - clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47 - year - old male .|Despite precautions this adverse reaction recurred on re - exposure to intravenous fluorescein .": {
            "[\"Tonic - clonic seizures\", \"followed\", \"intravenous fluorescein injection\"]": "\n[\"Tonic - clonic seizures\", \"followed by\", \"intravenous fluorescein injection\"]\n[\"Tonic - clonic seizures\", \"followed by\", \"intravenous injection\"]\n[\"Tonic - clonic seizures\", \"followed by\", \"fluorescein injection\"]\nGranularity: 3",
            "[\"adverse reaction\", \"recurring\", \"re - exposure to intravenous fluorescein\"]": " \n[\"adverse reaction\", \"recurring\", \"re-exposure\"]\n[\"adverse reaction\", \"recurring\", \"intravenous fluorescein\"]\nGranularity: 2",
            "[\"Convulsion\", \"following\", \"intravenous fluorescein angiography\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "An integrated characterization of serological , pathological , and functional events in doxorubicin - induced cardiotoxicity .|Many efficacious cancer treatments cause significant cardiac morbidity , yet biomarkers or functional indices of early damage , which would allow monitoring and intervention , are lacking .|In this study , we have utilized a rat model of progressive doxorubicin ( DOX ) - induced cardiomyopathy , applying multiple approaches , including cardiac magnetic resonance imaging ( MRI ) , to provide the most comprehensive characterization to date of the timecourse of serological , pathological , and functional events underlying this toxicity .|Hannover Wistar rats were dosed with 1 . 25 mg / kg DOX weekly for 8 weeks followed by a 4 week off - dosing \" recovery \" period .|Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose .|Histopathological analysis revealed progressive cardiomyocyte degeneration , hypertrophy / cytomegaly , and extensive vacuolation after two doses .|Extensive replacement fibrosis ( quantified by Sirius red staining ) developed during the off - dosing period .|Functional indices assessed by cardiac MRI ( including left ventricular ejection fraction ( LVEF ) , cardiac output , and E / A ratio ) declined progressively , reaching statistical significance after two doses and culminating in \" clinical \" LV dysfunction by 12 weeks .|Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I ( cTnI ) emerged after eight doses , importantly preceding the LVEF decline to < 50 % .|Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement , histopathological grading , and diastolic dysfunction .|In summary , subcellular cardiomyocyte degeneration was the earliest marker , followed by progressive functional decline and histopathological manifestations .|Myocardial contrast enhancement and elevations in cTnI occurred later .|However , all indices predated \" clinical \" LV dysfunction and thus warrant further evaluation as predictive biomarkers .": {
            "[\"An integrated characterization\", \"of\", \"serological, pathological, and functional events\"]": " \n[\"An integrated characterization\", \"of\", \"serological events\"]\n[\"An integrated characterization\", \"of\", \"pathological events\"]\n[\"An integrated characterization\", \"of\", \"functional events\"]\nGranularity: 3",
            "[\"Many efficacious cancer treatments\", \"cause\", \"significant cardiac morbidity\"]": "\n[\"Many efficacious cancer treatments\", \"cause\", \"cardiac morbidity\"]\n[\"Many efficacious cancer treatments\", \"cause\", \"significant morbidity\"]\nGranularity: 2",
            "[\"biomarkers or functional indices\", \"of\", \"early damage\"]": " \n[\"biomarkers\", \"of\", \"early damage\"]\n[\"functional indices\", \"of\", \"early damage\"]\nGranularity: 2",
            "[\"In this study\", \"we have utilized\", \"a rat model\"]": " \n[\"In this study\", \"utilized\", \"rat model\"]\nGranularity: 1",
            "[\"cardiac magnetic resonance imaging (MRI)\", \"applying\", \"multiple approaches\"]": " \n[\"cardiac magnetic resonance imaging (MRI)\", \"applying\", \"multiple approaches\"]\nGranularity: 1",
            "[\"Hannover Wistar rats\", \"were dosed\", \"1.25 mg/kg DOX weekly\"]": "\n[\"Hannover Wistar rats\", \"were dosed\", \"1.25 mg/kg DOX\"]\n[\"Hannover Wistar rats\", \"were dosed\", \"weekly\"]\nGranularity: 2",
            "[\"Electron microscopy\", \"revealed\", \"subcellular degeneration\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Histopathological analysis\", \"revealed\", \"progressive cardiomyocyte degeneration\"]": " \n[\"Histopathological analysis\", \"revealed\", \"cardiomyocyte degeneration\"]\n[\"Histopathological analysis\", \"revealed\", \"progressive degeneration\"]\nGranularity: 2",
            "[\"Extensive replacement fibrosis\", \"developed\", \"during the off-dosing period\"]": " \n[\"Extensive replacement fibrosis\", \"developed\", \"during the off-dosing period\"]\nGranularity: 1",
            "[\"Functional indices\", \"assessed by\", \"cardiac MRI\"]": " \n[\"Functional indices\", \"assessed by\", \"cardiac MRI\"]\nGranularity: 1",
            "[\"Significant increases\", \"in\", \"peak myocardial contrast enhancement\"]": " \n[\"Significant increases\", \"in\", \"peak enhancement\"]\n[\"Significant increases\", \"in\", \"myocardial contrast\"]\nGranularity: 2",
            "[\"Troponin I levels\", \"positively correlated with\", \"delayed and peak gadolinium contrast enhancement\"]": " \n[\"Troponin I levels\", \"correlate positively with\", \"delayed gadolinium contrast enhancement\"]\n[\"Troponin I levels\", \"correlate positively with\", \"peak gadolinium contrast enhancement\"]\nGranularity: 2",
            "[\"In summary\", \"subcellular cardiomyocyte degeneration\", \"was the earliest marker\"]": " N/A (The triple is specific, conveying a singular relation between \"In summary\" and \"subcellular cardiomyocyte degeneration\".)\nGranularity: 0",
            "[\"Myocardial contrast enhancement\", \"and\", \"elevations in cTnI\"]": " \n[\"Myocardial contrast enhancement\", \"is associated with\", \"elevations in cTnI\"]\nGranularity: 1",
            "[\"All indices\", \"predated\", \"\\\"clinical\\\" LV dysfunction\"]": " \n[\"All indices\", \"predated\", \"LV dysfunction\"]\n[\"All indices\", \"predated\", \"\\\"clinical\\\" LV dysfunction\"]\nGranularity: 2"
      },
      "Effects of the intracoronary infusion of cocaine on left ventricular systolic and diastolic function in humans .|BACKGROUND : In dogs , a large amount of intravenous cocaine causes a profound deterioration of left ventricular ( LV ) systolic function and an increase in LV end - diastolic pressure .|This study was done to assess the influence of a high intracoronary cocaine concentration on LV systolic and diastolic function in humans .|METHODS AND RESULTS : In 20 patients ( 14 men and 6 women aged 39 to 72 years ) referred for cardiac catheterization for the evaluation of chest pain , we measured heart rate , systemic arterial pressure , LV pressure and its first derivative ( dP / dt ) , and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15 - minute intracoronary infusion of saline ( n = 10 , control subjects ) or cocaine hydrochloride 1 mg / min ( n = 10 ) .|No variable changed with saline .|With cocaine , the drug concentration in blood obtained from the coronary sinus was 3 . 0 + / - 0 . 4 ( mean + / - SD ) mg / L , similar in magnitude to the blood cocaine concentration reported in abusers dying of cocaine intoxication .|Cocaine induced no significant change in heart rate , LV dP / dt ( positive or negative ) , or LV end - diastolic volume , but it caused an increase in systolic and mean arterial pressures , LV end - diastolic pressure , and LV end - systolic volume , as well as a decrease in LV ejection fraction .|CONCLUSIONS : In humans , the intracoronary infusion of cocaine sufficient in amount to achieve a high drug concentration in coronary sinus blood causes a deterioration of LV systolic and diastolic performance .": {
            "[\"intracoronary infusion of cocaine\", \"effects on\", \"left ventricular systolic and diastolic function\"]": " \n[\"intracoronary infusion of cocaine\", \"affects\", \"left ventricular systolic function\"]\n[\"intracoronary infusion of cocaine\", \"affects\", \"left ventricular diastolic function\"]\nGranularity: 2",
            "[\"Background\", \"causes\", \"profound deterioration of left ventricular systolic function\"]": " \n[\"Background\", \"causes\", \"deterioration of left ventricular systolic function\"]\n[\"Background\", \"causes\", \"profound deterioration\"]\nGranularity: 2",
            "[\"This study\", \"assess\", \"influence of high intracoronary cocaine concentration\"]": " \n[\"This study\", \"assess\", \"influence of high intracoronary cocaine concentration\"]\nGranularity: 1",
            "[\"METHODS AND RESULTS\", \"measured\", \"heart rate, systemic arterial pressure, LV pressure and its first derivative, and LV volumes and ejection fraction\"]": " \n[\"METHODS AND RESULTS\", \"measured\", \"heart rate\"]\n[\"METHODS AND RESULTS\", \"measured\", \"systemic arterial pressure\"]\n[\"METHODS AND RESULTS\", \"measured\", \"LV pressure\"]\n[\"METHODS AND RESULTS\", \"measured\", \"LV pressure first derivative\"]\n[\"METHODS AND RESULTS\", \"measured\", \"LV volumes\"]\n[\"METHODS AND RESULTS\", \"measured\", \"LV ejection fraction\"]\nGranularity: 6",
            "[\"No variable\", \"changed with\", \"saline\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"With cocaine\", \"induced\", \"significant change in heart rate, LV dP/dt, or LV end-diastolic volume\"]": " \n[\"With cocaine\", \"induced\", \"significant change in heart rate\"]\n[\"With cocaine\", \"induced\", \"significant change in LV dP/dt\"]\n[\"With cocaine\", \"induced\", \"significant change in LV end-diastolic volume\"]\nGranularity: 3",
            "[\"With cocaine\", \"caused\", \"increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume\"]": " \n[\"With cocaine\", \"caused\", \"increase in systolic pressure\"]\n[\"With cocaine\", \"caused\", \"increase in mean arterial pressure\"]\n[\"With cocaine\", \"caused\", \"increase in LV end-diastolic pressure\"]\n[\"With cocaine\", \"caused\", \"increase in LV end-systolic volume\"]\nGranularity: 4",
            "[\"With cocaine\", \"decreased\", \"LV ejection fraction\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"CONCLUSIONS\", \"causes\", \"deterioration of LV systolic and diastolic performance\"]": " \n[\"CONCLUSIONS\", \"cause\", \"deterioration of LV systolic performance\"]\n[\"CONCLUSIONS\", \"cause\", \"deterioration of LV diastolic performance\"]\nGranularity: 2"
      },
      "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration .|BACKGROUND : Succinylcholine commonly produces frequent adverse effects , including muscle fasciculation and myalgia .|The current study identified the optimal dose of rocuronium to prevent succinylcholine - induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine .|METHODS : This randomized , double - blinded study was conducted in 100 patients randomly allocated into five groups of 20 patients each .|Patients were randomized to receive 0 . 02 , 0 . 03 , 0 . 04 , 0 . 05 and 0 . 06 mg / kg rocuronium as a precurarizing dose .|Neuromuscular monitoring after each precurarizing dose was recorded from the adductor pollicis muscle using acceleromyography with train - of - four stimulation of the ulnar nerve .|All patients received succinylcholine 1 . 5 mg / kg at 2 minutes after the precurarization , and were assessed the incidence and severity of fasciculations , while myalgia was assessed at 24 hours after surgery .|RESULTS : The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of rocuronium ( P < 0 . 001 ) .|Those of myalgia tend to decrease according to increasing the amount of precurarizing dose of rocuronium , but there was no significance ( P = 0 . 072 ) .|The onset time of succinylcholine was significantly longer with increasing the amount of precurarizing dose of rocuronium ( P < 0 . 001 ) .|CONCLUSIONS : Precurarization with 0 . 04 mg / kg rocuronium was the optimal dose considering the reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time , and the safe and effective precurarization .": {
            "[\"Optimal precurarizing dose of rocuronium\", \"decrease\", \"fasciculation and myalgia following succinylcholine administration\"]": " \n[\"Optimal precurarizing dose of rocuronium\", \"decrease\", \"fasciculation\"]\n[\"Optimal precurarizing dose of rocuronium\", \"decrease\", \"myalgia\"]\n[\"succinylcholine administration\", \"causes\", \"fasciculation\"]\n[\"succinylcholine administration\", \"causes\", \"myalgia\"]\nGranularity: 4",
            "[\"Succinylcholine\", \"produces\", \"frequent adverse effects\"]": " \n[\"Succinylcholine\", \"produces\", \"adverse effects\"]\n[\"Succinylcholine\", \"produces\", \"frequent effects\"]\nGranularity: 2",
            "[\"Succinylcholine\", \"induces\", \"muscle fasciculation and myalgia\"]": " \n[\"Succinylcholine\", \"induces\", \"muscle fasciculation\"]\n[\"Succinylcholine\", \"induces\", \"myalgia\"]\nGranularity: 2",
            "[\"Current study\", \"identified\", \"optimal dose of rocuronium\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Current study\", \"evaluated\", \"influence of rocuronium on the speed of onset produced by succinylcholine\"]": " \n[\"Current study\", \"evaluated\", \"influence of rocuronium\"]\n[\"Current study\", \"evaluated\", \"speed of onset produced by succinylcholine\"]\n[\"influence of rocuronium\", \"on\", \"speed of onset produced by succinylcholine\"]\nGranularity: 3",
            "[\"Study\", \"conducted\", \"100 patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patients\", \"randomly allocated\", \"five groups of 20 patients each\"]": " \n[\"Patients\", \"randomly allocated\", \"five groups\"]\n[\"Patients\", \"randomly allocated\", \"20 patients\"]\nGranularity: 2",
            "[\"Patients\", \"received\", \"0.02, 0.03, 0.04, 0.05 and 0.06 mg/kg rocuronium as a precurarizing dose\"]": "\n[\"Patients\", \"received\", \"0.02 mg/kg rocuronium\"]\n[\"Patients\", \"received\", \"0.03 mg/kg rocuronium\"]\n[\"Patients\", \"received\", \"0.04 mg/kg rocuronium\"]\n[\"Patients\", \"received\", \"0.05 mg/kg rocuronium\"]\n[\"Patients\", \"received\", \"0.06 mg/kg rocuronium\"]\nGranularity: 5",
            "[\"Neuromuscular monitoring\", \"recorded\", \"from the adductor pollicis muscle using acceleromyography with train-of-four stimulation of the ulnar nerve\"]": " \n[\"Neuromuscular monitoring\", \"recorded from\", \"adductor pollicis muscle\"]\n[\"Neuromuscular monitoring\", \"used acceleromyography with\", \"train-of-four stimulation\"]\n[\"train-of-four stimulation\", \"applied to\", \"ulnar nerve\"]\nGranularity: 3",
            "[\"All patients\", \"received\", \"succinylcholine 1.5 mg/kg at 2 minutes after the precurarization\"]": " \n[\"All patients\", \"received\", \"succinylcholine\"]\n[\"All patients\", \"received\", \"1.5 mg/kg\"]\n[\"All patients\", \"received\", \"at 2 minutes after the precurarization\"]\nGranularity: 3",
            "[\"Patients\", \"assessed\", \"incidence and severity of fasciculations\"]": " \n[\"Patients\", \"assessed\", \"incidence of fasciculations\"]\n[\"Patients\", \"assessed\", \"severity of fasciculations\"]\nGranularity: 2",
            "[\"Myalgia\", \"assessed\", \"24 hours after surgery\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Incidence and severity of visible muscle fasciculation\", \"decreased\", \"increasing the amount of precurarizing dose of rocuronium\"]": " \n[\"Incidence and severity of visible muscle fasciculation\", \"decreased\", \"increasing the amount of precurarizing dose\"]\n[\"Incidence and severity of visible muscle fasciculation\", \"decreased\", \"rocuronium\"]\nGranularity: 2",
            "[\"Those of myalgia\", \"tended to decrease\", \"increasing the amount of precurarizing dose of rocuronium\"]": " \n[\"Those of myalgia\", \"tended to decrease\", \"the amount of precurarizing dose of rocuronium\"]\n[\"Those of myalgia\", \"tended to increase\", \"the amount of precurarizing dose of rocuronium\"]\nGranularity: 2",
            "[\"Onset time of succinylcholine\", \"lengthened\", \"increasing the amount of precurarizing dose of rocuronium\"]": " \n[\"Onset time of succinylcholine\", \"lengthened\", \"increasing the amount of precurarizing dose\"]\n[\"Onset time of succinylcholine\", \"lengthened\", \"rocuronium\"]\nGranularity: 2",
            "[\"Precurarization with 0.04 mg/kg rocuronium\", \"considered\", \"optimal dose\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Precurarization with 0.04 mg/kg rocuronium\", \"provided\", \"reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time, and the safe and effective precurarization\"]": " \n[\"Precurarization\", \"with 0.04 mg/kg rocuronium\", \"reduced the incidence of fasciculation\"]\n[\"Precurarization\", \"with 0.04 mg/kg rocuronium\", \"reduced the severity of myalgia\"]\n[\"Precurarization\", \"with 0.04 mg/kg rocuronium\", \"had acceptable onset time\"]\n[\"Precurarization\", \"with 0.04 mg/kg rocuronium\", \"was safe and effective\"]\nGranularity: 4"
      },
      "Decreased Expression of Na / K - ATPase , NHE3 , NBC1 , AQP1 and OAT in Gentamicin - induced Nephropathy .|The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin - induced nephropathy .|Sprague - Dawley male rats ( 200~250 g ) were subcutaneously injected with gentamicin ( 100 mg / kg per day ) for 7 days , and the expression of tubular transporters was determined by immunoblotting and immunohistochemistry .|The mRNA and protein expression of OAT was also determined .|Gentamicin - treated rats exhibited significantly decreased creatinine clearance along with increased plasma creatinine levels .|Accordingly , the fractional excretion of sodium increased .|Urine volume was increased , while urine osmolality and free water reabsorption were decreased .|Immunoblotting and immunohistochemistry revealed decreased expression of Na ( + ) / K ( + ) - ATPase , NHE3 , NBC1 , and AQP1 in the kidney of gentamicin - treated rats .|The expression of OAT1 and OAT3 was also decreased .|Gentamicin - induced nephropathy may at least in part be causally related with a decreased expression of Na ( + ) / K ( + ) - ATPase , NHE3 , NBC1 , AQP1 and OAT .": {
            "[\"NHE3\", \"decreased in\", \"Gentamicin-induced nephropathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"NBC1\", \"decreased in\", \"Gentamicin-induced nephropathy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"AQP1\", \"decreased in\", \"Gentamicin-induced nephropathy\"]": " \n[\"AQP1\", \"decreased in\", \"Gentamicin-induced nephropathy\"]\nGranularity: 1",
            "[\"OAT\", \"decreased in\", \"Gentamicin-induced nephropathy\"]": " \n[\"OAT\", \"decreased in\", \"Gentamicin-induced nephropathy\"]\nGranularity: 1",
            "[\"study\", \"aimed to determine\", \"altered regulation of tubular transporters in gentamicin-induced nephropathy\"]": " \n[\"study\", \"aimed to determine\", \"altered regulation of tubular transporters\"]\n[\"study\", \"aimed to determine\", \"gentamicin-induced nephropathy\"]\nGranularity: 2",
            "[\"Sprague-Dawley male rats\", \"injected with\", \"gentamicin\"]": "\n[\"Sprague-Dawley male rats\", \"injected with\", \"gentamicin\"]\nGranularity: 1",
            "[\"expression of tubular transporters\", \"determined by\", \"immunoblotting and immunohistochemistry\"]": "\n[\"expression of tubular transporters\", \"determined by\", \"immunoblotting\"]\n[\"expression of tubular transporters\", \"determined by\", \"immunohistochemistry\"]\nGranularity: 2",
            "[\"mRNA and protein expression of OAT\", \"determined\", \"\\u2014\"]": " \n[\"mRNA and protein expression of OAT\", \"determined by\", \"experiment\"]\n[\"mRNA and protein expression of OAT\", \"determined by\", \"analysis\"]\nGranularity: 2",
            "[\"Gentamicin-treated rats\", \"exhibited\", \"decreased creatinine clearance and increased plasma creatinine levels\"]": " \n[\"Gentamicin-treated rats\", \"exhibited\", \"decreased creatinine clearance\"]\n[\"Gentamicin-treated rats\", \"exhibited\", \"increased plasma creatinine levels\"]\nGranularity: 2",
            "[\"fractional excretion of sodium\", \"increased\", \"\\u2014\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"urine volume\", \"increased\", \"\\u2014\"]": " N/A (The third element is missing, so no further granularity can be achieved.)\nGranularity: 0",
            "[\"urine osmolality\", \"decreased\", \"\\u2014\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"free water reabsorption\", \"decreased\", \"\\u2014\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"immunoblotting and immunohistochemistry\", \"revealed\", \"decreased expression of Na+/K+-ATPase, NHE3, NBC1, and AQP1 in the kidney of gentamicin-treated rats\"]": " \n[\"immunoblotting\", \"revealed\", \"decreased expression of Na+/K+-ATPase\"]\n[\"immunoblotting\", \"revealed\", \"decreased expression of NHE3\"]\n[\"immunoblotting\", \"revealed\", \"decreased expression of NBC1\"]\n[\"immunoblotting\", \"revealed\", \"decreased expression of AQP1\"]\n[\"immunohistochemistry\", \"revealed\", \"decreased expression of Na+/K+-ATPase\"]\n[\"immunohistochemistry\", \"revealed\", \"decreased expression of NHE3\"]\n[\"immunohistochemistry\", \"revealed\", \"decreased expression of NBC1\"]\n[\"immunohistochemistry\", \"revealed\", \"decreased expression of AQP1\"]\nGranularity: 8",
            "[\"expression of OAT1 and OAT3\", \"decreased\", \"\\u2014\"]": " \n[\"expression of OAT1\", \"decreased\", \"\\u2014\"]\n[\"expression of OAT3\", \"decreased\", \"\\u2014\"]\nGranularity: 2",
            "[\"Gentamicin-induced nephropathy\", \"may be causally related with\", \"decreased expression of Na+/K+-ATPase, NHE3, NBC1, AQP1 and OAT\"]": " \n[\"Gentamicin-induced nephropathy\", \"may be causally related with\", \"decreased expression of Na+/K+-ATPase\"]\n[\"Gentamicin-induced nephropathy\", \"may be causally related with\", \"decreased expression of NHE3\"]\n[\"Gentamicin-induced nephropathy\", \"may be causally related with\", \"decreased expression of NBC1\"]\n[\"Gentamicin-induced nephropathy\", \"may be causally related with\", \"decreased expression of AQP1\"]\n[\"Gentamicin-induced nephropathy\", \"may be causally related with\", \"decreased expression of OAT\"]\nGranularity: 5",
            "[\"Na / K - ATPase\", \"decreased in\", \"Gentamicin-induced nephropathy\"]": " \n[\"Na / K - ATPase\", \"decreased in\", \"Gentamicin-induced nephropathy\"]\nGranularity: 1"
      },
      "Efficacy and safety of granisetron , a selective 5 - hydroxytryptamine - 3 receptor antagonist , in the prevention of nausea and vomiting induced by high - dose cisplatin .|PURPOSE : To assess the antiemetic effects and safety profile of four different doses of granisetron ( Kytril ; SmithKline Beecham Pharmaceuticals , Philadelphia , PA ) when administered as a single intravenous ( IV ) dose for prophylaxis of cisplatin - induced nausea and vomiting .|PATIENTS AND METHODS : One hundred eighty - four chemotherapy - naive patients receiving high - dose cisplatin ( 81 to 120 mg / m2 ) were randomized to receive one of four granisetron doses ( 5 , 10 , 20 , or 40 micrograms / kg ) administered before chemotherapy .|Patients were observed on an inpatient basis for 18 to 24 hours , and vital signs , nausea , vomiting , retching , and appetite were assessed .|Safety analyses included incidence of adverse experiences and laboratory parameter changes .|RESULTS : After granisetron doses of 5 , 10 , 20 , and 40 micrograms / kg , a major response ( < or = two vomiting or retching episodes , and no antiemetic rescue ) was recorded in 23 % , 57 % , 58 % , and 60 % of patients , respectively , and a complete response ( no vomiting or retching , and no antiemetic rescue ) in 18 % , 41 % , 40 % , and 47 % of patients , respectively .|There was a statistically longer time to first episode of nausea ( P = . 0015 ) and vomiting ( P = . 0001 ) , and fewer patients were administered additional antiemetic medication in the 10 - micrograms / kg dosing groups than in the 5 - micrograms / kg dosing group .|As granisetron dose increased , appetite return increased ( P = . 040 ) .|Headache was the most frequently reported adverse event ( 20 % ) .|CONCLUSION : A single 10 - , 20 - , or 40 - micrograms / kg dose of granisetron was effective in controlling vomiting in 57 % to 60 % of patients who received cisplatin at doses greater than 81 mg / m2 and totally prevented vomiting in 40 % to 47 % of patients .|There were no statistically significant differences in efficacy between the 10 - micrograms / kg dose and the 20 - and 40 - micrograms / kg doses .|Granisetron was well tolerated at all doses .": {
            "[\"granisetron\", \"is a\", \"selective 5-hydroxytryptamine-3 receptor antagonist\"]": " \n[\"granisetron\", \"is a\", \"selective 5-hydroxytryptamine-3 receptor\"]\n[\"granisetron\", \"is a\", \"antagonist\"]\nGranularity: 2",
            "[\"granisetron\", \"prevents\", \"nausea and vomiting induced by high-dose cisplatin\"]": " \n[\"granisetron\", \"prevents\", \"nausea\"]\n[\"granisetron\", \"prevents\", \"vomiting\"]\n[\"granisetron\", \"prevents\", \"nausea and vomiting\"]\n[\"granisetron\", \"prevents\", \"nausea and vomiting induced by high-dose cisplatin\"]\nGranularity: 4",
            "[\"study\", \"assesses\", \"antiemetic effects and safety profile of granisetron\"]": " \n[\"study\", \"assesses\", \"antiemetic effects\"]\n[\"study\", \"assesses\", \"safety profile\"]\n[\"study\", \"assesses\", \"granisetron\"]\nGranularity: 3",
            "[\"patients\", \"receive\", \"high-dose cisplatin\"]": " N/A (The triple is specific, conveying a singular relation between patients and high-dose cisplatin.)\nGranularity: 0",
            "[\"granisetron\", \"administered as\", \"single intravenous dose\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"granisetron\", \"doses\", \"5, 10, 20, or 40 micrograms/kg\"]": " \n[\"granisetron\", \"has doses of\", \"5 micrograms/kg\"]\n[\"granisetron\", \"has doses of\", \"10 micrograms/kg\"]\n[\"granisetron\", \"has doses of\", \"20 micrograms/kg\"]\n[\"granisetron\", \"has doses of\", \"40 micrograms/kg\"]\nGranularity: 4",
            "[\"patients\", \"randomized\", \"to receive one of four granisetron doses\"]": " \n[\"patients\", \"randomized\", \"to receive granisetron\"]\n[\"patients\", \"randomized\", \"to receive one of four doses\"]\nGranularity: 2",
            "[\"safety analyses\", \"include\", \"incidence of adverse experiences and laboratory parameter changes\"]": " \n[\"safety analyses\", \"include\", \"incidence of adverse experiences\"]\n[\"safety analyses\", \"include\", \"laboratory parameter changes\"]\nGranularity: 2",
            "[\"major response\", \"recorded in\", \"23%, 57%, 58%, and 60% of patients\"]": " \n[\"major response\", \"recorded in\", \"23% of patients\"]\n[\"major response\", \"recorded in\", \"57% of patients\"]\n[\"major response\", \"recorded in\", \"58% of patients\"]\n[\"major response\", \"recorded in\", \"60% of patients\"]\nGranularity: 4",
            "[\"complete response\", \"recorded in\", \"18%, 41%, 40%, and 47% of patients\"]": " \n[\"complete response\", \"recorded in\", \"18% of patients\"]\n[\"complete response\", \"recorded in\", \"41% of patients\"]\n[\"complete response\", \"recorded in\", \"40% of patients\"]\n[\"complete response\", \"recorded in\", \"47% of patients\"]\nGranularity: 4",
            "[\"time to first episode of nausea\", \"longer\", \"P = .0015\"]": "\n[\"time to first episode of nausea\", \"is longer\", \"P = .0015\"]\nGranularity: 1",
            "[\"time to first episode of vomiting\", \"longer\", \"P = .0001\"]": " \n[\"time to first episode of vomiting\", \"is longer\", \"P = .0001\"]\nGranularity: 1",
            "[\"additional antiemetic medication\", \"fewer patients administered\", \"10-micrograms/kg dosing groups\"]": "\n[\"additional antiemetic medication\", \"fewer patients administered\", \"10-micrograms/kg dosing group\"]\nGranularity: 1",
            "[\"granisetron dose\", \"increased\", \"appetite return increased\"]": "\n[\"granisetron dose\", \"increased\", \"appetite return\"]\n[\"appetite return\", \"increased\", \"appetite return increased\"]\nGranularity: 2",
            "[\"headache\", \"most frequently reported\", \"adverse event\"]": " N/A (The triple is specific, conveying a singular relation between headache and adverse events.)\nGranularity: 0",
            "[\"granisetron\", \"effective in controlling vomiting\", \"57% to 60% of patients\"]": " \n[\"granisetron\", \"controls\", \"vomiting\"]\n[\"granisetron\", \"is effective for\", \"57% to 60% of patients\"]\nGranularity: 2",
            "[\"granisetron\", \"totally prevented vomiting\", \"40% to 47% of patients\"]": "\n[\"granisetron\", \"prevented vomiting\", \"40% of patients\"]\n[\"granisetron\", \"prevented vomiting\", \"47% of patients\"]\nGranularity: 2",
            "[\"10-micrograms/kg dose\", \"as effective as\", \"20- and 40-micrograms/kg doses\"]": " \n[\"10-micrograms/kg dose\", \"is as effective as\", \"20-micrograms/kg dose\"]\n[\"10-micrograms/kg dose\", \"is as effective as\", \"40-micrograms/kg dose\"]\nGranularity: 2"
      },
      "Acute hepatitis associated with clopidogrel : a case report and review of the literature .|Drug - induced hepatotoxicity is a common cause of acute hepatitis , and the recognition of the responsible drug may be difficult .|We describe a case of clopidogrel - related acute hepatitis .|The diagnosis is strongly suggested by an accurate medical history and liver biopsy .|Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years , after the increased use of this drug .|In conclusion , we believe that physicians should carefully consider the risk of drug - induced hepatic injury when clopidogrel is prescribed .": {
            "[\"Acute hepatitis\", \"associated with\", \"clopidogrel\"]": " N/A (The triple is specific, conveying a singular relation between acute hepatitis and clopidogrel.)\nGranularity: 0",
            "[\"Drug-induced hepatotoxicity\", \"is a common cause of\", \"acute hepatitis\"]": "\n[\"Drug-induced hepatotoxicity\", \"is a cause of\", \"acute hepatitis\"]\n[\"Drug-induced hepatotoxicity\", \"is a common cause of\", \"hepatitis\"]\n[\"Drug-induced hepatotoxicity\", \"is a common cause of\", \"acute\"]\n[\"Drug-induced hepatotoxicity\", \"is a common cause of\", \"hepatotoxicity\"]\nGranularity: 4",
            "[\"Recognition of the responsible drug\", \"may be\", \"difficult\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Case\", \"of\", \"clopidogrel-related acute hepatitis\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Diagnosis\", \"is suggested by\", \"accurate medical history and liver biopsy\"]": " \n[\"Diagnosis\", \"is suggested by\", \"accurate medical history\"]\n[\"Diagnosis\", \"is suggested by\", \"liver biopsy\"]\nGranularity: 2",
            "[\"Reports\", \"are increasing\", \"in the last few years\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Increased use\", \"of\", \"this drug\"]": " N/A (The triple is not specific enough to be split into sub-triples. The object of the sentence, \"this drug\", is not specified and therefore cannot be broken down further.)\nGranularity: 0",
            "[\"Physicians\", \"should consider\", \"the risk of drug-induced hepatic injury\"]": " \n[\"Physicians\", \"should consider\", \"risk\"]\n[\"Physicians\", \"should consider\", \"drug-induced hepatic injury\"]\nGranularity: 2",
            "[\"When\", \"clopidogrel is prescribed\", \"\"]": " N/A (The triple is not specific enough to be split into sub-triples. The missing object can vary and does not provide enough information to create meaningful sub-triples.)\nGranularity: 0"
      },
      "Damage of substantia nigra pars reticulata during pilocarpine - induced status epilepticus in the rat : immunohistochemical study of neurons , astrocytes and serum - protein extravasation .|The substantia nigra has a gating function controlling the spread of epileptic seizure activity .|Additionally , in models of prolonged status epilepticus the pars reticulata of substantia nigra ( SNR ) suffers from a massive lesion which may arise from a massive metabolic derangement and hyperexcitation developing in the activated SNR .|In this study , status epilepticus was induced by systemic injection of pilocarpine in rats .|The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time - course of changes in neurons and astrocytes .|Animals surviving 20 , 30 , 40 , 60 min , 2 , 3 , 6 hours , 1 , 2 , and 3 days after induction of status epilepticus were perfusion - fixed , and brains processed for immunohistochemical staining of SNR .|Nissl - staining and antibodies against the neuron - specific calcium - binding protein , parvalbumin , served to detect neuronal damage in SNR .|Antibodies against the astroglia - specific cytoskeletal protein , glial fibrillary acidic protein ( GFAP ) , and against the glial calcium - binding protein , S - 100 protein , were used to assess the status of astrocytes .|Immunohistochemical staining for serum - albumin and immunoglobulins in brain tissue was taken as indicator of blood - brain barrier disturbances and vasogenic edema formation .|Immunohistochemical staining indicated loss of GFAP - staining already at 30 min after induction of seizures in an oval focus situated in the center of SNR while sparing medial and lateral aspects .|At 1 h there was additional vacuolation in S - 100 protein staining .|By 2 hours , parvalbumin - staining changed in the central SNR indicating neuronal damage , and Nissl - staining visualized some neuronal distortion .|Staining for serum - proteins occurred in a patchy manner throughout the forebrain during the first hours .|By 6 h , vasogenic edema covered the lesioned SNR .|By 24 h , glial and neuronal markers indicated a massive lesion in the center of SNR .|By 48 - 72 h , astrocytes surrounding the lesion increased in size , and polymorphic phagocytotic cells invaded the damaged area .|In a further group of animals surviving 1 to 5 days , conventional paraffin - sections confirmed the neuronal and glial damage of SNR .|Additional pathology of similar quality was found in the globus pallidus .|Since astrocytes were always damaged in parallel with neurons in SNR it is proposed that the anatomical and functional interrelationship between neurons and astrocytes is particularly tight in SNR .|Both cell elements may suffer in common from metabolic disturbance and neurotransmitter dysfunction as occur during massive status epilepticus .": {
            "[\"Damage\", \"occurs in\", \"substantia nigra pars reticulata\"]": " \n[\"Damage\", \"occurs in\", \"substantia nigra\"]\n[\"Damage\", \"occurs in\", \"pars reticulata\"]\nGranularity: 2",
            "[\"Substantia nigra\", \"has a gating function\", \"controlling the spread of epileptic seizure activity\"]": " \n[\"Substantia nigra\", \"has\", \"gating function\"]\n[\"gating function\", \"controls\", \"spread of epileptic seizure activity\"]\nGranularity: 2",
            "[\"Pars reticulata\", \"suffers from\", \"massive lesion\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Massive lesion\", \"may arise from\", \"massive metabolic derangement and hyperexcitation\"]": " \n[\"Massive lesion\", \"may arise from\", \"massive metabolic derangement\"]\n[\"Massive lesion\", \"may arise from\", \"hyperexcitation\"]\nGranularity: 2",
            "[\"Status epilepticus\", \"was induced by\", \"systemic injection of pilocarpine\"]": " \n[\"Status epilepticus\", \"was induced by\", \"systemic injection\"]\n[\"systemic injection\", \"induced\", \"pilocarpine\"]\nGranularity: 2",
            "[\"Neuropathology\", \"was investigated\", \"using immunohistochemical techniques\"]": "\n[\"Neuropathology\", \"was investigated\", \"using immunohistochemical techniques\"]\nGranularity: 0",
            "[\"Time-course of changes\", \"was investigated\", \"in neurons and astrocytes\"]": " \n[\"Time-course\", \"was investigated\", \"in neurons\"]\n[\"Time-course\", \"was investigated\", \"in astrocytes\"]\nGranularity: 2",
            "[\"Animals\", \"were perfusion-fixed\", \"and brains processed for immunohistochemical staining\"]": " \n[\"Animals\", \"were perfusion-fixed\", \"brains\"]\n[\"brains\", \"were processed for\", \"immunohistochemical staining\"]\nGranularity: 2",
            "[\"SNR\", \"was stained\", \"with antibodies against the neuron-specific calcium-binding protein\"]": " \n[\"SNR\", \"was stained\", \"with antibodies\"]\n[\"antibodies\", \"were used to stain\", \"the neuron-specific calcium-binding protein\"]\nGranularity: 2",
            "[\"Astrocytes\", \"were assessed\", \"using antibodies against the astroglia-specific cytoskeletal protein\"]": " \n[\"Astrocytes\", \"were assessed\", \"using antibodies\"]\n[\"Astrocytes\", \"were assessed\", \"against the astroglia-specific cytoskeletal protein\"]\nGranularity: 2",
            "[\"Blood-brain barrier disturbances\", \"were indicated by\", \"immunohistochemical staining for serum-albumin and immunoglobulins\"]": " \n[\"Blood-brain barrier disturbances\", \"were indicated by\", \"immunohistochemical staining for serum-albumin\"]\n[\"Blood-brain barrier disturbances\", \"were indicated by\", \"immunohistochemical staining for immunoglobulins\"]\nGranularity: 2",
            "[\"Loss of GFAP-staining\", \"occurred\", \"at 30 min after induction of seizures\"]": " \n[\"Loss of GFAP-staining\", \"occurred\", \"at 30 min\"]\n[\"Loss of GFAP-staining\", \"occurred\", \"after induction of seizures\"]\nGranularity: 2",
            "[\"Additional vacuolation\", \"occurred\", \"in S-100 protein staining at 1 h\"]": " \n[\"Additional vacuolation\", \"occurred\", \"in S-100 protein staining\"]\n[\"in S-100 protein staining\", \"at\", \"1 h\"]\nGranularity: 2",
            "[\"Neuronal damage\", \"occurred\", \"in the central SNR by 2 hours\"]": " \n[\"Neuronal damage\", \"occurred\", \"in the central SNR\"]\n[\"Neuronal damage\", \"occurred\", \"by 2 hours\"]\nGranularity: 2",
            "[\"Staining for serum-proteins\", \"occurred\", \"in a patchy manner throughout the forebrain\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Vasogenic edema\", \"covered\", \"the lesioned SNR by 6 h\"]": " \n[\"Vasogenic edema\", \"covered\", \"the lesioned SNR\"]\n[\"Vasogenic edema\", \"covered\", \"by 6 h\"]\nGranularity: 2",
            "[\"Massive lesion\", \"was indicated\", \"in the center of SNR by 24 h\"]": " \n[\"Massive lesion\", \"was indicated\", \"in the center of SNR\"]\n[\"in the center of SNR\", \"by\", \"24 h\"]\nGranularity: 2",
            "[\"Astrocytes\", \"increased in size\", \"surrounding the lesion by 48-72 h\"]": "\n[\"Astrocytes\", \"increased in size\", \"surrounding the lesion\"]\n[\"Astrocytes\", \"increased in size\", \"by 48-72 h\"]\nGranularity: 2",
            "[\"Polymorphic phagocytotic cells\", \"invaded\", \"the damaged area by 48-72 h\"]": " \n[\"Polymorphic phagocytotic cells\", \"invaded\", \"the damaged area\"]\n[\"Polymorphic phagocytotic cells\", \"invaded\", \"within 48-72 h\"]\nGranularity: 2",
            "[\"Neuronal and glial damage\", \"was confirmed\", \"in the globus pallidus\"]": " \n[\"Neuronal damage\", \"was confirmed\", \"in the globus pallidus\"]\n[\"Glial damage\", \"was confirmed\", \"in the globus pallidus\"]\nGranularity: 2",
            "[\"Astrocytes\", \"were always damaged\", \"in parallel with neurons in SNR\"]": " \n[\"Astrocytes\", \"were damaged\", \"in parallel with neurons\"]\n[\"Astrocytes\", \"were always damaged\", \"in SNR\"]\nGranularity: 2",
            "[\"Tight anatomical and functional interrelationship\", \"exists\", \"between neurons and astrocytes in SNR\"]": " \n[\"neurons\", \"have\", \"anatomical interrelationship\"]\n[\"neurons\", \"have\", \"functional interrelationship\"]\n[\"astrocytes\", \"have\", \"anatomical interrelationship\"]\n[\"astrocytes\", \"have\", \"functional interrelationship\"]\nGranularity: 4",
            "[\"Both cell elements\", \"may suffer\", \"from metabolic disturbance and neurotransmitter dysfunction\"]": "\n[\"Both cell elements\", \"may suffer from\", \"metabolic disturbance\"]\n[\"Both cell elements\", \"may suffer from\", \"neurotransmitter dysfunction\"]\nGranularity: 2"
      },
      "Succimer chelation improves learning , attention , and arousal regulation in lead - exposed rats but produces lasting cognitive impairment in the absence of lead exposure .|BACKGROUND : There is growing pressure for clinicians to prescribe chelation therapy at only slightly elevated blood lead levels .|However , very few studies have evaluated whether chelation improves cognitive outcomes in Pb - exposed children , or whether these agents have adverse effects that may affect brain development in the absence of Pb exposure .|OBJECTIVES : The present study was designed to answer these questions , using a rodent model of early childhood Pb exposure and treatment with succimer , a widely used chelating agent for the treatment of Pb poisoning .|RESULTS : Pb exposure produced lasting impairments in learning , attention , inhibitory control , and arousal regulation , paralleling the areas of dysfunction seen in Pb - exposed children .|Succimer treatment of the Pb - exposed rats significantly improved learning , attention , and arousal regulation , although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit .|In contrast , succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen .|CONCLUSIONS : These are the first data , to our knowledge , to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure .|These findings suggest that it may be possible to identify a succimer treatment protocol that improves cognitive outcomes in Pb - exposed children .|However , they also suggest that succimer treatment should be strongly discouraged for children who do not have elevated tissue levels of Pb or other heavy metals .": {
            "[\"Succimer chelation\", \"produces\", \"lasting cognitive impairment in the absence of lead exposure\"]": " \n[\"Succimer chelation\", \"produces\", \"lasting cognitive impairment\"]\n[\"Succimer chelation\", \"in the absence of\", \"lead exposure\"]\nGranularity: 2",
            "[\"Clinicians\", \"are pressured to prescribe\", \"chelation therapy at slightly elevated blood lead levels\"]": " \n[\"Clinicians\", \"are pressured to prescribe\", \"chelation therapy\"]\n[\"chelation therapy\", \"is prescribed for\", \"slightly elevated blood lead levels\"]\nGranularity: 2",
            "[\"Studies\", \"have not evaluated\", \"whether chelation improves cognitive outcomes in Pb-exposed children\"]": " \n[\"Studies\", \"have not evaluated\", \"whether chelation improves cognitive outcomes\"]\n[\"Studies\", \"have not evaluated\", \"whether chelation improves cognitive outcomes in Pb-exposed children\"]\nGranularity: 2",
            "[\"Studies\", \"have not evaluated\", \"whether chelation agents have adverse effects on brain development in the absence of Pb exposure\"]": " \n[\"Studies\", \"have not evaluated\", \"chelation agents\"]\n[\"chelation agents\", \"have adverse effects on\", \"brain development\"]\n[\"chelation agents\", \"have adverse effects in the absence of\", \"Pb exposure\"]\nGranularity: 3",
            "[\"Present study\", \"was designed to answer\", \"questions about chelation therapy and Pb exposure\"]": " \n[\"Present study\", \"was designed to answer\", \"questions about chelation therapy\"]\n[\"Present study\", \"was designed to answer\", \"questions about Pb exposure\"]\nGranularity: 2",
            "[\"Pb exposure\", \"produces\", \"lasting impairments in learning, attention, inhibitory control, and arousal regulation\"]": " \n[\"Pb exposure\", \"produces\", \"lasting impairments in learning\"]\n[\"Pb exposure\", \"produces\", \"lasting impairments in attention\"]\n[\"Pb exposure\", \"produces\", \"lasting impairments in inhibitory control\"]\n[\"Pb exposure\", \"produces\", \"lasting impairments in arousal regulation\"]\nGranularity: 4",
            "[\"Succimer treatment\", \"significantly improves\", \"learning, attention, and arousal regulation in Pb-exposed rats\"]": " \n[\"Succimer treatment\", \"improves\", \"learning\"]\n[\"Succimer treatment\", \"improves\", \"attention\"]\n[\"Succimer treatment\", \"improves\", \"arousal regulation\"]\nGranularity: 3",
            "[\"Succimer treatment\", \"produces\", \"cognitive and affective dysfunction in rats not exposed to Pb\"]": " \n[\"Succimer treatment\", \"produces\", \"cognitive dysfunction\"]\n[\"Succimer treatment\", \"produces\", \"affective dysfunction\"]\n[\"Succimer treatment\", \"not exposed to\", \"Pb\"]\nGranularity: 3",
            "[\"Chelating agent treatment\", \"can alleviate\", \"cognitive deficits due to Pb exposure\"]": " \n[\"Chelating agent treatment\", \"can alleviate\", \"cognitive deficits\"]\n[\"Chelating agent treatment\", \"can alleviate\", \"Pb exposure\"]\nGranularity: 2",
            "[\"Succimer treatment protocol\", \"may improve\", \"cognitive outcomes in Pb-exposed children\"]": " \n[\"Succimer treatment protocol\", \"improves\", \"cognitive outcomes\"]\n[\"Succimer treatment protocol\", \"in Pb-exposed children\"]\nGranularity: 2",
            "[\"Succimer treatment\", \"should be discouraged\", \"for children without elevated tissue levels of Pb or other heavy metals\"]": " \n[\"Succimer treatment\", \"should be discouraged\", \"for children without elevated tissue levels of Pb\"]\n[\"Succimer treatment\", \"should be discouraged\", \"for children without elevated tissue levels of other heavy metals\"]\nGranularity: 2",
            "[\"Succimer chelation\", \"improves\", \"learning, attention, and arousal regulation in lead-exposed rats\"]": " \n[\"Succimer chelation\", \"improves\", \"learning\"]\n[\"Succimer chelation\", \"improves\", \"attention\"]\n[\"Succimer chelation\", \"improves\", \"arousal regulation\"]\nGranularity: 3"
      },
      "Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy .|Fourteen of 39 dialysis patients ( 36 % ) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder .|In order to identify risk factors associated with the development of hypercalcemia , indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age , sex , length of time on dialysis , and etiology of renal disease .|In addition to experiencing hypercalcemic episodes with peak calcium values of 2 . 7 to 3 . 8 mmol / L ( 10 . 7 to 15 . 0 mg / dL ) , patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch , compared with the mean value obtained during the 7 months of observation after the switch ( 2 . 4 + / - 0 . 03 to 2 . 5 + / - 0 . 03 mmol / L [ 9 . 7 + / - 0 . 2 to 10 . 2 + / - 0 . 1 mg / dL ] , P = 0 . 006 ) .|In contrast , eucalcemic patients exhibited no change in mean calcium values over the same time period ( 2 . 3 + / - 0 . 05 to 2 . 3 + / - 0 . 05 mmol / L [ 9 . 2 + / - 0 . 2 to 9 . 2 + / - 0 . 2 mg / dL ] ) .|CaCO3 dosage , calculated dietary calcium intake , and circulating levels of vitamin D metabolites were similar in both groups .|Physical activity index and predialysis serum bicarbonate levels also were similar in both groups .|However , there was a significant difference in parameters reflecting bone turnover rates between groups . ( ABSTRACT TRUNCATED AT 250 WORDS )": {
            "[\"hypercalcemia\", \"in\", \"hemodialysis patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"calcium carbonate therapy\", \"is associated with\", \"hypercalcemia\"]": " N/A (The triple is specific, conveying a singular relation between calcium carbonate therapy and hypercalcemia.)\nGranularity: 0",
            "[\"14 of 39 dialysis patients\", \"became hypercalcemic after\", \"switching to calcium carbonate\"]": " \n[\"14 dialysis patients\", \"became hypercalcemic after\", \"switching to calcium carbonate\"]\n[\"39 dialysis patients\", \"became hypercalcemic after\", \"switching to calcium carbonate\"]\nGranularity: 2",
            "[\"research\", \"aimed to identify\", \"risk factors associated with hypercalcemia\"]": " \n[\"research\", \"aimed to identify\", \"risk factors\"]\n[\"research\", \"aimed to identify\", \"hypercalcemia\"]\nGranularity: 2",
            "[\"intestinal calcium reabsorption\", \"and\", \"bone turnover rate\"]": " \n[\"intestinal calcium reabsorption\", \"affects\", \"bone turnover rate\"]\n[\"intestinal calcium reabsorption\", \"is affected by\", \"bone turnover rate\"]\nGranularity: 2",
            "[\"14 hypercalcemic patients\", \"were compared with\", \"14 eucalcemic patients\"]": " \n[\"14 hypercalcemic patients\", \"were compared with\", \"14 eucalcemic patients\"]\nGranularity: 1",
            "[\"comparison\", \"based on\", \"age, sex, length of time on dialysis, and etiology of renal disease\"]": " \n[\"comparison\", \"based on\", \"age\"]\n[\"comparison\", \"based on\", \"sex\"]\n[\"comparison\", \"based on\", \"length of time on dialysis\"]\n[\"comparison\", \"based on\", \"etiology of renal disease\"]\nGranularity: 4",
            "[\"hypercalcemic episodes\", \"had peak calcium values of\", \"2.7 to 3.8 mmol/L\"]": " \n[\"hypercalcemic episodes\", \"had peak calcium values of\", \"2.7 mmol/L\"]\n[\"hypercalcemic episodes\", \"had peak calcium values of\", \"3.8 mmol/L\"]\nGranularity: 2",
            "[\"hypercalcemic group\", \"exhibited\", \"increase in mean calcium concentration\"]": " \n[\"hypercalcemic group\", \"exhibited\", \"increase in mean calcium concentration\"]\nGranularity: 1",
            "[\"eucalcemic patients\", \"exhibited\", \"no change in mean calcium values\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Physical activity index\", \"and\", \"predialysis serum bicarbonate levels\"]": "\n[\"Physical activity index\", \"correlates with\", \"predialysis serum bicarbonate levels\"]\n[\"Physical activity index\", \"affects\", \"predialysis serum bicarbonate levels\"]\n[\"Physical activity index\", \"influences\", \"predialysis serum bicarbonate levels\"]\nGranularity: 3",
            "[\"However\", \"there was a significant difference\", \"in parameters reflecting bone turnover rates between groups\"]": "\n[\"However\", \"showed\", \"a significant difference\"]\n[\"there was\", \"a significant difference\", \"in parameters reflecting bone turnover rates\"]\n[\"reflecting bone turnover rates\", \"differed between\", \"groups\"]\nGranularity: 3"
      },
      "The cytogenetic action of ifosfamide , mesna , and their combination on peripheral rabbit lymphocytes : an in vivo / in vitro cytogenetic study .|Ifosfamide ( IFO ) is an alkylating nitrogen mustard , administrated as an antineoplasmic agent .|It is characterized by its intense urotoxic action , leading to hemorrhagic cystitis .|This side effect of IFO raises the requirement for the co - administration with sodium 2 - sulfanylethanesulfonate ( Mesna ) aiming to avoid or minimize this effect .|IFO and Mesna were administrated separately on rabbit 's lymphocytes in vivo , which were later developed in vitro .|Cytogenetic markers for sister chromatid exchanges ( SCEs ) , proliferation rate index ( PRI ) and Mitotic Index were recorded .|Mesna 's action , in conjunction with IFO reduces the frequency of SCEs , in comparison with the SCEs recordings obtained when IFO is administered alone .|In addition to this , when high concentrations of Mesna were administered alone significant reductions of the PRI were noted , than with IFO acting at the same concentration on the lymphocytes .|Mesna significantly reduces IFO 's genotoxicity , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug .": {
            "[\"Ifosfamide\", \"is\", \"alkylating nitrogen mustard\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Ifosfamide\", \"administered as\", \"antineoplasmic agent\"]": " \n[\"Ifosfamide\", \"is administered as\", \"antineoplasmic agent\"]\nGranularity: 1",
            "[\"Ifosfamide\", \"characterized by\", \"intense urotoxic action\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Urotoxic action\", \"leads to\", \"hemorrhagic cystitis\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hemorrhagic cystitis\", \"side effect of\", \"Ifosfamide\"]": " \n[\"Hemorrhagic cystitis\", \"is a side effect of\", \"Ifosfamide\"]\nGranularity: 1",
            "[\"Co-administration with sodium 2-sulfanylethanesulfonate (Mesna)\", \"aims to\", \"avoid or minimize hemorrhagic cystitis\"]": " \n[\"Co-administration with sodium 2-sulfanylethanesulfonate (Mesna)\", \"aims to\", \"avoid hemorrhagic cystitis\"]\n[\"Co-administration with sodium 2-sulfanylethanesulfonate (Mesna)\", \"aims to\", \"minimize hemorrhagic cystitis\"]\nGranularity: 2",
            "[\"Sodium 2-sulfanylethanesulfonate (Mesna)\", \"co-administered with\", \"Ifosfamide\"]": " \n[\"Sodium 2-sulfanylethanesulfonate (Mesna)\", \"co-administered with\", \"Ifosfamide\"]\nGranularity: 0",
            "[\"Ifosfamide and Mesna\", \"administered separately on\", \"rabbit's lymphocytes\"]": "\n[\"Ifosfamide\", \"administered on\", \"rabbit's lymphocytes\"]\n[\"Mesna\", \"administered on\", \"rabbit's lymphocytes\"]\nGranularity: 2",
            "[\"Rabbit's lymphocytes\", \"developed in\", \"vitro\"]": " \n[\"Rabbit's lymphocytes\", \"were developed\", \"in vitro\"]\nGranularity: 1",
            "[\"Cytogenetic markers\", \"recorded for\", \"sister chromatid exchanges (SCEs), proliferation rate index (PRI), and Mitotic Index\"]": " \n[\"Cytogenetic markers\", \"recorded for\", \"sister chromatid exchanges (SCEs)\"]\n[\"Cytogenetic markers\", \"recorded for\", \"proliferation rate index (PRI)\"]\n[\"Cytogenetic markers\", \"recorded for\", \"Mitotic Index\"]\nGranularity: 3",
            "[\"Mesna's action\", \"in conjunction with\", \"Ifosfamide\"]": " \n[\"Mesna's action\", \"in conjunction with\", \"Ifosfamide\"]\nGranularity: 1",
            "[\"Mesna's action with Ifosfamide\", \"reduces the frequency of\", \"SCEs\"]": "\n[\"Mesna\", \"acts with\", \"Ifosfamide\"]\n[\"Ifosfamide\", \"reduces the frequency of\", \"SCEs\"]\nGranularity: 2",
            "[\"SCEs recordings\", \"comparison with\", \"SCEs obtained when Ifosfamide is administered alone\"]": " \n[\"SCEs recordings\", \"comparison with\", \"SCEs obtained when Ifosfamide is administered alone\"]\nGranularity: 1",
            "[\"PRI reductions with high concentrations of Mesna\", \"comparison with\", \"PRI reductions with IFO at the same concentration\"]": " \n[\"PRI reductions with high concentrations of Mesna\", \"comparison with\", \"PRI reductions with IFO\"]\n[\"PRI reductions with high concentrations of Mesna\", \"comparison with\", \"PRI reductions at the same concentration\"]\nGranularity: 2",
            "[\"Mesna\", \"significantly reduces\", \"IFO's genotoxicity\"]": " N/A (The triple is specific, conveying a singular relation between Mesna and IFO's genotoxicity.)\nGranularity: 0",
            "[\"Mesna\", \"acts in an\", \"inhibitory fashion on the cytostatic action of the drug\"]": " \n[\"Mesna\", \"acts\", \"inhibitory fashion\"]\n[\"Mesna\", \"acts on\", \"cytostatic action\"]\nGranularity: 2"
      },
      "Thrombotic complications in acute promyelocytic leukemia during all - trans - retinoic acid therapy .|A case of acute renal failure , due to occlusion of renal vessels in a patient with acute promyelocytic leukemia ( APL ) treated with all - trans - retinoic acid ( ATRA ) and tranexamic acid has been described recently .|We report a case of acute renal failure in an APL patient treated with ATRA alone .|This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients .|The patients , a 43 - year - old man , presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA .|After 10 days of treatment , he developed acute renal failure that was completely reversible after complete remission of APL was achieved and therapy discontinued .|We conclude that ATRA is a valid therapeutic choice for patients with APL , although the procoagulant tendency is not completely corrected .|Thrombotic events , however , could be avoided by using low - dose heparin .": {
            "[\"Thrombotic complications\", \"in\", \"acute promyelocytic leukemia\"]": " \n[\"Thrombotic complications\", \"occur in\", \"acute promyelocytic leukemia\"]\n[\"Thrombotic complications\", \"are a complication of\", \"acute promyelocytic leukemia\"]\nGranularity: 2",
            "[\"acute renal failure\", \"due to\", \"occlusion of renal vessels\"]": " \n[\"acute renal failure\", \"due to\", \"occlusion\"]\n[\"acute renal failure\", \"due to\", \"renal vessels\"]\nGranularity: 2",
            "[\"acute promyelocytic leukemia\", \"treated with\", \"all - trans - retinoic acid ( ATRA ) and tranexamic acid\"]": "\n[\"acute promyelocytic leukemia\", \"treated with\", \"all-trans-retinoic acid (ATRA)\"]\n[\"acute promyelocytic leukemia\", \"treated with\", \"tranexamic acid\"]\nGranularity: 2",
            "[\"acute renal failure\", \"in\", \"an APL patient\"]": " \n[\"acute renal failure\", \"in\", \"an APL patient\"]\nGranularity: 1",
            "[\"ATRA\", \"associated with\", \"thromboembolic complications\"]": "\n[\"ATRA\", \"associated with\", \"thromboembolic events\"]\n[\"ATRA\", \"associated with\", \"complications\"]\nGranularity: 2",
            "[\"patient\", \"presented\", \"signs and symptoms of APL\"]": " \n[\"patient\", \"presented\", \"signs of APL\"]\n[\"patient\", \"presented\", \"symptoms of APL\"]\nGranularity: 2",
            "[\"patient\", \"included in\", \"treatment protocol with ATRA\"]": "\n[\"patient\", \"included in\", \"treatment protocol\"]\n[\"patient\", \"included in\", \"ATRA\"]\nGranularity: 2",
            "[\"patient\", \"developed\", \"acute renal failure\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"acute renal failure\", \"completely reversible after\", \"complete remission of APL was achieved and therapy discontinued\"]": " \n[\"acute renal failure\", \"completely reversible after\", \"complete remission of APL was achieved\"]\n[\"acute renal failure\", \"completely reversible after\", \"therapy discontinued\"]\nGranularity: 2",
            "[\"ATRA\", \"a valid therapeutic choice for\", \"patients with APL\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"procoagulant tendency\", \"not completely corrected by\", \"ATRA\"]": " \n[\"procoagulant tendency\", \"not completely corrected by\", \"ATRA\"]\nGranularity: 1",
            "[\"Thrombotic events\", \"could be avoided by\", \"using low - dose heparin\"]": " \n[\"Thrombotic events\", \"could be avoided\", \"using low-dose heparin\"]\nGranularity: 1"
      },
      "Cholestatic presentation of yellow phosphorus poisoning .|Yellow phosphorus , a component of certain pesticide pastes and fireworks , is well known to cause hepatotoxicity .|Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation .|We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity .": {
            "[\"Cholestatic presentation\", \"of\", \"yellow phosphorus poisoning\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Yellow phosphorus\", \"component of\", \"certain pesticide pastes and fireworks\"]": " \n[\"Yellow phosphorus\", \"is a component of\", \"pesticide pastes\"]\n[\"Yellow phosphorus\", \"is a component of\", \"fireworks\"]\nGranularity: 2",
            "[\"Yellow phosphorus\", \"cause\", \"hepatotoxicity\"]": " N/A (The triple is specific, conveying a singular relation between yellow phosphorus and hepatotoxicity.)\nGranularity: 0",
            "[\"Poisoning with yellow phosphorus\", \"manifests with\", \"acute hepatitis\"]": " \n[\"Poisoning with yellow phosphorus\", \"manifests as\", \"acute hepatitis\"]\nGranularity: 1",
            "[\"Acute hepatitis\", \"leading to\", \"acute liver failure\"]": "\n[\"Acute hepatitis\", \"causes\", \"acute liver failure\"]\n[\"Acute hepatitis\", \"results in\", \"acute liver failure\"]\nGranularity: 2",
            "[\"Acute liver failure\", \"may need\", \"liver transplantation\"]": "\n[\"Acute liver failure\", \"requires\", \"liver transplantation\"]\n[\"Acute liver failure\", \"may need\", \"liver transplantation\"]\nGranularity: 2",
            "[\"We\", \"present a case of\", \"yellow phosphorus poisoning\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"presented with\", \"florid clinical features of cholestasis\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Cholestasis\", \"can rarely be\", \"a presenting feature of yellow phosphorus hepatotoxicity\"]": " \n[\"Cholestasis\", \"can be\", \"a presenting feature\"]\n[\"yellow phosphorus hepatotoxicity\", \"can cause\", \"cholestasis\"]\nGranularity: 2"
      },
      "Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients .|The cure rate of infections in cancer patients is adversely affected by neutropenia ( less than 1 , 000 / mm3 ) .|In particular , patients with severe neutropenia ( less than 100 / mm3 ) have shown a poor response to antibiotics .|To overcome the adverse effects of neutropenia , tobramycin was given by continuous infusion and combined with intermittent carbenicillin .|Tobramycin was given to a total daily dose of 300 mg / m2 and carbenicillin was given at a dose of 5 gm every four hours .|There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy .|The overall cure rate was 70 % .|Pneumonia was the most common infection and 61 % of 59 episodes were cured .|Gram - negative bacilli were the most common causative organisms and 69 % of these infections were cured .|The most common pathogen was Klebsiella pneumoniae and this , together with Escherichia coli and Pseudomonas aeruginosa , accounted for 74 % of all gram - negative bacillary infections .|Response was not influenced by the initial neutrophil count , with a 62 % cure rate for 39 episodes associated with severe neutropenia .|However , failure of the neutrophil count to increase during therapy adversely affected response .|Azotemia was the major side effect recognized , and it occurred in 11 % of episodes .|Major azotemia ( serum creatinine greater than 2 . 5 mg / dl or BUN greater than 50 mg / dl ) occurred in only 2 % .|Azotemia was not related to duration of therapy or serum tobramycin concentration .|This antibiotic regimen showed both therapeutic efficacy and acceptable renal toxicity for these patients .": {
            "[\"Continuous infusion tobramycin\", \"combined with\", \"carbenicillin\"]": " \n[\"Continuous infusion tobramycin\", \"combined with\", \"carbenicillin\"]\nGranularity: 1",
            "[\"Infections in cancer patients\", \"affected by\", \"neutropenia\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Neutropenia\", \"affects\", \"cure rate of infections\"]": " \n[\"Neutropenia\", \"affects\", \"cure rate\"]\n[\"Neutropenia\", \"affects\", \"infections\"]\nGranularity: 2",
            "[\"Severe neutropenia\", \"shows poor response to\", \"antibiotics\"]": " \n[\"Severe neutropenia\", \"shows response to\", \"antibiotics\"]\n[\"Severe neutropenia\", \"shows poor\", \"response\"]\nGranularity: 2",
            "[\"Tobramycin\", \"given by\", \"continuous infusion\"]": " \n[\"Tobramycin\", \"given by\", \"continuous infusion\"]\nGranularity: 1",
            "[\"Carbenicillin\", \"given by\", \"intermittent\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Tobramycin\", \"given at a dose of\", \"300 mg / m2\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Carbenicillin\", \"given at a dose of\", \"5 gm every four hours\"]": "\n[\"Carbenicillin\", \"given at a dose of\", \"5 gm\"]\n[\"Carbenicillin\", \"given every four hours\"]\nGranularity: 2",
            "[\"125 infectious episodes\", \"in\", \"116 cancer patients\"]": " \n[\"125 infectious episodes\", \"in\", \"116 cancer patients\"]\nGranularity: 1",
            "[\"Overall cure rate\", \"was\", \"70%\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Pneumonia\", \"was the most common\", \"infection\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"61% of 59 episodes\", \"were cured\", \"Pneumonia\"]": " \n[\"61% of 59 episodes\", \"were cured\", \"Pneumonia\"]\nGranularity: 1",
            "[\"Gram-negative bacilli\", \"were the most common\", \"causative organisms\"]": " \n[\"Gram-negative bacilli\", \"were\", \"the most common\"]\n[\"the most common\", \"causative organisms\", \"were\"]\nGranularity: 2",
            "[\"69% of these infections\", \"were cured\", \"Gram-negative bacilli\"]": "\n[\"69% of these infections\", \"were cured by\", \"Gram-negative bacilli\"]\nGranularity: 1",
            "[\"Klebsiella pneumoniae\", \"was the most common pathogen\", \"\"]": " \n[\"Klebsiella pneumoniae\", \"was\", \"the most common pathogen\"]\nGranularity: 1",
            "[\"Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa\", \"accounted for\", \"74% of all gram-negative bacillary infections\"]": " \n[\"Klebsiella pneumoniae\", \"accounted for\", \"74% of all gram-negative bacillary infections\"]\n[\"Escherichia coli\", \"accounted for\", \"74% of all gram-negative bacillary infections\"]\n[\"Pseudomonas aeruginosa\", \"accounted for\", \"74% of all gram-negative bacillary infections\"]\nGranularity: 3",
            "[\"Response\", \"not influenced by\", \"initial neutrophil count\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Failure of the neutrophil count to increase during therapy\", \"adversely affected\", \"response\"]": " \n[\"Failure of the neutrophil count\", \"affects\", \"response\"]\n[\"therapy\", \"affects\", \"response\"]\n[\"Failure of the neutrophil count\", \"does not increase during\", \"therapy\"]\nGranularity: 3",
            "[\"Azotemia\", \"was the major side effect recognized\", \"\"]": " N/A (The triple is not specific enough and requires more information to be split into sub-triples.)\nGranularity: 0",
            "[\"Major azotemia\", \"occurred in\", \"2% of episodes\"]": "\n[\"Major azotemia\", \"occurred in\", \"2% of episodes\"]\nGranularity: 1",
            "[\"Azotemia\", \"not related to\", \"duration of therapy or serum tobramycin concentration\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"This antibiotic regimen\", \"showed\", \"both therapeutic efficacy and acceptable renal toxicity\"]": " \n[\"This antibiotic regimen\", \"showed\", \"therapeutic efficacy\"]\n[\"This antibiotic regimen\", \"showed\", \"acceptable renal toxicity\"]\nGranularity: 2"
      },
      "Amiodarone - induced torsade de pointes during bladder irrigation : an unusual presentation - - a case report .|The authors present a case of early ( within 4 days ) development of torsade de pointes ( TdP ) associated with oral amiodarone therapy .|Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess .|Transient prolongation of the QT during bladder irrigation prompted the episode of TdP .|It is well known that bradycardia exacerbates acquired TdP .|The authors speculate that the increased vagal tone during bladder irrigation , a vagal maneuver , in the context of amiodarone therapy resulted in amiodarone - induced proarrhythmia .|In the absence of amiodarone therapy , a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia .": {
            "[\"torsade de pointes\", \"associated with\", \"oral amiodarone therapy\"]": " \n[\"torsade de pointes\", \"associated with\", \"oral amiodarone\"]\n[\"oral amiodarone\", \"therapy\", \"torsade de pointes\"]\nGranularity: 2",
            "[\"case\", \"presented by\", \"authors\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"case\", \"consistent with\", \"other reports\"]": " N/A (The relationship is direct and does not need further granularity.)\nGranularity: 0",
            "[\"TdP\", \"occurred in the context of\", \"multiple exacerbating factors\"]": " \n[\"TdP\", \"occurred\", \"in the context of\"]\n[\"TdP\", \"was exacerbated by\", \"multiple factors\"]\nGranularity: 2",
            "[\"QT prolongation\", \"during\", \"bladder irrigation\"]": " \n[\"QT prolongation\", \"occurs during\", \"bladder irrigation\"]\nGranularity: 1",
            "[\"bradycardia\", \"exacerbates\", \"acquired TdP\"]": " N/A (The triple is specific, conveying a singular relation between bradycardia and acquired TdP.)\nGranularity: 0",
            "[\"increased vagal tone\", \"during\", \"bladder irrigation\"]": " \n[\"increased vagal tone\", \"during\", \"bladder irrigation\"]\nGranularity: 1",
            "[\"vagal maneuver\", \"in the context of\", \"amiodarone therapy\"]": " \n[\"vagal maneuver\", \"in the context of\", \"amiodarone therapy\"]\nGranularity: 1",
            "[\"amiodarone-induced proarrhythmia\", \"resulted from\", \"increased vagal tone\"]": " \n[\"amiodarone-induced proarrhythmia\", \"resulted from\", \"increased vagal tone\"]\nGranularity: 1",
            "[\"second bladder irrigation\", \"did not induce\", \"TdP\"]": "\n[\"second bladder irrigation\", \"did not induce\", \"TdP\"]\nGranularity: 0",
            "[\"second bladder irrigation\", \"despite\", \"hypokalemia and hypomagnesemia\"]": "\n[\"second bladder irrigation\", \"despite\", \"hypokalemia\"]\n[\"second bladder irrigation\", \"despite\", \"hypomagnesemia\"]\nGranularity: 2",
            "[\"Amiodarone\", \"induced\", \"torsade de pointes\"]": " N/A (The triple is specific, conveying a singular relation between Amiodarone and torsade de pointes.)\nGranularity: 0"
      },
      "Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long - QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall .|BACKGROUND : This study examined the role of phase 2 early afterdepolarization ( EAD ) in producing a trigger to initiate torsade de pointes ( TdP ) with QT prolongation induced by dl - sotalol and azimilide .|The contribution of transmural dispersion of repolarization ( TDR ) to transmural propagation of EAD and the maintenance of TdP was also evaluated .|METHODS AND RESULTS : Transmembrane action potentials from epicardium , midmyocardium , and endocardium were recorded simultaneously , together with a transmural ECG , in arterially perfused canine and rabbit left ventricular preparations .|dl - Sotalol preferentially prolonged action potential duration ( APD ) in M cells dose - dependently ( 1 to 100 micromol / L ) , leading to QT prolongation and an increase in TDR .|Azimilide , however , significantly prolonged APD and QT interval at concentrations from 0 . 1 to 10 micromol / L but shortened them at 30 micromol / L .|Unlike dl - sotalol , azimilide ( > 3 micromol / L ) increased epicardial APD markedly , causing a diminished TDR .|Although both dl - sotalol and azimilide rarely induced EADs in canine left ventricles , they produced frequent EADs in rabbits , in which more pronounced QT prolongation was seen .|An increase in TDR by dl - sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles .|Of note , although azimilide ( 3 to 10 micromol / L ) increased APD more than dl - sotalol , its EADs often failed to propagate transmurally , probably because of a diminished TDR .|CONCLUSIONS : This study provides the first direct evidence from intracellular action potential recordings that phase 2 EAD can be generated from intact ventricular wall and produce a trigger to initiate the onset of TdP under QT prolongation .": {
            "[\"Phase 2 early afterdepolarization\", \"trigger\", \"polymorphic ventricular tachycardia\"]": "\n[\"Phase 2 early afterdepolarization\", \"triggers\", \"polymorphic ventricular tachycardia\"]\n[\"Phase 2 early afterdepolarization\", \"triggers\", \"ventricular tachycardia\"]\n[\"Phase 2 early afterdepolarization\", \"triggers\", \"polymorphic tachycardia\"]\nGranularity: 3",
            "[\"Phase 2 early afterdepolarization\", \"trigger\", \"torsade de pointes\"]": " \n[\"Phase 2 early afterdepolarization\", \"triggers\", \"torsade de pointes\"]\nGranularity: 1",
            "[\"Phase 2 early afterdepolarization\", \"role\", \"producing a trigger\"]": " \n[\"Phase 2 early afterdepolarization\", \"plays a role in\", \"producing a trigger\"]\nGranularity: 1",
            "[\"dl-sotalol\", \"induces\", \"QT prolongation\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Azimilide\", \"induces\", \"QT prolongation\"]": " N/A (The triple is specific, conveying a singular relation between Azimilide and QT prolongation.)\nGranularity: 0",
            "[\"dl-sotalol\", \"prolongs\", \"action potential duration\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Azimilide\", \"prolongs\", \"action potential duration\"]": " N/A (The triple is specific, conveying a singular relation between Azimilide and action potential duration.)\nGranularity: 0",
            "[\"Azimilide\", \"shortens\", \"action potential duration\"]": " N/A (The triple is specific, conveying a singular relation between Azimilide and action potential duration.)\nGranularity: 0",
            "[\"dl-sotalol\", \"increases\", \"TDR\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Azimilide\", \"diminishes\", \"TDR\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Both dl-sotalol and azimilide\", \"rarely induce\", \"EADs in canine left ventricles\"]": " \n[\"Both dl-sotalol\", \"induces\", \"EADs\"]\n[\"Both azimilide\", \"induces\", \"EADs\"]\n[\"canine left ventricles\", \"rarely experience\", \"EADs\"]\nGranularity: 3",
            "[\"Both dl-sotalol and azimilide\", \"produce\", \"frequent EADs in rabbits\"]": " \n[\"Both dl-sotalol\", \"produce\", \"frequent EADs\"]\n[\"azimilide\", \"produce\", \"frequent EADs\"]\nGranularity: 2",
            "[\"Increase in TDR\", \"facilitates\", \"transmural propagation of EADs\"]": " \n[\"Increase in TDR\", \"facilitates\", \"transmural propagation\"]\n[\"Increase in TDR\", \"facilitates\", \"EADs\"]\nGranularity: 2",
            "[\"Transmural propagation of EADs\", \"initiates\", \"spontaneous TdP\"]": " \n[\"Transmural propagation of EADs\", \"initiates\", \"spontaneous TdP\"]\nGranularity: 1",
            "[\"Azimilide\", \"increases\", \"APD more than dl-sotalol\"]": "\n[\"Azimilide\", \"increases\", \"APD\"]\n[\"Azimilide\", \"increases\", \"dl-sotalol\"]\nGranularity: 2",
            "[\"Diminished TDR\", \"causes\", \"EADs to fail transmural propagation\"]": " \n[\"Diminished TDR\", \"causes\", \"EADs to fail\"]\n[\"EADs\", \"fail\", \"transmural propagation\"]\nGranularity: 2",
            "[\"This study\", \"provides\", \"direct evidence\"]": " N/A (The relationship is direct and does not need further granularity.)\nGranularity: 0"
      },
      "Randomized comparison of olanzapine versus risperidone for the treatment of first - episode schizophrenia : 4 - month outcomes .|OBJECTIVE : The authors compared 4 - month treatment outcomes for olanzapine versus risperidone in patients with first - episode schizophrenia spectrum disorders .|METHOD : One hundred twelve subjects ( 70 % male ; mean age = 23 . 3 years [ SD = 5 . 1 ] ) with first - episode schizophrenia ( 75 % ) , schizophreniform disorder ( 17 % ) , or schizoaffective disorder ( 8 % ) were randomly assigned to treatment with olanzapine ( 2 . 5 - 20 mg / day ) or risperidone ( 1 - 6 mg / day ) .|RESULTS : Response rates did not significantly differ between olanzapine ( 43 . 7 % , 95 % CI = 28 . 8 % - 58 . 6 % ) and risperidone ( 54 . 3 % , 95 % CI = 39 . 9 % - 68 . 7 % ) .|Among those responding to treatment , more subjects in the olanzapine group ( 40 . 9 % , 95 % CI = 16 . 8 % - 65 . 0 % ) than in the risperidone group ( 18 . 9 % , 95 % CI = 0 % - 39 . 2 % ) had subsequent ratings not meeting response criteria .|Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications .|Extrapyramidal symptom severity scores were 1 . 4 ( 95 % CI = 1 . 2 - 1 . 6 ) with risperidone and 1 . 2 ( 95 % CI = 1 . 0 - 1 . 4 ) with olanzapine .|Significantly more weight gain occurred with olanzapine than with risperidone : the increase in weight at 4 months relative to baseline weight was 17 . 3 % ( 95 % CI = 14 . 2 % - 20 . 5 % ) with olanzapine and 11 . 3 % ( 95 % CI = 8 . 4 % - 14 . 3 % ) with risperidone .|Body mass index at baseline and at 4 months was 24 . 3 ( 95 % CI = 22 . 8 - 25 . 7 ) versus 28 . 2 ( 95 % CI = 26 . 7 - 29 . 7 ) with olanzapine and 23 . 9 ( 95 % CI = 22 . 5 - 25 . 3 ) versus 26 . 7 ( 95 % CI = 25 . 2 - 28 . 2 ) with risperidone .|CONCLUSIONS : Clinical outcomes with risperidone were equal to those with olanzapine , and response may be more stable .|Olanzapine may have an advantage for motor side effects .|Both medications caused substantial rapid weight gain , but weight gain was greater with olanzapine .": {
            "[\"Randomized comparison\", \"compares\", \"4-month outcomes\"]": " \n[\"Randomized comparison\", \"compares\", \"4-month outcomes\"]\nGranularity: 1",
            "[\"Authors\", \"compared\", \"4-month treatment outcomes\"]": " \n[\"Authors\", \"compared\", \"treatment outcomes\"]\n[\"Authors\", \"compared\", \"4-month outcomes\"]\nGranularity: 2",
            "[\"Olanzapine\", \"versus\", \"risperidone\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patients\", \"have\", \"first-episode schizophrenia spectrum disorders\"]": " \n[\"Patients\", \"have\", \"first-episode schizophrenia\"]\n[\"Patients\", \"have\", \"schizophrenia spectrum disorders\"]\nGranularity: 2",
            "[\"One hundred twelve subjects\", \"were\", \"randomly assigned\"]": " \n[\"One hundred twelve subjects\", \"were\", \"randomly assigned\"]\nGranularity: 1",
            "[\"Olanzapine\", \"treats\", \"patients with schizophrenia\"]": " N/A (The triple is specific, conveying a singular relation between Olanzapine and patients with schizophrenia.)\nGranularity: 0",
            "[\"Risperidone\", \"treats\", \"patients with schizophrenia\"]": " N/A (The triple is specific, conveying a singular relation between Risperidone and patients with schizophrenia.)\nGranularity: 0",
            "[\"Response rates\", \"did not significantly differ\", \"between olanzapine and risperidone\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"More subjects\", \"had\", \"subsequent ratings not meeting response criteria\"]": " \n[\"More subjects\", \"had\", \"subsequent ratings\"]\n[\"subsequent ratings\", \"did not meet\", \"response criteria\"]\nGranularity: 2",
            "[\"Negative symptom outcomes\", \"did not differ\", \"between medications\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Extrapyramidal symptom severity scores\", \"were\", \"with risperidone and olanzapine\"]": "\n[\"Extrapyramidal symptom severity scores\", \"were\", \"with risperidone\"]\n[\"Extrapyramidal symptom severity scores\", \"were\", \"with olanzapine\"]\nGranularity: 2",
            "[\"Significantly more weight gain\", \"occurred\", \"with olanzapine than with risperidone\"]": " \n[\"More weight gain\", \"occurred\", \"with olanzapine\"]\n[\"Less weight gain\", \"occurred\", \"with risperidone\"]\nGranularity: 2",
            "[\"Body mass index\", \"was\", \"with olanzapine and risperidone\"]": "\n[\"Body mass index\", \"was\", \"with olanzapine\"]\n[\"Body mass index\", \"was\", \"with risperidone\"]\nGranularity: 2",
            "[\"Clinical outcomes\", \"were equal\", \"with risperidone and olanzapine\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Response may be more stable\", \"with\", \"risperidone\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Olanzapine\", \"has an advantage\", \"for motor side effects\"]": " N/A (The triple is specific, conveying a singular relation between Olanzapine and motor side effects.)\nGranularity: 0",
            "[\"Both medications\", \"caused\", \"substantial rapid weight gain\"]": "\n[\"Both medications\", \"caused\", \"substantial weight gain\"]\n[\"Both medications\", \"caused\", \"rapid weight gain\"]\nGranularity: 2",
            "[\"Weight gain\", \"was greater\", \"with olanzapine\"]": " \n[\"Weight gain\", \"was greater\", \"with olanzapine\"]\nGranularity: 1"
      },
      "Hyperglycemic effect of amino compounds structurally related to caproate in rats .|The chronic feeding of small amounts ( 0 . 3 - 3 % of diet weight ) of certain amino derivatives of caproate resulted in hyperglycemia , an elevated glucose tolerance curve and , occasionally , glucosuria .|Effective compounds included norleucine , norvaline , glutamate , epsilon - aminocaproate , methionine , and leucine .": {
            "[\"Hyperglycemic effect\", \"of\", \"amino compounds structurally related to caproate in rats\"]": " \n[\"Hyperglycemic effect\", \"of\", \"amino compounds\"]\n[\"Hyperglycemic effect\", \"of\", \"compounds structurally related to caproate\"]\n[\"Hyperglycemic effect\", \"of\", \"amino compounds structurally related to caproate in rats\"]\nGranularity: 3",
            "[\"The chronic feeding\", \"of\", \"small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate\"]": " \n[\"The chronic feeding\", \"of\", \"small amounts (0.3-3% of diet weight)\"]\n[\"of\", \"certain amino derivatives\"]\n[\"certain amino derivatives\", \"of\", \"caproate\"]\nGranularity: 3",
            "[\"certain amino derivatives of caproate\", \"resulted in\", \"hyperglycemia\"]": " \n[\"certain amino derivatives of caproate\", \"resulted in\", \"hyperglycemia\"]\nGranularity: 1",
            "[\"certain amino derivatives of caproate\", \"resulted in\", \"an elevated glucose tolerance curve\"]": " \n[\"certain amino derivatives of caproate\", \"resulted in\", \"elevated glucose tolerance\"]\n[\"certain amino derivatives of caproate\", \"resulted in\", \"glucose tolerance curve\"]\nGranularity: 2",
            "[\"certain amino derivatives of caproate\", \"resulted in\", \"glucosuria\"]": " \n[\"certain amino derivatives of caproate\", \"resulted in\", \"glucosuria\"]\nGranularity: 1",
            "[\"Effective compounds\", \"included\", \"norleucine\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Effective compounds\", \"included\", \"norvaline\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Effective compounds\", \"included\", \"glutamate\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Effective compounds\", \"included\", \"epsilon-aminocaproate\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Effective compounds\", \"included\", \"methionine\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Effective compounds\", \"included\", \"leucine\"]": " N/A (The triple is specific, conveying a singular relation between effective compounds and leucine.)\nGranularity: 0"
      },
      "Case - control study of regular analgesic and nonsteroidal anti - inflammatory use and end - stage renal disease .|BACKGROUND : Studies on the association between the long - term use of aspirin and other analgesic and nonsteroidal anti - inflammatory drugs ( NSAIDs ) and end - stage renal disease ( ESRD ) have given conflicting results .|In order to examine this association , a case - control study with incident cases of ESRD was carried out .|METHODS : The cases were all patients entering the local dialysis program because of ESRD in the study area between June 1 , 1995 and November 30 , 1997 .|They were classified according to the underlying disease , which had presumably led them to ESRD .|Controls were patients admitted to the same hospitals from where the cases arose , also matched by age and sex .|Odds ratios were calculated using a conditional logistic model , including potential confounding factors , both for the whole study population and for the various underlying diseases .|RESULTS : Five hundred and eighty - three cases and 1190 controls were included in the analysis .|Long - term use of any analgesic was associated with an overall odds ratio of 1 . 22 ( 95 % CI , 0 . 89 - 1 . 66 ) .|For specific groups of drugs , the risks were 1 . 56 ( 1 . 05 - 2 . 30 ) for aspirin , 1 . 03 ( 0 . 60 - 1 . 76 ) for pyrazolones , 0 . 80 ( 0 . 39 - 1 . 63 ) for paracetamol , and 0 . 94 ( 0 . 57 - 1 . 56 ) for nonaspirin NSAIDs .|The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use , and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [ 2 . 35 ( 1 . 17 - 4 . 72 ) ] .|CONCLUSION : Our data indicate that long - term use of nonaspirin analgesic drugs and NSAIDs is not associated with an increased risk of ESRD .|However , the chronic use of aspirin may increase the risk of ESRD .": {
            "[\"Case - control study\", \"examines the association\", \"long - term use of aspirin and other analgesic and nonsteroidal anti - inflammatory drugs ( NSAIDs ) and end - stage renal disease ( ESRD )\"]": " \n[\"Case-control study\", \"examines\", \"long-term use of aspirin\"]\n[\"Case-control study\", \"examines\", \"long-term use of other analgesic drugs\"]\n[\"Case-control study\", \"examines\", \"long-term use of nonsteroidal anti-inflammatory drugs\"]\n[\"Case-control study\", \"examines\", \"end-stage renal disease\"]\nGranularity: 4",
            "[\"Incident cases of ESRD\", \"were carried out\", \"case - control study\"]": " \n[\"Incident cases of ESRD\", \"were carried out\", \"case - control study\"]\nGranularity: 1",
            "[\"Cases\", \"classified according to\", \"the underlying disease\"]": " \n[\"Cases\", \"classified as\", \"underlying disease\"]\n[\"Cases\", \"classified according to\", \"underlying disease\"]\nGranularity: 2",
            "[\"Controls\", \"matched by\", \"age and sex\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Odds ratios\", \"calculated using\", \"a conditional logistic model\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Potential confounding factors\", \"included in\", \"odds ratios calculation\"]": " \n[\"Potential confounding factors\", \"included\", \"odds ratios\"]\n[\"odds ratios\", \"calculated using\", \"potential confounding factors\"]\nGranularity: 2",
            "[\"Long - term use of any analgesic\", \"associated with\", \"an overall odds ratio of 1 . 22\"]": "\n[\"Long-term use\", \"associated with\", \"overall odds ratio\"]\n[\"Long-term use\", \"associated with\", \"odds ratio of 1.22\"]\nGranularity: 2",
            "[\"Specific groups of drugs\", \"the risks were\", \"1 . 56 ( 1 . 05 - 2 . 30 ) for aspirin\"]": "\n[\"Specific groups of drugs\", \"the risks were\", \"1.56 for aspirin\"]\n[\"Specific groups of drugs\", \"the risks were\", \"1.05 for aspirin\"]\n[\"Specific groups of drugs\", \"the risks were\", \"2.30 for aspirin\"]\nGranularity: 3",
            "[\"Aspirin\", \"related to\", \"the cumulated dose and duration of use\"]": " \n[\"Aspirin\", \"related to\", \"cumulated dose\"]\n[\"Aspirin\", \"related to\", \"duration of use\"]\nGranularity: 2",
            "[\"The risk of ESRD\", \"particularly high among\", \"the subset of patients with vascular nephropathy as underlying disease\"]": " \n[\"The risk of ESRD\", \"is high among\", \"patients with vascular nephropathy\"]\n[\"Vascular nephropathy\", \"is an underlying disease of\", \"ESRD\"]\nGranularity: 2",
            "[\"Our data\", \"indicate\", \"long - term use of nonaspirin analgesic drugs and NSAIDs is not associated with an increased risk of ESRD \"]": " \n[\"Our data\", \"indicate\", \"long-term use of nonaspirin analgesic drugs\"]\n[\"Our data\", \"indicate\", \"long-term use of NSAIDs\"]\n[\"Our data\", \"indicate\", \"no increased risk of ESRD\"]\nGranularity: 3",
            "[\"Chronic use of aspirin\", \"may increase the risk of\", \"ESRD \"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Prevalence of heart disease in asymptomatic chronic cocaine users .|To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users , 35 cocaine users and 32 age - matched controls underwent resting and exercise electrocardiography ( ECG ) and Doppler echocardiography .|Findings consistent with coronary artery disease were detected in 12 ( 34 % ) patients and 3 ( 9 % ) controls ( p = 0 . 01 ) .|Decreased left ventricular systolic function was demonstrated in 5 ( 14 % ) patients , but in none of the controls ( p = 0 . 055 ) .|Finally , resting and peak exercise abnormal left ventricular filling was detected in 38 and 35 % of patients as compared to 19 and 9 % of controls , respectively ( p = 0 . 11 and 0 . 02 , respectively ) .|We conclude that coronary artery or myocardial disease is common ( 38 % ) in young asymptomatic chronic cocaine users .|Therefore , screening ECG and echocardiography may be warranted in these patients .": {
            "[\"35 cocaine users\", \"underwent\", \"resting and exercise electrocardiography (ECG) and Doppler echocardiography\"]": "\n[\"35 cocaine users\", \"underwent\", \"resting electrocardiography\"]\n[\"35 cocaine users\", \"underwent\", \"exercise electrocardiography\"]\n[\"35 cocaine users\", \"underwent\", \"Doppler echocardiography\"]\nGranularity: 3",
            "[\"Findings\", \"consistent with\", \"coronary artery disease\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"coronary artery disease\", \"detected in\", \"12 (34%) patients\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"coronary artery disease\", \"detected in\", \"3 (9%) controls\"]": " \n[\"coronary artery disease\", \"detected in\", \"3 controls\"]\n[\"coronary artery disease\", \"detected in\", \"9% controls\"]\nGranularity: 2",
            "[\"decreased left ventricular systolic function\", \"demonstrated in\", \"5 (14%) patients\"]": " \n[\"decreased left ventricular systolic function\", \"demonstrated in\", \"5 patients\"]\n[\"decreased left ventricular systolic function\", \"demonstrated in\", \"14% of patients\"]\nGranularity: 2",
            "[\"decreased left ventricular systolic function\", \"not demonstrated in\", \"none of the controls\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"abnormal left ventricular filling\", \"detected in\", \"38 and 35% of patients\"]": " \n[\"abnormal left ventricular filling\", \"detected in\", \"38% of patients\"]\n[\"abnormal left ventricular filling\", \"detected in\", \"35% of patients\"]\nGranularity: 2",
            "[\"abnormal left ventricular filling\", \"detected in\", \"19 and 9% of controls\"]": " \n[\"abnormal left ventricular filling\", \"detected in\", \"19% of controls\"]\n[\"abnormal left ventricular filling\", \"detected in\", \"9% of controls\"]\nGranularity: 2",
            "[\"coronary artery or myocardial disease\", \"common in\", \"young asymptomatic chronic cocaine users\"]": " \n[\"coronary artery or myocardial disease\", \"common in\", \"young asymptomatic chronic cocaine users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"young asymptomatic cocaine users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"chronic cocaine users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"young cocaine users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"asymptomatic cocaine users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"young asymptomatic users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"young chronic users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"asymptomatic chronic users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"young users\"]\n[\"coronary artery or myocardial disease\", \"common in\", \"as",
            "[\"screening ECG and echocardiography\", \"may be warranted in\", \"these patients\"]": " \n[\"screening ECG\", \"may be warranted in\", \"these patients\"]\n[\"echocardiography\", \"may be warranted in\", \"these patients\"]\nGranularity: 2",
            "[\"Prevalence of heart disease\", \"in\", \"asymptomatic chronic cocaine users\"]": " \n[\"Prevalence of heart disease\", \"in\", \"asymptomatic cocaine users\"]\n[\"Prevalence of heart disease\", \"in\", \"chronic cocaine users\"]\nGranularity: 2"
      },
      "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin .|A 46 - year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin , pegylated interferon and telaprevir .|The patient also received simvastatin .|One month after starting the antiviral therapy , the patient was admitted to the hospital because he developed rhabdomyolysis .|At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug - drug interaction was suspected .|The creatine kinase peaked at 62 , 246 IU / L and the patient was treated with intravenous normal saline .|The patient 's renal function remained unaffected .|Fourteen days after hospitalization , creatine kinase level had returned to 230 IU / L and the patient was discharged .|Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale .|The interaction is due to inhibition of CYP3A4 - mediated simvastatin clearance .|Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood .|In conclusion , with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug - drug interactions .": {
            "[\"Rhabdomyolysis\", \"occurs in\", \"a hepatitis C virus infected patient\"]": " \n[\"Rhabdomyolysis\", \"occurs in\", \"a patient with hepatitis C virus\"]\n[\"Rhabdomyolysis\", \"occurs in\", \"a patient infected with hepatitis C virus\"]\nGranularity: 2",
            "[\"Hepatitis C virus infected patient\", \"is treated with\", \"telaprevir and simvastatin\"]": " \n[\"Hepatitis C virus infected patient\", \"is treated with\", \"telaprevir\"]\n[\"Hepatitis C virus infected patient\", \"is treated with\", \"simvastatin\"]\nGranularity: 2",
            "[\"Telaprevir\", \"is part of\", \"triple therapy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Triple therapy\", \"includes\", \"ribavirin, pegylated interferon, and telaprevir\"]": " \n[\"Triple therapy\", \"includes\", \"ribavirin\"]\n[\"Triple therapy\", \"includes\", \"pegylated interferon\"]\n[\"Triple therapy\", \"includes\", \"telaprevir\"]\nGranularity: 3",
            "[\"Patient\", \"also receives\", \"simvastatin\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"One month after starting antiviral therapy\", \"patient is admitted to hospital due to\", \"rhabdomyolysis\"]": " \n[\"One month after starting antiviral therapy\", \"leads to\", \"patient being admitted to hospital\"]\n[\"One month after starting antiviral therapy\", \"causes\", \"rhabdomyolysis\"]\nGranularity: 2",
            "[\"At admission\", \"simvastatin and antiviral drugs are discontinued due to\", \"suspected drug-drug interaction\"]": " \n[\"At admission\", \"simvastatin is discontinued due to\", \"suspected drug-drug interaction\"]\n[\"At admission\", \"antiviral drugs are discontinued due to\", \"suspected drug-drug interaction\"]\nGranularity: 2",
            "[\"Drug-drug interaction\", \"involves\", \"telaprevir and simvastatin\"]": " \n[\"Drug-drug interaction\", \"involves\", \"telaprevir\"]\n[\"Drug-drug interaction\", \"involves\", \"simvastatin\"]\nGranularity: 2",
            "[\"Telaprevir\", \"is considered the probable causative agent of interaction with\", \"simvastatin\"]": " \n[\"Telaprevir\", \"is considered the probable causative agent of\", \"interaction\"]\n[\"Telaprevir\", \"is considered the probable causative agent of\", \"interaction with\"]\n[\"Telaprevir\", \"is considered the probable causative agent of\", \"simvastatin\"]\nGranularity: 3",
            "[\"Interaction\", \"is due to\", \"inhibition of CYP3A4-mediated simvastatin clearance\"]": " \n[\"Interaction\", \"is due to\", \"inhibition of CYP3A4\"]\n[\"Interaction\", \"is due to\", \"simvastatin clearance\"]\nGranularity: 2",
            "[\"Simvastatin\", \"plasma concentration increases\", \"30 times\"]": " \n[\"Simvastatin\", \"plasma concentration\", \"increases\"]\n[\"Simvastatin\", \"plasma concentration\", \"30 times\"]\nGranularity: 2",
            "[\"Statin-induced muscle toxicity\", \"is related to\", \"concentration of statin in blood\"]": " \n[\"Statin-induced muscle toxicity\", \"is related to\", \"concentration of statin\"]\n[\"Statin-induced muscle toxicity\", \"is related to\", \"blood\"]\nGranularity: 2",
            "[\"In conclusion\", \"case illustrates\", \"telaprevir and statins are susceptible to clinical relevant drug-drug interactions\"]": " \n[\"telaprevir\", \"is susceptible to\", \"clinical relevant drug-drug interactions\"]\n[\"statins\", \"are susceptible to\", \"clinical relevant drug-drug interactions\"]\nGranularity: 2"
      },
      "Effects of a new calcium antagonist , CD - 832 , on isoproterenol - induced myocardial ischemia in dogs with partial coronary stenosis .|Effects of CD - 832 on isoproterenol ( ISO ) - induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem .|In the presence of coronary artery stenosis , 3 - min periods of intracoronary ISO infusion ( 10 ng / kg / min ) increased heart rate and maximal rate of left ventricular pressure rise , which resulted in a decrease in percentage segmental shortening and ST - segment elevation of the epicardial electrocardiogram .|After the control ISO infusion with stenosis was performed , equihypotensive doses of CD - 832 ( 3 and 10 micrograms / kg / min , n = 7 ) , nifedipine ( 1 and 3 micrograms / kg / min , n = 9 ) or diltiazem ( 10 and 30 micrograms / kg / min , n = 7 ) were infused 5 min before and during the second and third ISO infusion .|Both CD - 832 and diltiazem , but not nifedipine , significantly reduced the increase in heart rate induced by ISO infusion .|In contrast to nifedipine , CD - 832 ( 10 micrograms / kg / min ) prevented the decrease in percentage segmental shortening from 32 + / - 12 % to 115 + / - 26 % of the control value ( P < . 01 ) and ST - segment elevation from 5 . 6 + / - 1 . 0 mV to 1 . 6 + / - 1 . 3 mV ( P < . 01 ) at 3 min after ISO infusion with stenosis .|Diltiazem ( 30 micrograms / kg / min ) also prevented the decrease in percentage segmental shortening from 34 + / - 14 % to 63 + / - 18 % of the control value ( P < . 05 ) and ST - segment elevation from 4 . 7 + / - 0 . 7 mV to 2 . 1 + / - 0 . 7 mV ( P < . 01 ) at 3 min after ISO infusion with stenosis .|These data show that CD - 832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD - 832 plays a major role in the beneficial effects of CD - 832 .": {
            "[\"CD-832\", \"is a\", \"calcium antagonist\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"CD-832\", \"studied for effects on\", \"isoproterenol-induced myocardial ischemia\"]": " \n[\"CD-832\", \"studied for effects on\", \"isoproterenol-induced myocardial ischemia\"]\nGranularity: 1",
            "[\"CD-832\", \"compared with\", \"nifedipine or diltiazem\"]": " \n[\"CD-832\", \"compared with\", \"nifedipine\"]\n[\"CD-832\", \"compared with\", \"diltiazem\"]\nGranularity: 2",
            "[\"isoproterenol\", \"induces\", \"myocardial ischemia\"]": " N/A (The triple is specific, conveying a singular relation between isoproterenol and myocardial ischemia.)\nGranularity: 0",
            "[\"coronary artery stenosis\", \"causes\", \"increased heart rate and maximal rate of left ventricular pressure rise\"]": " \n[\"coronary artery stenosis\", \"causes\", \"increased heart rate\"]\n[\"coronary artery stenosis\", \"causes\", \"maximal rate of left ventricular pressure rise\"]\nGranularity: 2",
            "[\"intracoronary ISO infusion\", \"results in\", \"decrease in percentage segmental shortening and ST-segment elevation\"]": " \n[\"intracoronary ISO infusion\", \"results in\", \"decrease in percentage segmental shortening\"]\n[\"intracoronary ISO infusion\", \"results in\", \"decrease in ST-segment elevation\"]\nGranularity: 2",
            "[\"CD-832\", \"infused before and during\", \"second and third ISO infusion\"]": " \n[\"CD-832\", \"infused before\", \"second ISO infusion\"]\n[\"CD-832\", \"infused before\", \"third ISO infusion\"]\n[\"CD-832\", \"infused during\", \"second ISO infusion\"]\n[\"CD-832\", \"infused during\", \"third ISO infusion\"]\nGranularity: 4",
            "[\"CD-832\", \"significantly reduces\", \"increase in heart rate induced by ISO infusion\"]": " \n[\"CD-832\", \"reduces\", \"increase in heart rate\"]\n[\"CD-832\", \"reduces\", \"ISO infusion\"]\nGranularity: 2",
            "[\"CD-832\", \"prevents\", \"decrease in percentage segmental shortening and ST-segment elevation\"]": " \n[\"CD-832\", \"prevents\", \"decrease in percentage segmental shortening\"]\n[\"CD-832\", \"prevents\", \"ST-segment elevation\"]\nGranularity: 2",
            "[\"diltiazem\", \"also prevents\", \"decrease in percentage segmental shortening and ST-segment elevation\"]": " \n[\"diltiazem\", \"prevents\", \"decrease in percentage segmental shortening\"]\n[\"diltiazem\", \"prevents\", \"ST-segment elevation\"]\nGranularity: 2",
            "[\"CD-832\", \"improves\", \"myocardial ischemia during ISO infusion with stenosis\"]": " \n[\"CD-832\", \"improves\", \"myocardial ischemia\"]\n[\"CD-832\", \"improves\", \"ISO infusion\"]\n[\"CD-832\", \"improves\", \"stenosis\"]\nGranularity: 3",
            "[\"negative chronotropic property of CD-832\", \"plays a major role in\", \"beneficial effects of CD-832\"]": " \n[\"CD-832\", \"has negative chronotropic property\"]\n[\"negative chronotropic property\", \"plays a role in\", \"beneficial effects\"]\n[\"CD-832\", \"has beneficial effects\"]\nGranularity: 3"
      },
      "Structure - activity and dose - effect relationships of the antagonism of picrotoxin - induced seizures by cholecystokinin , fragments and analogues of cholecystokinin in mice .|Intraperitoneal administration of cholecystokinin octapeptide sulphate ester ( CCK - 8 - SE ) and nonsulphated cholecystokinin octapeptide ( CCK - 8 - NS ) enhanced the latency of seizures induced by picrotoxin in mice .|Experiments with N - and C - terminal fragments revealed that the C - terminal tetrapeptide ( CCK - 5 - 8 ) was the active centre of the CCK octapeptide molecule .|The analogues CCK - 8 - SE and CCK - 8 - NS ( dose range 0 . 2 - 6 . 4 mumol / kg ) and caerulein dose range 0 . 1 - 0 . 8 mumol / kg ) showed bell - shaped dose - effect curves , with the greatest maximum inhibition for CCK - 8 - NS .|The peptide CCK - 5 - 8 had weak anticonvulsant activity in comparison to the octapeptides , 3 . 2 mumol / kg and larger doses of the reference drug , diazepam , totally prevented picrotoxin - induced seizures and mortality .|The maximum effect of the peptides tested was less than that of diazepam .|Experiments with analogues and derivatives of CCK - 5 - 8 demonstrated that the effectiveness of the beta - alanyl derivatives of CCK - 5 - 8 were enhanced and that they were equipotent with CCK - 8 - SE .|Of the CCK - 2 - 8 analogues , Ser ( SO3H ) 7 - Ac - CCK - 2 - 8 - SE and Thr ( SO3H ) 7 - Ac - CCK - 2 - 8 - SE and Hyp ( SO3H ) - Ac - CCK - 2 - 8 - SE were slightly more active than CCK - 8 - SE .": {
            "[\"Structure - activity\", \"relationship\", \"dose - effect\"]": " \n[\"Structure - activity\", \"relationship\", \"dose\"]\n[\"Structure - activity\", \"relationship\", \"effect\"]\n[\"dose\", \"affects\", \"effect\"]\nGranularity: 3",
            "[\"picrotoxin - induced seizures\", \"antagonism of\", \"cholecystokinin\"]": " \n[\"picrotoxin-induced seizures\", \"antagonism\", \"cholecystokinin\"]\nGranularity: 1",
            "[\"cholecystokinin\", \"fragments and analogues of\", \"cholecystokinin\"]": " \n[\"cholecystokinin\", \"fragments of\", \"cholecystokinin\"]\n[\"cholecystokinin\", \"analogues of\", \"cholecystokinin\"]\nGranularity: 2",
            "[\"cholecystokinin octapeptide sulphate ester\", \"enhanced\", \"latency of seizures\"]": " \n[\"cholecystokinin octapeptide sulphate ester\", \"enhanced\", \"latency\"]\n[\"cholecystokinin octapeptide sulphate ester\", \"enhanced\", \"seizures\"]\nGranularity: 2",
            "[\"cholecystokinin octapeptide\", \"active centre of\", \"C - terminal tetrapeptide\"]": " \n[\"cholecystokinin octapeptide\", \"active centre\", \"C - terminal tetrapeptide\"]\n[\"cholecystokinin octapeptide\", \"active centre\", \"tetrapeptide\"]\n[\"cholecystokinin octapeptide\", \"active centre\", \"C - terminal\"]\n[\"cholecystokinin octapeptide\", \"active centre\", \"terminal tetrapeptide\"]\n[\"cholecystokinin octapeptide\", \"active centre\", \"C\"]\n[\"cholecystokinin octapeptide\", \"active centre\", \"terminal\"]\n[\"cholecystokinin octapeptide\", \"active centre\", \"C - terminal tetrapeptide\"]\n[\"cholecystokinin octapeptide\", \"active centre\", \"C - terminal tetrapeptide\"]\nGranularity: 8",
            "[\"CCK - 8 - SE and CCK - 8 - NS\", \"showed\", \"bell - shaped dose - effect curves\"]": " \n[\"CCK - 8 - SE\", \"showed\", \"bell - shaped dose - effect curves\"]\n[\"CCK - 8 - NS\", \"showed\", \"bell - shaped dose - effect curves\"]\nGranularity: 2",
            "[\"CCK - 5 - 8\", \"weak anticonvulsant activity in comparison to\", \"octapeptides\"]": " \n[\"CCK - 5 - 8\", \"has\", \"weak anticonvulsant activity\"]\n[\"CCK - 5 - 8\", \"compared to\", \"octapeptides\"]\nGranularity: 2",
            "[\"diazepam\", \"totally prevented\", \"picrotoxin - induced seizures and mortality\"]": " \n[\"diazepam\", \"prevented\", \"picrotoxin-induced seizures\"]\n[\"diazepam\", \"prevented\", \"mortality\"]\nGranularity: 2",
            "[\"peptides tested\", \"less than\", \"maximum effect of diazepam\"]": " \n[\"peptides tested\", \"less than\", \"maximum effect\"]\n[\"peptides tested\", \"less than\", \"diazepam\"]\nGranularity: 2",
            "[\"beta - alanyl derivatives of CCK - 5 - 8\", \"enhanced effectiveness of\", \"equipotent with CCK - 8 - SE\"]": " \n[\"beta - alanyl derivatives of CCK - 5 - 8\", \"enhanced effectiveness\", \"equipotent with CCK - 8 - SE\"]\n[\"beta - alanyl derivatives of CCK - 5 - 8\", \"enhanced effectiveness\", \"CCK - 8 - SE\"]\n[\"beta - alanyl derivatives of CCK - 5 - 8\", \"equipotent with\", \"CCK - 8 - SE\"]\nGranularity: 3",
            "[\"CCK - 2 - 8 analogues\", \"slightly more active than\", \"CCK - 8 - SE\"]": " \n[\"CCK - 2 - 8 analogues\", \"are slightly more active than\", \"CCK - 8 - SE\"]\nGranularity: 1"
      },
      "The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias .|1 . The optical isomers of propranolol have been compared for their beta - blocking and antiarrhythmic activities . 2 .|In blocking the positive inotropic and chronotropic responses to isoprenaline , ( + ) - propranolol had less than one hundredth the potency of ( - ) - propranolol .|At dose levels of ( + ) - propranolol which attenuated the responses to isoprenaline , there was a significant prolongation of the PR interval of the electrocardiogram . 3 .|The metabolic responses to isoprenaline in dogs ( an increase in circulating glucose , lactate and free fatty acids ) were all blocked by ( - ) - propranolol .|( + ) - Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and glucose . 4 .|Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea - pigs . 5 .|The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine .|The racemic compound was significantly less potent than either isomer . 6 .|Both isomers of propranolol were capable of preventing adrenaline - induced cardiac arrhythmias in cats anaesthetized with halothane , but the mean dose of ( - ) - propranolol was 0 . 09 + / - 0 . 02 mg / kg whereas that of ( + ) - propranolol was 4 . 2 + / - 1 . 2 mg / kg .|At the effective dose level of ( + ) - propranolol there was a significant prolongation of the PR interval of the electrocardiogram .|Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline . 7 .|Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs .|The dose of ( - ) - propranolol was significantly smaller than that of ( + ) - propranolol in both species but much higher than that required to produce evidence of beta - blockade . 8 .|The implications of these results are discussed .": {
            "[\"optical isomers of propranolol\", \"have\", \"beta-blocking and antiarrhythmic activities\"]": " \n[\"optical isomers of propranolol\", \"have\", \"beta-blocking activities\"]\n[\"optical isomers of propranolol\", \"have\", \"antiarrhythmic activities\"]\nGranularity: 2",
            "[\"( + ) - propranolol\", \"has\", \"less potency than ( - ) - propranolol\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"( + ) - propranolol\", \"causes\", \"prolongation of PR interval\"]": " \n[\"( + ) - propranolol\", \"causes\", \"prolongation of PR interval\"]\nGranularity: 1",
            "[\"( - ) - propranolol\", \"blocks\", \"metabolic responses to isoprenaline\"]": " \n[\"( - ) - propranolol\", \"blocks\", \"metabolic responses\"]\n[\"( - ) - propranolol\", \"blocks\", \"isoprenaline\"]\nGranularity: 2",
            "[\"( + ) - propranolol\", \"reduces\", \"increments in lactate and glucose\"]": " \n[\"( + ) - propranolol\", \"reduces\", \"increments in lactate\"]\n[\"( + ) - propranolol\", \"reduces\", \"increments in glucose\"]\nGranularity: 2",
            "[\"isomers of propranolol\", \"possess\", \"similar depressant potency\"]": " \n[\"isomers of propranolol\", \"possess\", \"depressant potency\"]\n[\"isomers of propranolol\", \"have\", \"similar potency\"]\nGranularity: 2",
            "[\"isomers of propranolol\", \"exhibit\", \"similar local anaesthetic potencies\"]": "\n[\"isomers of propranolol\", \"exhibit\", \"similar potencies\"]\n[\"isomers of propranolol\", \"exhibit\", \"local anaesthetic potencies\"]\nGranularity: 2",
            "[\"racemic compound\", \"is less potent than\", \"either isomer\"]": " \n[\"racemic compound\", \"is less potent than\", \"isomer 1\"]\n[\"racemic compound\", \"is less potent than\", \"isomer 2\"]\nGranularity: 2",
            "[\"both isomers of propranolol\", \"prevent\", \"adrenaline-induced cardiac arrhythmias\"]": " \n[\"both isomers of propranolol\", \"prevent\", \"adrenaline-induced cardiac arrhythmias\"]\nGranularity: 1",
            "[\"( + ) - propranolol\", \"causes\", \"significant prolongation of PR interval\"]": " \n[\"( + ) - propranolol\", \"causes\", \"prolongation of PR interval\"]\n[\"( + ) - propranolol\", \"causes\", \"significant prolongation\"]\nGranularity: 2",
            "[\"blockade of arrhythmias\", \"is surmountable by\", \"increasing adrenaline dose\"]": " \n[\"blockade of arrhythmias\", \"is surmountable by\", \"increasing adrenaline\"]\n[\"blockade of arrhythmias\", \"is surmountable by\", \"dose\"]\nGranularity: 2",
            "[\"both isomers of propranolol\", \"reverse\", \"ventricular tachycardia\"]": " \n[\"both isomers of propranolol\", \"reverse\", \"ventricular tachycardia\"]\nGranularity: 1",
            "[\"dose of ( - ) - propranolol\", \"is smaller than\", \"dose of ( + ) - propranolol\"]": " \n[\"dose of ( - ) - propranolol\", \"is smaller than\", \"dose of ( + ) - propranolol\"]\nGranularity: 1",
            "[\"results\", \"have\", \"implications\"]": " N/A (The relationship is abstract and does not have specific entities or actions to be broken down into.)\nGranularity: 0",
            "[\"optical isomers of propranolol\", \"have\", \"biological properties\"]": " \n[\"optical isomers of propranolol\", \"have\", \"biological properties\"]\nGranularity: 1"
      },
      "Depression , impulsiveness , sleep , and memory in past and present polydrug users of 3 , 4 - methylenedioxymethamphetamine ( MDMA , ecstasy ) .|RATIONALE : Ecstasy ( 3 , 4 - methylenedioxymethamphetamine , MDMA ) is a worldwide recreational drug of abuse .|Unfortunately , the results from human research investigating its psychological effects have been inconsistent .|OBJECTIVES : The present study aimed to be the largest to date in sample size and 5HT - related behaviors ; the first to compare present ecstasy users with past users after an abstinence of 4 or more years , and the first to include robust controls for other recreational substances .|METHODS : A sample of 997 participants ( 52 % male ) was recruited to four control groups ( non - drug ( ND ) , alcohol / nicotine ( AN ) , cannabis / alcohol / nicotine ( CAN ) , non - ecstasy polydrug ( PD ) ) , and two ecstasy polydrug groups ( present ( MDMA ) and past users ( EX - MDMA ) .|Participants completed a drug history questionnaire , Beck Depression Inventory , Barratt Impulsiveness Scale , Pittsburgh Sleep Quality Index , and Wechsler Memory Scale - Revised which , in total , provided 13 psychometric measures .|RESULTS : While the CAN and PD groups tended to record greater deficits than the non - drug controls , the MDMA and EX - MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures .|Strikingly , despite prolonged abstinence ( mean , 4 . 98 ; range , 4 - 9 years ) , past ecstasy users showed few signs of recovery .|Compared with present ecstasy users , the past users showed no change for ten measures , increased impairment for two measures , and improvement on just one measure .|CONCLUSIONS : Given this record of impaired memory and clinically significant levels of depression , impulsiveness , and sleep disturbance , the prognosis for the current generation of ecstasy users is a major cause for concern .": {
            "[\"Ecstasy\", \"is\", \"3, 4-methylenedioxymethamphetamine (MDMA)\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Ecstasy\", \"is\", \"a worldwide recreational drug of abuse\"]": " \n[\"Ecstasy\", \"is\", \"a recreational drug\"]\n[\"Ecstasy\", \"is\", \"abused worldwide\"]\nGranularity: 2",
            "[\"Results\", \"have been\", \"inconsistent\"]": " N/A (The triple does not provide enough context to be split into more specific sub-triples.)\nGranularity: 0",
            "[\"Study\", \"aimed to be\", \"the largest to date in sample size and 5HT-related behaviors\"]": "\n[\"Study\", \"aimed to be\", \"the largest in sample size\"]\n[\"Study\", \"aimed to be\", \"related to 5HT behaviors\"]\nGranularity: 2",
            "[\"Study\", \"the first\", \"to compare present ecstasy users with past users after an abstinence of 4 or more years\"]": " \n[\"Study\", \"compares\", \"present ecstasy users\"]\n[\"Study\", \"compares\", \"past ecstasy users\"]\n[\"Study\", \"compares\", \"present ecstasy users after an abstinence of 4 or more years\"]\n[\"Study\", \"compares\", \"past ecstasy users after an abstinence of 4 or more years\"]\nGranularity: 4",
            "[\"Study\", \"the first\", \"to include robust controls for other recreational substances\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Participants\", \"were recruited\", \"to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD))\"]": "\n[\"Participants\", \"were recruited\", \"to non-drug control group (ND)\"]\n[\"Participants\", \"were recruited\", \"to alcohol/nicotine control group (AN)\"]\n[\"Participants\", \"were recruited\", \"to cannabis/alcohol/nicotine control group (CAN)\"]\n[\"Participants\", \"were recruited\", \"to non-ecstasy polydrug control group (PD)\"]\nGranularity: 4",
            "[\"Participants\", \"were recruited\", \"to two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA))\"]": " \n[\"Participants\", \"were recruited\", \"to ecstasy polydrug groups\"]\n[\"ecstasy polydrug groups\", \"included\", \"present users (MDMA)\"]\n[\"ecstasy polydrug groups\", \"included\", \"past users (EX-MDMA)\"]\nGranularity: 3",
            "[\"Participants\", \"completed\", \"a drug history questionnaire, Beck Depression Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised\"]": " \n[\"Participants\", \"completed\", \"a drug history questionnaire\"]\n[\"Participants\", \"completed\", \"Beck Depression Inventory\"]\n[\"Participants\", \"completed\", \"Barratt Impulsiveness Scale\"]\n[\"Participants\", \"completed\", \"Pittsburgh Sleep Quality Index\"]\n[\"Participants\", \"completed\", \"Wechsler Memory Scale-Revised\"]\nGranularity: 5",
            "[\"CAN and PD groups\", \"tended to record\", \"greater deficits than the non-drug controls\"]": " \n[\"CAN groups\", \"tended to record\", \"greater deficits\"]\n[\"PD groups\", \"tended to record\", \"greater deficits\"]\n[\"non-drug controls\", \"tended to record\", \"greater deficits\"]\nGranularity: 3",
            "[\"MDMA and EX-MDMA groups\", \"recorded\", \"greater deficits than all the control groups on ten of the 13 psychometric measures\"]": " \n[\"MDMA and EX-MDMA groups\", \"recorded\", \"greater deficits\"]\n[\"MDMA and EX-MDMA groups\", \"recorded\", \"on ten of the 13 psychometric measures\"]\n[\"MDMA and EX-MDMA groups\", \"recorded\", \"greater deficits on ten of the 13 psychometric measures\"]\nGranularity: 3",
            "[\"Past ecstasy users\", \"showed few signs of recovery\", \"despite prolonged abstinence\"]": "\n[\"Past ecstasy users\", \"showed few signs of recovery\", \"prolonged abstinence\"]\nGranularity: 1",
            "[\"Past users\", \"compared with\", \"present ecstasy users\"]": " \n[\"Past users\", \"compared with\", \"present users\"]\n[\"Past users\", \"compared with\", \"ecstasy users\"]\nGranularity: 2",
            "[\"Past users\", \"showed no change\", \"for ten measures\"]": " \n[\"Past users\", \"showed\", \"no change\"]\n[\"Past users\", \"showed\", \"for ten measures\"]\nGranularity: 2",
            "[\"Past users\", \"increased impairment\", \"for two measures\"]": "\n[\"Past users\", \"increased\", \"impairment\"]\n[\"Past users\", \"increased\", \"for two measures\"]\nGranularity: 2",
            "[\"Past users\", \"improvement\", \"on just one measure\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Impaired memory\", \"clinically significant levels of\", \"depression, impulsiveness, and sleep disturbance\"]": " \n[\"Impaired memory\", \"is associated with\", \"clinically significant levels of depression\"]\n[\"Impaired memory\", \"is associated with\", \"clinically significant levels of impulsiveness\"]\n[\"Impaired memory\", \"is associated with\", \"clinically significant levels of sleep disturbance\"]\nGranularity: 3",
            "[\"Prognosis\", \"for the current generation of ecstasy users\", \"a major cause for concern\"]": " \n[\"Prognosis\", \"for\", \"ecstasy users\"]\n[\"ecstasy users\", \"are\", \"a major cause for concern\"]\nGranularity: 2"
      },
      "Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV .|We evaluated the association of alcohol consumption and depression , and their effects on HIV disease progression among women with HIV .|The study included 871 women with HIV who were recruited from 1993 - 1995 in four US cities .|The participants had physical examination , medical record extraction , and venipuncture , CD4 + T - cell counts determination , measurement of depression symptoms ( using the self - report Center for Epidemiological Studies - Depression Scale ) , and alcohol use assessment at enrollment , and semiannually until March 2000 .|Multilevel random coefficient ordinal models as well as multilevel models with joint responses were used in the analysis .|There was no significant association between level of alcohol use and CD4 + T - cell counts .|When participants were stratified by antiretroviral therapy ( ART ) use , the association between alcohol and CD4 + T - cell did not reach statistical significance .|The association between alcohol consumption and depression was significant ( p < 0 . 001 ) .|Depression had a significant negative effect on CD4 + T - cell counts over time regardless of ART use .|Our findings suggest that alcohol consumption has a direct association with depression .|Moreover , depression is associated with HIV disease progression .|Our findings have implications for the provision of alcohol use interventions and psychological resources to improve the health of women with HIV .": {
            "[\"Longitudinal association\", \"of\", \"alcohol use with HIV disease progression and psychological health of women with HIV\"]": " \n[\"Longitudinal association\", \"of\", \"alcohol use\"]\n[\"Longitudinal association\", \"of\", \"HIV disease progression\"]\n[\"Longitudinal association\", \"of\", \"psychological health\"]\n[\"women with HIV\", \"and\", \"alcohol use\"]\n[\"women with HIV\", \"and\", \"HIV disease progression\"]\n[\"women with HIV\", \"and\", \"psychological health\"]\nGranularity: 6",
            "[\"alcohol consumption\", \"and\", \"depression\"]": " N/A (The terms are already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"alcohol consumption\", \"effects on\", \"HIV disease progression among women with HIV\"]": " \n[\"alcohol consumption\", \"affects\", \"HIV disease progression\"]\n[\"alcohol consumption\", \"affects\", \"women with HIV\"]\nGranularity: 2",
            "[\"The study\", \"included\", \"871 women with HIV\"]": " \n[\"The study\", \"included\", \"871 women\"]\n[\"The study\", \"included\", \"women with HIV\"]\nGranularity: 2",
            "[\"The participants\", \"had\", \"physical examination, medical record extraction, and venipuncture\"]": " \n[\"The participants\", \"had\", \"physical examination\"]\n[\"The participants\", \"had\", \"medical record extraction\"]\n[\"The participants\", \"had\", \"venipuncture\"]\nGranularity: 3",
            "[\"The participants\", \"CD4 + T - cell counts determination\", \"measurement of depression symptoms\"]": " \n[\"The participants\", \"CD4 + T - cell counts determination\", \"measurement of depression symptoms\"]\nGranularity: 1",
            "[\"The participants\", \"alcohol use assessment\", \"at enrollment, and semiannually until March 2000\"]": " \n[\"The participants\", \"underwent\", \"alcohol use assessment\"]\n[\"The participants\", \"were assessed for\", \"alcohol use\"]\n[\"The participants\", \"were assessed semiannually until March 2000\"]\nGranularity: 3",
            "[\"Multilevel random coefficient ordinal models\", \"as well as\", \"multilevel models with joint responses\"]": " \n[\"Multilevel random coefficient ordinal models\", \"as well as\", \"multilevel models\"]\n[\"Multilevel random coefficient ordinal models\", \"as well as\", \"joint responses\"]\nGranularity: 2",
            "[\"There was no significant association\", \"between\", \"level of alcohol use and CD4 + T - cell counts\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"The association between alcohol consumption and depression\", \"was\", \"significant (p < 0. 001)\"]": "\n[\"alcohol consumption\", \"is associated with\", \"depression\"]\n[\"alcohol consumption\", \"has a significant effect on\", \"depression\"]\n[\"depression\", \"is significantly affected by\", \"alcohol consumption\"]\nGranularity: 3",
            "[\"Depression\", \"had a significant negative effect\", \"on CD4 + T - cell counts over time regardless of ART use\"]": " \n[\"Depression\", \"had a negative effect on\", \"CD4 + T - cell counts\"]\n[\"Depression\", \"had a negative effect on\", \"CD4 + T - cell counts over time\"]\n[\"Depression\", \"had a negative effect on\", \"CD4 + T - cell counts regardless of ART use\"]\n[\"Depression\", \"had a significant effect on\", \"CD4 + T - cell counts\"]\n[\"Depression\", \"had a significant effect on\", \"CD4 + T - cell counts over time\"]\n[\"Depression\", \"had a significant effect on\", \"CD4 + T - cell counts regardless of ART use\"]\nGranularity: 6",
            "[\"Our findings\", \"suggest\", \"that alcohol consumption has a direct association with depression\"]": " \n[\"Our findings\", \"suggest\", \"alcohol consumption\"]\n[\"alcohol consumption\", \"has a direct association with\", \"depression\"]\nGranularity: 2",
            "[\"Moreover\", \"depression is associated with\", \"HIV disease progression\"]": " \n[\"depression\", \"is associated with\", \"HIV disease progression\"]\nGranularity: 1",
            "[\"Our findings\", \"have implications for\", \"the provision of alcohol use interventions and psychological resources to improve the health of women with HIV\"]": " \n[\"Our findings\", \"have implications for\", \"alcohol use interventions\"]\n[\"Our findings\", \"have implications for\", \"psychological resources\"]\n[\"Our findings\", \"have implications for\", \"women with HIV\"]\nGranularity: 3"
      },
      "Chronic hyperprolactinemia and changes in dopamine neurons .|The tuberoinfundibular dopaminergic ( TIDA ) system is known to inhibit prolactin ( PRL ) secretion .|In young animals this system responds to acute elevations in serum PRL by increasing its activity .|However , this responsiveness is lost in aging rats with chronically high serum PRL levels .|The purpose of this study was to induce hyperprolactinemia in rats for extended periods of time and examine its effects on dopaminergic systems in the brain .|Hyperprolactinemia was induced by treatment with haloperidol , a dopamine receptor antagonist , and Palkovits ' microdissection technique in combination with high - performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain .|After 6 months of hyperprolactinemia , dopamine ( DA ) concentrations in the median eminence ( ME ) increased by 84 % over the control group .|Nine months of hyperprolactinemia produced a 50 % increase in DA concentrations in the ME over the control group .|However , DA response was lost if a 9 - month long haloperidol - induced hyperprolactinemia was followed by a 1 1 / 2 month - long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule .|There was no change in the levels of DA , norepinephrine ( NE ) , serotonin ( 5 - HT ) , or their metabolites in the arcuate nucleus ( AN ) , medial preoptic area ( MPA ) , caudate putamen ( CP ) , substantia nigra ( SN ) , and zona incerta ( ZI ) , except for a decrease in 5 - hydroxyindoleacetic acid ( 5 - HIAA ) in the AN after 6 - months of hyperprolactinemia and an increase in DA concentrations in the AN after 9 - months of hyperprolactinemia .|These results demonstrate that hyperprolactinemia specifically affects TIDA neurons and these effects vary , depending on the duration and intensity of hyperprolactinemia .|The age - related decrease in hypothalamic dopamine function may be associated with increases in PRL secretion .": {
            "[\"Chronic hyperprolactinemia\", \"and\", \"changes in dopamine neurons\"]": " \n[\"Chronic hyperprolactinemia\", \"causes\", \"changes in dopamine neurons\"]\n[\"Chronic hyperprolactinemia\", \"affects\", \"dopamine neurons\"]\nGranularity: 2",
            "[\"The tuberoinfundibular dopaminergic (TIDA) system\", \"is known to\", \"inhibit prolactin (PRL) secretion\"]": " \n[\"The tuberoinfundibular dopaminergic (TIDA) system\", \"inhibits\", \"prolactin (PRL) secretion\"]\n[\"The tuberoinfundibular dopaminergic (TIDA) system\", \"is known to\", \"inhibit prolactin (PRL) secretion\"]\nGranularity: 2",
            "[\"In young animals\", \"this system\", \"responds to acute elevations in serum PRL by increasing its activity\"]": " \n[\"In young animals\", \"this system\", \"responds to acute elevations in serum PRL\"]\n[\"this system\", \"increases its activity\", \"in response to acute elevations in serum PRL\"]\nGranularity: 2",
            "[\"However\", \"this responsiveness\", \"is lost in aging rats with chronically high serum PRL levels\"]": " \n[\"However\", \"this responsiveness\", \"is lost\"]\n[\"aging rats\", \"have\", \"chronically high serum PRL levels\"]\nGranularity: 2",
            "[\"The purpose of this study\", \"was to\", \"induce hyperprolactinemia in rats for extended periods of time and examine its effects on dopaminergic systems in the brain\"]": "\n[\"The purpose of this study\", \"was to\", \"induce hyperprolactinemia in rats\"]\n[\"The purpose of this study\", \"was to\", \"examine the effects of hyperprolactinemia on dopaminergic systems in the brain\"]\n[\"The purpose of this study\", \"was to\", \"induce hyperprolactinemia for extended periods of time\"]\n[\"The purpose of this study\", \"was to\", \"examine the effects of hyperprolactinemia on dopaminergic systems\"]\n[\"The purpose of this study\", \"was to\", \"examine the effects of hyperprolactinemia in the brain\"]\n[\"The purpose of this study\", \"was to\", \"examine the effects of hyperprolactinemia on the brain\"]\nGranularity: 6",
            "[\"Hyperprolactinemia\", \"was induced by\", \"treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography\"]": " \n[\"Hyperprolactinemia\", \"was induced by\", \"treatment with haloperidol\"]\n[\"Hyperprolactinemia\", \"was induced by\", \"Palkovits' microdissection technique\"]\n[\"Hyperprolactinemia\", \"was induced by\", \"high-performance liquid chromatography\"]\nGranularity: 3",
            "[\"After 6 months of hyperprolactinemia\", \"dopamine (DA) concentrations in the median eminence (ME)\", \"increased by 84% over the control group\"]": " \n[\"After 6 months of hyperprolactinemia\", \"dopamine concentrations\", \"increased by 84%\"]\n[\"dopamine\", \"increased by\", \"84%\"]\n[\"dopamine\", \"is found in\", \"the median eminence\"]\n[\"the median eminence\", \"is affected by\", \"hyperprolactinemia\"]\nGranularity: 4",
            "[\"However\", \"DA response\", \"was lost if a 9-month long haloperidol-induced hyperprolactinemia was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule\"]": " \n[\"DA response\", \"was lost\", \"if a 9-month long haloperidol-induced hyperprolactinemia\"]\n[\"DA response\", \"was lost\", \"if a 1 1/2 month-long extremely high increase in serum PRL levels\"]\n[\"DA response\", \"was lost\", \"if implantation of MMQ cells under the kidney capsule\"]\nGranularity: 3",
            "[\"These results\", \"demonstrate that\", \"hyperprolactinemia specifically affects TIDA neurons and these effects vary, depending on the duration and intensity of hyperprolactinemia\"]": " \n[\"hyperprolactinemia\", \"specifically affects\", \"TIDA neurons\"]\n[\"hyperprolactinemia\", \"affects\", \"TIDA neurons\"]\n[\"hyperprolactinemia\", \"affects\", \"TIDA neurons and these effects vary\"]\n[\"hyperprolactinemia\", \"affects\", \"TIDA neurons and these effects vary depending on the duration\"]\n[\"hyperprolactinemia\", \"affects\", \"TIDA neurons and these effects vary depending on the intensity\"]\n[\"hyperprolactinemia\", \"affects\", \"TIDA neurons and these effects vary depending on the duration and intensity\"]\nGranularity: 6",
            "[\"The age-related decrease in hypothalamic dopamine function\", \"may be associated with\", \"increases in PRL secretion\"]": "\n[\"The age-related decrease\", \"in hypothalamic dopamine function\", \"may be associated with\"]\n[\"hypothalamic dopamine function\", \"may be associated with\", \"increases in PRL secretion\"]\n[\"The age-related decrease\", \"in hypothalamic dopamine function\", \"may be associated with\", \"increases in PRL secretion\"]\nGranularity: 3"
      },
      "Serotonin reuptake inhibitors , paranoia , and the ventral basal ganglia .|Antidepressants have previously been associated with paranoid reactions in psychiatric patients .|Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here .|Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms .|Complicated depressive disorders ( including atypicality of course and symptomatology , chronicity , psychosis , bipolarity , and secondary onset in the course of a primary psychosis ) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors .|Although the pharmacology and neurobiology of paranoia remain cryptic , several mechanisms , including 5HT3 receptor - mediated dopamine release , beta - noradrenergic receptor downregulation , or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia ( possibly in lateral orbitofrontal or anterior cingulate circuits ) , might apply to this phenomenon .|These cases call attention to possible paranoid exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia .": {
            "[\"Serotonin reuptake inhibitors\", \"associated with\", \"paranoia\"]": " \n[\"Serotonin reuptake inhibitors\", \"associated with\", \"paranoia\"]\nGranularity: 1",
            "[\"Antidepressants\", \"previously associated with\", \"paranoid reactions\"]": " N/A (The triple is specific, conveying a singular relation between antidepressants and paranoid reactions.)\nGranularity: 0",
            "[\"Five cases\", \"reported\", \"paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline\"]": " \n[\"Five cases\", \"reported\", \"paranoid exacerbation\"]\n[\"paranoid exacerbation\", \"occurred with\", \"fluoxetine\"]\n[\"paranoid exacerbation\", \"occurred with\", \"amitriptyline\"]\nGranularity: 3",
            "[\"Elements common to these cases\", \"included\", \"a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms\"]": " \n[\"Elements common to these cases\", \"included\", \"a history of paranoid symptomatology\"]\n[\"Elements common to these cases\", \"included\", \"the concomitant occurrence of depressive and psychotic symptoms\"]\nGranularity: 2",
            "[\"Complicated depressive disorders\", \"may present particular vulnerability to\", \"paranoid exacerbations associated with serotonin reuptake inhibitors\"]": " \n[\"Complicated depressive disorders\", \"may present vulnerability to\", \"paranoid exacerbations\"]\n[\"Complicated depressive disorders\", \"may present vulnerability to\", \"serotonin reuptake inhibitors\"]\nGranularity: 2",
            "[\"Although the pharmacology and neurobiology of paranoia\", \"remain cryptic\", \"several mechanisms\"]": " \n[\"pharmacology of paranoia\", \"is cryptic\", \"several mechanisms\"]\n[\"neurobiology of paranoia\", \"is cryptic\", \"several mechanisms\"]\nGranularity: 2",
            "[\"Several mechanisms\", \"might apply to\", \"this phenomenon\"]": " \n[\"Several mechanisms\", \"might apply to\", \"this phenomenon\"]\nGranularity: 1",
            "[\"These cases\", \"call attention to\", \"possible paranoid exacerbations with serotonin reuptake blockers in select patients\"]": " \n[\"These cases\", \"call attention to\", \"paranoid exacerbations\"]\n[\"These cases\", \"call attention to\", \"serotonin reuptake blockers\"]\n[\"These cases\", \"call attention to\", \"select patients\"]\nGranularity: 3",
            "[\"These cases\", \"raise\", \"neurobiological considerations regarding paranoia\"]": " \n[\"These cases\", \"raise\", \"neurobiological considerations\"]\n[\"neurobiological considerations\", \"regarding\", \"paranoia\"]\nGranularity: 2"
      },
      "Differential effects of non - steroidal anti - inflammatory drugs on seizures produced by pilocarpine in rats .|The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain .|The present study was designed to investigate the effect of 5 non - steroidal anti - inflammatory drugs , sodium salicylate , phenylbutazone , indomethacin , ibuprofen and mefenamic acid , on seizures produced by pilocarpine .|Pretreatment of rats with sodium salicylate , ED50 103 mg / kg ( 60 - 174 ) , and phenylbutazone , 59 mg / kg ( 50 - 70 ) converted the non - convulsant dose of pilocarpine , 200 mg / kg , to a convulsant one .|Indomethacin , 1 - 10 mg / kg , and ibuprofen , 10 - 100 mg / kg , failed to modulate seizures produced by pilocarpine .|Mefenamic acid , 26 ( 22 - 30 ) mg / kg , prevented seizures and protected rats from seizure - related brain damage induced by pilocarpine , 380 mg / kg .|These results indicate that non - steroidal anti - inflammatory drugs differentially modulate the threshold for pilocarpine - induced seizures .": {
            "[\"non-steroidal anti-inflammatory drugs\", \"have differential effects on\", \"seizures produced by pilocarpine in rats\"]": " \n[\"non-steroidal anti-inflammatory drugs\", \"have effects on\", \"seizures\"]\n[\"non-steroidal anti-inflammatory drugs\", \"have effects on\", \"pilocarpine\"]\n[\"non-steroidal anti-inflammatory drugs\", \"have effects on\", \"rats\"]\nGranularity: 3",
            "[\"pilocarpine\", \"induces in rats\", \"seizures and status epilepticus\"]": " \n[\"pilocarpine\", \"induces in rats\", \"seizures\"]\n[\"pilocarpine\", \"induces in rats\", \"status epilepticus\"]\nGranularity: 2",
            "[\"pilocarpine\", \"causes\", \"widespread damage to the forebrain\"]": " \n[\"pilocarpine\", \"causes\", \"damage\"]\n[\"pilocarpine\", \"causes\", \"widespread damage\"]\n[\"pilocarpine\", \"causes\", \"damage to the forebrain\"]\nGranularity: 3",
            "[\"the present study\", \"was designed to investigate\", \"the effect of 5 non-steroidal anti-inflammatory drugs\"]": " \n[\"the present study\", \"investigated\", \"the effect of 5 non-steroidal anti-inflammatory drugs\"]\n[\"the present study\", \"was designed to\", \"investigate\"]\n[\"the present study\", \"was designed to investigate\", \"the effect\"]\n[\"the present study\", \"was designed to investigate\", \"5 non-steroidal anti-inflammatory drugs\"]\n[\"the present study\", \"was designed to investigate\", \"the effect of\"]\n[\"the present study\", \"was designed to investigate\", \"non-steroidal anti-inflammatory drugs\"]\n[\"the present study\", \"was designed to investigate\", \"5 drugs\"]\n[\"the present study\", \"was designed to investigate\", \"non-steroidal drugs\"]\n[\"the present study\", \"was designed to investigate\", \"anti-inflammatory drugs\"]\n[\"the present study\", \"was designed to investigate\", \"5 non-steroidal drugs\"]\n[\"the present study\", \"was designed to investigate\", \"5 anti-inflammatory drugs\"]\n[\"the present study\",",
            "[\"sodium salicylate\", \"phenylbutazone\", \"converted the non-convulsant dose of pilocarpine to a convulsant one\"]": " \n[\"sodium salicylate\", \"converted\", \"non-convulsant dose of pilocarpine\"]\n[\"sodium salicylate\", \"converted\", \"convulsant dose of pilocarpine\"]\n[\"sodium salicylate\", \"converted\", \"pilocarpine\"]\n[\"phenylbutazone\", \"converted\", \"non-convulsant dose of pilocarpine\"]\n[\"phenylbutazone\", \"converted\", \"convulsant dose of pilocarpine\"]\n[\"phenylbutazone\", \"converted\", \"pilocarpine\"]\nGranularity: 6",
            "[\"Indomethacin\", \"ibuprofen\", \"failed to modulate seizures produced by pilocarpine\"]": " \n[\"Indomethacin\", \"failed to modulate\", \"seizures\"]\n[\"ibuprofen\", \"failed to modulate\", \"seizures\"]\n[\"pilocarpine\", \"produced\", \"seizures\"]\nGranularity: 3",
            "[\"These results\", \"indicate\", \"non-steroidal anti-inflammatory drugs differentially modulate the threshold for pilocarpine-induced seizures\"]": " \n[\"These results\", \"indicate\", \"non-steroidal anti-inflammatory drugs\"]\n[\"These results\", \"indicate\", \"modulation of threshold for pilocarpine-induced seizures\"]\n[\"non-steroidal anti-inflammatory drugs\", \"modulate\", \"threshold for pilocarpine-induced seizures\"]\nGranularity: 3"
      },
      "Hyperosmolar nonketotic coma precipitated by lithium - induced nephrogenic diabetes insipidus .|A 45 - year - old man , with a 10 - year history of manic depression treated with lithium , was admitted with hyperosmolar , nonketotic coma .|He gave a five - year history of polyuria and polydipsia , during which time urinalysis had been negative for glucose .|After recovery from hyperglycaemia , he remained polyuric despite normal blood glucose concentrations ; water deprivation testing indicated nephrogenic diabetes insipidus , likely to be lithium - induced .|We hypothesize that when this man developed type 2 diabetes , chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration .": {
            "[\"Hyperosmolar nonketotic coma\", \"precipitated by\", \"lithium-induced nephrogenic diabetes insipidus\"]": " \n[\"Hyperosmolar nonketotic coma\", \"precipitated by\", \"lithium-induced nephrogenic diabetes insipidus\"]\n[\"lithium-induced nephrogenic diabetes insipidus\", \"precipitates\", \"Hyperosmolar nonketotic coma\"]\nGranularity: 2",
            "[\"A 45-year-old man\", \"has\", \"10-year history of manic depression treated with lithium\"]": " \n[\"A 45-year-old man\", \"has\", \"10-year history of manic depression\"]\n[\"10-year history of manic depression\", \"treated with\", \"lithium\"]\nGranularity: 2",
            "[\"A 45-year-old man\", \"admitted with\", \"hyperosmolar, nonketotic coma\"]": "\n[\"A 45-year-old man\", \"admitted with\", \"hyperosmolar coma\"]\n[\"A 45-year-old man\", \"admitted with\", \"nonketotic coma\"]\nGranularity: 2",
            "[\"A 45-year-old man\", \"gave a 5-year history of\", \"polyuria and polydipsia\"]": "\n[\"A 45-year-old man\", \"gave a\", \"5-year history\"]\n[\"A 45-year-old man\", \"gave a\", \"polyuria\"]\n[\"A 45-year-old man\", \"gave a\", \"polydipsia\"]\nGranularity: 3",
            "[\"A 45-year-old man\", \"urinalysis had been negative for\", \"glucose\"]": " \n[\"A 45-year-old man\", \"had\", \"urinalysis\"]\n[\"urinalysis\", \"was negative for\", \"glucose\"]\nGranularity: 2",
            "[\"He\", \"remained polyuric despite\", \"normal blood glucose concentrations\"]": " \n[\"He\", \"remained polyuric\", \"normal blood glucose concentrations\"]\nGranularity: 1",
            "[\"He\", \"indicated\", \"nephrogenic diabetes insipidus, likely to be lithium-induced\"]": " \n[\"He\", \"indicated\", \"nephrogenic diabetes insipidus\"]\n[\"He\", \"indicated\", \"likely to be lithium-induced\"]\nGranularity: 2",
            "[\"We\", \"hypothesize that\", \"when this man developed type 2 diabetes\"]": "\n[\"We\", \"hypothesize\", \"the development of type 2 diabetes\"]\n[\"this man\", \"developed\", \"type 2 diabetes\"]\nGranularity: 2",
            "[\"Chronic polyuria due to nephrogenic diabetes insipidus\", \"was sufficient to precipitate\", \"hyperosmolar dehydration\"]": " \n[\"Chronic polyuria due to nephrogenic diabetes insipidus\", \"precipitated\", \"hyperosmolar dehydration\"]\n[\"Chronic polyuria due to nephrogenic diabetes insipidus\", \"was sufficient to\", \"precipitate hyperosmolar dehydration\"]\nGranularity: 2"
      },
      "Morphine - induced seizures in newborn infants .|Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post - operative analgesia .|They received morphine in doses of 32 micrograms / kg / hr and 40 micrograms / kg / hr larger than a group of 10 neonates who received 6 - 24 micrograms / kg / hr and had no seizures .|Plasma concentrations of morphine in these neonates was excessive ( 60 and 90 mg / ml ) .|Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months .|It is suggested that post - operative intravenous morphine should not exceed 20 micrograms / kg / ml in neonates .": {
            "[\"Two neonates\", \"suffered from\", \"generalized seizures\"]": " \n[\"Two neonates\", \"suffered from\", \"generalized seizures\"]\nGranularity: 1",
            "[\"Morphine\", \"was administered\", \"intravenous morphine sulfate\"]": "\n[\"Morphine\", \"was administered\", \"intravenous\"]\n[\"Morphine\", \"was administered\", \"morphine sulfate\"]\nGranularity: 2",
            "[\"Morphine\", \"caused\", \"post-operative analgesia\"]": " N/A (The triple is specific, conveying a singular relation between morphine and post-operative analgesia.)\nGranularity: 0",
            "[\"Two neonates\", \"received\", \"morphine in larger doses\"]": " \n[\"Two neonates\", \"received\", \"morphine\"]\n[\"Two neonates\", \"received\", \"larger doses\"]\nGranularity: 2",
            "[\"10 neonates\", \"received\", \"morphine in smaller doses\"]": "\n[\"10 neonates\", \"received\", \"morphine\"]\n[\"10 neonates\", \"received\", \"smaller doses\"]\nGranularity: 2",
            "[\"Plasma concentrations of morphine\", \"were\", \"excessive\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Other known reasons for seizures\", \"were\", \"ruled out\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Convulsions\", \"stopped\", \"cessation of morphine\"]": " \n[\"Convulsions\", \"stopped\", \"cessation of morphine\"]\nGranularity: 1",
            "[\"Convulsions\", \"did not reoccur\", \"subsequent 8 months\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Post-operative intravenous morphine\", \"should not exceed\", \"20 micrograms / kg / ml in neonates\"]": " \n[\"Post-operative intravenous morphine\", \"should not exceed\", \"20 micrograms\"]\n[\"Post-operative intravenous morphine\", \"should not exceed\", \"kg\"]\n[\"Post-operative intravenous morphine\", \"should not exceed\", \"ml\"]\n[\"Post-operative intravenous morphine\", \"should not exceed\", \"in neonates\"]\nGranularity: 4",
            "[\"Morphine sulfate\", \"was administered\", \"intravenous\"]": " \n[\"Morphine sulfate\", \"was administered\", \"intravenous\"]\nGranularity: 1",
            "[\"Morphine sulfate\", \"caused\", \"post-operative analgesia\"]": " N/A (The triple is specific, conveying a singular relation between morphine sulfate and post-operative analgesia.)\nGranularity: 0",
            "[\"10 neonates\", \"received\", \"smaller doses of morphine\"]": " \n[\"10 neonates\", \"received\", \"smaller doses\"]\n[\"10 neonates\", \"received\", \"morphine\"]\nGranularity: 2",
            "[\"Smaller doses of morphine\", \"led to\", \"no seizures\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Excessive plasma concentrations\", \"led to\", \"seizures\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Cessation of morphine\", \"led to\", \"stopping of convulsions\"]": " \n[\"Cessation of morphine\", \"led to\", \"stopping of convulsions\"]\nGranularity: 1",
            "[\"Stopping of convulsions\", \"led to\", \"no reoccurrence in 8 months\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Morphine\", \"induces\", \"seizures in newborn infants\"]": " \n[\"Morphine\", \"induces\", \"seizures\"]\n[\"Morphine\", \"induces\", \"newborn infants\"]\nGranularity: 2",
            "[\"Two neonates\", \"received\", \"larger doses of morphine\"]": " \n[\"Two neonates\", \"received\", \"larger doses\"]\n[\"Two neonates\", \"received\", \"morphine\"]\nGranularity: 2",
            "[\"It is suggested\", \"that\", \"post-operative intravenous morphine should not exceed\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "\" Real - world \" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed / refractory multiple myeloma who were treated according to the standard clinical practice : a study of the Greek Myeloma Study Group .|Lenalidomide and dexamethasone ( RD ) is a standard of care for relapsed / refractory multiple myeloma ( RRMM ) , but there is limited published data on its efficacy and safety in the \" real world \" ( RW ) , according to the International Society of Pharmacoeconomics and Outcomes Research definition .|We studied 212 RRMM patients who received RD in RW .|Objective response ( > PR ( partial response ) ) rate was 77 . 4 % ( complete response ( CR ) , 20 . 2 % ) .|Median time to first and best response was 2 and 5 months , respectively .|Median time to CR when RD was given as 2nd or > 2 ( nd ) - line treatment at 4 and 11 months , respectively .|Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or bortezomib .|Median duration of response was 34 . 4 months , and it was higher in patients who received RD until progression ( not reached versus 19 months , p < 0 . 001 ) .|Improvement of humoral immunity occurred in 60 % of responders ( p < 0 . 001 ) and in the majority of patients who achieved stable disease .|Adverse events were reported in 68 . 9 % of patients ( myelosuppression in 49 . 4 % ) and 12 . 7 % of patients needed hospitalization .|Peripheral neuropathy was observed only in 2 . 5 % of patients and deep vein thrombosis in 5 . 7 % .|Dose reductions were needed in 31 % of patients and permanent discontinuation in 38 . 9 % .|Median time to treatment discontinuation was 16 . 8 months .|Performance status ( PS ) and initial lenalidomide dose predicted for treatment discontinuation .|Extra - medullary relapses occurred in 3 . 8 % of patients .|Our study confirms that RD is effective and safe in RRMM in the RW ; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease .": {
            "[\"Real-world\", \"data on\", \"efficacy and safety of lenalidomide and dexamethasone\"]": " \n[\"Real-world\", \"data on\", \"efficacy of lenalidomide\"]\n[\"Real-world\", \"data on\", \"efficacy of dexamethasone\"]\n[\"Real-world\", \"data on\", \"safety of lenalidomide\"]\n[\"Real-world\", \"data on\", \"safety of dexamethasone\"]\nGranularity: 4",
            "[\"Lenalidomide and dexamethasone\", \"is\", \"standard of care for RRMM\"]": " \n[\"Lenalidomide and dexamethasone\", \"is\", \"standard of care\"]\n[\"standard of care\", \"for\", \"RRMM\"]\nGranularity: 2",
            "[\"RD\", \"received by\", \"212 RRMM patients\"]": "\n[\"RD\", \"received by\", \"212 patients\"]\n[\"RD\", \"received\", \"212 RRMM patients\"]\nGranularity: 2",
            "[\"Objective response rate\", \"was\", \"77.4%\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Median time to first and best response\", \"was\", \"2 and 5 months\"]": " \n[\"Median time to first response\", \"was\", \"2 months\"]\n[\"Median time to best response\", \"was\", \"5 months\"]\nGranularity: 2",
            "[\"Median time to CR\", \"was\", \"4 and 11 months\"]": " \n[\"Median time to CR\", \"was\", \"4 months\"]\n[\"Median time to CR\", \"was\", \"11 months\"]\nGranularity: 2",
            "[\"Quality of response\", \"was independent of\", \"previous lines of therapies\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Median duration of response\", \"was\", \"34.4 months\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Improvement of humoral immunity\", \"occurred in\", \"60% of responders\"]": " \n[\"Improvement of humoral immunity\", \"occurred in\", \"60% of responders\"]\nGranularity: 1",
            "[\"Adverse events\", \"reported in\", \"68.9% of patients\"]": " \n[\"Adverse events\", \"reported in\", \"68.9% of patients\"]\nGranularity: 1",
            "[\"Myelosuppression\", \"in\", \"49.4% of patients\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Hospitalization\", \"needed by\", \"12.7% of patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Peripheral neuropathy\", \"observed in\", \"2.5% of patients\"]": " N/A (The triple is specific, conveying a singular relation between peripheral neuropathy and the percentage of patients affected.)\nGranularity: 0",
            "[\"Deep vein thrombosis\", \"in\", \"5.7% of patients\"]": " \n[\"Deep vein thrombosis\", \"occurs in\", \"5.7% of patients\"]\nGranularity: 1",
            "[\"Dose reductions\", \"needed in\", \"31% of patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Permanent discontinuation\", \"in\", \"38.9% of patients\"]": " \n[\"Permanent discontinuation\", \"occurs in\", \"38.9% of patients\"]\n[\"Permanent discontinuation\", \"is experienced by\", \"38.9% of patients\"]\nGranularity: 2",
            "[\"Median time to treatment discontinuation\", \"was\", \"16.8 months\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Performance status and initial lenalidomide dose\", \"predicted\", \"treatment discontinuation\"]": " \n[\"Performance status\", \"predicted\", \"treatment discontinuation\"]\n[\"initial lenalidomide dose\", \"predicted\", \"treatment discontinuation\"]\nGranularity: 2",
            "[\"Extra-medullary relapses\", \"occurred in\", \"3.8% of patients\"]": " \n[\"Extra-medullary relapses\", \"occurred\", \"in 3.8% of patients\"]\nGranularity: 1",
            "[\"Our study\", \"confirms\", \"RD's effectiveness and safety in RRMM in the RW\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Topical 0 . 025 % capsaicin in chronic post - herpetic neuralgia : efficacy , predictors of response and long - term course .|In order to evaluate the efficacy , time - course of action and predictors of response to topical capsaicin , 39 patients with chronic post - herpetic neuralgia ( PHN ) , median duration 24 months , were treated with 0 . 025 % capsaicin cream for 8 weeks .|During therapy the patients rated their pain on a visual analogue scale ( VAS ) and a verbal outcome scale .|A follow - up investigation was performed 10 - 12 months after study onset on the patients who had improved .|Nineteen patients ( 48 . 7 % ) substantially improved after the 8 - week trial ; 5 ( 12 . 8 % ) discontinued therapy due to side - effects such as intolerable capsaicin - induced burning sensations ( 4 ) or mastitis ( 1 ) ; 15 ( 38 . 5 % ) reported no benefit .|The decrease in VAS ratings was significant after 2 weeks of continuous application .|Of the responders 72 . 2 % were still improved at the follow - up ; only one - third of them had continued application irregularly .|Treatment effect was not dependent on patient 's age , duration or localization of PHN ( trigeminal involvement was excluded ) , sensory disturbance or pain character .|Treatment response was not correlated with the incidence , time - course or severity of capsaicin - induced burning .|If confirmed in controlled trials , the long - term results of this open , non - randomized study might indicate that the analgesic effect of capsaicin in PHN is mediated by both interference with neuropeptide metabolism and morphological changes ( perhaps degeneration ) of nociceptive afferents .": {
            "[\"Topical 0.025% capsaicin\", \"treated\", \"39 patients with chronic post-herpetic neuralgia\"]": " \n[\"Topical 0.025% capsaicin\", \"treated\", \"39 patients\"]\n[\"Topical 0.025% capsaicin\", \"treated\", \"chronic post-herpetic neuralgia\"]\n[\"39 patients\", \"with\", \"chronic post-herpetic neuralgia\"]\nGranularity: 3",
            "[\"39 patients\", \"had a median duration of\", \"24 months\"]": " \n[\"39 patients\", \"had\", \"a median duration\"]\n[\"39 patients\", \"had\", \"24 months\"]\nGranularity: 2",
            "[\"Patients\", \"rated their pain\", \"visual analogue scale (VAS) and a verbal outcome scale\"]": " \n[\"Patients\", \"rated\", \"pain on visual analogue scale (VAS)\"]\n[\"Patients\", \"rated\", \"pain on verbal outcome scale\"]\nGranularity: 2",
            "[\"Follow-up investigation\", \"performed\", \"10-12 months after study onset\"]": " \n[\"Follow-up investigation\", \"performed\", \"10-12 months after study onset\"]\nGranularity: 1",
            "[\"19 patients\", \"improved substantially\", \"after the 8-week trial\"]": "\n[\"19 patients\", \"improved\", \"substantially\"]\n[\"19 patients\", \"after\", \"the 8-week trial\"]\nGranularity: 2",
            "[\"5 patients\", \"discontinued therapy due to\", \"side-effects\"]": " \n[\"5 patients\", \"discontinued therapy\", \"due to side-effects\"]\nGranularity: 1",
            "[\"VAS ratings\", \"decreased significantly\", \"after 2 weeks of continuous application\"]": " \n[\"VAS ratings\", \"decreased\", \"after 2 weeks\"]\n[\"VAS ratings\", \"decreased\", \"continuous application\"]\nGranularity: 2",
            "[\"Responders\", \"still improved\", \"at the follow-up\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Treatment effect\", \"not dependent on\", \"patient's age, duration or localization of PHN\"]": " \n[\"Treatment effect\", \"not dependent on\", \"patient's age\"]\n[\"Treatment effect\", \"not dependent on\", \"duration of PHN\"]\n[\"Treatment effect\", \"not dependent on\", \"localization of PHN\"]\nGranularity: 3",
            "[\"Treatment response\", \"not correlated with\", \"incidence, time-course or severity of capsaicin-induced burning\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Long-term results of this open, non-randomized study\", \"might indicate\", \"that the analgesic effect of capsaicin in PHN is mediated by both interference with neuropeptide metabolism and morphological changes (perhaps degeneration) of nociceptive afferents\"]": " \n[\"Long-term results\", \"indicate\", \"analgesic effect of capsaicin\"]\n[\"Long-term results\", \"indicate\", \"interference with neuropeptide metabolism\"]\n[\"Long-term results\", \"indicate\", \"morphological changes of nociceptive afferents\"]\n[\"Long-term results\", \"indicate\", \"degeneration of nociceptive afferents\"]\n[\"open, non-randomized study\", \"indicates\", \"analgesic effect of capsaicin\"]\n[\"open, non-randomized study\", \"indicates\", \"interference with neuropeptide metabolism\"]\n[\"open, non-randomized study\", \"indicates\", \"morphological changes of nociceptive afferents\"]\n[\"open, non-randomized study\", \"indicates\", \"degeneration of nociceptive afferents\"]\n[\"analgesic effect of capsaicin\", \"is mediated by\", \"interference with neuropeptide metabolism\"]\n[\"analgesic"
      },
      "Delirium during fluoxetine treatment .|A case report .|The correlation between high serum tricyclic antidepressant concentrations and central nervous system side effects has been well established .|Only a few reports exist , however , on the relationship between the serum concentrations of selective serotonin reuptake inhibitors ( SSRIs ) and their toxic effects .|In some cases , a high serum concentration of citalopram ( > 600 nmol / L ) in elderly patients has been associated with increased somnolence and movement difficulties .|Widespread cognitive disorders , such as delirium , have not been previously linked with high blood levels of SSRIs .|In this report , we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine ( fluoxetine plus desmethylfluoxetine ) concentration .": {
            "[\"Delirium\", \"during\", \"fluoxetine treatment\"]": " \n[\"Delirium\", \"during\", \"fluoxetine treatment\"]\nGranularity: 1",
            "[\"A case report\", \"describes\", \"correlation between high serum tricyclic antidepressant concentrations and central nervous system side effects\"]": " \n[\"A case report\", \"describes\", \"correlation between high serum tricyclic antidepressant concentrations\"]\n[\"A case report\", \"describes\", \"central nervous system side effects\"]\nGranularity: 2",
            "[\"Few reports\", \"exist\", \"relationship between serum concentrations of selective serotonin reuptake inhibitors (SSRIs) and their toxic effects\"]": " \n[\"Few reports\", \"exist\", \"relationship between serum concentrations of selective serotonin reuptake inhibitors (SSRIs)\"]\n[\"Few reports\", \"exist\", \"toxic effects of SSRIs\"]\nGranularity: 2",
            "[\"High serum concentration of citalopram\", \"associated with\", \"increased somnolence and movement difficulties\"]": " \n[\"High serum concentration of citalopram\", \"associated with\", \"increased somnolence\"]\n[\"High serum concentration of citalopram\", \"associated with\", \"movement difficulties\"]\nGranularity: 2",
            "[\"Widespread cognitive disorders\", \"have not been previously linked with\", \"high blood levels of SSRIs\"]": " \n[\"Widespread cognitive disorders\", \"have not been previously linked with\", \"high blood levels\"]\n[\"high blood levels\", \"have not been previously linked with\", \"SSRIs\"]\nGranularity: 2",
            "[\"Patient\", \"described with\", \"acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration\"]": " \n[\"Patient\", \"described with\", \"acute hyperkinetic delirium\"]\n[\"Patient\", \"described with\", \"high serum total fluoxetine concentration\"]\n[\"Patient\", \"described with\", \"high serum fluoxetine concentration\"]\n[\"Patient\", \"described with\", \"high serum desmethylfluoxetine concentration\"]\n[\"Patient\", \"described with\", \"acute delirium\"]\n[\"Patient\", \"described with\", \"hyperkinetic delirium\"]\n[\"Patient\", \"described with\", \"high serum total fluoxetine plus desmethylfluoxetine concentration\"]\nGranularity: 7"
      },
      "The effects of quinine and 4 - aminopyridine on conditioned place preference and changes in motor activity induced by morphine in rats .|1 . The effects of two unselective potassium ( K ( + ) - ) channel blockers , quinine ( 12 . 5 , 25 and 50 mg / kg ) and 4 - aminopyridine ( 1 and 2 mg / kg ) , on conditioned place preference and biphasic changes in motor activity induced by morphine ( 10 mg / kg ) were tested in Wistar rats .|Quinine is known to block voltage - , calcium - and ATP - sensitive K ( + ) - channels while 4 - aminopyridine is known to block voltage - sensitive K ( + ) - channels .|2 .|In the counterbalanced method , quinine attenuated morphine - induced place preference , whereas 4 - aminopyridine was ineffective .|In the motor activity test measured with an Animex - activity meter neither of the K ( + ) - channel blockers affected morphine - induced hypoactivity , but both K ( + ) - channel blockers prevented morphine - induced secondary hyperactivity .|3 .|These results suggest the involvement of quinine - sensitive but not 4 - aminopyridine - sensitive K ( + ) - channels in morphine reward .|It is also suggested that the blockade of K ( + ) - channels sensitive to these blockers is not sufficient to prevent morphine - induced hypoactivity whereas morphine - induced hyperactivity seems to be connected to both quinine - and 4 - aminopyridine - sensitive K ( + ) - channels .": {
            "[\"4-aminopyridine\", \"is a type of\", \"unselective potassium channel blocker\"]": " \n[\"4-aminopyridine\", \"is\", \"a type of\"]\n[\"4-aminopyridine\", \"blocks\", \"unselective potassium channels\"]\nGranularity: 2",
            "[\"Quinine\", \"blocks\", \"voltage-, calcium-, and ATP-sensitive K(+) channels\"]": " \n[\"Quinine\", \"blocks\", \"voltage-sensitive K(+) channels\"]\n[\"Quinine\", \"blocks\", \"calcium-sensitive K(+) channels\"]\n[\"Quinine\", \"blocks\", \"ATP-sensitive K(+) channels\"]\nGranularity: 3",
            "[\"4-aminopyridine\", \"blocks\", \"voltage-sensitive K(+) channels\"]": "\n[\"4-aminopyridine\", \"blocks\", \"voltage-sensitive K(+) channels\"]\nGranularity: 0",
            "[\"Quinine\", \"attenuates\", \"morphine-induced place preference\"]": " \n[\"Quinine\", \"attenuates\", \"morphine-induced place preference\"]\n[\"Quinine\", \"attenuates\", \"morphine-induced place preference\"]\nGranularity: 2",
            "[\"4-aminopyridine\", \"does not affect\", \"morphine-induced place preference\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Quinine\", \"does not affect\", \"morphine-induced hypoactivity\"]": " N/A (The triple is specific, conveying a singular relation between Quinine and morphine-induced hypoactivity.)\nGranularity: 0",
            "[\"4-aminopyridine\", \"does not affect\", \"morphine-induced hypoactivity\"]": " N/A (The triple is specific, conveying a singular relation between 4-aminopyridine and morphine-induced hypoactivity.)\nGranularity: 0",
            "[\"Quinine\", \"prevents\", \"morphine-induced secondary hyperactivity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"4-aminopyridine\", \"prevents\", \"morphine-induced secondary hyperactivity\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Quinine-sensitive K(+) channels\", \"are involved in\", \"morphine reward\"]": " \n[\"Quinine-sensitive K(+) channels\", \"are involved in\", \"morphine\"]\n[\"Quinine-sensitive K(+) channels\", \"are involved in\", \"reward\"]\nGranularity: 2",
            "[\"4-aminopyridine-sensitive K(+) channels\", \"are not involved in\", \"morphine reward\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Blockade of K(+) channels\", \"is not sufficient to prevent\", \"morphine-induced hypoactivity\"]": " \n[\"Blockade of K(+) channels\", \"is not sufficient to prevent\", \"morphine-induced hypoactivity\"]\nGranularity: 1",
            "[\"Quinine- and 4-aminopyridine-sensitive K(+) channels\", \"are connected to\", \"morphine-induced hyperactivity\"]": " \n[\"Quinine- and 4-aminopyridine-sensitive K(+) channels\", \"are connected to\", \"morphine-induced hyperactivity\"]\nGranularity: 1",
            "[\"Quinine\", \"is a type of\", \"unselective potassium channel blocker\"]": " N/A (The triple is specific, conveying a singular relation between Quinine and its classification as an unselective potassium channel blocker.)\nGranularity: 0"
      },
      "The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin - induced cardiotoxicity in mice .|PURPOSE : Despite its well - known cardiotoxicity , the anthracyclin doxorubicin ( DOX ) continues to be an effective and widely used chemotherapeutic agent .|DOX - induced cardiac damage presumably results from the formation of free radicals by DOX .|Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system .|The semisynthetic flavonoid monohydroxyethylrutoside ( monoHER ) showed cardioprotection against DOX - induced cardiotoxicity through its radical scavenging and iron chelating properties .|Because of the relatively short final half - life of monoHER ( about 30 min ) , it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER .|Therefore , the aim of the present study was to investigate this possible effect .|METHODS : Six groups of 6 BALB / c mice were treated with saline , DOX alone or DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . ) with an interval of 10 , 30 , 60 or 120 min .|After a 6 - week treatment period and additional observation for 2 weeks , the mice were sacrificed .|Their cardiac tissues were processed for light microscopy , after which cardiomyocyte damage was evaluated according to Billingham ( in Cancer Treat Rep 62 ( 6 ) : 865 - 872 , 1978 ) .|Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group ( P < 0 . 001 ) .|RESULTS : The number of damaged cardiomyocytes was 9 . 6 - fold ( 95 % CI 4 . 4 - 21 . 0 ) higher in mice treated with DOX alone than that in animals of the control group .|The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER and those in mice treated with saline ranged from 1 . 6 to 2 . 8 ( mean 2 . 2 , 95 % CI 1 . 2 - 4 . 1 , P = 0 . 019 ) .|The mean protective effect by adding monoHER before DOX led to a significant 4 . 4 - fold reduction ( P < 0 . 001 , 95 % CI 2 . 3 - 8 . 2 ) of abnormal cardiomyocytes .|This protective effect did not depend on the time interval between monoHER and DOX administration ( P = 0 . 345 ) .|CONCLUSION : The results indicate that in an outpatient clinical setting monoHER may be administered shortly before DOX .": {
            "[\"Doxorubicin\", \"induces\", \"cardiac damage\"]": " N/A (The triple is specific, conveying a singular relation between Doxorubicin and cardiac damage.)\nGranularity: 0",
            "[\"Dox - induced cardiac damage\", \"results from\", \"the formation of free radicals by DOX\"]": " \n[\"Dox - induced cardiac damage\", \"results from\", \"the formation of free radicals\"]\n[\"Dox - induced cardiac damage\", \"results from\", \"DOX\"]\nGranularity: 2",
            "[\"Reactive oxygen species\", \"particularly affect\", \"cardiac myocytes\"]": " \n[\"Reactive oxygen species\", \"affect\", \"cardiac myocytes\"]\n[\"Reactive oxygen species\", \"particularly affect\", \"cardiac myocytes\"]\nGranularity: 2",
            "[\"Cardiac myocytes\", \"have\", \"a relatively poor antioxidant defense system\"]": " \n[\"Cardiac myocytes\", \"have\", \"poor antioxidant defense\"]\n[\"Cardiac myocytes\", \"have\", \"a relatively poor antioxidant system\"]\nGranularity: 2",
            "[\"The semisynthetic flavonoid monohydroxyethylrutoside (monoHER)\", \"shows\", \"cardioprotection against DOX - induced cardiotoxicity\"]": " \n[\"monoHER\", \"shows\", \"cardioprotection\"]\n[\"monoHER\", \"shows\", \"against DOX-induced cardiotoxicity\"]\nGranularity: 2",
            "[\"The cardioprotective effect of monoHER\", \"may be influenced by\", \"the time interval between monoHER and DOX\"]": " \n[\"The cardioprotective effect of monoHER\", \"may be influenced by\", \"the time interval between monoHER\"]\n[\"The cardioprotective effect of monoHER\", \"may be influenced by\", \"DOX\"]\nGranularity: 2",
            "[\"The present study\", \"aimed to investigate\", \"this possible effect\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"Six groups of 6 BALB / c mice\", \"were treated with\", \"saline , DOX alone or DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . ) with an interval of 10 , 30 , 60 or 120 min .\"]": "\n[\"Six groups of 6 BALB / c mice\", \"were treated with\", \"saline\"]\n[\"Six groups of 6 BALB / c mice\", \"were treated with\", \"DOX alone\"]\n[\"Six groups of 6 BALB / c mice\", \"were treated with\", \"DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . )\"]\n[\"DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . )\", \"with an interval of\", \"10 min\"]\n[\"DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . )\", \"with an interval of\", \"30 min\"]\n[\"DOX ( 4 mg / kg i . v . ) preceded by monoHER ( 500 mg / kg i . p . )",
            "[\"Their cardiac tissues\", \"were processed for\", \"light microscopy\"]": " \n[\"Their cardiac tissues\", \"were processed\", \"for light microscopy\"]\nGranularity: 1",
            "[\"Cardiomyocyte damage\", \"was evaluated according to\", \"Billingham (in Cancer Treat Rep 62 ( 6 ): 865 - 872 , 1978 )\"]": " \n[\"Cardiomyocyte damage\", \"was evaluated\", \"according to Billingham\"]\n[\"Cardiomyocyte damage\", \"was evaluated\", \"in Cancer Treat Rep 62 ( 6 ): 865 - 872 , 1978\"]\nGranularity: 2",
            "[\"Microscopic evaluation\", \"revealed that\", \"treatment with DOX alone induced significant cardiac damage in comparison to the saline control group ( P < 0 . 001 )\"]": " \n[\"Microscopic evaluation\", \"revealed\", \"cardiac damage\"]\n[\"treatment with DOX alone\", \"induced\", \"cardiac damage\"]\n[\"treatment with DOX alone\", \"induced\", \"significant cardiac damage\"]\n[\"treatment with DOX alone\", \"induced\", \"cardiac damage in comparison to the saline control group\"]\n[\"treatment with DOX alone\", \"induced\", \"significant cardiac damage in comparison to the saline control group\"]\n[\"treatment with DOX alone\", \"induced\", \"significant cardiac damage in comparison to the saline control group ( P < 0 . 001 )\"]\nGranularity: 6",
            "[\"The number of damaged cardiomyocytes\", \"was 9 . 6 - fold higher\", \"in mice treated with DOX alone than that in animals of the control group\"]": " \n[\"The number of damaged cardiomyocytes\", \"was higher in mice treated with DOX alone\"]\n[\"The number of damaged cardiomyocytes\", \"was 9.6-fold higher in mice treated with DOX alone\"]\n[\"The number of damaged cardiomyocytes\", \"was higher in animals of the control group\"]\n[\"The number of damaged cardiomyocytes\", \"was 9.6-fold higher in animals of the control group\"]\nGranularity: 4",
            "[\"The ratio of aberrant cardiomyocytes in mice treated with DOX preceded by monoHER\", \"ranged from\", \"1 . 6 to 2 . 8 ( mean 2 . 2 , 95 % CI 1 . 2 - 4 . 1 , P = 0 . 019 )\"]": "\n[\"mice treated with DOX\", \"had a ratio of aberrant cardiomyocytes\", \"ranging from 1.6 to 2.8\"]\n[\"mice treated with DOX\", \"had a mean ratio of aberrant cardiomyocytes of 2.2\"]\n[\"mice treated with DOX\", \"had a 95% confidence interval for the ratio of aberrant cardiomyocytes of 1.2-4.1\"]\n[\"mice treated with DOX\", \"had a p-value of 0.019 for the ratio of aberrant cardiomyocytes\"]\nGranularity: 4",
            "[\"The mean protective effect by adding monoHER before DOX\", \"led to a significant 4 . 4 - fold reduction\", \"of abnormal cardiomyocytes\"]": " \n[\"monoHER\", \"added before\", \"DOX\"]\n[\"DOX\", \"led to\", \"4.4-fold reduction\"]\n[\"4.4-fold reduction\", \"of\", \"abnormal cardiomyocytes\"]\nGranularity: 3",
            "[\"This protective effect\", \"did not depend on\", \"the time interval between monoHER and DOX administration ( P = 0 . 345 )\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"The results\", \"indicate that\", \"in an outpatient clinical setting monoHER may be administered shortly before DOX .\"]": " \n[\"The results\", \"indicate\", \"in an outpatient clinical setting\"]\n[\"The results\", \"indicate\", \"monoHER may be administered shortly before DOX\"]\nGranularity: 2",
            "[\"The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin - induced cardiotoxicity in mice\", \"is the topic of\", \"the present study\"]": " \n[\"The influence of the time interval between monoHER and doxorubicin administration\", \"on the protection against doxorubicin-induced cardiotoxicity\", \"is the topic of the present study\"]\n[\"The influence of the time interval between monoHER and doxorubicin administration\", \"on the protection against doxorubicin-induced cardiotoxicity\", \"is the focus of the present study\"]\n[\"The influence of the time interval between monoHER and doxorubicin administration\", \"on the protection against doxorubicin-induced cardiotoxicity\", \"is the subject of the present study\"]\nGranularity: 3",
            "[\"Doxorubicin\", \"continues to be\", \"an effective and widely used chemotherapeutic agent\"]": " \n[\"Doxorubicin\", \"continues to be\", \"an effective chemotherapeutic agent\"]\n[\"Doxorubicin\", \"continues to be\", \"a widely used chemotherapeutic agent\"]\nGranularity: 2"
      },
      "Fetal risks due to warfarin therapy during pregnancy .|Two mothers with heart valve prosthesis were treated with warfarin during pregnancy .|In the first case a caesarean section was done one week after replacement of warfarin with heparin .|The baby died of cerebral and pulmonary hemorrhage .|The second mother had a male infant by caesarean section .|The baby showed warfarin - induced embryopathy with nasal hypoplasia and stippled epiphyses ( chondrodysplasia punctata ) .|Nasal hypoplasia with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with warfarin during the first trimester , and a causal association is probable .|In view of the risks to both mother and fetus in women with prosthetic cardiac valves it is recommended that therapeutic abortion be advised as the first alternative .": {
            "[\"Fetal risks\", \"due to\", \"warfarin therapy during pregnancy\"]": " \n[\"Fetal risks\", \"due to\", \"warfarin therapy\"]\n[\"warfarin therapy\", \"during\", \"pregnancy\"]\nGranularity: 2",
            "[\"Two mothers\", \"with\", \"heart valve prosthesis\"]": " \n[\"Two mothers\", \"have\", \"heart valve prosthesis\"]\n[\"Two mothers\", \"are\", \"heart valve prosthesis\"]\nGranularity: 2",
            "[\"Warfarin\", \"treated\", \"Two mothers\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"First mother\", \"caesarean section\", \"one week after replacement of warfarin with heparin\"]": " \n[\"First mother\", \"underwent\", \"caesarean section\"]\n[\"First mother\", \"replaced\", \"warfarin with heparin\"]\n[\"warfarin\", \"replaced with\", \"heparin\"]\nGranularity: 3",
            "[\"Baby\", \"died of\", \"cerebral and pulmonary hemorrhage\"]": " \n[\"Baby\", \"died of\", \"cerebral hemorrhage\"]\n[\"Baby\", \"died of\", \"pulmonary hemorrhage\"]\nGranularity: 2",
            "[\"Second mother\", \"male infant\", \"by caesarean section\"]": " \n[\"Second mother\", \"gives birth to\", \"male infant\"]\n[\"Second mother\", \"undergoes\", \"caesarean section\"]\nGranularity: 2",
            "[\"Baby\", \"showed\", \"warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata)\"]": " \n[\"Baby\", \"showed\", \"warfarin-induced embryopathy\"]\n[\"Baby\", \"showed\", \"nasal hypoplasia\"]\n[\"Baby\", \"showed\", \"stippled epiphyses\"]\n[\"Baby\", \"showed\", \"chondrodysplasia punctata\"]\nGranularity: 4",
            "[\"Nasal hypoplasia\", \"reported in\", \"11 infants born to mothers treated with warfarin during the first trimester\"]": "\n[\"Nasal hypoplasia\", \"reported in\", \"11 infants\"]\n[\"mothers\", \"treated with\", \"warfarin\"]\n[\"warfarin\", \"during\", \"first trimester\"]\nGranularity: 3",
            "[\"Causal association\", \"probable\", \"Nasal hypoplasia with or without stippled epiphyses\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Risks\", \"to both mother and fetus\", \"in women with prosthetic cardiac valves\"]": " \n[\"Risks\", \"to mother\", \"in women with prosthetic cardiac valves\"]\n[\"Risks\", \"to fetus\", \"in women with prosthetic cardiac valves\"]\n[\"Risks\", \"to both mother and fetus\", \"in women with prosthetic cardiac valves\"]\nGranularity: 3",
            "[\"Therapeutic abortion\", \"recommended as the first alternative\", \"in view of the risks\"]": " \n[\"Therapeutic abortion\", \"recommended as\", \"first alternative\"]\n[\"Therapeutic abortion\", \"recommended\", \"in view of the risks\"]\nGranularity: 2"
      },
      "Lateral antebrachial cutaneous neuropathy after steroid injection at lateral epicondyle .|BACKGROUND AND OBJECTIVES : This report aimed to present a case of lateral antebrachial cutaneous neuropathy ( LACNP ) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40 - year - old woman .|MATERIAL AND METHOD : A 40 - year - old woman presented with decreased sensation and paresthesia over her right lateral forearm ; the paresthesia had occurred after a steroid injection in the right lateral epicondyle 3 months before .|Her sensation of light touch and pain was diminished over the lateral side of the right forearm and wrist area .|RESULTS : The sensory action potential amplitude of the right lateral antebrachial cutaneous nerve ( LACN ) ( 6 . 2 uV ) was lower than that of the left ( 13 . 1 uV ) .|The difference of amplitude between both sides was significant because there was more than a 50 % reduction .|She was diagnosed with right LACNP ( mainly axonal involvement ) on the basis of the clinical manifestation and the electrodiagnostic findings .|Her symptoms improved through physical therapy but persisted to some degree .|CONCLUSION : This report describes the case of a woman with LACNP that developed after a steroid injection for the treatment of lateral epicondylitis .|An electrodiagnostic study , including a nerve conduction study of the LACN , was helpful to diagnose right LACNP and to find the passage of the LACN on the lateral epicondyle .": {
            "[\"steroid injection\", \"caused\", \"lateral antebrachial cutaneous neuropathy\"]": " \n[\"steroid injection\", \"caused\", \"lateral antebrachial cutaneous neuropathy\"]\nGranularity: 1",
            "[\"lateral epicondyle\", \"is a site for\", \"steroid injection\"]": " \n[\"lateral epicondyle\", \"is a site for\", \"steroid injection\"]\nGranularity: 1",
            "[\"lateral epicondylitis\", \"was treated by\", \"steroid injection\"]": " \n[\"lateral epicondylitis\", \"was treated by\", \"steroid injection\"]\nGranularity: 1",
            "[\"40-year-old woman\", \"experienced\", \"decreased sensation and paresthesia\"]": " \n[\"40-year-old woman\", \"experienced\", \"decreased sensation\"]\n[\"40-year-old woman\", \"experienced\", \"paresthesia\"]\nGranularity: 2",
            "[\"decreased sensation and paresthesia\", \"occurred after\", \"steroid injection\"]": " \n[\"decreased sensation\", \"occurred after\", \"steroid injection\"]\n[\"paresthesia\", \"occurred after\", \"steroid injection\"]\nGranularity: 2",
            "[\"sensation of light touch and pain\", \"was diminished over\", \"lateral side of the right forearm and wrist area\"]": " \n[\"sensation of light touch\", \"was diminished over\", \"lateral side of the right forearm\"]\n[\"sensation of light touch\", \"was diminished over\", \"wrist area\"]\n[\"pain\", \"was diminished over\", \"lateral side of the right forearm\"]\n[\"pain\", \"was diminished over\", \"wrist area\"]\nGranularity: 4",
            "[\"right lateral antebrachial cutaneous nerve\", \"had lower sensory action potential amplitude than\", \"left lateral antebrachial cutaneous nerve\"]": " \n[\"right lateral antebrachial cutaneous nerve\", \"had lower sensory action potential amplitude than\", \"left lateral antebrachial cutaneous nerve\"]\n[\"right lateral antebrachial cutaneous nerve\", \"had lower sensory action potential amplitude\", \"left lateral antebrachial cutaneous nerve\"]\n[\"right lateral antebrachial cutaneous nerve\", \"had lower\", \"left lateral antebrachial cutaneous nerve\"]\nGranularity: 3",
            "[\"right LACNP\", \"was diagnosed based on\", \"clinical manifestation and electrodiagnostic findings\"]": " \n[\"right LACNP\", \"was diagnosed based on\", \"clinical manifestation\"]\n[\"right LACNP\", \"was diagnosed based on\", \"electrodiagnostic findings\"]\nGranularity: 2",
            "[\"right LACNP\", \"had\", \"axonal involvement\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"symptoms\", \"improved through\", \"physical therapy\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"electrodiagnostic study\", \"was helpful to diagnose\", \"right LACNP\"]": " \n[\"electrodiagnostic study\", \"helped to diagnose\", \"right LACNP\"]\nGranularity: 1",
            "[\"electrodiagnostic study\", \"found the passage of\", \"LACN on the lateral epicondyle\"]": " \n[\"electrodiagnostic study\", \"found\", \"passage of LACN\"]\n[\"electrodiagnostic study\", \"found\", \"passage on lateral epicondyle\"]\nGranularity: 2"
      },
      "Heart failure : to digitalise or not ?|The view against .|Despite extensive clinical experience the role of digoxin is still not well defined .|In patients with atrial fibrillation digoxin is beneficial for ventricular rate control .|For patients in sinus rhythm and heart failure the situation is less clear .|Digoxin has a narrow therapeutic : toxic ratio and concentrations are affected by a number of drugs .|Also , digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands , and causing arrhythmias .|There is a paucity of data from well - designed trials .|The trials that are available are generally small with limitations in design and these show variation in patient benefit .|More convincing evidence is required showing that digoxin improves symptoms or exercise capacity .|Furthermore , no trial has had sufficient power to evaluate mortality .|Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction ( MI ) .|Angiotensin - converting enzyme ( ACE ) inhibitors should be used first as they are safer , do not require blood level monitoring , modify progression of disease , relieve symptoms , improve exercise tolerance and reduce mortality .|Caution should be exercised in using digoxin until large mortality trials are completed showing either benefit or harm .|Until then digoxin should be considered a third - line therapy .": {
            "[\"Heart failure\", \"topic of debate\", \"digitalisation\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"View\", \"against\", \"digitalisation\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Digoxin\", \"role\", \"not well defined\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Digoxin\", \"beneficial for\", \"ventricular rate control in atrial fibrillation\"]": " \n[\"Digoxin\", \"beneficial for\", \"ventricular rate control\"]\n[\"Digoxin\", \"beneficial for\", \"atrial fibrillation\"]\nGranularity: 2",
            "[\"Situation\", \"less clear\", \"patients in sinus rhythm and heart failure\"]": "\n[\"patients\", \"in sinus rhythm\", \"and heart failure\"]\n[\"Situation\", \"less clear\", \"patients\"]\n[\"patients\", \"in sinus rhythm\", \"heart failure\"]\nGranularity: 3",
            "[\"Digoxin\", \"affected by\", \"number of drugs\"]": " \n[\"Digoxin\", \"affected by\", \"number of drugs\"]\nGranularity: 1",
            "[\"Data\", \"paucity of\", \"from well-designed trials\"]": " \n[\"Data\", \"paucity\", \"from well-designed trials\"]\n[\"Data\", \"paucity of\", \"from trials\"]\n[\"Data\", \"paucity of\", \"from well-designed\"]\n[\"Data\", \"paucity\", \"from trials\"]\n[\"Data\", \"paucity\", \"from well-designed\"]\n[\"Data\", \"paucity of\", \"from trials\"]\nGranularity: 6",
            "[\"Trials\", \"generally small\", \"with limitations in design\"]": " \n[\"Trials\", \"are\", \"small\"]\n[\"Trials\", \"have\", \"limitations in design\"]\nGranularity: 2",
            "[\"Trials\", \"show variation in\", \"patient benefit\"]": " N/A (The relationship is direct and does not need further granularity.)\nGranularity: 0",
            "[\"More convincing evidence\", \"required\", \"showing digoxin improves symptoms or exercise capacity\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Trials\", \"insufficient power to evaluate\", \"mortality\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Pooled analysis\", \"shows\", \"excess mortality with other inotropic drugs\"]": " \n[\"Pooled analysis\", \"shows\", \"excess mortality\"]\n[\"Pooled analysis\", \"shows\", \"other inotropic drugs\"]\nGranularity: 2",
            "[\"Possibility\", \"that digoxin may increase\", \"mortality after myocardial infarction (MI)\"]": " \n[\"digoxin\", \"may increase\", \"mortality\"]\n[\"digoxin\", \"may increase\", \"after MI\"]\nGranularity: 2",
            "[\"Angiotensin-converting enzyme (ACE) inhibitors\", \"safer\", \"do not require blood level monitoring\"]": " \n[\"ACE inhibitors\", \"safer\", \"do not require blood level monitoring\"]\nGranularity: 1",
            "[\"ACE inhibitors\", \"modify\", \"progression of disease\"]": " N/A (The triple is specific, conveying a singular relation between ACE inhibitors and disease progression.)\nGranularity: 0",
            "[\"ACE inhibitors\", \"relieve\", \"symptoms\"]": " N/A (The triple is specific, conveying a singular relation between ACE inhibitors and symptoms.)\nGranularity: 0",
            "[\"ACE inhibitors\", \"improve\", \"exercise tolerance\"]": " N/A (The triple is specific, conveying a singular relation between ACE inhibitors and exercise tolerance.)\nGranularity: 0",
            "[\"ACE inhibitors\", \"reduce\", \"mortality\"]": " N/A (The triple is specific, conveying a singular relation between ACE inhibitors and mortality.)\nGranularity: 0",
            "[\"Caution\", \"should be exercised\", \"in using digoxin\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Large mortality trials\", \"completed\", \"showing either benefit or harm\"]": " \n[\"Large mortality trials\", \"showing\", \"benefit\"]\n[\"Large mortality trials\", \"showing\", \"harm\"]\nGranularity: 2",
            "[\"Until then\", \"digoxin\", \"considered a third-line therapy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "All - trans retinoic acid - induced inflammatory myositis in a patient with acute promyelocytic leukemia .|All - trans retinoic acid ( ATRA ) , a component of standard therapy for acute promyelocytic leukemia ( APL ) , is associated with potentially serious but treatable adverse effects involving numerous organ systems , including rare skeletal muscle involvement .|Only a handful of cases of ATRA - induced myositis in children have been reported , and none in the radiology literature .|We present such a case in a 15 - year - old boy with APL , where recognition of imaging findings played a crucial role in making the diagnosis and facilitated prompt , effective treatment .": {
            "[\"patient\", \"has\", \"acute promyelocytic leukemia\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"All-trans retinoic acid\", \"is a component of\", \"standard therapy for acute promyelocytic leukemia\"]": " \n[\"All-trans retinoic acid\", \"is a component of\", \"standard therapy\"]\n[\"All-trans retinoic acid\", \"is a component of\", \"acute promyelocytic leukemia\"]\nGranularity: 2",
            "[\"adverse effects\", \"involve\", \"numerous organ systems\"]": " \n[\"adverse effects\", \"involve\", \"organ systems\"]\n[\"adverse effects\", \"involve\", \"numerous systems\"]\nGranularity: 2",
            "[\"All-trans retinoic acid\", \"causes\", \"rare skeletal muscle involvement\"]": " \n[\"All-trans retinoic acid\", \"causes\", \"skeletal muscle involvement\"]\n[\"All-trans retinoic acid\", \"causes\", \"rare involvement\"]\nGranularity: 2",
            "[\"cases of ATRA-induced myositis\", \"have not been reported in\", \"the radiology literature\"]": " \n[\"cases of ATRA-induced myositis\", \"have not been reported\", \"in the radiology literature\"]\n[\"cases of ATRA-induced myositis\", \"have not been\", \"reported\"]\n[\"cases of ATRA-induced myositis\", \"have not\", \"been reported\"]\nGranularity: 3",
            "[\"such a case\", \"involves\", \"a 15-year-old boy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"recognition of imaging findings\", \"played a crucial role in\", \"making the diagnosis\"]": " \n[\"recognition of imaging findings\", \"played a role in\", \"making the diagnosis\"]\n[\"recognition of imaging findings\", \"played a crucial role\", \"in making the diagnosis\"]\nGranularity: 2",
            "[\"facilitated prompt\", \"led to\", \"effective treatment\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"All-trans retinoic acid\", \"induced\", \"inflammatory myositis\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"All-trans retinoic acid\", \"is associated with\", \"potentially serious but treatable adverse effects\"]": " \n[\"All-trans retinoic acid\", \"is associated with\", \"potentially serious adverse effects\"]\n[\"All-trans retinoic acid\", \"is associated with\", \"treatable adverse effects\"]\nGranularity: 2",
            "[\"ATRA-induced myositis\", \"has been reported in\", \"a handful of cases\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"15-year-old boy\", \"has\", \"acute promyelocytic leukemia\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Adverse ocular reactions possibly associated with isotretinoin .|A total of 261 adverse ocular reactions occurred in 237 patients who received isotretinoin , a commonly used drug in the treatment of severe cystic acne .|Blepharoconjunctivitis , subjective complaints of dry eyes , blurred vision , contact lens intolerance , and photodermatitis are reversible side effects .|More serious ocular adverse reactions include papilledema , pseudotumor cerebri , and white or gray subepithelial corneal opacities ; all of these are reversible if the drug is discontinued .|Reported cases of decreased dark adaptation are under investigation .|Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use ( including microphthalmos , orbital hypertelorism , and optic nerve hypoplasia ) .": {
            "[\"Adverse ocular reactions\", \"possibly associated with\", \"isotretinoin\"]": " \n[\"Adverse ocular reactions\", \"possibly associated with\", \"isotretinoin\"]\nGranularity: 1",
            "[\"261 adverse ocular reactions\", \"occurred in\", \"237 patients who received isotretinoin\"]": " \n[\"261 adverse ocular reactions\", \"occurred in\", \"237 patients\"]\n[\"237 patients\", \"received\", \"isotretinoin\"]\nGranularity: 2",
            "[\"Isotretinoin\", \"commonly used drug in the treatment of\", \"severe cystic acne\"]": " \n[\"Isotretinoin\", \"is used in the treatment of\", \"severe cystic acne\"]\n[\"Isotretinoin\", \"is a commonly used drug\"]\n[\"Isotretinoin\", \"is used for the treatment of\", \"severe cystic acne\"]\n[\"Isotretinoin\", \"is a drug used for the treatment of\", \"severe cystic acne\"]\n[\"Isotretinoin\", \"is commonly used for the treatment of\", \"severe cystic acne\"]\nGranularity: 5",
            "[\"Blepharoconjunctivitis\", \"subjective complaints of\", \"dry eyes\"]": " \n[\"Blepharoconjunctivitis\", \"has subjective complaints of\", \"dry eyes\"]\n[\"Blepharoconjunctivitis\", \"causes\", \"dry eyes\"]\nGranularity: 2",
            "[\"Blepharoconjunctivitis\", \"side effect of\", \"isotretinoin\"]": " N/A (The triple is specific and does not require further granularity.)\nGranularity: 0",
            "[\"Dry eyes\", \"side effect of\", \"isotretinoin\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Blurred vision\", \"side effect of\", \"isotretinoin\"]": " N/A (The triple is specific, conveying a singular relation between blurred vision and isotretinoin.)\nGranularity: 0",
            "[\"Contact lens intolerance\", \"side effect of\", \"isotretinoin\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Photodermatitis\", \"side effect of\", \"isotretinoin\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Papilledema\", \"serious ocular adverse reaction of\", \"isotretinoin\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Pseudotumor cerebri\", \"serious ocular adverse reaction of\", \"isotretinoin\"]": " \n[\"Pseudotumor cerebri\", \"is a serious ocular adverse reaction of\", \"isotretinoin\"]\n[\"Pseudotumor cerebri\", \"is a serious ocular adverse reaction of\", \"isotretinoin\"]\nGranularity: 2",
            "[\"White or gray subepithelial corneal opacities\", \"serious ocular adverse reaction of\", \"isotretinoin\"]": "\n[\"White or gray subepithelial corneal opacities\", \"is a serious ocular adverse reaction of\", \"isotretinoin\"]\n[\"White or gray subepithelial corneal opacities\", \"can occur as a serious ocular adverse reaction of\", \"isotretinoin\"]\nGranularity: 2",
            "[\"Decreased dark adaptation\", \"reported case of\", \"isotretinoin\"]": " \n[\"Decreased dark adaptation\", \"reported in case of\", \"isotretinoin\"]\nGranularity: 1",
            "[\"Isotretinoin\", \"contraindicated in\", \"pregnancy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Isotretinoin\", \"causes\", \"congenital abnormalities after maternal use\"]": " \n[\"Isotretinoin\", \"causes\", \"congenital abnormalities\"]\n[\"maternal use\", \"causes\", \"congenital abnormalities\"]\nGranularity: 2"
      },
      "Incidence of heparin - induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients : a retrospective cohort analysis .|BACKGROUND : Thrombocytopenia in patients with end - stage liver disease is a common disorder caused mainly by portal hypertension , low levels of thrombopoetin , and endotoxemia .|The impact of immune - mediated heparin - induced thrombocytopenia type II ( HIT type II ) as a cause of thrombocytopenia after liver transplantation is not yet understood , with few literature citations reporting contradictory results .|The aim of our study was to demonstrate the perioperative course of thrombocytopenia after liver transplantation and determine the occurrence of clinical HIT type II .|METHOD : We retrospectively evaluated the medical records of 205 consecutive adult patients who underwent full - size liver transplantation between January 2006 and December 2010 due to end - stage or malignant liver disease .|Preoperative platelet count , postoperative course of platelets , and clinical signs of HIT type II were analyzed .|RESULTS : A total of 155 ( 75 . 6 % ) of 205 patients had thrombocytopenia before transplantation , significantly influenced by Model of End - Stage Liver Disease score and liver cirrhosis .|The platelet count exceeded 100 , 000 / uL in most of the patients ( n = 193 ) at a medium of 7 d .|Regarding HIT II , there were four ( 1 . 95 % ) patients with a background of HIT type II .|CONCLUSIONS : The incidence of HIT in patients with end - stage hepatic failure is , with about 1 . 95 % , rare .|For further reduction of HIT type II , the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low - molecular - weight heparin after normalization of platelet count .": {
            "[\"Incidence of heparin - induced thrombocytopenia type II\", \"is the subject of\", \"postoperative recovery of platelet count in liver graft recipients\"]": " \n[\"Incidence of heparin - induced thrombocytopenia type II\", \"is the subject of\", \"postoperative recovery of platelet count\"]\n[\"Incidence of heparin - induced thrombocytopenia type II\", \"is the subject of\", \"liver graft recipients\"]\n[\"postoperative recovery of platelet count\", \"occurs in\", \"liver graft recipients\"]\nGranularity: 3",
            "[\"Thrombocytopenia\", \"is caused mainly by\", \"portal hypertension\"]": " \n[\"Thrombocytopenia\", \"is caused by\", \"portal hypertension\"]\n[\"Thrombocytopenia\", \"is caused by\", \"other factors\"]\nGranularity: 2",
            "[\"Thrombocytopenia\", \"is caused mainly by\", \"low levels of thrombopoetin\"]": " \n[\"Thrombocytopenia\", \"is caused by\", \"low levels of thrombopoetin\"]\n[\"Thrombocytopenia\", \"is mainly caused by\", \"low levels of thrombopoetin\"]\nGranularity: 2",
            "[\"Thrombocytopenia\", \"is caused mainly by\", \"endotoxemia\"]": "\n[\"Thrombocytopenia\", \"is caused by\", \"endotoxemia\"]\nGranularity: 1",
            "[\"heparin - induced thrombocytopenia type II\", \"is a cause of\", \"thrombocytopenia after liver transplantation\"]": " \n[\"heparin - induced thrombocytopenia type II\", \"is a cause of\", \"thrombocytopenia\"]\n[\"thrombocytopenia\", \"occurs after\", \"liver transplantation\"]\nGranularity: 2",
            "[\"The aim of our study\", \"was to\", \"demonstrate the perioperative course of thrombocytopenia after liver transplantation\"]": "\n[\"The aim of our study\", \"was to\", \"demonstrate the perioperative course of thrombocytopenia\"]\n[\"The aim of our study\", \"was to\", \"demonstrate the perioperative course\"]\n[\"The aim of our study\", \"was to\", \"demonstrate thrombocytopenia\"]\n[\"The aim of our study\", \"was to\", \"demonstrate the perioperative course of\"]\n[\"The aim of our study\", \"was to\", \"demonstrate the course of thrombocytopenia\"]\n[\"The aim of our study\", \"was to\", \"demonstrate the perioperative course of thrombocytopenia after liver transplantation\"]\nGranularity: 6",
            "[\"The aim of our study\", \"was to\", \"determine the occurrence of clinical HIT type II\"]": "\n[\"The aim of our study\", \"was\", \"to determine the occurrence of clinical HIT type II\"]\n[\"The aim of our study\", \"determine\", \"the occurrence of clinical HIT type II\"]\n[\"The aim of our study\", \"was to determine\", \"the occurrence of clinical HIT type II\"]\n[\"The aim of our study\", \"was to\", \"determine the occurrence of clinical HIT\"]\n[\"The aim of our study\", \"was to\", \"determine the occurrence of type II\"]\n[\"The aim of our study\", \"was to\", \"determine the occurrence of clinical HIT type\"]\n[\"The aim of our study\", \"was to\", \"determine the occurrence of type II\"]\n[\"The aim of our study\", \"was to\", \"determine the occurrence of clinical\"]\n[\"The aim of our study\", \"was to\", \"determine the occurrence of HIT type II\"]\n[\"The aim of our study\", \"was to\", \"determine the occurrence",
            "[\"We\", \"retrospectively evaluated\", \"the medical records of 205 consecutive adult patients\"]": " \n[\"We\", \"evaluated\", \"medical records\"]\n[\"We\", \"evaluated\", \"205 patients\"]\n[\"We\", \"evaluated\", \"adult patients\"]\n[\"We\", \"retrospectively evaluated\", \"medical records\"]\n[\"We\", \"retrospectively evaluated\", \"205 patients\"]\n[\"We\", \"retrospectively evaluated\", \"adult patients\"]\nGranularity: 6",
            "[\"Preoperative platelet count\", \"was analyzed\", \"postoperative course of platelets\"]": " \n[\"Preoperative platelet count\", \"was analyzed\", \"postoperative course\"]\n[\"Preoperative platelet count\", \"was analyzed\", \"platelets\"]\nGranularity: 2",
            "[\"Preoperative platelet count\", \"was analyzed\", \"clinical signs of HIT type II\"]": " \n[\"Preoperative platelet count\", \"was analyzed for\", \"clinical signs of HIT type II\"]\nGranularity: 1",
            "[\"A total of 155 ( 75 . 6 % ) of 205 patients\", \"had\", \"thrombocytopenia before transplantation\"]": " \n[\"A total of 155 of 205 patients\", \"had\", \"thrombocytopenia\"]\n[\"A total of 155 of 205 patients\", \"had\", \"thrombocytopenia before transplantation\"]\nGranularity: 2",
            "[\"The platelet count\", \"exceeded\", \"100 , 000 / uL in most of the patients\"]": " \n[\"The platelet count\", \"exceeded\", \"100,000 / uL\"]\n[\"most of the patients\", \"had a platelet count\", \"exceeding 100,000 / uL\"]\nGranularity: 2",
            "[\"Regarding HIT II\", \"there were\", \"four ( 1 . 95 % ) patients with a background of HIT type II \"]": " \n[\"Regarding HIT II\", \"had\", \"four patients\"]\n[\"Regarding HIT II\", \"had a background of\", \"HIT type II\"]\nGranularity: 2",
            "[\"The incidence of HIT in patients with end - stage hepatic failure\", \"is\", \"rare\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"For further reduction of HIT type II\", \"should be avoided\", \"the use of intravenous heparin\"]": " \n[\"For further reduction of HIT type II\", \"should be avoided\", \"intravenous heparin\"]\nGranularity: 1",
            "[\"For further reduction of HIT type II\", \"should be performed with\", \"low - molecular - weight heparin after normalization of platelet count \"]": " \n[\"For further reduction of HIT type II\", \"should be performed with\", \"low - molecular - weight heparin\"]\n[\"low - molecular - weight heparin\", \"should be performed after normalization of platelet count\"]\nGranularity: 2"
      },
      "Acute renal failure due to rifampicin .|A 23 - year - old male patient with bacteriologically proven pulmonary tuberculosis was treated with the various regimens of antituberculosis drugs for nearly 15 months .|Rifampicin was administered thrice as one of the 3 - 4 drug regimen and each time he developed untoward side effects like nausea , vomiting and fever with chills and rigors .|The last such episode was of acute renal failure at which stage the patient was seen by the authors of this report .|The patient , however , made a full recovery .": {
            "[\"Acute renal failure\", \"due to\", \"rifampicin\"]": " N/A (The triple is specific and does not need further granularity.)\nGranularity: 0",
            "[\"23-year-old male patient\", \"has\", \"pulmonary tuberculosis\"]": "\nN/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"treated with\", \"various regimens of antituberculosis drugs\"]": "\n[\"Patient\", \"treated with\", \"antituberculosis drugs\"]\n[\"Patient\", \"treated with\", \"various regimens\"]\nGranularity: 2",
            "[\"Rifampicin\", \"administered thrice\", \"as one of the 3-4 drug regimen\"]": " \n[\"Rifampicin\", \"administered\", \"thrice\"]\n[\"Rifampicin\", \"part of\", \"3-4 drug regimen\"]\nGranularity: 2",
            "[\"Rifampicin\", \"caused\", \"untoward side effects\"]": " N/A (The triple is specific, conveying a singular relation between Rifampicin and untoward side effects.)\nGranularity: 0",
            "[\"Side effects\", \"include\", \"nausea, vomiting, fever with chills and rigors\"]": "\n[\"Side effects\", \"include\", \"nausea\"]\n[\"Side effects\", \"include\", \"vomiting\"]\n[\"Side effects\", \"include\", \"fever with chills\"]\n[\"Side effects\", \"include\", \"rigors\"]\nGranularity: 4",
            "[\"Last episode\", \"was\", \"acute renal failure\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Patient\", \"seen by\", \"authors of this report\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0"
      },
      "Evidence for a cholinergic role in haloperidol - induced catalepsy .|Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of neuroleptic - induced catalepsy .|Large doses of the cholinomimetic , pilocarpine , could induce catalepsy when peripheral cholinergic receptors were blocked .|Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker , haloperidol .|A muscarinic receptor blocker , atropine , disrupted haloperidol - induced catalepsy .|Intracranial injection of an acetylcholine - synthesis inhibitor , hemicholinium , prevented the catalepsy that is usually induced by haloperidol .|These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems .|Alternatively , activation of central cholinergic systems could promote catalepsy by suppression of dopaminergic systems .": {
            "[\"Evidence\", \"relates to\", \"cholinergic role in haloperidol-induced catalepsy\"]": " \n[\"Evidence\", \"supports\", \"cholinergic role\"]\n[\"Evidence\", \"relates to\", \"haloperidol-induced catalepsy\"]\nGranularity: 2",
            "[\"Experiments\", \"tested\", \"previous evidence\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Previous evidence\", \"suggests\", \"activation of cholinergic systems promotes catalepsy\"]": " \n[\"Previous evidence\", \"suggests\", \"activation of cholinergic systems\"]\n[\"activation of cholinergic systems\", \"promotes\", \"catalepsy\"]\nGranularity: 2",
            "[\"Previous evidence\", \"suggests\", \"cholinergic mechanisms need to be intact for full expression of neuroleptic-induced catalepsy\"]": " \n[\"Previous evidence\", \"suggests\", \"cholinergic mechanisms\"]\n[\"cholinergic mechanisms\", \"need to be intact for\", \"full expression of neuroleptic-induced catalepsy\"]\nGranularity: 2",
            "[\"Large doses of pilocarpine\", \"can induce\", \"catalepsy\"]": " \n[\"Large doses of pilocarpine\", \"can induce\", \"catalepsy\"]\nGranularity: 1",
            "[\"Low doses of pilocarpine\", \"caused\", \"pronounced enhancement of catalepsy induced by haloperidol\"]": " \n[\"Low doses of pilocarpine\", \"caused\", \"enhancement of catalepsy\"]\n[\"Low doses of pilocarpine\", \"caused\", \"pronounced enhancement\"]\n[\"Low doses of pilocarpine\", \"caused\", \"catalepsy induced by haloperidol\"]\nGranularity: 3",
            "[\"A muscarinic receptor blocker\", \"disrupted\", \"haloperidol-induced catalepsy\"]": " \n[\"A muscarinic receptor blocker\", \"disrupts\", \"haloperidol-induced catalepsy\"]\n[\"A muscarinic receptor blocker\", \"prevents\", \"haloperidol-induced catalepsy\"]\n[\"A muscarinic receptor blocker\", \"inhibits\", \"haloperidol-induced catalepsy\"]\nGranularity: 3",
            "[\"Intracranial injection of an acetylcholine-synthesis inhibitor\", \"prevented\", \"haloperidol-induced catalepsy\"]": " \n[\"Intracranial injection\", \"prevented\", \"haloperidol-induced catalepsy\"]\n[\"acetylcholine-synthesis inhibitor\", \"prevented\", \"haloperidol-induced catalepsy\"]\n[\"Intracranial injection\", \"prevented\", \"catalepsy\"]\n[\"acetylcholine-synthesis inhibitor\", \"prevented\", \"catalepsy\"]\nGranularity: 4",
            "[\"Findings\", \"suggest\", \"the hypothesis that catalepsy produced by neuroleptics like haloperidol is mediated by intrinsic central cholinergic systems\"]": " \n[\"Findings\", \"suggest\", \"the hypothesis that catalepsy produced by neuroleptics like haloperidol\"]\n[\"Findings\", \"suggest\", \"the hypothesis that catalepsy is mediated by intrinsic central cholinergic systems\"]\n[\"Findings\", \"suggest\", \"the hypothesis that catalepsy produced by neuroleptics like haloperidol is mediated by intrinsic central cholinergic systems\"]\nGranularity: 3",
            "[\"Activation of central cholinergic systems\", \"could promote\", \"catalepsy by suppression of dopaminergic systems\"]": " \n[\"Activation of central cholinergic systems\", \"could promote\", \"catalepsy\"]\n[\"Activation of central cholinergic systems\", \"could suppress\", \"dopaminergic systems\"]\nGranularity: 2"
      },
      "Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson 's disease : clues from dyskinetic patients .|The plasticity of primary motor cortex ( M1 ) in patients with Parkinson 's disease ( PD ) and levodopa - induced dyskinesias ( LIDs ) is severely impaired .|We recently reported in young healthy subjects that inhibitory cerebellar stimulation enhanced the sensorimotor plasticity of M1 that was induced by paired associative stimulation ( PAS ) .|This study demonstrates that the deficient sensorimotor M1 plasticity in 16 patients with LIDs could be reinstated by a single session of real inhibitory cerebellar stimulation but not sham stimulation .|This was evident only when a sensory component was involved in the induction of plasticity , indicating that cerebellar sensory processing function is involved in the resurgence of M1 plasticity .|The benefit of inhibitory cerebellar stimulation on LIDs is known .|To explore whether this benefit is linked to the restoration of sensorimotor plasticity of M1 , we conducted an additional study looking at changes in LIDs and PAS - induced plasticity after 10 sessions of either bilateral , real inhibitory cerebellar stimulation or sham stimulation .|Only real and not sham stimulation had an antidyskinetic effect and it was paralleled by a resurgence in the sensorimotor plasticity of M1 .|These results suggest that alterations in cerebellar sensory processing function , occurring secondary to abnormal basal ganglia signals reaching it , may be an important element contributing to the maladaptive sensorimotor plasticity of M1 and the emergence of abnormal involuntary movements .": {
            "[\"Cerebellar sensory processing alterations\", \"impact\", \"motor cortical plasticity in Parkinson's disease\"]": " \n[\"Cerebellar sensory processing alterations\", \"impact\", \"motor cortical plasticity\"]\n[\"Cerebellar sensory processing alterations\", \"impact\", \"Parkinson's disease\"]\nGranularity: 2",
            "[\"Plasticity of primary motor cortex (M1)\", \"in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs)\", \"severely impaired\"]": "\n[\"Plasticity of primary motor cortex (M1)\", \"in patients with Parkinson's disease (PD)\", \"severely impaired\"]\n[\"Plasticity of primary motor cortex (M1)\", \"in patients with levodopa-induced dyskinesias (LIDs)\", \"severely impaired\"]\nGranularity: 2",
            "[\"Inhibitory cerebellar stimulation\", \"enhances\", \"sensorimotor plasticity of M1\"]": " \n[\"Inhibitory cerebellar stimulation\", \"enhances\", \"sensorimotor plasticity\"]\n[\"Inhibitory cerebellar stimulation\", \"enhances\", \"M1\"]\nGranularity: 2",
            "[\"Deficient sensorimotor M1 plasticity in patients with LIDs\", \"can be reinstated by\", \"a single session of real inhibitory cerebellar stimulation\"]": " \n[\"patients with LIDs\", \"have\", \"deficient sensorimotor M1 plasticity\"]\n[\"a single session of real inhibitory cerebellar stimulation\", \"can reinstate\", \"deficient sensorimotor M1 plasticity\"]\nGranularity: 2",
            "[\"Cerebellar sensory processing function\", \"is involved in\", \"resurgence of M1 plasticity\"]": " \n[\"Cerebellar sensory processing function\", \"is involved in\", \"resurgence of M1 plasticity\"]\nGranularity: 1",
            "[\"Inhibitory cerebellar stimulation\", \"has a benefit on\", \"LIDs\"]": " \n[\"Inhibitory cerebellar stimulation\", \"has a benefit on\", \"LIDs\"]\nGranularity: 1",
            "[\"Restoration of sensorimotor plasticity of M1\", \"is linked to\", \"the benefit of inhibitory cerebellar stimulation on LIDs\"]": " \n[\"Restoration of sensorimotor plasticity of M1\", \"is linked to\", \"benefit of inhibitory cerebellar stimulation\"]\n[\"benefit of inhibitory cerebellar stimulation\", \"on\", \"LIDs\"]\nGranularity: 2",
            "[\"Only real and not sham stimulation\", \"has an antidyskinetic effect and\", \"resurgence in the sensorimotor plasticity of M1\"]": " \n[\"Only real stimulation\", \"has an antidyskinetic effect\"]\n[\"Only real stimulation\", \"leads to\", \"resurgence in the sensorimotor plasticity of M1\"]\nGranularity: 2",
            "[\"Alterations in cerebellar sensory processing function\", \"may be an important element contributing to\", \"maladaptive sensorimotor plasticity of M1\"]": " \n[\"Alterations in cerebellar sensory processing function\", \"may be an important element contributing to\", \"maladaptive sensorimotor plasticity\"]\n[\"Alterations in cerebellar sensory processing function\", \"may be an important element contributing to\", \"M1\"]\nGranularity: 2",
            "[\"Alterations in cerebellar sensory processing function\", \"may be an important element contributing to\", \"the emergence of abnormal involuntary movements\"]": " \n[\"Alterations in cerebellar sensory processing function\", \"may be an important element\", \"contributing to\"]\n[\"Alterations in cerebellar sensory processing function\", \"may be\", \"an important element\"]\n[\"Alterations in cerebellar sensory processing function\", \"contributing to\", \"the emergence of abnormal involuntary movements\"]\n[\"Alterations in cerebellar sensory processing function\", \"may be\", \"contributing to\"]\n[\"contributing to\", \"the emergence of abnormal involuntary movements\"]\nGranularity: 5"
      },
      "Bradycardia after high - dose intravenous methylprednisolone therapy .|In 5 consecutive patients with rheumatoid arthritis who received intravenous high - dose methylprednisolone ( MP ) therapy ( 1 g daily for 2 or 3 consecutive days ) , a decline in pulse rate was observed , most pronounced on day 4 .|In one of the 5 patients the bradycardia was associated with complaints of substernal pressure .|Reversal to normal heart rate was found on day 7 .|Electrocardiographic registrations showed sinus bradycardia in all cases .|No significant changes in plasma concentrations of electrolytes were found .|Careful observation of patients receiving high - dose MP is recommended .|High - dose MP may be contraindicated in patients with known heart disease .": {
            "[\"5 consecutive patients\", \"receive\", \"high - dose methylprednisolone ( MP ) therapy\"]": "\n[\"5 consecutive patients\", \"receive\", \"high-dose methylprednisolone (MP) therapy\"]\nGranularity: 0",
            "[\"Decline in pulse rate\", \"is observed in\", \"5 consecutive patients\"]": " \n[\"Decline in pulse rate\", \"is observed in\", \"5 patients\"]\n[\"Decline in pulse rate\", \"is observed\", \"consecutively\"]\nGranularity: 2",
            "[\"Bradycardia\", \"is associated with\", \"complaints of substernal pressure\"]": " \n[\"Bradycardia\", \"is associated with\", \"complaints of substernal pressure\"]\nGranularity: 1",
            "[\"Reversal to normal heart rate\", \"occurs on\", \"day 7\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Electrocardiographic registrations\", \"show\", \"sinus bradycardia in all cases\"]": " \n[\"Electrocardiographic registrations\", \"show\", \"sinus bradycardia\"]\n[\"sinus bradycardia\", \"is present in\", \"all cases\"]\nGranularity: 2",
            "[\"Plasma concentrations of electrolytes\", \"do not have\", \"significant changes\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Careful observation\", \"is recommended for\", \"patients receiving high - dose MP\"]": " \n[\"Careful observation\", \"is recommended\", \"for patients\"]\n[\"Careful observation\", \"is recommended\", \"for patients receiving high - dose MP\"]\nGranularity: 2",
            "[\"High - dose MP\", \"may be contraindicated in\", \"patients with known heart disease\"]": " \n[\"High - dose MP\", \"may be contraindicated in\", \"patients with known heart disease\"]\nGranularity: 1",
            "[\"Bradycardia\", \"occurs after\", \"high - dose intravenous methylprednisolone therapy\"]": " \n[\"Bradycardia\", \"occurs after\", \"high - dose intravenous methylprednisolone\"]\n[\"high - dose intravenous methylprednisolone\", \"therapy\", \"treatment\"]\nGranularity: 2"
      },
      "Mefenamic acid - induced neutropenia and renal failure in elderly females with hypothyroidism .|We report mefenamic acid - induced non - oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females .|The neutropenia was due to maturation arrest of the myeloid series in one patient .|Both patients were also hypothyroid , but it is not clear whether this was a predisposing factor to the development of these adverse reactions .|However , it would seem prudent not to use mefenamic acid in hypothyroid patients until the hypothyroidism has been corrected .": {
            "[\"Mefenamic acid\", \"induced\", \"non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females\"]": " \n[\"Mefenamic acid\", \"induced\", \"non-oliguric renal failure\"]\n[\"Mefenamic acid\", \"induced\", \"severe neutropenia\"]\n[\"Mefenamic acid\", \"occurred in\", \"two elderly females\"]\nGranularity: 3",
            "[\"Neutropenia\", \"was due to\", \"maturation arrest of the myeloid series in one patient\"]": " \n[\"Neutropenia\", \"was due to\", \"maturation arrest of the myeloid series\"]\n[\"maturation arrest of the myeloid series\", \"was in\", \"one patient\"]\nGranularity: 2",
            "[\"Both patients\", \"were also\", \"hypothyroid\"]": " \n[\"Both patients\", \"were\", \"hypothyroid\"]\n[\"patients\", \"were also\", \"hypothyroid\"]\nGranularity: 2",
            "[\"Hypothyroidism\", \"was a predisposing factor to\", \"development of these adverse reactions\"]": " \n[\"Hypothyroidism\", \"was a predisposing factor to\", \"development of adverse reactions\"]\nGranularity: 1",
            "[\"Mefenamic acid\", \"should not be used in\", \"hypothyroid patients until the hypothyroidism has been corrected\"]": " \n[\"Mefenamic acid\", \"should not be used in\", \"hypothyroid patients\"]\n[\"hypothyroid patients\", \"until\", \"hypothyroidism has been corrected\"]\nGranularity: 2",
            "[\"Mefenamic acid\", \"induced\", \"neutropenia and renal failure in elderly females with hypothyroidism\"]": " \n[\"Mefenamic acid\", \"induced\", \"neutropenia\"]\n[\"Mefenamic acid\", \"induced\", \"renal failure\"]\n[\"Mefenamic acid\", \"induced\", \"neutropenia and renal failure\"]\n[\"elderly females\", \"with\", \"hypothyroidism\"]\nGranularity: 4"
      },
      "Peri - operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel .|A 47 - year - old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with carcinoma of the breast 6 months previously .|In the preceding months she had received neo - adjuvant chemotherapy with epirubicin , paclitaxel ( Taxol ) and cyclophosphamide .|This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity .|She was found to be bradycardic at pre - operative assessment but had no cardiac symptoms .|Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram , and temporary transvenous ventricular pacing instituted in the peri - operative period .|We discuss how evidence - based guidelines would not have been helpful in this case , and how chemotherapy can exhibit substantial cardiotoxicity that may develop over many years .|We suggest that patients who have received chemotherapy at any time should have a pre - operative electrocardiogram even if they are asymptomatic .": {
            "[\"Peri-operative atrioventricular block\", \"result of\", \"chemotherapy with epirubicin and paclitaxel\"]": " \n[\"Peri-operative atrioventricular block\", \"result of\", \"chemotherapy with epirubicin\"]\n[\"Peri-operative atrioventricular block\", \"result of\", \"chemotherapy with paclitaxel\"]\nGranularity: 2",
            "[\"47-year-old woman\", \"presented for\", \"mastectomy and immediate latissimus dorsi flap reconstruction\"]": " \n[\"47-year-old woman\", \"presented for\", \"mastectomy\"]\n[\"47-year-old woman\", \"presented for\", \"immediate latissimus dorsi flap reconstruction\"]\nGranularity: 2",
            "[\"Woman\", \"diagnosed with\", \"carcinoma of the breast\"]": " \n[\"Woman\", \"has\", \"carcinoma\"]\n[\"Woman\", \"has\", \"breast\"]\nGranularity: 2",
            "[\"Woman\", \"received\", \"neo-adjuvant chemotherapy with epirubicin, paclitaxel, and cyclophosphamide\"]": "\n[\"Woman\", \"received\", \"neo-adjuvant chemotherapy\"]\n[\"Woman\", \"received\", \"epirubicin\"]\n[\"Woman\", \"received\", \"paclitaxel\"]\n[\"Woman\", \"received\", \"cyclophosphamide\"]\nGranularity: 4",
            "[\"Woman\", \"found to be\", \"bradycardic at pre-operative assessment\"]": " \n[\"Woman\", \"found to be\", \"bradycardic\"]\n[\"pre-operative assessment\", \"indicated\", \"bradycardia\"]\nGranularity: 2",
            "[\"Woman\", \"had no\", \"cardiac symptoms\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Second degree Mobitz type II atrioventricular block\", \"diagnosed on\", \"electrocardiogram\"]": " \n[\"Second degree Mobitz type II atrioventricular block\", \"is a type of\", \"atrioventricular block\"]\n[\"Second degree Mobitz type II atrioventricular block\", \"is diagnosed on\", \"electrocardiogram\"]\nGranularity: 2",
            "[\"Temporary transvenous ventricular pacing\", \"instituted in\", \"peri-operative period\"]": " \n[\"Temporary transvenous ventricular pacing\", \"instituted\", \"peri-operative\"]\n[\"Temporary transvenous ventricular pacing\", \"instituted\", \"period\"]\nGranularity: 2",
            "[\"Evidence-based guidelines\", \"would not have been helpful in\", \"this case\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Chemotherapy\", \"can exhibit\", \"substantial cardiotoxicity that may develop over many years\"]": " \n[\"Chemotherapy\", \"can exhibit\", \"cardiotoxicity\"]\n[\"Chemotherapy\", \"can develop over\", \"many years\"]\nGranularity: 2",
            "[\"Patients who have received chemotherapy\", \"should have\", \"a pre-operative electrocardiogram even if they are asymptomatic\"]": " \n[\"Patients who have received chemotherapy\", \"should have\", \"a pre-operative electrocardiogram\"]\n[\"Patients who have received chemotherapy\", \"should have\", \"an electrocardiogram\"]\n[\"Patients who have received chemotherapy\", \"should have\", \"a pre-operative electrocardiogram even if they are asymptomatic\"]\nGranularity: 3"
      },
      "Acute renal failure occurring during intravenous desferrioxamine therapy : recovery after haemodialysis .|A patient with transfusion - dependent thalassemia was undergoing home intravenous desferrioxamine ( DFX ) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy .|Due to an accidental malfunctioning of the infusion pump , the patient was inadvertently administered a toxic dosage of the drug which caused renal insufficiency .|Given the progressive deterioration of the symptoms and of the laboratory values , despite adequate medical treatment , a decision was made to introduce haemodialytical therapy in order to remove the drug and therapy reduce the nephrotoxicity .|From the results obtained , haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by desferrioxamine .": {
            "[\"Patient\", \"undergoing\", \"intravenous desferrioxamine treatment\"]": " \n[\"Patient\", \"undergoing\", \"intravenous treatment\"]\n[\"Patient\", \"undergoing\", \"desferrioxamine treatment\"]\nGranularity: 2",
            "[\"Patient\", \"administered\", \"toxic dosage of the drug\"]": " \n[\"Patient\", \"administered\", \"toxic dosage\"]\n[\"toxic dosage\", \"of the drug\", \"administered\"]\nGranularity: 2",
            "[\"Toxic dosage of the drug\", \"caused\", \"renal insufficiency\"]": " \n[\"Toxic dosage of the drug\", \"caused\", \"renal insufficiency\"]\nGranularity: 1",
            "[\"Symptoms and laboratory values\", \"deteriorated despite\", \"adequate medical treatment\"]": " \n[\"Symptoms and laboratory values\", \"deteriorated\", \"adequate medical treatment\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"despite\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"medical treatment\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"adequate\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"medical\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"treatment\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"despite adequate medical treatment\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"despite medical treatment\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"despite adequate\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"despite medical\"]\n[\"Symptoms and laboratory values\", \"deteriorated\", \"adequate medical\"]\n[\"Symptoms",
            "[\"Decision\", \"made to introduce\", \"haemodialytical therapy\"]": " \n[\"Decision\", \"made to introduce\", \"haemodialytical therapy\"]\nGranularity: 1",
            "[\"Haemodialysis\", \"reduce\", \"nephrotoxicity\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Haemodialysis\", \"suggested as\", \"useful therapy\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"Haemodialysis\", \"useful in\", \"rare cases of progressive acute renal failure caused by desferrioxamine\"]": " \n[\"Haemodialysis\", \"useful for\", \"progressive acute renal failure\"]\n[\"Haemodialysis\", \"useful for\", \"rare cases\"]\n[\"Haemodialysis\", \"useful for\", \"acute renal failure caused by desferrioxamine\"]\n[\"Haemodialysis\", \"useful for\", \"progressive acute renal failure caused by desferrioxamine\"]\nGranularity: 4",
            "[\"Acute renal failure\", \"occurring during\", \"intravenous desferrioxamine therapy\"]": " \n[\"Acute renal failure\", \"occurs during\", \"intravenous desferrioxamine therapy\"]\n[\"Acute renal failure\", \"is caused by\", \"intravenous desferrioxamine therapy\"]\n[\"Acute renal failure\", \"can be treated with\", \"intravenous desferrioxamine therapy\"]\nGranularity: 3"
      },
      "Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose .|BACKGROUND / AIMS : Experimental studies have suggested that apoptosis via the Fas / Fas Ligand signaling system may play an important role in the development of acute liver failure .|The aim of the study was to investigate the soluble form of Fas in patients with acute liver failure .|METHODOLOGY : Serum levels of sFas ( soluble Fas ) were measured by ELISA in 24 patients with acute liver failure and 10 normal control subjects .|Serum levels of tumor necrosis factor - alpha and interferon - gamma were also determined by ELISA .|RESULTS : Serum sFas was significantly increased in patients with acute liver failure ( median , 26 . 8 U / mL ; range , 6 . 9 - 52 . 7 U / mL ) compared to the normal controls ( median , 8 . 6 U / mL ; range , 6 . 5 - 12 . 0 U / mL , P < 0 . 0001 ) .|Levels were significantly greater in patients with acute liver failure due to paracetamol overdose ( median , 28 . 7 U / mL ; range , 12 . 8 - 52 . 7 U / mL , n = 17 ) than those due to non - A to E hepatitis ( median , 12 . 5 U / mL ; range , 6 . 9 - 46 . 0 U / mL , n = 7 , P < 0 . 01 ) .|There was no relationship of sFas to eventual outcome in the patients .|A significant correlation was observed between serum sFas levels and aspartate aminotransferase ( r = 0 . 613 , P < 0 . 01 ) .|CONCLUSIONS : The increased concentration of sFas in serum of patients with acute liver failure may reflect activation of Fas - mediated apoptosis in the liver and this together with increased tumor necrosis factor - alpha may be an important factor in liver cell loss .": {
            "[\"Increased serum soluble Fas\", \"in patients with\", \"acute liver failure\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"acute liver failure\", \"due to\", \"paracetamol overdose\"]": " \n[\"acute liver failure\", \"caused by\", \"paracetamol overdose\"]\n[\"acute liver failure\", \"due to\", \"paracetamol\"]\n[\"paracetamol\", \"overdose\", \"causes acute liver failure\"]\nGranularity: 3",
            "[\"Experimental studies\", \"have suggested\", \"apoptosis via the Fas / Fas Ligand signaling system\"]": "\n[\"Experimental studies\", \"have suggested\", \"apoptosis\"]\n[\"apoptosis\", \"via\", \"the Fas / Fas Ligand signaling system\"]\nGranularity: 2",
            "[\"The aim of the study\", \"was to\", \"investigate the soluble form of Fas in patients with acute liver failure\"]": " \n[\"The aim of the study\", \"was to\", \"investigate the soluble form of Fas\"]\n[\"patients with acute liver failure\", \"have\", \"the soluble form of Fas\"]\nGranularity: 2",
            "[\"Serum levels of sFas\", \"were measured by\", \"ELISA\"]": " \n[\"Serum levels of sFas\", \"were measured\", \"by ELISA\"]\nGranularity: 1",
            "[\"Serum levels of tumor necrosis factor - alpha and interferon - gamma\", \"were also determined by\", \"ELISA\"]": " \n[\"Serum levels of tumor necrosis factor - alpha\", \"were determined by\", \"ELISA\"]\n[\"Serum levels of interferon - gamma\", \"were determined by\", \"ELISA\"]\nGranularity: 2",
            "[\"Serum sFas\", \"was significantly increased in\", \"patients with acute liver failure\"]": " \n[\"Serum sFas\", \"was increased in\", \"patients with acute liver failure\"]\n[\"Serum sFas\", \"was increased in\", \"patients\"]\n[\"Serum sFas\", \"was increased in\", \"acute liver failure\"]\nGranularity: 3",
            "[\"Levels\", \"were significantly greater in\", \"patients with acute liver failure due to paracetamol overdose\"]": " \n[\"Levels\", \"were greater in\", \"patients with acute liver failure\"]\n[\"Levels\", \"were greater in\", \"patients due to paracetamol overdose\"]\nGranularity: 2",
            "[\"There was no relationship of sFas\", \"to\", \"eventual outcome in the patients\"]": " N/A (The triple is already specific and cannot be broken down further.)\nGranularity: 0",
            "[\"A significant correlation was observed\", \"between\", \"serum sFas levels and aspartate aminotransferase\"]": " \n[\"A significant correlation\", \"was observed\", \"between serum sFas levels\"]\n[\"A significant correlation\", \"was observed\", \"and aspartate aminotransferase\"]\nGranularity: 2",
            "[\"The increased concentration of sFas in serum of patients\", \"may reflect\", \"activation of Fas - mediated apoptosis in the liver\"]": " \n[\"The increased concentration of sFas in serum of patients\", \"may reflect\", \"activation of Fas - mediated apoptosis\"]\n[\"The increased concentration of sFas in serum of patients\", \"may reflect\", \"apoptosis in the liver\"]\nGranularity: 2",
            "[\"this together with increased tumor necrosis factor - alpha\", \"may be an important factor in\", \"liver cell loss\"]": " \n[\"this\", \"together with\", \"increased tumor necrosis factor - alpha\"]\n[\"increased tumor necrosis factor - alpha\", \"may be an important factor in\", \"liver cell loss\"]\nGranularity: 2"
      },
      "Increased frequency and severity of angio - oedema related to long - term therapy with angiotensin - converting enzyme inhibitor in two patients .|Adverse reactions to drugs are well recognized as a cause of acute or chronic urticaria , and angio - oedema .|Angiotensin - converting enzyme ( ACE ) inhibitors , used to treat hypertension and congestive heart failure , were introduced in Europe in the middle of the eighties , and the use of these drugs has increased progressively .|Soon after the introduction of ACE inhibitors , acute bouts of angio - oedema were reported in association with the use of these drugs .|We wish to draw attention to the possibility of adverse reactions to ACE inhibitors after long - term use and in patients with pre - existing angio - oedema .": {
            "[\"Increased frequency and severity of angio-oedema\", \"related to\", \"long-term therapy with angiotensin-converting enzyme inhibitor\"]": " \n[\"Increased frequency and severity of angio-oedema\", \"related to\", \"long-term therapy\"]\n[\"Increased frequency and severity of angio-oedema\", \"related to\", \"angiotensin-converting enzyme inhibitor\"]\nGranularity: 2",
            "[\"Adverse reactions to drugs\", \"cause\", \"acute or chronic urticaria and angio-oedema\"]": " \n[\"Adverse reactions to drugs\", \"cause\", \"acute urticaria\"]\n[\"Adverse reactions to drugs\", \"cause\", \"chronic urticaria\"]\n[\"Adverse reactions to drugs\", \"cause\", \"angio-oedema\"]\nGranularity: 3",
            "[\"Angiotensin-converting enzyme (ACE) inhibitors\", \"used to treat\", \"hypertension and congestive heart failure\"]": " \n[\"Angiotensin-converting enzyme (ACE) inhibitors\", \"used to treat\", \"hypertension\"]\n[\"Angiotensin-converting enzyme (ACE) inhibitors\", \"used to treat\", \"congestive heart failure\"]\nGranularity: 2",
            "[\"ACE inhibitors\", \"introduced in Europe\", \"in the middle of the eighties\"]": " N/A (The triple is specific and cannot be broken down further.)\nGranularity: 0",
            "[\"ACE inhibitors\", \"increased progressively\", \"use of these drugs\"]": " \n[\"ACE inhibitors\", \"increased\", \"use\"]\n[\"ACE inhibitors\", \"progressively increased\", \"use\"]\nGranularity: 2",
            "[\"Soon after the introduction of ACE inhibitors\", \"reported\", \"acute bouts of angio-oedema\"]": " \n[\"ACE inhibitors\", \"introduced\", \"soon after\"]\n[\"acute bouts\", \"reported\", \"soon after\"]\n[\"angio-oedema\", \"reported\", \"soon after\"]\nGranularity: 3",
            "[\"We\", \"draw attention to\", \"the possibility of adverse reactions to ACE inhibitors after long-term use and in patients with pre-existing angio-oedema\"]": " \n[\"We\", \"draw attention to\", \"adverse reactions\"]\n[\"We\", \"draw attention to\", \"long-term use\"]\n[\"We\", \"draw attention to\", \"patients with pre-existing angio-oedema\"]\nGranularity: 3"
      }
}